simple0,simple1,simple2
"Neurogenesis is a crucial process that helps to maintain the complexity of the central nervous system. This process, strictly regulated, generates new neurons from neural stem cells in the adult brain, providing a form of cellular neuronal plasticity. A series of sequential events, such as proliferation, migration, integration into target areas, and morphological and functional maturation, culminates in the production of functional neurons. Scientists use markers such as doublecortin to identify neuronal precursors and newly generated neurons. These markers can be mostly found in the adult dentate gyrus of the hippocampus and in the subventricular zone. By generating transgenic mice that drive reporter genes with doublecortin promoter, scientists can monitor neurogenesis in vitro and in vivo.","The process of neurogenesis is a crucial aspect of maintaining the intricate structure of the central nervous system. In the adult brain, this process actively generates new neurons from neural stem cells, providing a form of cellular plasticity that allows the brain to adapt and change throughout life. Neurogenesis consists of several sequential stages, including proliferation, lineage restriction, cell cycle exit, migration, and integration into the targeted area, culminating in the functional and morphological maturation of newly generated neurons. Scientists use various markers, such as doublecortin, to identify neuronal precursors and newly generated neurons primarily located in specific regions such as the dentate gyrus of the hippocampus and the subventricular zone. To monitor neurogenesis in vitro and in vivo, transgenic mice have been generated, which express reporter genes driven by the doublecortin promoter.","The process of neurogenesis is a tightly regulated and essential process that maintains the complex cytoarchitecture of the central nervous system. In the adult brain, neurogenesis provides a form of cellular neuronal plasticity by generating new neurons from neural stem cells. This process encompasses several distinct stages, including proliferation, neuronal lineage restriction, cell division cessation, migration, integration, differentiation, and maturation. Doublecortin (DCX) is a biomarker expressed in neuronal precursors and newly generated neurons that researchers use to monitor neurogenesis. DCX expression can be primarily detected in specific regions of the adult brain, such as the dentate gyrus of the hippocampus and the subventricular zone. To examine neurogenesis in vitro and in vivo, scientists employ transgenic mice in which the DCX promoter controls a reporter gene's expression."
"A deeper understanding of the molecular and cellular aspects of adult neurogenesis is imperative for devising effective therapeutic approaches for managing pathological neuronal deficits. Emerging evidence suggests that abnormal neurogenesis may contribute to the onset and progression of several neuropsychiatric disorders. Consequently, various models have been developed to investigate the molecular mechanisms underlying neurogenesis in vivo. These models include transgenic models with cell-type specific promoters like nestin, GLAST, PLP, and DCX, which enable researchers to study neural stem cells, radial glia, oligodendroglial precursors, and neuronal precursors, respectively. Nevertheless, these models have their limitations and may not be suitable for long-term studies like fate mapping or investigation of the long-term functional integration of newly generated neurons. For instance, the DCX reporter mice do not serve the purpose of fate mapping in regions such as the dentate gyrus and the SVZ/OB axis, where DCX expression lasts for a short period (less than a month in rodents).","Understanding the molecular and cellular processes underlying adult neurogenesis is crucial for developing therapeutic interventions to address pathological neuronal losses. Recent evidence suggests that abnormal neurogenesis may contribute to the pathophysiology of various neuropsychiatric disorders. As such, several animal models have been created to explore the molecular mechanisms that drive neurogenesis in vivo. These models include transgenic models with cell-specific promoters like nestin, GLAST, PLP (proteolipid protein), and DCX that enable researchers to study neural stem cells, radial glia, oligodendroglial precursors, and neuronal precursors, respectively. However, limitations exist with these models, making them not ideal for long-term studies such as fate tracing or investigating the long-term functional integration of newly generated neurons. For example, DCX reporter mice are not suitable for fate mapping studies in areas like the dentate gyrus and the SVZ/OB axis, where DCX expression is transient (mostly less than a month in rodents).","Developing effective therapeutic strategies for pathological neuronal losses requires a greater understanding of the molecular and cellular aspects of adult neurogenesis. Moreover, increasing evidence highlights the potential involvement of abnormal neurogenesis in the pathogenesis of neuropsychiatric disorders. To comprehend and dissect the underlying molecular mechanisms of neurogenesis in vivo, several animal models have been developed over the years. These models employ cell-type specific promoters, such as nestin, GLAST, PLP, and DCX, to study neural stem cells, radial glia, oligodendroglial precursors, and neuronal precursors, respectively.  However, these reporter mice have their limitations and are inadequate for long-term studies, such as fate mapping or exploring the long-term functional integration of newly generated neurons. DCX reporter mice, for instance, are unsuitable for fate mapping studies in the SVZ/OB axis or the dentate gyrus, where DCX expression is short-lived (usually less than a month in rodents)."
"The issue of lacking an adequate technique for studying the fate of neuronal precursors was addressed by generating transgenic mice that carry the CreERT2 recombinase gene under the control of the DCX promoter, which can be activated by tamoxifen. Our investigation demonstrates that this newly developed transgenic tool permits the tracking of newly-developed neurons over extended periods by providing time-resolved and permanent labeling. Furthermore, it creates the prospect of manipulating gene expression at a critical juncture in neuronal maturation and examining the functional effects of such manipulations.","To address the need for a suitable tool to study the fate of neuronal precursors, we developed a new approach by engineering transgenic mice carrying the tamoxifen-inducible CreERT2 recombinase gene, controlled by the DCX promoter. Our findings demonstrate that this innovative transgenic tool allows for the long-term analysis of newly generated neurons by means of time-resolved, permanent labeling. Furthermore, it establishes a framework for manipulating gene expression during a critical stage of neuronal maturation, allowing for the investigation of functional consequences.","In order to overcome the lack of appropriate methods for analyzing the fate of neuronal precursors, we developed a novel approach by creating transgenic mice with the tamoxifen-inducible CreERT2 recombinase gene under the control of the DCX promoter. Our study shows that this innovative genetic tool facilitates the time-resolved and permanent labeling of newly-formed neurons, allowing for their fate to be monitored over an extended period. Furthermore, it provides a platform for the induction and removal of gene expression during a critical phase of neuronal maturation to investigate the functional consequences of such changes."
"The entire CreERT2 cDNA sequence was extracted from the pCAG-CreERT2bpA-SS1 vector and subcloned into the phuDCX-3509-DsRed2 cassette that already contained the human DCX promoter region. The resulting vector, phuDCX-3509-CreERT2 (Additional File 1), was used for targeting. A 7.7-kb 3'UTR region of the DCX gene was amplified using specific primers, and the resulting product was cloned into the pCRII vector to obtain the pCRIITOPO-3'UTR plasmid. Next, a 7.7-kb Spe I-Not I fragment of pCRII-TOPO-3'UTR was inserted into the Spe I and Not I sites of the phuDCX-3509-CreERT2 cassette, resulting in the phuDCX-3509-CreERT2-3'UTR targeting plasmid.","To target the human DCX promoter region, the CreERT2 cDNA was subcloned into the pDCX-3509-DsRed2 cassette, a vector that already contained the promoter region. Subsequently, a 7.7-kb 3'UTR of the DCX gene was amplified by RT-PCR and cloned into the pCRII vector to obtain the pCRIITOPO-3'UTR plasmid. The 3'UTR fragment was then extracted from the pCRIITOPO-3'UTR plasmid and subcloned into the pDCX-3509-CreERT2 vector to generate the phuDCX-3509-CreERT2-3'UTR vector. This vector consisted of the human DCX promoter, followed by the CreERT2 cDNA and the 3'UTR.","To modify the human DCX promoter, the CreERT2 cDNA from the pCAG-CreERT2bpA-SS1 vector was introduced into the phuDCX-3509-DsRed2 cassette that harbored the promoter region. The resulting vector, phuDCX-3509-CreERT2 (Additional File 1), was then used for targeted genetic modifications. A 7.7-kb 3'UTR region of the DCX gene was obtained by RT-PCR and cloned into the pCRII vector to generate the pCRIITOPO-3'UTR plasmid. Subsequently, a 7.7-kb Spe I-Not I fragment of the pCRIITOPO-3'UTR plasmid was subcloned into the Spe I and Not I sites of the phuDCX-3509-CreERT2 cassette, resulting in the phuDCX-3509-CreERT2-3'UTR targeting plasmid. This plasmid contained the human DCX promoter region, followed by the CreERT2 cDNA and the 3'UTR sequence."
"The plasmid phuDCX-3509-CreERT2-3’-UTR underwent linearization via Sal I-Not I digestion before being microinjected into fertilized oocytes of FVB inbred mice. The genotypes of the offspring were determined through both PCR analysis and Southern Blot of their tail DNA. In order to identify Cre-positive mice, they were further analyzed using Southern Blot with a 1.27-kb Sal I-Hind III fragment of pCAG-CreERT2-bpA-SS1 vector as a probe. If there was a positive insertion, a 7424 bp fragment would be detectable following genomic DNA digestion with Kpn I, or alternatively two fragments would be detectable after digestion with EcoR V. All restriction enzymes utilized in this process were from Roche Applied Science.","By digesting the targeting plasmid phuDCX-3509-CreERT2-3’-UTR with Sal I-Not I and subsequently microinjecting the linearized DNA into the pronuclei of fertilized oocytes of FVB inbred mice, the genotypes of the offspring were determined by PCR analysis and Southern Blot of tail DNA. To identify Cre-positive mice, a probe was prepared from a 1.27-kb Sal I-Hind III fragment of pCAG-CreERT2-bpA-SS1 vector using random primer (GE Healthcare Kit; catalog No. RPN 1633). Southern Blot was then used to further analyze Cre-positive mice, with a positive insertion resulting in detection of either a 7424 bp fragment after genomic DNA digestion with Kpn I or two fragments after digestion with EcoR V, with the size of one fragment being 8415 bp and the other at least over 4103 bp. All of the restriction enzymes used in this process were from Roche Applied Science.","In order to target the plasmid phuDCX-3509-CreERT2-3’-UTR, it was subjected to Sal I-Not I digestion and then microinjected into the pronuclei of fertilized oocytes of FVB inbred mice. The genotypes of the offspring were determined using both PCR analysis and Southern Blot of their tail DNA. The Cre-positive mice were further analyzed with Southern Blotting by employing a probe prepared using random primer labelling from a 1.27-kb Sal I-Hind III fragment of pCAG-CreERT2-bpA-SS1 vector. In case of positive insertion, this probe would detect either a 7424 bp fragment after genomic DNA digestion with Kpn I or two fragments after digestion with EcoR V (the size of one fragment is 8415 bp and the other is over 4103 bp). All restriction enzymes used during this process were sourced from Roche Applied Science."
"The animal experiments that were conducted followed the guidelines of the Council of European Communities Directive of 24 November 1986 (86/609/EEC). To expand the DCXCreERT2 transgenic mouse line, the researchers backcrossed DCX-CreERT2 transgenic mice with wildtype C57Bl/6J mice. Furthermore, DCX-CreERT2 transgenic mice were crossbred with two reporter lines - CAG-CAT-EGFP mice [22] or ROSA26lacZ mice [23] - to obtain DCX-CreERT2: ROSA26lacZ or DCX-CreERT2:CAG-CAT-EGFP double transgenic mice. The expression of the relevant reporter gene was induced by recombination activity in these lines, and it was subsequently used for diverse analyses carried out afterward. The HelmholtzZentrum Munich Institutional Animal Care and Use Committee approved all animal experiments.","The animal experiments performed were compliant with the Council of European Communities Directive of 24 November 1986 (86/609/EEC) and were approved by the Animal Care and Use Committee of HelmholtzZentrum Munich. To broaden the DCXCreERT2 transgenic mouse line, DCX-CreERT2 transgenic mice were crossbred with wildtype C57Bl/6J mice. Additionally, DCX-CreERT2 transgenic mice were crossbred with two reporter lines, CAG-CAT-EGFP mice [22] or ROSA26lacZ mice [23], enabling the researchers to obtain DCX-CreERT2: ROSA26lacZ or DCX-CreERT2:CAG-CAT-EGFP double transgenic mice. The expression of the corresponding reporter gene was activated by recombination activity in these lines, and this was employed for the various analyses performed later.","All the animal experiments were carried out in accordance with the Council of European Communities Directive of 24 November 1986 (86/609/EEC) and received approval from the Institutional Animal Care and Use Committee of HelmholtzZentrum Munich. The DCXCreERT2 transgenic mouse line was expanded by breeding DCX-CreERT2 transgenic mice with wildtype C57Bl/6J mice. In addition, DCX-CreERT2 transgenic mice were mated with two reporter lines - CAG-CAT-EGFP mice [22] and ROSA26lacZ mice [23] - resulting in the production of DCX-CreERT2: ROSA26lacZ or DCX-CreERT2:CAG-CAT-EGFP double transgenic mice. The expression of the correspondent reporter gene was stimulated by recombination activity in these lines, and this was employed for the numerous analyses that were described afterward."
"The experimental procedure involved dissolving Tamoxifen in corn oil at a stock concentration of 10 mg/ml. Different doses of Tamoxifen were injected intraperitoneally into pregnant mice at various gestational stages to study gene expression in their embryos. The same protocol was used on pregnant mice of the 17.5 day gestational stage to observe the fate of targeted cells during adulthood. In order to test CreERT2 recombination activation in adult mouse brains, mice were injected with 200 μg Tamoxifen/g bodyweight. The expression patterns of CreERT2, reporter genes, and cell-type specific markers were studied in adult mouse brains through daily injections of 100 μg Tamoxifen/g bodyweight for 5 days, with mice analyzed after different periods following the last injection.","The stock concentration of Tamoxifen was 10 mg/ml, which was created by dissolving Tamoxifen in corn oil. To observe gene expression in embryos, different doses of Tamoxifen were injected intraperitoneally into pregnant mice at different gestational stages. The protocol was also used on pregnant mice of 17.5 day gestational stage to examine the destiny of targeted cells throughout adulthood. To activate CreERT2 recombination in adult brains, 200 μg Tamoxifen/g bodyweight was injected. The expression patterns of genes and markers in adult brains were studied through daily injections of 100 μg Tamoxifen/g bodyweight for 5 days, with mice analyzed after different periods following the last injection. Finally, mice were dissected after one day post- Tamoxifen injection to perform whole-mount X-Gal staining or immunostaining.","Tamoxifen was prepared by dissolving it in corn oil at 10 mg/ml concentration, which was then injected intraperitoneally into pregnant mice at varying gestational stages to analyze gene expression in embryos. The same protocol was applied in pregnant mice of 17.5-day gestational stage to track the future of targeted cells in adulthood. To activate CreERT2 recombination in adult mouse brains, mice were injected with 200 μg Tamoxifen/g bodyweight. To study the expression of CreERT2, reporter genes, and cell-type specific markers in the brains of mice, a daily injection of 100 μg Tamoxifen/g bodyweight was given consecutively for 5 days, resulting in the mice being analyzed after different post-injection periods. Finally, embryos were dissected one day after Tamoxifen injection for staining using whole-mount X-Gal or immunostaining techniques."
"The mice were subjected to an injection of BrdU (5-Bromo-2’deoxyuridine) in sterile PBS, pH7.4, one day prior to the perfusion procedure. The injection contained 200 μg/g bodyweight of BrdU, which was appropriately prepared using a supply from Sigma-Aldrich.",BrdU (5-Bromo-2’deoxyuridine) was injected into the mice 24 hours before the perfusion experiment. The dosage administered was 200 μg/g bodyweight and it was prepared in sterile PBS with a pH of 7.4. The BrdU was procured from Sigma-Aldrich and was prepared as per the instructions.,"In preparation for the perfusion procedure, the mice were given a dosage of 200 μg/g bodyweight injection of BrdU (5-Bromo-2’deoxyuridine) in sterile PBS with a pH of 7.4. The injection was administered 24 hours prior and the BrdU was obtained from Sigma-Aldrich, prepared according to the predetermined instructions."
"To perform whole-mount X-gal staining, the embryos were soaked in a PBS solution containing 4% paraformaldehyde (PFA), 10 mM MgCl2, and 5 mM EGTA for thirty minutes at room temperature (RT). The embryos were then rinsed in a sodium phosphate buffer (PB) that contained 0.01% sodium deoxycholate, 2 mM MgCl2, and 0.02% NP-40. After which, they were incubated with X-gal staining buffer that contained K3Fe(CN)6, K4Fe(CN)6, 0.02% NP-40, 0.01% sodium deoxycholate, 2 mM MgCl2, and 0.1% X-gal to visualize the activity of beta-galactosidase (b-gal). The stained embryos were then washed twice in PBS and post-fixed with 4% PFA in PBS, at 4°C overnight. For the X-gal staining of free-floating sections, the sections were post-fixed with 4% PFA in PBS, at room temperature for only one hour and then lightly counterstained with Eosin Y (0.1%).","The process of whole-mount X-gal staining involved immersing the embryos in a PBS solution that included 4% paraformaldehyde (PFA), 5 mM EGTA, and 10 mM MgCl2 for thirty minutes while at room temperature (RT). Afterward, they were rinsed in 0.1 M sodium phosphate buffer (PB), 2 mM MgCl2, 0.01% sodium deoxycholate, and 0.02% NP-40, and then incubated in X-gal staining buffer. This included K3Fe(CN)6, K4Fe(CN)6, 0.02% NP-40, 0.01% sodium deoxycholate, 2 mM MgCl2, and 0.1% X-gal, and was carried out in the dark and at 37°C for several hours to visualize the blue reaction product of beta-galactosidase (b-gal) activity. Following this, embryos went through two washes in PBS and were post-fixed in 4% PFA in PBS, overnight at 4°C. For X-gal staining of free-floating sections, the process was the same as before, except for post-fixing with 4% PFA in PBS, for only 1 hour while at RT, and then lightly counterstained with Eosin Y (0.1%).","In order to conduct whole-mount X-gal staining, the embryos were immersed in a PBS solution containing 4% paraformaldehyde (PFA), 5 mM EGTA, and 10 mM MgCl2 for 30 minutes while at room temperature (RT). Then, they were rinsed in 0.1 M sodium phosphate buffer (PB), 2 mM MgCl2, 0.01% sodium deoxycholate, and 0.02% NP-40 solution. The embryos were then incubated with a X-gal staining buffer that contained 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 0.02% NP-40, 0.01% sodium deoxycholate, 2 mM MgCl2, and 0.1% X-gal. The reaction product, visualizing beta-galactosidase (b-gal) activity was established after several hours of dark incubation at 37°C. Stained embryos were washed twice with PBS and were then embedded in a blocking buffer (2% skim milk in PBST) followed by overnight post-fixation with 4% PFA in PBS at 4°C. For X-gal staining of free-floating sections, the process was similar except that the sections were post-fixed with 4% PFA in phosphate-buffered saline (PBS) for only 1 hour at RT before undergoing Eosin Y (0.1%) counterstaining."
"The embryos were treated with 4% paraformaldehyde (PFA) immersed in 0.1 M phosphate buffer and left for 2-8 hours, to enable fixation. Afterward, the embryo was fixed in paraffin and subject to sagittal sectioning (8 μm) using a Microm HM 355 s Microtome (Leica). For the adult mouse brains, extraction followed transcardial perfusion with 4% PFA in 0.1 M phosphate buffer pH 7.5. To ensure further fixation, the brain was post-fixed for two hours in the same fixative before immersion in 20% sucrose at 4°C overnight. Subsequently, OCT compound was used for embedding, enabling the use of a Leica cryostat to make systematic samples of the entire brain through serial coronal or sagittal (40 μm) sections.","Embryos designated for immunohistology received treatment with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer and remained immersed for 2-8 hours to facilitate fixation. Next, the whole embryo was embedded in paraffin followed by sagittal sectioning (8 μm) using a Microm HM 355 s Microtome (Leica). In the case of adult mouse brains, they were taken out post transcardial perfusion using 4% PFA in 0.1 M phosphate buffer pH 7.5. The brains were later subjected to post-fixation for 2 hours using the same fixative, then submerged in 20% sucrose in a 4°C condition overnight which allowed for the utilization of the OCT compound to achieve proper embedding. Through systematic coronal or sagittal sectioning (40 μm) using a Leica cryostat, the entire brain was sampled.","In order to prepare embryos for immunohistology, they were immersed in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer with a pH of 7.5 for a duration of 2-8 hours. Once fixation was achieved, the whole embryo was embedded in paraffin and sectioned sagittally (8 μm) with the help of a Microm HM 355 s Microtome (Leica). For the adult mouse brains, they were removed post-perfusion that utilized 4% PFA in 0.1 M phosphate buffer pH 7.5. Post-fixation was then done for 2 hours in the same fixative after which the brains were placed in 20% sucrose at 4°C overnight for further preservation. To achieve proper embedding, the brains were placed in OCT compound before they were finally cut into serial coronal or sagittal sections (40 μm) using Leica cryostats. This systematic sampling of the entire brain was necessary for a comprehensive analysis of the brains."
"In order to perform immunofluorescence staining, free-floating sections were thoroughly rinsed with PBS and subsequently incubated in PBS++ solution (PB++ solution is made up of 5% fetal calf serum and 0.3% Triton X-100 in PBS) for one hour at room temperature to block nonspecific antibody binding. However, if BrdU detection was required, sections were treated with 2 N HCl at 37°C for 30 minutes and then neutralized with 0.1 M borate buffer for 10 minutes, followed by six washes in PBS before blocking. The sections were then incubated overnight at 4°C with primary antibody dilutions (as given in Table 1) in PBS++, followed by three quick washes in PBS. Next, secondary antibody conjugated with either cyanine 2 (cy2), cy3, or cy5 was added and incubated for two hours at room temperature in a 1:400 dilution in PBS++. After another three washes in PBS for 10 minutes each, the sections were treated with DAPI (SigmaAldrich, D9564) at a concentration of 5 mg/ml for 20 minutes, followed by another three 5-minute washes in PBS. Finally, the sections were mounted with Aqua poly/Mount (Polysciences, 18606) before being imaged.","To prepare the free-floating sections for immunofluorescence staining, they were first washed with PBS and then blocked with a solution of PBS++ (PBS++ comprises 5% fetal calf serum and 0.3% Triton X-100 in PBS) for one hour at room temperature. When staining was required using BrdU detection, the sections were pretreated with 2 N HCl for 30 minutes at 37°C, neutralized with 0.1 M borate buffer for 10 minutes, and then washed six times in PBS before being blocked with PBS++. Subsequently, the sections were incubated in a primary antibody solution diluted in PBS++ (see Table 1) for 24 hours at 4°C, followed by three washes of 10 minutes each in PBS. The sections were then incubated with a secondary antibody that had been conjugated with cyanine 2 (cy2), cy3 or cy5 for two hours at room temperature in PBS++ in a dilution of 1:400 (Jackson ImmunoResearch Lab). Following this, the sections were washed thrice in PBS for 10 minutes each and then treated with DAPI (SigmaAldrich, D9564) at a concentration of 5 mg/ml for 20 minutes, followed by another three 5-minute washes in PBS. Finally, the sections were mounted using Aqua poly/Mount (Polysciences, 18606) prior to imaging.","The free-floating sections were first washed with PBS and blocked with PBS++ (PBS++ is a mixture of 5% fetal calf serum, 0.3% Triton X-100 in PBS) for one hour at room temperature to prevent nonspecific antibody binding, for immunofluorescence staining. However, if BrdU detection was required, the sections were exposed to 2 N HCl for 30 minutes at 37°C followed by neutralization with 0.1 M borate buffer for 10 minutes and six washes in PBS prior to blocking with PBS++. The sections were then incubated for 24 hours at 4°C with primary antibody dilutions (as given in Table 1) using PBS++. After being briefly washed in PBS, they were then exposed to secondary antibody conjugated with cyanine 2 (cy2), cy3 or cy5, which was diluted in PBS++ in a ratio of 1:400 for two hours at room temperature (Jackson ImmunoResearch Lab). Subsequently, the sections were gently washed in PBS three times for 10 minutes each before being treated with DAPI (SigmaAldrich, D9564) at 5 mg/ml concentration for 20 minutes and a further wash in PBS thrice for 5 minutes each. Finally, the sections were mounted using Aqua poly/Mount (Polysciences, 18606) for imaging."
"To determine the frequency of recombination events, the number of positive cells in each region of interest was counted, with a minimum of 100 cells being counted for each animal and time point. The results were then presented as the mean ± standard deviation to provide a summary of the data.","In order to quantify the frequency of recombination events, the positive cells in the region of interest were counted, with a minimum of 100 cells being counted for each time point and animal. The results were plotted as the mean value with standard deviation error bars to provide a clear visual representation of the data.","The recombination events were quantified by counting a minimum of 100 positive cells in each region of interest for each time point and animal. To present data, the mean value was calculated and reported with the standard deviation as an estimate of the variability observed."
"The efficacy of a DCX genomic fragment spanning 3509-bp for driving the expression of reporter genes in immature neurons and neuronal precursors was previously documented (9,10). As a result, the CreERT2 encoding sequences were cloned downstream of this DCX regulatory region. Two male founders carrying the CreERT2 transgene were created through pronuclear injection. Both the founders transmitted the transgene to their offspring, and Southern blot analysis suggested that only one copy of the integrated transgene was present in the host genome (Additional file 1).","In previous research, it was demonstrated that a 3509-bp DCX genomic fragment effectively drove the expression of reporter genes in neuronal precursors and immature neurons both in vitro and in vivo (9,10). Consequently, the CreERT2 encoding sequences were cloned after this DCX regulatory fragment (Additional File 1). After pronuclear injection, two male founders carrying the CreERT2 transgene were identified. Both founders passed down the transgene to their offspring, and Southern blot analysis indicated that only one copy of the transgene was inserted into the host genome (Additional File 1).","Previous studies showed that a 3509-bp DCX genomic fragment could facilitate the expression of reporter genes in neuronal precursor cells and immature neurons both in vitro and in vivo (9,10). Based on this finding, the CreERT2 encoding sequences were introduced downstream of this DCX regulatory fragment (Additional file 1). Two male mice carrying the CreERT2 transgene were obtained after pronuclear injection. Both mice transmitted their transgene to the F1 generation, and Southern blot analysis indicated the integration of a single copy of the transgene into the host genome (Additional file 1)."
"The activity of Cre-recombinase was analyzed in the first-generation of two founder-derived lines, by mating them with mice carrying the Rosa26 lacZ reporter gene. The lacZ expression cassette was activated after recombination [23]. After two weeks of tamoxifen (TAM) or vehicle injection, 2-month-old DCX-CreERT2:Rosa26 lacZ mice were perfused and evaluated for b-gal activity. The expected TAM-induced b-gal expression was seen in both DCX-CreERT2 transgenic lines, in adult neurogenic regions including the SVZ and dentate gyrus (Additional file 1). Unexpectedly, no b-gal activity was detected following vehicle injections in the offspring derived from founder 2. On the other hand, mice from founder 1 showed numerous b-gal positive profiles after vehicle injection, indicating non-specific recombination events (data not shown). As a result, only the transgenic DCXCreERT2 founder 2 line was expanded and used for further experiments.","To assess Cre-recombinase activity, two founder-derived lines were mated with Rosa26 lacZ reporter mice which carry a lacZ expression cassette that becomes activated after recombination [23]. After a two-week injection of either tamoxifen (TAM) or vehicle, 2-month-old DCX-CreERT2:Rosa26 lacZ mice were perfused and analysed for the presence of b-gal activity. As anticipated, the expected TAM-induced b-gal expression was observed in both DCX-CreERT2 transgenic lines in the SVZ and dentate gyrus, as shown in Additional file 1. Surprisingly, the progeny derived from founder 2 showed no b-gal activity upon vehicle injection. In contrast, mice resulting from founder 1 had several b-gal positive profiles after vehicle injection, indicating that there were unspecific recombination events (data not shown). Consequently, only the DCXCreERT2 founder 2 line was used for downstream experiments.","The activity of Cre-recombinase was evaluated in the first-generation of two founder-derived lines by mating them with Rosa26 lacZ reporter mice that could activate a lacZ expression cassette after recombination [23]. Following either a tamoxifen or vehicle injection, 2-month-old DCX-CreERT2:Rosa26 lacZ mice were perfused and stained for b-gal activity. As predicted, the expected TAM-induced b-gal expression was detected in both DCX-CreERT2 transgenic lines in adult neurogenic regions such as the SVZ and dentate gyrus, as shown in Additional file 1. However, there was no b-gal activity seen in the progeny derived from founder 2 after vehicle injection. In contrast, mice that were offspring of founder 1 showed several b-gal positive profiles after vehicle injection, reflecting non-specific recombination events (data not shown). Therefore, only the DCXCreERT2 founder 2 line was expanded and used in the subsequent experiments."
"To investigate the coincidence between CreERT2 expression and endogenous DCX expression in the DCX-CreERT2 transgenic mice, we studied their respective expression patterns. On a cellular level, CreERT2 was observed in almost all DCX+ cells of the developing CNS (E15.5). Moreover, after the administration of TAM, CreERT2 was translocated to the nucleus one day later (Figure 1a). Also, in adult brains, CreERT2 expression was restricted to the nucleus of DCX+ cells strictly following TAM injection (Figure 1b). The prerequisite for CreERT2 activity was triggerred by TAM administration, allowing for nuclear localization.","In order to validate the coincidence of CreERT2 expression with that of endogenous DCX expression in DCX-CreERT2 transgenic mice, we analyzed their respective expression patterns. At the individual cell level, CreERT2 was identified in almost all DCX+ cells of the developing CNS (E15.5). Further to this, after TAM injection, CreERT2 was translocated to the nucleus one day later (Figure 1a). Similarly, in the adult brain, CreERT2 expression was confined to the nucleus of DCX+ cells specifically following TAM injection (Figure 1b). The activity of CreERT2 was only possible following nuclear localization which was triggered by TAM administration.","To confirm the alignment of CreERT2 expression and endogenous DCX expression in DCX-CreERT2 transgenic mice, we analyzed their corresponding expression patterns. At the cellular level, CreERT2 was detected in virtually all DCX+ cells during the development of CNS (E15.5). Also, one day after administering TAM, CreERT2 was translocated to the nucleus (Figure 1a). Similarly, in the adult brain, CreERT2 expression was strictly limited to the nucleus of DCX+ cells one day after TAM injection (Figure 1b). The prerequisite for CreERT2 activity was the induction of nuclear localization, which was triggered by TAM administration."
"In order to identify the time period in which the nucleus experiences the effect of CreERT2 after the TAM injection, experiments were conducted on DCX-CreERT2 adult mice. These mice were perfused after different time intervals post-injection, and the sub-cellular location of CreERT2 was analyzed. The nuclear location of CreERT2 had a significant decrease in comparison with the primary day after seven days following the TAM injection. Co-localization of CreERT2 expression with DCX was still observed during this time period, but the distribution returned to being mostly cytoplasmic (Figure 1c). In addition, two weeks following the TAM injection, CreERT2 was found to be only located in the cytoplasm (Figure 1d and 1e). Our discoveries indicate that nuclear localization of CreERT2 recedes right away after the last TAM administration, proposing that the activity of CreERT2 was short-lived and was nearly ceased after a week.","DCX-CreERT2 adult mice were utilized to evaluate the timeframe during which CreERT2 impacts the nucleus following TAM injection. Mice were perfused at various time intervals post-injection before analyzing the sub-cellular localization of CreERT2. Substantial decline in the nuclear localization of CreERT2 was observed seven days following TAM injection as compared to the first day. During this period, while CreERT2 expression was still co-localized with DCX, its distribution moved back to predominantly cytoplasmic (Figure 1c). Moreover, two weeks following TAM injection, CreERT2 was exclusively located in the cytoplasm (Figure 1d and 1e). These findings suggest that nuclear localization of CreERT2 rapidly declines after the final TAM administration and thus, indicating that CreERT2 activity is temporary and nearly stopped after 7 days.","To evaluate the time frame during which the CreERT2 impacts the nucleus in DCX-CreERT2 adult mice following the TAM injection, mice were perfused at different time points post-injection before analyzing the sub-cellular localization of CreERT2. Comparing it to the earlier days, a significant decrease was noted in the nuclear localization of CreERT2 seven days after the TAM injection. During this phase, CreERT2 still co-localized with DCX, but its distribution predominantly moved to cytoplasmic (Figure 1c). Furthermore, after two weeks of the TAM injection, CreERT2 was exclusively localized in the cytoplasm (Figure 1d and 1e). These findings indicate that the nuclear localization of CreERT2 swiftly declines following the last TAM administration, suggesting that the activity of CreERT2 is short-lived and almost completely ceases after 7 days."
"After verifying the correct co-localization of CreERT2 and DCX+ cells, we proceeded to investigate the specificity and efficacy of recombination. For this purpose, we crossbred DCX-CreERT2 mice with Rosa26 lacZ or CAG-CATEGFP reporter mice, which allowed us to track the activation of the relevant reporter gene expression following successful excision of the loxP-flanked cassette. By analyzing the expression of reporter genes at different time intervals post-recombination, we can trace the fate of DCX-expressing cells.","With the confirmation of appropriate co-localization between CreERT2 and DCX+ cells, we proceeded to evaluate the specificity and accuracy of recombination activity. To achieve this, we crossbred DCX-CreERT2 mice with Rosa26 lacZ or CAG-CATEGFP reporter mice, enabling us to monitor the activation of the reporter gene expression upon successful excision of the loxP-flanked cassette. By examining the reporter gene expression at various time points after recombination, we can track the fate of DCX-expressing cells.","Our initial step was to validate the appropriate co-localization between CreERT2 and DCX+ cells, after which we proceeded to examine the specificity and effectiveness of recombination. For this purpose, we crossed DCX-CreERT2 mice with Rosa26 lacZ or CAG-CATEGFP reporter mice to track the activation of the relevant reporter gene expression after a successful excision of the loxP-flanked cassette. We analyzed the expression of reporter genes at different time intervals post-recombination, allowing us to monitor the fate of DCX-expressing cells."
"The examination of CreERT2 activity was conducted in embryonic stages to determine its effect. After the injection of TAM on E14.5, the distribution of b-gal expression was noted to be limited to the development of CNS and DRGs, which corresponded to the natural pattern of endogenous DCX expression at that stage. Administering a single TAM-injection led to the expression of EGFP reporter in various regions of the brain parenchyma after activating CreERT2 on E17.5. EGFP+ cells were present in several regions of the brain parenchyma such as granular cell layer of dentate gyrus, striatum, cortex, thalamus, and Ammon's horn (CA1), which followed the DCX expression pattern at E17.5.","To determine the efficacy of CreERT2 activity at the embryonic stage, a single dose of TAM was injected on E14.5, and the distribution of b-gal expression was studied as revealed by X-gal staining. The results showed that expression was only confined to the developing CNS and dorsal root ganglia (DRGs), following the same pattern of endogenous DCX at E14.5. CreERT2 activation on E17.5 by administering a single TAM-injection displayed an extensive distribution of EGFP reporter expression in the adult brain, covering most regions of the brain parenchyma, including the granular cell layer of dentate gyrus, striatum, cortex, thalamus, and Ammon's horn (CA1). These findings were consistent with the DCX expression pattern at E17.5.","The study aimed to evaluate the effects of CreERT2 activity during embryonic stages. X-gal staining was performed to reveal b-gal expression 24 hours after administering a single TAM injection on E14.5. Results depicted that b-gal expression was restricted to develop the CNS and DRGs, which was similar to the pattern of endogenous DCX expression. Further, a single TAM injection was administered on E17.5 to activate CreERT2, enabling EGFP reporter expression all over the brain parenchyma in the adult brain. The expression patterns were detected in several regions such as the granular cell layer of dentate gyrus, cortex, thalamus, striatum, and Ammon's horn (CA1) corresponding to the DCX expression pattern at E17.5."
"It is worth noting that almost all the cells that expressed EGFP showed the presence of NeuN which suggests that they had differentiated into neurons that are no longer in their early stages (Figure 2d to 2g). Interestingly, EGFP expression was not detected in DCX-positive cells located in the SVZ (Figure 2f and 2g), the RMS (data not shown) or the subgranular zone (SGZ) of the dentate gyrus (Figure 2d and 2e). A small number of EGFP+ cells were found in or in close proximity to the ependymal layer of the lateral ventricles (Figure 2f, indicated by arrows). These EGFP+ cells, however, did not display NeuN or DCX, and thus their identity still remains to be investigated.","It is notable that nearly all EGFP-expressing cells also expressed NeuN, indicating that they had become mature neurons (Figure 2d to 2g). Interestingly, we did not find EGFP expression in DCX-positive cells in the SVZ (Figure 2f and 2g), the RMS (data not shown), or the SGZ of the dentate gyrus (Figure 2d and 2e). There were, however, a few EGFP+ cells present either within, or in close association with, the ependymal layer of the lateral ventricles (Figure 2f, arrows). These cells, however, did not co-express NeuN or DCX and their exact nature is yet to be determined.","Almost all the EGFP+ cells were seen to express NeuN indicating that they had successfully undergone differentiation into mature neurons (Figure 2d to 2g). Meanwhile, we did not observe any EGFP expression in DCX-positive cells of the SVZ (Figure 2f and 2g), RMS (data not shown), or SGZ of the dentate gyrus (Figure 2d and 2e). In the ependymal layer of the lateral ventricles, a few EGFP+ cells were present (Figure 2f, indicated by arrows), but these cells neither co-expressed NeuN nor DCX, the specific role of these cells is currently unknown."
"To explore the extent of neuron production in the adult central nervous system, a group of adult mice were subjected to TAM injections for five consecutive days. After four weeks following the last injection, the mice were analyzed and it was observed that EGFP+ cells generated from the SVZ moved towards the OB and were located mainly in the GrO layer of the OB, with a lesser presence in the pGl layer. These cells in the OB were found to express NeuN, indicating maturation while the expression of DCX was not detected. The limited number of EGFP+ cells expressing DCX were sporadically found in the rostral RMS, and EGFP+ cells were scarcely present in the SVZ. Furthermore, the EGFP+ cells in the dentate gyrus also expressed NeuN, and no detection of DCX expression was observed. (Figure 2h–k).","A study investigating the generation of neurons in the adult central nervous system administered TAM injections to a group of adult mice over a period of five consecutive days. After four weeks post-injection, the mice were analyzed, and it was observed that the EGFP+ cells generated from the SVZ made their way toward the OB and were predominantly distributed in the GrO layer, with a smaller amount being found in the pGl layer. The cells that had arrived at the OB expressed the mature neuronal marker NeuN, while DCX expression was absent. In contrast, only a handful of scattered EGFP+ cells that still expressed DCX were present in the rostral RMS, and EGFP+ cells were barely detectable in the SVZ. Moreover, the EGFP+ cells in the dentate gyrus expressed NeuN and did not express DCX. (Figure 2h–k).","To assess the production of new neurons in the central nervous system of adult mice, a study used TAM injections over five consecutive days. After a four-week period since the last injection, the mice were observed and it was seen that EGFP+ cells produced from the SVZ had reached the OB, mainly situated in the GrO layer while the pGl layer had fewer of these cells. The cells in the OB expressed the mature neuronal marker NeuN, whilst DCX expression was absent. Only a handful of EGFP+ cells expressing DCX were present in the rostral RMS and EGFP+ cells were scarcely noticeable in the SVZ. Similarly, the EGFP+ cells in the dentate gyrus expressed NeuN but not DCX. (Figure 2h–k)."
"The assessment of the recombination event in DCX-expressing cells in the adult SVZ and SGZ involved evaluating the efficiency and specificity. Measuring the percentage of EGFP-expressing DCX+ cells quantified efficiency while the proportion of DCX-expressing EGFP+ cells determined the specificity. To enhance EGFP signals amplification using an anti-EGFP antibody was necessary, due to their low levels of accumulation. The results showed that approximately 94% of DCX+ cells expressed EGFP in the SVZ two days after the last TAM injection. In the SGZ, EGFP was detected in approximately 77% of DCX-expressing cells. In the SVZ, approximately 96% of EGFP+ cells and 90% of EGFP+ cells in the SGZ co-expressed DCX, indicating high efficiency and specificity of CreERT2 activity.","The efficiency and specificity of the recombination event were evaluated in DCX-expressing cells in the adult SVZ and SGZ. The efficiency was calculated by measuring the percentage of DCX+ cells that expressed EGFP while the specificity was calculated by measuring the percentage of EGFP+ cells that expressed DCX. As EGFP accumulation levels were initially low, an anti-EGFP antibody was used to amplify signals in all subsequent experiments. The results showed that around 94% of DCX+ cells expressed EGFP in the SVZ two days after the last TAM injection, while in the SGZ, approximately 77% of DCX-expressing cells expressed EGFP. Furthermore, almost 96% of EGFP+ cells in the SVZ and about 90% of EGFP+ cells in the SGZ were co-expressing DCX, indicating a highly efficient and specific CreERT2 activity.","To evaluate the efficiency and specificity of the recombination event, DCX-expressing cells were analyzed in the adult SVZ and SGZ. The proportion of DCX+ cells expressing EGFP determined the efficiency while the proportion of EGFP+ cells expressing DCX determined the specificity. Low levels of EGFP within cells were observed in the initial time point, leading to the amplification of the EGFP signals using anti-EGFP antibodies in subsequent experiments. The findings indicated that roughly 94% of DCX+ cells in the SVZ expressed EGFP two days after the last TAM injection, while in the SGZ about 77% of DCX-expressing cells co-expressed EGFP. Additionally, nearly 96% of EGFP+ cells in SVZ and about 90% in SGZ co-expressed DCX, reflecting the high efficiency and specificity of CreERT2 activity."
"To examine the kinetics of DCX+ cells' emigration from their original site to their target structures, EGFP-expressing cells were analyzed at different time points after recombination. The researchers sacrificed adult mice on days eight, twelve or twenty-five after their last TAM injection (D8, D12, and D25, respectively), to evaluate the co-localization of EGFP expression with DCX and NeuN within the SVZ-RMS-OB axis and in the dentate gyrus at these specific intervals.","The researchers aimed to understand how DCX+ cells migrate from their original site to target structures, so they investigated the distribution of EGFP-expressing cells at different time points after recombination. The experiments involved sacrificing adult mice eight, seventeen, or thirty-two days after the last TAM injection (D8, D17, and D32, accordingly). The co-localization of EGFP expression with DCX and NeuN was analyzed within the SVZ-RMS-OB axis and dentate gyrus at these specific intervals to identify any changes in the distribution of DCX+ cells.","To determine the kinetics of DCX+ cells' migration from their place of origin to their target structures, the distribution of EGFP-expressing cells following recombination was evaluated over different time intervals. The researchers sacrificed adult mice on days eight, sixteen, or thirty-four after the last TAM administration (D8, D16, and D34, correspondingly). Within the SVZ-RMS-OB axis and dentate gyrus, the co-localization of EGFP expression with DCX and NeuN was analyzed to determine changes in the distribution of DCX+ cells at these specific time points."
"The expression of EGFP was initially high within DCX+ cells 48 hours after TAM injection, but it gradually decreased over time, reaching 25% of all DCX+ cells by day 15. Simultaneously, there was a decrease in the frequency of co-localization in the SVZ, falling from 26.7% at day 8 to 12.5% at day 15. By day 29, only occasional EGFP+ cells that expressed DCX were present within the SVZ, with no co-localization being found in the SGZ at this point. These findings suggest that most of the EGFP-labeled neurons migrated away from the SVZ within the first 15 days of the experiment, as illustrated in Figure 3.","Following TAM injection, EGFP-expression within DCX+ cells was high at day 2 but decreased gradually to 25% by day 15 in the SGZ. Co-localization in the SVZ also declined from 26.7% at day 8 to 12.5% by day 15. By day 29, there were only few EGFP+ cells, which expressed DCX, remaining within the SVZ and no co-localization was found in the SGZ. These results illustrate that the majority of EGFP-labeled neurons departed from the SVZ within the first 15 days, as seen in Figure 3.","The percentage of EGFP-expressing DCX+ cells was originally high two days after the last TAM injection, but decreased gradually to approximately 25% of all DCX+ cells by day 15 in the SGZ. In addition, the frequency of co-localization in the SVZ also declined from 26.7% at day 8 to 12.5% at day 15. At day 29, only rare EGFP+ cells expressing DCX were found within the SVZ, and no co-localization was detected in the SGZ. These observations support the notion that the primary emigration wave of EGFP-labeled neurons occurred within the first 15 days of the experiment, as depicted in Figure 3."
"The study discovered that during the migration of EGFP+ cells from D2 to D15 along the RMS, these cells maintained an immature neuronal morphology, and only sporadic co-localization with NeuN was observed (illustrated in Figure 4). In the following four weeks, as the cells approached the GrO or the pGl of the olfactory bulb, the expression of NeuN in EGFP+ cells was generally induced (as observed in Figure 2h and 2i, Figure 4 a, e and 4i). Interestingly, DCX expression in EGFP+ cells was significantly weaker in the GrO, unlike the cytoplasm of EGFP+ cells at the RMS's anterior end, where DCX was highly expressed (as denoted by the arrow in Figure 2i), suggesting that the DCX expression regulation in cells migrating towards the olfactory bulb highly depends on their location. Similarly, in the dentate gyrus, EGFP-expressing cells gradually integrated into the inner granular layer with time, eventually inducing the expression of NeuN. By the last TAM administration, more than 80% of EGFP+ cells in the dentate gyrus (as depicted in Figure 4m) and almost all EGFP+ cells in the olfactory bulb expressed the mature neuronal marker NeuN, confirming their neurogenic capacity.","The migration of EGFP+ cells along the RMS from D2 to D15 was characterized by the maintenance of an immature neuronal morphology, and only occasional co-localization with NeuN was observed (as depicted in Figure 4). However, as the cells approached the GrO or the pGl of the olfactory bulb in the following four weeks, the expression of NeuN in EGFP+ cells was broadly induced (as demonstrated in Figure 2h and 2i, Figure 4 a, e and 4i). Additionally, the DCX expression in EGFP+ cells was noticeably weaker in the GrO than in the cytoplasm of EGFP+ cells located at the RMS's front end, where it was still highly expressed (as highlighted by the arrow in Figure 2i), indicating that the expression of DCX varies regionally during the migration of cells to the olfactory bulb. Likewise, EGFP-expressing cells in the dentate gyrus gradually integrated into the inner granular layer over time and induced the expression of NeuN. The quantitative analysis showed that over 80% of EGFP+ cells in the dentate gyrus (Figure 4m) and almost all EGFP+ cells in the olfactory bulb expressed the mature neuronal marker NeuN by 15 days after the last TAM administration, indicating that these cells have the potential for neurogenesis.","The study showed that EGFP+ cells migrating along the RMS from D2 to D15 retained an immature neuronal morphology, with only a few instances of co-localization with NeuN observed (as presented in Figure 4). However, as the cells arrived at GrO or pGl of the olfactory bulb over the next four weeks, the expression of NeuN in EGFP+ cells was broadly triggered (as displayed in Figure 2h and 2i, Figure 4 a, e and 4i). Interestingly, DCX expression in EGFP+ cells was weak in the GrO, while it remained strong in the cytoplasm of EGFP+ cells located at the front of the RMS (as indicated by the arrow in Figure 2i), suggesting that the regulation of DCX expression in cells migrating towards the olfactory bulb is region-specific. Similarly, in the dentate gyrus, EGFP-expressing cells gradually integrated into the inner granular layer and induced the expression of NeuN over time. More than 80% of EGFP+ cells in the dentate gyrus (as revealed in Figure 4m) and nearly all EGFP+ cells detected in the olfactory bulb (data not reported) expressed the mature neuronal marker NeuN by 15 days after the last TAM administration, signifying the neurogenic potential of these cells."
"In order to gain a more comprehensive understanding of the neuronal phenotypes of EGFP-labeled neurons, an immunohistological study was conducted at D29 to investigate the presence of neurotransmitter-specific markers and calcium-binding proteins (Figure 5). Results were in accordance with previous research [25,26], identifying GAD65 expression, a marker commonly found in GABAergic neurons, in EGFP-expressing cells located in the OB. Furthermore, a certain subset of periglomerular EGFP+ cells were shown to co-express TH, which is a marker that is unique to dopaminergic neurons (Figure 5).","The neuronal phenotypes of EGFP-labeled neurons were explored by immunohistology at D29 to further characterize them according to the presence of neurotransmitter-specific markers and calcium-binding proteins (Figure 5). The results affirmed previous evidence [25,26] that GAD65 expression, which is commonly found in GABAergic neurons, could be detected in EGFP-expressing cells located in the OB. Another subset of periglomerular EGFP+ cells demonstrated co-expression of TH, a marker unique to dopaminergic neurons (Figure 5).","Immunohistological assessment at D29 was performed to investigate the presence of neurotransmitter-specific markers and calcium-binding proteins and to further characterize the neuronal phenotypes of EGFP-labeled neurons (Figure 5). EGFP-expressing cells located in the OB showed expression of GAD65, which is a marker typically found in GABAergic neurons, in accordance with previous studies [25,26]. In addition, a distinct subset of periglomerular EGFP+ cells exhibited co-expression of TH, a marker specific to dopaminergic neurons (Figure 5)."
"The researchers were able to detect VGLUT2 in the granular layer of the dentate gyrus and its surrounding EGFP+ cells at D29, indicating the reception of glutamatergic inputs by EGFP-expressing cells (Figure 5). Furthermore, the study explored the expression of calcium-binding proteins such as calbindin-D28K, calretinin and parvalbumin in EGFP-labeled granule neurons at this point in time. Interestingly, while most EGFP+ cells of the dentate gyrus showed the expression of calbindin-D28K (which is indicative of mature granule neurons), EGFP+ cells displayed no or weak calretinin expression and no parvalbumin expression. Nonetheless, the researchers found cells with high levels of parvalbumin or calretinin, with the latter seen in newly generated granule cells in the vicinity (as demonstrated by the arrow in Figure 5e).","The granular layer of the dentate gyrus showed VGLUT2 detection in this study, reflecting the reception of glutamatergic inputs by EGFP-expressing cells at D29 (Figure 5). The researchers went further to examine the expression of the calcium-binding proteins calbindin-D28K, calretinin and parvalbumin in the EGFP-labeled granule neurons at this stage. It was observed that calbindin-D28K was expressed in most EGFP+ cells of the dentate gyrus, implying the existence of mature granule neurons. Conversely, no parvalbumin or only weak calretinin expression was observed in EGFP+ cells at this time point. Interestingly, cells with high levels of parvalbumin or calretinin were present in the vicinity, with calretinin specifically found in newly generated granule cells as demonstrated by the arrow in Figure 5e.","At D29, EGFP-expressing cells in the granular layer of the dentate gyrus received glutamatergic inputs, as detected by the presence of VGLUT2 (Figure 5). Additionally, the researchers looked for the expression of calcium-binding proteins including calbindin-D28K, calretinin, and parvalbumin in EGFP-labeled granule neurons at this point. A majority of the EGFP+ cells in the dentate gyrus expressed calbindin-D28K, indicating mature granule neurons. However, no parvalbumin and weak to no calretinin expression was observed in EGFP+ cells at this time. In contrast, cells expressing high levels of parvalbumin or calretinin, mainly newly generated granule cells, were present in close proximity, with newly generated granule cells expressing higher levels of calretinin (as indicated by the arrow in Figure 5e)."
"DCX expression happens in a heterogeneous population of young neurons and neuronal precursors with varying maturation stages and proliferation statuses. Researchers utilized BrdU to label proliferative cells at various time points after recombination. At the earliest time point, D2, about 51.1% of EGFP+ cells in the SVZ but only 7.7% of EGFP+ cells in the SGZ incorporated BrdU, which indicates that some cells had a high rate of proliferation. The larger proportion of mitotically active cells in the SVZ could possibly be explained by the migration of newly created post-mitotic neurons out of the SVZ towards the OB, leaving the most premature cells in place. Additionally, little to no BrdU incorporation occurred in EGFP+ cells in SGZ at D15, revealing the limited time frame of DCX+ cells' proliferative ability. However, a few BrdU+/EGFP+ co-labeling cells were discovered in RMS at D15, indicating that some EGFP+ cells in SVZ/RMS/OB axis could keep their proliferative capacity.","The expression of DCX occurs in a diverse population of neuronal precursors and young neurons that are at different stages of maturation and have varying proliferation statuses. Researchers administered BrdU to label proliferative cells during different time points after recombination. At D2, the earliest time point studied, 51.1% of EGFP+ cells in the SVZ and 7.7% of EGFP+ cells in the SGZ incorporated BrdU, suggesting that some cells were still in the process of proliferation. The higher number of actively dividing cells in the SVZ may be the result of the migration of post-mitotic young neurons out of the SVZ towards the OB, leaving the immature cells behind. No further BrdU incorporation in EGFP+ cells was detected in SGZ at D15, indicating the limited proliferative capacity of DCX+ cells. Contrarily, a few BrdU+/EGFP+ co-labeling cells were noticed in RMS but not in SGZ at D15, providing evidence that some EGFP+ cells in SVZ/RMS/OB axis could maintain their proliferative capacity.","DCX expression takes place in young neurons and neuronal precursors that possess variable stages of maturation and proliferation capacity. To label proliferative cells, scientists used BrdU at different time points after recombination. At the earliest investigated time point (D2), 51.1% of EGFP+ cells in the SVZ and only 7.7% of EGFP+ cells in the SGZ incorporated BrdU, suggesting that some cells were undergoing proliferation. The higher proportion of actively dividing cells in the SVZ could result from post-mitotic young neurons exiting the SVZ and leaving immature cells behind. No more BrdU incorporation was observed in EGFP+ cells in SGZ at D15, indicating the temporal limitation of DCX+ cells' proliferative capacity. However, a few BrdU+/EGFP+ co-labeling cells were detected in RMS, indicating that some EGFP+ cells in SVZ/RMS/OB axis could maintain their proliferative ability until at least D15."
"Adult DCXCreERT2:CAG-CAT-EGFP mice were administered TAM and EGFP+ cells were observed outside of the neurogenic regions. Previous studies have also reported the presence of DCX-expressing cells scattered throughout the cerebral cortex of adult mice, cats, and primates. To confirm the co-expression of DCX and EGFP in cells located outside of the neurogenic regions, the entire adult brain was analyzed for DCX expression using immunohistochemistry in relation to the activation of EGFP expression.","The application of TAM to adult DCXCreERT2:CAG-CAT-EGFP mice resulted in the detection of EGFP+ cells outside of the described neurogenic regions. This finding aligns with earlier reports of scattered DCX-expressing cells in the cerebral cortex of adult rodents, cats, and primates. To confirm that DCX expression correlated with EGFP expression in cells found outside of the neurogenic regions, the expression pattern of DCX throughout the entire adult brain was analyzed using immunohistochemistry.","Administering TAM to adult DCXCreERT2:CAG-CAT-EGFP mice led to the detection of EGFP+ cells outside of the neurogenic regions. This observation is consistent with earlier findings of scattered DCX-expressing cells in the cerebral cortex of adult rodents, cats, and primates. To verify that DCX expression corresponded to EGFP expression in cells located outside of the neurogenic regions, the DCX expression pattern was examined using immunohistochemistry throughout the entire adult brain in relation to EGFP expression activation."
"Within the cerebral cortex, scattered cells were found to exhibit DCX expression at low to moderate levels (as depicted in Figure 7). The corpus callosum, 3rd ventricle, hypothalamus, and molecular cell and granular cell layers of the cerebellum also showed signs of weak DCX expression, which was not illustrated in the data. Following the administration of TAM, EGFP+ cells appeared in these same regions after four weeks (as shown in Figure 7), but the expression levels were significantly greater than those of endogenous DCX. This is due to the fact that upon recombination, a potent promoter control was employed for the reporter gene. It is crucial to note that non-proliferative EGFP+ cells were observed outside of the neurogenic regions, as there was no BrdU incorporation. The true nature and future of these immature neurons is yet to be unearthed.","DCX expression was found in cells dispersed throughout the cerebral cortex with low to moderate levels (see Figure 7). In addition, weak DCX expression was evident in certain regions such as corpus callosum, around the 3rd ventricle, hypothalamus and cerebellar molecular cell layer (MCL) and granular cell layer (GCL), although this data was not displayed. After four weeks of TAM injection, EGFP+ cells were observed in these regions (as seen in Figure 7); however, the reporter expression levels were much higher than the levels of endogenous DCX expression since the reporter gene was regulated with a strong promoter upon recombination. It is important to note that EGFP+ cells located outside of the neurogenic regions did not exhibit proliferation and there was no indication of BrdU labeling. Therefore, more research is necessary to determine the fate and nature of these immature neurons.","Throughout the cerebral cortex, cells with low to moderate levels of DCX expression were found to be dispersed (Figure 7). In addition, weak DCX expression was also evident in some regions including the corpus callosum, around the 3rd ventricle, hypothalamus, and the cerebellar molecular and granular cell layers (MCL and GCL); however, this data wasn't depicted. Following TAM injection, EGFP+ cells appeared in these regions after four weeks (Figure 7), but the reporter expression levels were notably higher than the endogenous DCX levels since the expression of the reporter gene was under the influence of a strong promoter. It's noteworthy that non-proliferative EGFP+ cells were spotted outside of the neurogenic regions as there was no BrdU incorporation. Therefore, further investigation is necessary to comprehend the true identity and destiny of these immature neurons."
"The present study demonstrates the successful targeting of CreERT2-mediated recombination in DCX-expressing cells using a DCX promoter-driven system in vivo. The construction further incorporates the 3’UTR region of the DCX mRNA which is known to contain post-transcriptional regulation elements of gene expression. While this aspect did not produce significant differences in CreERT2 expression pattern in our experiments when compared to previous lines lacking the DCX 3’UTR sequences, the presence of these regions could potentially contribute to a more precise CreERT2 expression within the DCX-expressing cell population. Further studies are needed to explore this possibility.","The aim of the study was to investigate the efficacy of CreERT2-mediated recombination in vivo targeting DCX-expressing cells using a DCX promoter-driven approach. The DCX promoter-driven CreERT2 construct used in this study was designed to include the 3’UTR region of the DCX mRNA which contains post-transcriptional regulation elements of gene expression. While no significant differences in CreERT2 expression pattern were observed between the construct used in this study and previous lines that lacked the DCX 3’UTR sequences, the potential for more accurate CreERT2 expression within the DCX-expressing cell population cannot be ruled out. Further studies are recommended to gain a better understanding of the function of DCX 3’UTR in this context.","This study aimed to explore the potential of CreERT2-mediated recombination in targeting DCX-expressing cells in vivo using a DCX promoter-driven approach. The construct utilized in this study included the 3’UTR region of the DCX mRNA, which is known to house post-transcriptional regulation elements of gene expression. While there were no overt differences in CreERT2 expression pattern compared to previous lines lacking the DCX 3’UTR sequences, it is possible that the inclusion of this region contributes to a more accurate CreERT2 expression within the DCX-expressing cell population. Additional investigations are required to fully understand the implications of the DCX 3’UTR in this context."
"Upon receiving a dose of TAM, the CreERT2 protein relocated to the nucleus of DCX-expressing cells where it facilitated recombination. This resulted in swift activation of reporter expression with visible b-gal or EGFP in both embryonic and adult CNS just a day after the injection was administered (as seen in Figure 2). After subjecting the cells to five consecutive doses of TAM, 94% of DCX+ cells in SVZ and 77% in the dentate gyrus showed EGFP expression, demonstrating the high level of efficiency of recombination in our experimental setup. Further analysis showed that 96% of EGFP+ cells in SVZ and 90% of them in SGZ also co-expressed DCX, confirming the specificity of the recombination process (as seen in Figure 3). The study concluded that cells with EGFP expression had a strictly neuronal fate, although a small fraction of the cells did not express DCX, perhaps due to the down-regulation of DCX expression throughout the period of five days of TAM injection.","After administering TAM, the CreERT2 protein made its way to the nucleus of cells with DCX expression, allowing recombination to occur. This resulted in a rapid activation of reporter expression, with both b-gal and EGFP visible in the embryonic and adult CNS just a day after injection (as illustrated in Figure 2). With five consecutive doses of TAM, the expression of EGFP in DCX+ cells was evident in 94% of cells in SVZ and 77% in dentate gyrus, indicating a high efficiency of the recombination process in our experimental set up. Further analysis revealed that 96% of EGFP+ cells in SVZ and 90% of them in SGZ also co-expressed DCX, providing evidence for the specificity of the recombination process (see Figure 3). As only neurons displayed EGFP expression in the study, a small percentage of EGFP+ cells lacking DCX expression were observed, likely indicating the maturation-associated downregulation of DCX expression over the 5-day TAM injection period.","Upon the administration of TAM, the CreERT2 protein translocated into the nuclear region of DCX-expressing cells, facilitating recombination. The result was a swift activation of reporter expression, with observable b-gal or EGFP in the embryonic and adult CNS a day after the injection (as shown in Figure 2). Following five daily doses of TAM, an EGFP expression rate of 94% for DCX+ cells in SVZ and 77% in the dentate gyrus demonstrated the high efficiency of our experimental paradigm. As seen in Figure 3, 96% of EGFP+ cells in SVZ and 90% of them in SGZ exhibited co-expression with DCX, providing evidence of the specificity of the recombination process. Finally, as the absence of DCX expression in a subset of the EGFP+ cells was observed, the study concluded that this might have been a result of the maturation-associated downregulation of DCX expression during the five days of TAM injection."
"Following recombination, the CreERT2 nuclear translocation was temporary, but it led to the permanent induction of reporter expression, and this allows for the long-term analysis of cell types that emerge from DCX+ cells. A month after the DCX-CreERT2 recombination, the majority of the EGFP+ cells in the neurogenic target regions expressed NeuN, a marker of mature neurons. While a few EGFP+ cells along the neuroblasts' migratory path or outside the neurogenic regions expressed low levels of DCX. Notably, a month after the last TAM injection, no co-localization between the EGFP signal and astrocyte, oligodendrocyte, or microglia markers were observed (data not shown), confirming that DCX-expressing cells under physiological conditions turn into neurons. In contrast, the utilization of the nestin promoter to mediate the expression of the CreERT caused labeling of the neural stem cell population, which continuously generated new neurons and glia [17].","The CreERT2 nuclear translocation was temporary after recombination. However, reporter expression was induced permanently, and this subsequently allowed for the long-term analysis of cell types emerging from DCX+ cells. One month following recombination in the DCX-CreERT2, the majority of the EGFP+ cells in the neurogenic target regions expressed the mature neuron marker NeuN. While a few EGFP+ cells along the migratory route of the neuroblasts or localized outside the neurogenic regions expressed DCX at low levels. No co-localization between GFAP, CNPase, or Iba I markers and the EGFP signal was observed one month after the last TAM injection (data not shown). This signifies that DCX-expressing cells are predisposed to become neurons in normal physiological conditions. In contrast, the utilization of the nestin promoter to regulate the expression of CreERT led to the labeling of the neural stem cell population, generating a consistent flow of fresh neurons and glia [17].","Recombination led to a transient CreERT2 nuclear translocation. However, after recombination, reporter expression was permanently induced, which enabled long-term analysis of cell types arising from DCX+ cells. A month after recombination in the DCX-CreERT2, NeuN, a mature neuron marker, was expressed by the vast majority of EGFP+ cells in neurogenic regions. Along the neuroblasts' migratory path or in non-neurogenic regions, some EGFP+ cells expressed low levels of DCX. One month after the last TAM injection, no co-localization between the EGFP signal and GFAP, CNPase, or Iba I markers was detected (data not shown), indicating that DCX expression triggers the development of neurons in physiological conditions. Unlike the nestin promoter-driven CreERT, which labeled the neural stem cell population and generated a constant influx of new neurons and glia [17]."
"Calcium-binding proteins, such as Calbindin-D28K, calretinin, and parvalbumin, can be used to differentiate different types of neurons. Calbindin-D28K is a marker for granule cells, while calretinin is only expressed in postmitotic newly generated neurons. Our observations of EGFP+ granular cells in the dentate gyrus showed that most of them were expressing Calbindin-D28K, with only a small percentage expressing calretinin. None of the cells analyzed expressed parvalbumin, which suggests that this particular GABAergic subpopulation is not constantly replenished by the addition of new neurons in the adult dentate gyrus. More research is necessary to understand fully the mechanisms behind this phenomenon.","The superfamily of low molecular weight calcium-binding proteins, including Calbindin-D28K, calretinin, and parvalbumin, are characteristic of specific subpopulations of neurons. Mature granule cells are identified by the expression of Calbindin-D28K, while calretinin is transiently expressed in newly generated neurons. Our analysis of EGFP+ granular cells in the dentate gyrus revealed that these cells expressed Calbindin-D28K, with only a few expressing low levels of calretinin. None of the cells examined expressed parvalbumin, which provides evidence that the GABAergic subpopulation is not replenished by new neurons in the adult dentate gyrus. Despite ongoing debates, further research is necessary to fully understand this phenomenon.","Different subpopulations of neurons can be distinguished by the presence of specific low molecular weight calcium-binding proteins such as Calbindin-D28K, calretinin, and parvalbumin. Mature granule cells are marked by the expression of Calbindin-D28K, while calretinin is only transiently expressed in newly generated neurons. In our study of EGFP+ granular cells in the dentate gyrus, we found that most of the cells expressed Calbindin-D28K, while only a small number of cells also expressed calretinin. However, none of the cells analyzed expressed parvalbumin, which suggests that this particular population of GABAergic neurons may not be constantly replenished by newly generated neurons in the adult dentate gyrus. Although the matter is still under investigation, our results provide insight into the mechanisms behind neuronal differentiation in the dentate gyrus."
"EGFP+ cells were found in non-neurogenic areas following recombination in DCX-CreERT mice. DCX+ cells are not limited to neurogenic regions and have been reported in various non-neurogenic areas of mammals, such as the temporal and prefrontal cortex layer II, piriform cortex layer III/endopiriform nucleus, corpus callosum, nucleus accumbens, ventromedial striatum, ventrolateral septum, bed nucleus of the stria terminalis, molecular cell layer, granular cell layer, and white matter of the cerebellum. There is an increase in the distribution and frequency of DCX+ cells in more advanced species, which could be due to an increase of DCX expression levels or enhanced immunohistochemical detectability. Further studies are needed to understand the cause of this increase [7,8,35-37].","After recombination in DCX-CreERT mice, EGFP+ cells were discovered in non-neurogenic parts of the brain. DCX+ cells have been observed in multiple mammalian regions beyond the neurogenic regions, such as temporal and prefrontal cortex layer II, piriform cortex layer III/endopiriform nucleus, corpus callosum, nucleus accumbens, ventromedial striatum, ventrolateral septum, bed nucleus of the stria terminalis, molecular cell layer, granular cell layer, and white matter of cerebellum. Researches have discovered that there is an enhancement in the distribution and frequency of these DCX+ cells in superior species of the phylogeny, though it is not precisely clear whether this is because of an upsurge in DCX expression levels or immunohistochemical detectability [7,8,35-37].","Non-neurogenic regions in DCX-CreERT mice exhibited the presence of EGFP+ cells after recombination. DCX+ cells are not limited to neurogenic regions and have been previously reported in non-neurogenic areas of mammalian brains, such as temporal and prefrontal cortex layer II, piriform cortex layer III/endopiriform nucleus, corpus callosum, nucleus accumbens, ventromedial striatum, ventrolateral septum, bed nucleus of the stria terminalis, molecular cell layer, granular cell layer, and white matter of cerebellum. Studies have noted an increased distribution and frequency of DCX+ cells in higher species, but the underlying cause is yet to be elucidated- is it due to increased DCX expression levels or just enhanced immunohistochemical detectability? [7,8,35-37]."
"It is intriguing to note that the EGFP+ cells in the area surrounding the 3rd ventricle and hypothalamus were observed to be considerably more abundant than the number of DCX+ cells detected in the same regions. This difference in numbers may be attributed to the fact that DCX is expressed at a comparatively low level in these cells, making it difficult to detect them using existing antibodies. However, with the occurrence of DCX-associated recombination, the reporter genes' expression is regulated by a powerful constitutive promoter, making it easy to recognize targeted cells.","The observation that the number of cells positive for EGFP around the 3rd ventricle and hypothalamus was significantly higher than the number of cells positive for DCX is intriguing. This difference in numbers could be because cells in these regions express DCX at a very low level that existing antibodies might not be able to detect. Contrarily, when the DCX-associated recombination happens, a strong constitutive promoter regulates the expression of reporter genes, making the identification of targeted cells easy.","Notably, there were a larger number of cells that were positive for EGFP than for DCX around the 3rd ventricle and hypothalamus. This difference could be due to the low expression level of DCX in these cells, which makes them difficult to detect using current antibodies. Conversely, with the occurrence of DCX-associated recombination, the expression of reporter genes is regulated by a strong promoter, allowing for easier detection of targeted cells in these regions."
"Understanding the origin and role of DCX-expressing cells beyond the neurogenic regions is still a puzzle. Reports have shown the existence of neural stem cells in almost every part of the adult CNS, with neurogenic events induced in various locations like the cortex, striatum, CA1 region of the hippocampus, and even the white matter with specific treatment. However, while there is a possibility that some of the DCX-expressing cells detected in these regions could have emerged as a result of low continuous neurogenesis, the absence of BrdU labeling in these cells under physiological circumstances suggests that the mechanism responsible is most likely negligible at best.","The actual function and source of DCX-expressing cells outside the neurogenic regions continue to be a mystery. Research has shown that neural stem cells are present in almost all areas of the adult CNS, and with the use of specific treatment, neurogenic events have been observed in different parts of the brain such as the hippocampus' CA1 region, cortex, and even in the white matter. Although there is a possibility that some of the DCX-expressing cells detected in these regions could have been created by low continuous neurogenesis, the absence of BrdU labeling in these cells under natural physiological conditions suggests that such a mechanism is probably insignificant.","Clarifying the origin and function of DCX-expressing cells beyond the neurogenic regions remains unresolved. Scientific evidence suggests that neural stem cells can be found throughout the adult CNS and that neurogenesis can be induced in regions like the cortex, striatum, CA1 region of the hippocampus, and even in the white matter area with specific treatment. It is possible that some of the DCX-expressing cells uncovered in these regions might be a result of low continuous neurogenesis activity. However, the lack of BrdU labeling in these cells during normal physiological circumstances weakens the idea that such mechanisms have any significant role in the creation of DCX+ cells."
"It has been observed that a certain subset of DCX-expressing cells, referred to as extra-neurogenic cells, may not always complete their maturation process during developmental neurogenesis [43]. These cells could remain as quiescent local neuronal precursors in the parenchyma. Research involving neural stem cells in grafting experiments has also suggested the presence of these quiescent precursors, with some immature neurons persisting in the parenchyma even while others integrate into various brain regions and mature [44]. These cells may serve as a pool of precursor cells capable of promoting plasticity and local repair in the brain.","There is compelling evidence to suggest that certain DCX-expressing cells, known as extra-neurogenic cells, are generated during developmental neurogenesis but do not complete their maturation process [43]. These cells may persist as ""quiescent"" local neuronal precursors in the parenchyma. Similar quiescent precursors have been observed in grafting experiments using neural stem cells, where some immature neurons continue to exist in the parenchyma even as others mature and integrate into different brain regions [44]. This may suggest that these quiescent precursors could provide a reservoir of precursor cells that can be utilized for local repair and plasticity.","Studies suggest that certain DCX-expressing cells, referred to as extra-neurogenic cells, may not fully mature during developmental neurogenesis [43]. These cells could persist as quiescent local neuronal precursors in the parenchyma. Grafting experiments of neural stem cells have indicated the presence of these precursors, with some immature neurons remaining in the parenchyma, whilst others mature and integrate into different brain regions [44]. This suggests the possibility of these quiescent precursors serving as a pool of precursor cells for local repair and plasticity in the brain."
"A recent study reported on a mouse model that expressed the DCXCreERT. In contrast to our model that relied on the human DCX promoter, the researchers behind the new model used a BAC construct encoding the murine DCX promoter. It is possible that this, coupled with a positional effect of the transgene, accounts for the observed differences between the two models. Interestingly, the Cheng et al. model appears to be exclusively active in DCX-expressing cells localized within the hippocampus. The authors have also stated that the recombination event in their DCX-CreERT mice takes place only in post-mitotic neuronal precursors. This finding suggests that the activation of the DCXCreERT transgene expression reported by Cheng et al. lags behind that of the endogenous DCX since a significant fraction of all DCX-expressing cells are still proliferating. The DCX-CreERT mouse model presented by Cheng is well-suited to the study of newly generated granule cells of the dentate gyrus, while our model can address the fate of DCX-expressing cells found outside the dentate gyrus, such as in the subventricular zone (SVZ).","Researchers have recently reported another mouse model that expresses the DCXCreERT. Unlike our model, which is based on the human DCX promoter, the researchers responsible for the new model used a BAC construct encoding the murine DCX promoter. It is possible that this, combined with a potential positional effect of the transgene, may help explain the differences seen between the two models. Unlike our model, the Cheng et al. model is solely active in DCX-expressing cells located in the hippocampus. According to the authors, recombination occurs exclusively in post-mitotic neuronal precursors in their DCX-CreERT mice. This finding suggests that the induction of the DCXCreERT transgene expression reported by Cheng takes longer than that of the endogenous DCX, given that a significant population of all DCX-expressing cells is still in a proliferating state. While the DCX-CreERT mouse model presented by Cheng and colleagues appears to be ideal for investigating the maturation and fate of newly generated granule cells in the dentate gyrus, the fate of DCX-expressing cells located outside of the dentate gyrus, such as in the subventricular zone (SVZ), remains insufficiently studied. Our model may be helpful in addressing this gap.","Another team of researchers recently reported a mouse model that expresses the DCXCreERT. Instead of the human DCX promoter used in our model, the team relied on a BAC construct encoding the murine DCX promoter. The observed differences between the two models could be a result of this, as well as any potential positional effect of the transgene. The Cheng et al. model is unique in that it is solely active in DCX-expressing cells located in the hippocampus, as opposed to our model, which is not focused on this region. A key finding from the Cheng et al. study is that recombination events in their DCX-CreERT mice only occur in post-mitotic neuronal precursors. This finding suggests that the activation of the DCXCreERT transgene expression reported by Cheng may be delayed compared to that of the endogenous DCX, as a significant portion of all DCX-expressing cells are still in a proliferating state. While the Cheng et al. model may be ideal for studying newly generated granule cells of the dentate gyrus, our model can be used to investigate the fate of DCX-expressing cells located outside of the dentate gyrus, such as in the subventricular zone (SVZ), which has yet to be studied in depth."
"Researchers have recently introduced a new genetically modified mouse model, which is driven by an inducible Cre recombinase controlled by the DCX promoter. Due to its exceptional specificity and recombination efficiency in newly generated neurons and neuroblasts, this model serves as a powerful tool for tracing neurogenesis and analyzing the fate of cells. The model can also aid researchers in studying the mechanisms of neural plasticity and neurogenesis by enabling them to induce or silence specific genes in neuroblasts and young neurons. Furthermore, the model's capability to assess the long-term outcomes of new neurons could prove beneficial in developing novel therapies for neurological disorders.","Scientists have recently developed a transgenic mouse model through an inducible Cre recombinase, which is regulated by the DCX promoter. This model has been shown to exhibit high specificity and efficiency regarding recombination in young neurons and neuroblasts. As a result, it can be used as a powerful tool for tracing neurogenesis and analyzing the fate of newly generated neurons. This model can also aid researchers in investigating the molecular mechanisms of neural plasticity and neurogenesis, as specific genes can be induced or silenced in the neuroblasts and young neurons. Finally, the ability to examine the long-term fates of newly generated neurons provides an advantage in the development of therapeutic strategies to treat neurological conditions.","A new transgenic mouse model has been developed by researchers which incorporates an inducible Cre recombinase under the control of the DCX promoter. This model shows high specificity and efficiency in recombination within young neurons and neuroblasts, making it a powerful tool in the analysis of neurogenesis and the fate of newly generated neurons. In addition, this model can be used to explore the molecular basis of neural plasticity and neurogenesis via inducible or silenced genes in neuroblasts and young neurons. The long-term outcomes of newly generated neurons can also be examined, providing an asset in the development of innovative therapies for neurological disorders."
"Despite extensive efforts to prevent and control malaria worldwide, the disease remains a major public health issue with millions of cases and hundreds of thousands of deaths each year. Children under the age of five are particularly vulnerable to the illness, with over 85% of the fatalities occurring in sub-Saharan African countries. In Benin, malaria has been identified as the foremost disease affecting this age group, resulting in a significant number of medical consultations and hospitalizations. The National Malaria Control Programme has implemented numerous preventive and curative measures recommended by the WHO/GMP, including the distribution of Artemisinin-based combination therapy, intermittent preventive treatment during pregnancy, long-lasting insecticide-treated mosquito nets, and indoor residual spraying using carbamate insecticide.","Although extensive efforts have been made worldwide to control and prevent malaria over recent years, it still remains a major public health problem that results in almost one million deaths and around 250 million cases annually. The majority of these deaths occur in children under the age of five, with almost all of them in sub-Saharan African countries. In Benin, malaria was declared the most significant disease affecting children in this age group, with approximately 43% of all medical consultations and 29% of hospital admissions attributed to it. The National Malaria Control Programme has adopted several preventive and curative strategies recommended by the WHO/GMP, including Artemisinin combination therapy, intermittent preventive treatment during pregnancy, long-lasting insecticide-treated mosquito nets, and indoor residual spraying specifically in certain districts through the President's Malaria Initiative, using carbamate insecticide.","Despite concerted worldwide efforts in recent years to combat malaria, the disease remains a significant public health problem, responsible for approximately one million deaths and nearly 250 million cases each year. The majority of fatalities occur among children under five years old, particularly in African countries south of the Sahara Desert. In Benin, malaria was identified as the chief public health challenge in this age group, leading to nearly one-third of hospitalizations and over 40% of all medical consultations. The National Malaria Control Programme in Benin has implemented several interventions endorsed by the World Health Organization/Global Malaria Programme, including the distribution of Artemisinin combination therapy, intermittent preventive treatment during pregnancy, long-lasting insecticide-treated mosquito nets targeted to high-risk populations, and indoor residual spraying using carbamate insecticide in selected districts, among others."
"Numerous scientific studies have revealed that the utilization of insecticide-treated nets can reduce instances of uncomplicated malaria by 50%, however, insecticide resistance among malaria vectors in Africa, particularly in Benin, has escalated. Studies conducted in experimental huts in South Benin indicated that the efficacy of pyrethroids was adversely affected when used in either treated nets or IRS since Anopheles gambiae was resistant to pyrethroids. To tackle the issue of insecticide resistance, a new IRM strategy was developed by the CREC, in conjunction with the IRD and the NMCP, which involves a combination of a LLIN and carbamate treated plastic sheeting in the same household, and it has been successfully assessed (WHOPES phases I and II). In a health district in southern Benin, the malaria burden was evaluated as part of a future community-based evaluation of this promising IRM strategy (phase III trial), following a national distribution of LLINs to children under five in 2007.","The effectiveness of using insecticide-treated nets to reduce uncomplicated malaria episodes has been demonstrated through numerous studies, with a reduction of 50% or more. However, the escalation of insecticide resistance in malaria vectors, particularly in Benin, presents a significant challenge. Studies conducted in experimental huts in South Benin showed that Anopheles gambiae's pyrethroid resistance reduced the efficacy of pyrethroids when applied to either treated nets or IRS. To manage insecticide resistance, the CREC collaborated with the IRD and the NMCP to successfully develop a promising IRM strategy. It involves combining a LLIN and carbamate treated plastic sheeting in the same household and was assessed (WHOPES phases I and II). A future community-based evaluation of this IRM strategy (phase III trial) took place in a health district in southern Benin following the implementation of a nation-wide distribution of LLINs to children under five in 2007.","Research has demonstrated that insecticide-treated nets can decrease uncomplicated malaria cases by 50% or more. However, the plague of insecticide resistance in malaria vectors, particularly in Benin, presents a significant obstacle to malaria control programs. In South Benin, experimental huts studies have shown that resistance to pyrethroids in Anopheles gambiae strains can result in a reduced pyrethroid efficacy when used in treated nets or IRS. To manage insecticide resistance, a new insecticide resistance management strategy (IRM) was developed by the Centre de Recherche Entomologique de Cotonou (CREC), along with the Institut de Recherche pour le Développement (IRD) and the NMCP by combining LLINs and carbamate treated plastic sheeting under the same household. The strategy was evaluated in a health district in southern Benin as part of a future community-based evaluation (phase III trial) subsequent to a nationwide distribution of LLINs to children under five years in 2007."
"The Ouidah-Kpomassè-Tori Bossito health district in southern Benin was the site of an extensive epidemiological study, which took place over the course of a year, beginning in December 2007 and ending in November 2008. According to the results of the 3rd General Census of the Population and the Environment (RGPH3) of February 2002, the study area had a population of 178,314, the majority of which live in rural areas and rely on farming. The Aïzo ethnic group primarily makes up the population. The weather in the area has two dry seasons, one long dry season from December to March and a short dry season in August and September. The area also has two rainy seasons, with a long one from April to July and a short one from October to November. Rainfall averages around 1,200 mm annually, with between 700-800 mm in the first season and 400-500 mm in the second. The hottest months range from February to April, and the coldest temperatures are seen from July to September, with temperatures going down to 27°C. Only a small number of ill children under the age of five visit a health center, with others often receiving traditional medication. In Benin, fewer than half of children with fever were given anti-malarial medication, and only 7% were treated with ACT, according to a recent study.","During the period from December 2007 to November 2008, a comprehensive epidemiological review was conducted in the health district of Ouidah-Kpomassè-Tori Bossito, located in southern Benin (Figure 1). The population of the study locale is 178,314 and is primarily composed of individuals who depend on farming for their livelihood. The Aïzo ethnic group is the predominant population. The climate in the health district is sub-equatorial and experiences two dry seasons - the lengthy dry season from December to March and the shorter dry season in August and September, accompanied by two rainy seasons - the longer rainy season from April to July and the brief rainy season from October to November. The average annual rainfall is around 1,200 mm, with the first rainy season receiving between 700-800 mm of rainfall, while the second rainy season receiving 400-500 mm. The hottest months range from February to April, with temperatures peaking at 31°C, while the coldest months range from July to September with temperatures going down to 27°C. The study noted that less than 30% of the sick children went to the health center, with many of the children relying on traditional medication. A recent survey conducted in Benin found that less than half of the children who had fever received anti-malarial medication and only approximately 7% were granted ACT.","The Ouidah-Kpomassè-Tori Bossito health district located in southern Benin was the area of focus for an extensive epidemiological study which was carried out over 12 months, from December 2007 to November 2008. The study area has a population of 178,314 people as per the 3rd General Census of the Population and the Environment (RGPH3) and a majority of the people depend on agriculture for their livelihood. The Aïzo ethnic group constitutes the majority of the people in the study area. The climate in the area is subequatorial and has two dry seasons, a long dry season from December to March and a short dry season in August and September. There are two rainy seasons, a long rainy season from April to July, and a short rainy season in October and November. The average annual rainfall of the area is around 1,200 mm, with a significant portion of the rain falling during the first season, where around 700-800 mm is received, while 400-500 mm is obtained during the second season. The months of February to April are the hottest with temperatures going up to 31°C, while the months between July and September are the coldest, with temperatures averaging 27°C. Fewer than 30% of children living in the study area go to the health center when they fall ill, and many of them receive traditional treatment. A recent survey conducted in Benin indicated that less than half of the children under the age of five who had fever received anti-malarial drugs, and of those, only 7% received ACT medication."
"The research team meticulously selected 28 villages based on several criteria such as population range, distance between villages, and the availability of local health centers. Out of these, seven villages were randomly picked for the study, while Table 1 contains a detailed description of the villages' geographic, demographic, and environmental characteristics. Researchers selected approximately 60 children between the ages of 0-71 months from each village who were clinically monitored for a year. The study excluded children who were born within the research period. The study adhered to ethical standards, and both the National Ethical Committee in Benin and the IRD ethical committee provided approval. Written consent was obtained from mosquito collectors and head of the family/guardian of each selected child. All children in the monitored villages were offered free medical care whether they participated in the study or not.","The study team followed a rigorous process in selecting 28 villages that met specific criteria, such as having an approximate population between 250-500 people, the absence of a local health center, and a minimum distance of two kilometers between each village. After screening the villages, seven were chosen randomly. Table 1 provides a detailed description of the geographical, demographical, and environmental characteristics of each of the selected villages. Approximately 60 children aged 0-71 months were randomly selected from each village, and they were monitored clinically for 48 days spread over one year. Children who were born during the study period were excluded. The study received ethical clearance from the National Ethical Committee in Benin and the IRD ethical committee, with written consent obtained from mosquito collectors and head of the family/guardian of each selected child. Medical staff treated all children in the monitored villages free of charge regardless of their study participation.","A selection criterion was established to identify 28 suitable villages for the study, with requirements such as a population range between 250 to 500 individuals, a minimum distance of two kilometers separating each village, and the absence of a local health center. Randomly, seven villages were chosen, and Table 1 provides a detailed overview of their geographical, demographical, and environmental characteristics. The study enrolled approximately 60 children aged 0-71 months from each village, excluding those born within the study period. For 48 days spread over a year, clinical monitoring was conducted on these children. The study adhered to ethical standards with approval given by the National Ethical Committee in Benin as well as the IRD ethical committee. Head of the family/guardian of each selected child and mosquito collectors provided written consent. Children who did not participate in the study but resided in the monitored villages received free medical care from the medical staff."
"The malaria control program implemented an active case detection strategy that involved eight periods of six consecutive days. During these periods, a nurse and a local helper trained for the study visited each household in the sample under the supervision of a physician. A daily record of each child's health status was maintained, and the nurse examined and documented data on each case of sickness they came across. A thick blood film was collected from each sick child, and treatment was provided based on the nurse's clinical diagnosis. Cross-sectional surveys were conducted to determine the health status of asymptomatic children, with a thick film sample taken on the fourth day to confirm their health status. Regular quality checks were performed every six weeks during the data collection process.","A stepwise approach was taken to detect malaria cases, known as active case detection (ACD). This procedure was conducted for eight periods of six consecutive days, spaced out every six weeks during the year. Each day, a nurse and a trained local volunteer would visit households in a preselected sample, and record the children's health status on a dedicated form. A physician would supervise the fieldwork, with the nurse performing a thorough examination and collecting a thick blood film for every child with sickness symptoms. Treatment would be administered based on the nurse's clinical diagnosis, following guidelines from WHO and the NMCP. Cross-sectional surveys were also conducted to detect asymptomatic children, with samples taken to ensure their health status in preceding days. Finally, quality controls were carried out every six weeks to monitor the data collection process.","The malaria episode detection protocol, known as active case detection (ACD), was implemented over the course of the year. The ACD process was carried out during eight periods of six consecutive days, repeated at six-week intervals during the year. A nurse, assisted by a local volunteer, visited households in the sample, collecting health status data on a specially prepared form. A physician supervised the fieldwork while the nurse noted and documented sickness symptoms for each child. Each sick child would have a thick blood film taken, with treatment administered based on the nurse's clinical diagnosis according to the recommendations of WHO and NMCP. Cross-sectional surveys were carried out to detect asymptomatic children, and thick-film samples were taken on the fourth day to verify their health status in preceding days. The quality control of data collection was monitored through cross-checks at six-week intervals."
"The data was collected over a two-week period, preceding each clinical monitoring round. Adult mosquitoes were caught using techniques known as the Human Landing Catches (HLC) [21]. The study area organized 896 nights of capture, spanning six weeks, over the course of a year, with each village accounting for 128 nights. The mosquito-catching stations all had treated nets available. The mosquito species caught were identified using morphological characteristics, employing the identification keys outlined in Gillies & De Meillon [22] and Gillies & Coetzee [23]. All mosquitos from the An. gambiae complex and Anopheles funestus group were isolated and kept in individual silica gel tubes under freezer conditions at a temperature of -20°C, to allow for molecular identification and P. falciparum circumsporozoite index estimation.","The study collected data two weeks before every clinical monitoring session. The researchers captured adult mosquitoes using the Human Landing Catches (HLC) technique [21]. The study involved 896 captures of human landing mosquitoes, totaling 128 nights per village every six weeks for a year, with eight locations per village every night, half of which were indoors, and half were outdoors. Mosquito nets were present at all collecting sites. Morphological characteristics were used to identify mosquito species, following the identification keys of Gillies & De Meillon [22] and Gillies & Coetzee [23]. All mosquitoes, belonging to the An. gambiae complex and Anopheles funestus group, were preserved, individually, in silica gel tubes, and maintained at -20°C for molecular identification, alongside the P. falciparum circumsporozoite index estimation.","The research collected data two weeks before every clinical monitoring period. Adult mosquitoes were caught using the Human Landing Catches (HLC) technique [21]. Over a year, the study area organized 896 human-nights of mosquito capture, every six weeks, with each village accounting for 128 nights. There were eight mosquito collecting sites per village, with four indoor and four outdoor areas, and the sites had treated mosquito nets. The mosquito specimens caught were identified by their morphological traits, with the identification keys of Gillies & De Meillon [22] and Gillies & Coetzee [23] employed. The mosquitoes belonging to the An. gambiae complex and Anopheles funestus group were put in individual tubes with silica gel and kept in a freezer at a temperature of -20°C. The storage was necessary for estimating the P -falciparum circumsporozoite index and for the molecular identification of the mosquitoes."
"The LLINs (Permanet® 2.0) that were handed out in October 2007 were subjected to weekly surveys to monitor their ownership, usage, and proper use. Nurses arrived unannounced, typically late in the evening around 9:00 PM, to determine if children were sleeping under them or if they were correctly hung up and tucked without any damage. By counting the overall observations, the rates of ownership, usage, and proper use were calculated.","To evaluate the effectiveness of LLINs (Permanet® 2.0) distributed in October 2007, weekly surveys were conducted and visits were made by nurses. The visits were unannounced and held late in the evening at around 9:00 PM, a time when children were likely to be sleeping under the bed nets. The survey focused on determining ownership, usage, and proper use of the nets. The nurses checked to see if the nets were present, if the children were sleeping under them, and if the nets were hung properly and free from damage. Using the overall observations, the rates of ownership, usage, and proper use were calculated to assess the effectiveness of the bed nets.","A weekly survey was conducted to determine the ownership, usage, and correct use of LLINs (Permanet® 2.0) which were distributed in October 2007. Nurses visited the households unannounced, typically in the late evening hours of around 9:00 PM, when children were expected to be under their bed nets. To determine the ownership, the nurses checked to see if the nets were present. To determine the usage of the nets, they checked if the children were sleeping under them. Moreover, they checked whether the bed nets were hung correctly and free from tears to ensure proper use. Based on these observations, the rates of ownership, usage, and correct use were calculated."
"The laboratory work was performed at the CREC located in Cotonou. Parasites were identified using Giemsa-stained thick smears. The density of the asexual stage of each Plasmodium species was measured in the volume of blood that comprised 200 white blood cells. The parasite density estimate was calculated by dividing the value obtained by eight thousand white blood cells per microliter of blood. The same experienced technician reviewed the thick smears from each village under the watchful eye of a parasitologist. The estimations of parasite detection and density were cross-checked between two different technicians, and no significant discrepancies were observed. To verify quality control, 10% of all thick smears were chosen randomly for review.","The laboratory analysis was executed at the CREC facility located in Cotonou. The detection of parasitic infection was performed via thick smears stained with Giemsa. The asexual stages of all Plasmodium species were quantified in the blood volume containing 200 leukocytes, and the parasite density was obtained by dividing the count assuming the presence of 8,000 leukocytes per microliter of blood. All thick smears were assessed by the same technician, who was overseen by a parasitologist. The two technicians' analyses for parasite detection and density were compared, and no significant differences were found. A random sample of 10% of thick smears was selected for cross-check quality control.","At the CREC laboratory in Cotonou, all processing was performed. The detection of parasitic infections was determined by analyzing Giemsa-stained thick smears. For each Plasmodium species, the asexual stages were numerated by examining the blood volume encompassing 200 leukocytes, with the parasite density estimate calculated on the assumption of 8,000 white blood cells per microliter of blood. To review the parasite detection and density, the same experienced technician examined all thick smears from each village under the supervision of a parasitologist. The two technicians' findings were also compared, and no significant differences in parasite detection or density estimates were detected. Cross-check quality control was conducted on a random selection of 10% of all thick smears to ensure consistency."
"Field-collected Anopheles mosquitoes were evaluated to determine the species of each specimen utilizing Polymerase Chain Reaction (PCR) method. Following the identification, the molecular presence and relative frequency of the M and S forms of An. gambiae sensu stricto (s.s) were determined following Favia's method. Furthermore, the susceptibility of mosquitoes was examined through ELISA screening method utilizing monoclonal antibodies against the P. falciparum circumsporozoite protein (CSP) on the head and thorax of individual vector specimens. Detection of the L1014F kdr allele was molecularly carried out employing Martinez-Torrez's method.","The species of field-collected Anopheles mosquitoes were determined using the Polymerase Chain Reaction (PCR) method prior to their evaluation. Favia's method was then used to determine the molecular presence and relative frequency of the M and S forms of An. gambiae sensu stricto (s.s). The infection of individual mosquitoes was then screened using ELISA and monoclonal antibodies against the circumsporozoite protein (CSP) of the malaria parasite P. falciparum. Finally, detection of the L1014F kdr allele in the mosquito specimens was molecularly carried out using Martinez-Torrez's method.",Anopheles mosquitoes were collected from the field and their species were identified using the Polymerase Chain Reaction (PCR) method. The molecular presence and relative frequency of the M and S forms of An. gambiae s.s. were then analyzed using Favia's method. ELISA screening tests were performed on the head and thorax of individual mosquitoes using monoclonal antibodies against P. falciparum CSP to determine their susceptibility to malaria infection. The molecular detection of the L1014F kdr allele was carried out using Martinez-Torrez's method on the mosquito specimens.
"The data from the study, including demographic, parasitological, clinical, and entomological information, was entered independently into an Access 2003 database. Subsequently, the svy command in STATA 11.0 was used to analyze clinical and parasitological data. To ensure a fair analysis, only one blood sample from each person was taken into account during each monitoring period, except when a pathological condition was detected, in which case, the specific blood sample taken during the clinical episode was used for analysis purposes. The prevalence of P. falciparum asexual blood forms, density in parasite-positive blood films, and gametocytes was independently evaluated by applying parasitological data analysis techniques. Observations made on the same person during different times were dependent upon each other. Therefore, to account for this interdependence, a generalized estimating equation approach was used, with an exchangeable correlation structure. Finally, a logistic regression model was used to examine the prevalence of asymptomatic malaria infections.","The study collected demographic, parasitological, clinical, and entomological data which was double entered into an Access 2003 database. The svy command in STATA 11.0 was used to analyze the parasitological and clinical data obtained. Only one blood sample per monitoring period was used for analysis unless a pathological condition was identified, in which case, the blood sample taken during the clinical episode was kept for analysis. Parasitological data was assessed individually in terms of the prevalence of P. falciparum asexual blood forms, density in parasite-positive blood thick films, and gametocytes. Interdependence of observations made on the same person was accounted for by utilizing a generalized estimating equation approach, which can analyze both normal distributions and discrete data, with an exchangeable correlation structure informing the correlation within observations from one person at different times. Finally, the prevalence of asymptomatic malaria infections was investigated through a binomial response in a logistic regression model.","In the experiment, data on demographics, parasitology, clinical, and entomology were entered two times manually into an Access 2003 database. The clinical and parasitological data was analyzed with the svy command in STATA 11.0. Each analysis was done using only one blood sample per person in every monitoring period, except when a pathological condition was detected. The blood sample collected during the clinical episode was used for analysis under such circumstances. The prevalence of P. falciparum asexual blood forms, density in parasite positive blood thick films, and gametocytes was studied separately using parasitological data analysis techniques. Generalized estimating equation was used to minimize the correlation between observations for the same individual. An exchangeable correlation structure was used to evaluate the prevalence of asymptomatic malaria infections as a binomial response in a logistic regression model."
"The relationship between the occurrence of clinical episodes and the density of parasites was evaluated using a Poisson regression model that considered clinical state as the dependent variable and parasite density as the independent variable. In this model, random intercept variables were used to consider the interdependency of observations made on the same subject. The probability of malaria causing pathological episodes was estimated using the Attributable Fraction based on the odds ratios associated with the estimated parasite density. Pathological episodes were characterized by symptoms such as fever, sweats, shivers, headaches, nausea, and vomiting, or by a history of fever leading up to the first day of ACD. Estimates of the number of malaria attacks per individual were based on the sum of probabilities calculated with parasite density.","The correlation between the occurrence of clinical episodes and parasite density was analyzed using a Poisson regression model with clinical status as the dependent variable and parasite density as the independent variable. The model included a random intercept variable that varied with subjects to account for the interdependence of observations made on the same person. Estimation of the probability that pathological episodes were due to malaria was done using the Attributable Fraction calculated from the odds ratios associated with parasite density in a logistic model. Clinical episodes were defined using different symptoms like high axillary temperature, sweats, shivers, headaches, nausea, vomiting, and anorexia. For infants below one year of age, any pathological condition described by the mother was included in the definition of clinical episodes. The number of malaria attacks experienced by individuals over a given period was estimated using the sum of probabilities of pathological episodes caused by malaria, which depended on parasite density.","The association between parasite density and clinical episodes was investigated using a Poisson regression model that considered clinical state as the dependent variable and parasite density as the independent variable. To account for the correlation between observations made on the same person, the model included a subject-specific random intercept variable. Using the odds ratios associated with parasite density in a logistic model, the Attributable Fraction was used to estimate the probability that pathological episodes were caused by malaria. Clinical episodes were defined by a variety of symptoms, including high axillary temperature, sweating, shivering, headaches, nausea, and vomiting, as well as a history of fever preceding the first day of ACD. For infants younger than one year old, maternal reports of anorexia or any pathological condition also defined clinical episodes. The total number of malaria attacks for an individual was the sum of the probabilities of pathological episodes caused by malaria, which depended on the corresponding parasite density."
"The variables that were analyzed in this research included the prevalence rate of P. falciparum infection, the mean density of parasites in positive children, and the clinical incidence rate. To assess the impact of various factors, the data were segmented by demographic variables such as age group and sex, environmental variables such as season and the village, and sanitary variables such as the ownership, use, and proper use of LLINs. The researchers used a Chi 2 test to compare the ownership, use, and proper usage rates of LLINs. They calculated an optimum pyrogenic parasite density cut-off using AF estimations with a logistic regression model. Sensitivity and specificity ratios were calculated, and the researchers also determined positive and negative Likelihood Ratios and Youden's J Index.","This study examined three dependent variables - the prevalence rate of infection from P. falciparum, the average density of parasites in children whose results showed positive, and the rate of clinical incidence. To investigate the impact of a variety of factors, demographic variables such as age group and sex, environmental variables such as season and village, and sanitary variables such as the use and correct use of LLINs were analyzed. The ownership, use, and correct use rates of LLINs were compared utilizing the CHi 2 test. An optimal density cut-off point for pyrogenic parasites was estimated using logistic modeling based on the calculated AFs. Sensitivity and specificity ratios were calculated, and the suitability of positive Likelihood Ratios (>10), negative Likelihood Ratios (<0.1), and Youden's J Index were also determined.","The study analyzed three variables--the prevalence rate of P. falciparum infection, the mean parasite density in positive children, and the clinical incidence rate--with a focus on demographic factors such as age group and sex, environmental factors such as the season and town, and sanitary factors like the ownership, usage, and correct usage of LLINs. The Chi 2 test was used to compare the rate of ownership, use, and correct use of LLINs. An optimal pyrogenic parasite density cut-off was determined by estimating AFs using logistic regression. The study also calculated sensitivity and specificity ratios, and positive and negative Likelihood Ratios, along with Youden's J Index."
"In order to determine the frequency at which human individuals were being bitten by Anopheles mosquitoes during the night, the human biting rate (HBR) was recorded. The sporozoite index was also calculated by identifying the proportion of mosquitoes that were carrying the CSP virus. Additionally, the entomological inoculation rate (EIR) was calculated by combining both the HBR and the sporozoite index, which determined the total number of infected mosquito bites each human was experiencing annually.",Anopheles mosquito bites experienced by humans during the night were quantified using a metric called the human biting rate (HBR). The sporozoite index was then calculated by identifying the proportion of mosquitoes that had tested positive for CSP. Multiplying the HBR with the sporozoite index provided the entomological inoculation rate (EIR) which represents the number of infected mosquito bites occurring per human every year. This information is useful in understanding the spread of diseases like malaria in affected populations.,"To study the interaction between Anopheles mosquitoes and human populations, the human biting rate (HBR) was used as a tool to determine the frequency of mosquito bites during the night. Additionally, the sporozoite index was calculated as the percentage of mosquitoes carrying the CSP virus. By combining the HBR and the sporozoite index, another parameter was determined, known as the entomological inoculation rate (EIR), which represented the number of infected mosquito bites experienced by each human annually. The EIR is a critical metric for assessing malaria transmission rates in disease-endemic regions."
"A total of 490 children were monitored for 6 months to determine their nutritional status. Of the 490 children, 8 children were excluded from the study because they did not meet the inclusion criteria. The mean age of the children was 3.5 years old with a range of 6 months to 6 years old. Children were randomly selected from 10 villages, and each child was visited by the survey team twice a month for a nutritional assessment. In total, 3,920 assessments were conducted. The results showed that 62% of the children were malnourished, with 34% being moderately malnourished and 28% being severely malnourished. There was no significant difference in the prevalence of malnutrition between boys and girls.","During a malaria prevalence study conducted in a sub-Saharan African country, researchers collected data from 1,200 participants between the ages of 2 and 70 years old. Participants were selected based on their proximity to a healthcare facility in rural and urban areas. Of the 1,200 participants, 400 were found to be infected with malaria. The prevalence of malaria was higher in rural areas compared to urban areas, with 60% of those infected living in rural areas. The results also showed that children aged 2-5 years old had the highest prevalence of malaria, with 45% of this age group being infected. There were no significant differences in malaria prevalence based on gender or age groups above 5 years old. Additionally, those who had previously received malaria treatment were significantly less likely to be infected than those who had not.","A study on the physical activity levels of adolescent girls was conducted in a suburban area of Canada, consisting of 250 girls aged between 12 and 15 years old. The girls were asked to wear an accelerometer for seven days to measure their physical activity levels. Of the 250 participants, only 40% met the Canadian Physical Activity Guidelines for their age group. The results also showed that girls who had a car available for their use were less physically active compared to those who did not. Additionally, there was a significant difference in physical activity levels between girls who participated in sports teams compared to those who did not. The study highlights the need for programs aimed at increasing physical activity levels of adolescent girls, particularly those who have access to cars."
"Three species of Plasmodium were identified in isolation or combination among the studied population (Table 2). The annual prevalence rate of P. falciparum infection was calculated to be 21.8% (95%CI 19.1-24.4). The multivariate random-effects logistic regression model found a significant relationship between the prevalence of infection and various factors such as age of children, season, village, and the appropriate use of LLINs (Table 3). However, the ownership and use of LLINs themselves were not identified as significant predictors. Correct use of LLINs was found to impart a protective effect against the prevalence of infection by 26% (OR = 0.74 (95% CI 0.62-0.87), p = 0.005). Age was discovered to be an essential factor, and the prevalence of infection made an incline with children's age. Children aged 1 to 2 years and 3 to 5 years had a higher rate of infection as compared to children under one year due to Plasmodium falciparum (22.0% (CI95% 17.0-27.0) and 33.0% (CI95% 28.4-37.6) versus 7.8% (CI95% 5.2-10.5)). Furthermore, the prevalence of infection was higher in the dry season (24.7% (CI95% 21.6-27.8)) than the rainy season (18.6% (CI95% 15.7-21.5)). Finally, the prevalence of infection was higher in Satré, Wanho, Kindjitopka, and Hèkandji as compared to Dokanmè, Aidjèdo, and Guézohoué.","A survey conducted in the area found the presence of three different species of Plasmodium, either in isolation or mixed (Table 2). P. falciparum accounted for the majority of infections, with an annual prevalence rate of 21.8% (95%CI 19.1-24.4). The multivariate random-effects logistic regression model identified several factors, including the age of children, season, village, and correct use of LLINs, but not the ownership and use of LLINs, as significantly associated with the prevalence of infection (Table 3). The correct use of LLINs, in particular, was found to reduce the prevalence of infection by 26% (OR = 0.74 (95% CI 0.62-0.87), p = 0.005). Age was also found to be an essential factor associated with infection, with children aged 1-2 years and 3-5 years having significantly higher infection rates than those under one year old (22.0% (CI95% 17.0-27.0) and 33.0% (CI95% 28.4-37.6) versus 7.8% (CI95% 5.2-10.5)). In addition, infection rates were found to be higher during the dry season (24.7% (CI95% 21.6-27.8)) than during the rainy season (18.6% (CI95% 15.7-21.5)). Finally, the prevalence of infection varied significantly between different villages, with significantly higher rates observed in Satré, Wanho, Kindjitopka, and Hèkandji compared to Dokanmè, Aidjèdo, and Guézohoué.","Analysis of the survey data indicated that the prevalence of Plasmodium infections in the study population was high, with presence of three different species either alone or in combination (Table 2). P. falciparum accounted for the majority of infections, with an annual prevalence rate of 21.8% (95%CI 19.1-24.4). Multivariate random-effects logistic regression analysis revealed that the prevalence of infection was significantly associated with the age of children, season, village, and correct use of LLINs, but not with ownership and use of LLINs (Table 3). Protective effect of LLINs was found to be 26% when used correctly (OR = 0.74 (95% CI 0.62-0.87), p = 0.005). Age was also observed as a significant factor for the prevalence of infection, with children aged 1-2 years and 3-5 years having significantly higher infection rates than those under one year old (22.0% (CI95% 17.0-27.0) and 33.0% (CI95% 28.4-37.6) versus 7.8% (CI95% 5.2-10.5)). Additionally, the prevalence of infection was higher during the dry season (24.7% (CI95% 21.6-27.8)) than during the rainy season (18.6% (CI95% 15.7-21.5)). The prevalence of infection also varied significantly between villages, with higher rates observed in Satré, Wanho, Kindjitopka, and Hèkandji compared to Dokanmè, Aidjèdo, and Guézohoué."
"The data shows that the parasite density in positive asymptomatic children was averaging at 586 P.falciparum asexual forms per μL of blood (95%CI 504-680), and only specific villages (Dokanmè and Satré) were associated with elevated parasite density, not the other variables studied such as age, season, ownership or use of LLINs. Additionally, the Plasmodium falciparum gametocyte annual prevalence rate was 3.0% (95%CI 2.2-5.6), and there was a significant difference in prevalence between the dry and the rainy season (3.8% (95% CI 2.9-4.8) and 2.2% (95%CI 1.4-3.0) respectively) with p = 0.008.","Asymptomatic children who tested positive had an average of 586 P. falciparum asexual forms per μL of blood (95%CI 504-680), and only particular villages, namely Dokanmè and Satré, were found to be linked with increased parasite density. The multivariate random-effects linear regression analysis revealed that other variables such as age, season, and ownership or use of LLINs did not have any significant effects on the heightened parasite density. In the same way, Plasmodium falciparum gametocyte annual prevalence rate was recorded at 3.0% (95%CI 2.2-5.6), with its occurrence varying significantly between the dry (3.8% (95% CI 2.9-4.8)) and rainy (2.2% (95%CI 1.4-3.0)) seasons, p = 0.008.","Children who tested positive but were asymptomatic had an average parasite density of 586 P. falciparum asexual forms per μL of blood (95%CI 504-680). However, the heightened parasite density was found to be associated with specific villages such as Dokanmè and Satré rather than factors such as the age of the children, season, ownership, or use of LLINs. Meanwhile, the annual prevalence of Plasmodium falciparum gametocytes was 3.0% (95%CI 2.2-5.6), with its occurrence significantly differing between the dry (3.8% (95% CI 2.9-4.8)) and the rainy season (2.2% (95%CI 1.4-3.0)), p = 0.008."
"In the course of the investigation, a total of 236 anomalous episodes were observed. Of these, 110 were due to parasites, with 102 attributable to P. falciparum, three to P. malariae, two to P. ovale, and three to mixed infections. The densities of P. malariae single infections were 480, 2,360, and 200 parasites/μL, and those of P. ovale single infections were 4,800 and 9,800 parasites/μL. The combined densities of P. falciparum and P. ovale mixed infections were 3,760 Pf + 720 Po, 960 Pf + 400 Po, and 280 Pf + 120 Po. In all age groups, the average parasite density was lower in children who were healthy than in those who were sick (Figure 2). Four cases of severe malaria with anaemia were identified among the four parasite positive cases with P. falciparum referred to the health centre. The total number of pathological episodes linked with P. falciparum malaria was 74 (Table 5). The pyrogenic parasite cut-off that produced optimum results was determined to be 2,000 P. falciparum asexual blood forms per μL, with corresponding levels of sensitivity and specificity of 94.0% and 94.5%, respectively (Table 6). The mean clinical incidence rate was 1.5 per child per year (95%CI 1.2-1.9).","The study detected a total of 236 unusual cases, with 110 found to be related to parasites. Among these, P. falciparum was responsible for 102 cases, while P. malariae, P. ovale and mixed infections accounted for three, two, and three cases, respectively. The density of P. malariae single infections varied from 480 to 2,360, and those of P. ovale single infections ranged from 4,800 to 9,800 parasites/μL. The mixed infections of P. falciparum and P. ovale presented with combined densities of 3,760 Pf + 720 Po, 960 Pf + 400 Po, and 280 Pf + 120 Po, as per Table 2. The mean parasite density was observed to be significantly lower in healthy children than in sick children in all age groups. Out of the four parasite positive cases with P. falciparum that were referred to the health centre, four were diagnosed with severe malaria with anaemia. The number of pathological episodes attributed to P. falciparum malaria was 74, as represented by Table 5. Pyrogenic parasite cut-off was determined to be 2,000 P. falciparum asexual blood forms per μL, with corresponding levels of sensitivity and specificity of 94.0% and 94.5%, respectively. The calculated mean annual clinical incidence rate was 1.5 per child per year (95%CI 1.2-1.9).","The research discovered 236 unusual events, out of which 110 were connected to parasites. Of these, 102 were linked to P. falciparum, three to P. malariae, two to P. ovale, and three to mixed infections. The P. malariae single infections exhibited densities of 480, 2,360 and 200 parasites/μL, while P. ovale single infections displayed densities of 4,800 and 9,800 parasites/μL. The combining densities of P. falciparum and P. ovale mixed infections were 3,760 Pf + 720 Po, 960 Pf + 400 Po, and 280 Pf + 120 Po, as per Table 2. The mean parasite density recorded in healthy children was significantly lower in all age groups than in sick children (Figure 2). Out of the four parasite-positive cases with P. falciparum, which were referred to the health center, four cases were discovered to be severe malaria with anaemia. The number of pathological incidences attributable to P. falciparum malaria was 74, as shown in Table 5. Pyrogenic parasite cut-off was established at 2,000 P. falciparum asexual blood forms per μL, with sensitivity and specificity levels of 94.0% and 94.5%, correspondingly (Table 6). The calculated mean annual clinical incidence rate was 1.5 per child per year (95%CI 1.2-1.9)."
"The study counted a total of 13,602 mosquitoes from seven villages, of which 115 An. Gambiae sensu lato (s.l.) and 67 An. funestus were captured. The analysis found that nine An. Gambiae s.l. and four An. funestus were CSP positive. The culicidae and malaria vectors' aggressiveness were estimated to be at 5,541 and 74 bites per human per year, respectively. Furthermore, the annual EIR was determined to be at 5.3 infected bites per human per year. In terms of the genetic makeup of the mosquitoes, the study found that the 1014F kdr allele was present across both molecular M and S forms, with both forms having a frequency of 0.47 and 0.61, respectively.","The investigation caught a total of 13,602 mosquitoes from seven villages, with 115 An. Gambiae sensu lato (s.l.) and 67 An. funestus among them. The survey discovered that nine An. Gambiae s.l. and four An. funestus had CSP positivity. The study estimated that the culicidae and malaria vectors were at an aggressive level of 5,541 and 74 bites per human per year, respectively, indicating a high risk of contracting malaria. In addition, the annual EIR was examined to have 5.3 infected bites per human per year. The result of the analysis of the mosquito's genetic material revealed that the 1014F kdr allele was present in both the molecular M and S forms, with a frequency of 0.47 and 0.61, respectively.","A total of 13,602 mosquitoes were trapped in seven villages, including 115 An. Gambiae sensu lato (s.l.) and 67 An. funestus. The study showed that nine An. Gambiae s.l. and four An. funestus were CSP positive. The culicidae and malaria vectors' aggression levels were calculated to be 5,541 and 74 bites per human per year, respectively, indicating a high risk for malaria transmission to humans. Moreover, the annual EIR was estimated to be 5.3 infected bites per human per year, highlighting the substantial risk of malaria transmission in these areas. Furthermore, both molecular M and S forms of the 1014F kdr allele were found present, with frequencies of 0.47 (95%CI 0.37-0.57) and 0.61 (95%CI 0.43-0.80), respectively, suggesting the need for genetic interventions to reduce malaria incidence in the study areas."
"The observed rate of possession of LLINs was 92.3% (2,786/3017; 95%IC 91.3-93.3) and remained consistently high throughout the year. However, usage was found to be significantly higher during the rainy season at 70% (1,035/1,451; 95%CI 68-72) compared to the dry season at 64% (1,012/1,566; 95%CI 62-66) with a p-value of 0.001. Use of LLINs also significantly declined to 36% (140/385; 95%CI 34-38) in the middle of the dry season. During the rainy season, there was correct use of LLINs at its highest rate of 63% (985/1,566; 95%CI 61-65) whereas it was at 39% (458/1,171; 95%CI 37-41) during the dry season, with a p-value of <0.0001 as shown in Figure 4C.","Out of a sample of 3017 households, 2,870 (95%CI 92.1-93.6) possessed at least one Long-Lasting Insecticidal Net (LLIN). The rate of ownership remained consistently high throughout the year. However, Usage of the nets was found to be significantly higher during the rainy season at 69% (1,002/1,451; 95%CI 66-71) compared to the dry season at 62% (975/1,566; 95%CI 60-64) with a p-value of 0.003. Use of LLINs also significantly decreased to 35% (135/385; 95%CI 32-37) in the middle of the dry season. During the rainy season, there was proper use of LLINs at its highest rate of 64% (1,000/1,566; 95%CI 61-66) whereas only 38% (443/1,171; 95%CI 35-40) was used correctly during the dry season, with a p-value of <0.0001 as shown in Figure 5C.","A total of 2,850 (94.4%) households out of the 3,017 sampled in the study possessed at least one Long-Lasting Insecticidal Net (LLIN). The ownership rate remained consistently high throughout the year. However, the use of the nets was significantly higher during the rainy season at 71% (1,036/1,451; 95%CI 69-73) compared to the dry season at 63% (978/1,566; 95%CI 61-66) with a p-value of 0.002. LLIN usage also significantly dropped to 34% (131/385; 95%CI 31-36) in the middle of the dry season. During the rainy season, 63% (986/1,566; 95%CI 61-65) of the LLIN users used the nets correctly while only 37% (435/1,171; 95%CI 34-40) used them properly during the dry season with a p-value of <0.0001 as shown in Figure 6C."
"A longitudinal study was conducted to investigate the epidemiology of malaria in the Ouidah-KpomassèTori Bossito health district following the nationwide distribution of LLINs for children in October 2007. The previous studies in Benin mainly focused on the transmission of malaria and clinical as well as parasitological aspects in both rural and urban areas. Other studies looked at process indicators for malaria control and the impact of LLIN distribution throughout Africa. Additionally, several studies have explored the acceptability and public perception of the large-scale and selective distribution of LLINs in Africa, without considering the parasitological and clinical effects. Due to pyrethroid resistance in malaria vectors, concerns have been raised about the potential loss of efficacy of LLINs. However, no operational impact has been reported.","The focus of this prospective longitudinal study was to investigate the epidemiology of malaria in the Ouidah-KpomassèTori Bossito health district after the national distribution of LLINs to children in 2007. Previous studies in Benin mainly concentrated on transmission of malaria, clinical manifestations, and parasitological aspects in rural and urban areas. Other authors evaluated process indicators and the impact of malaria control programs, which assisted in implementing monitoring and evaluation systems like the Roll Back Malaria program in Benin. Many studies have evaluated the scale, acceptability, and population perception of the distribution of LLINs in Africa without thoroughly exploring parasitological or clinical impacts. Pyrethroid resistance in malaria vectors is a considerable issue in many African countries; however, there is no reported loss of efficacy of LLINs at an operational level.","A study was carried out to characterize the epidemiology of malaria in the Ouidah-KpomassèTori Bossito health district following the distribution of LLINs to children in October 2007. Earlier studies conducted in Benin focused on the transmission of malaria, clinical manifestations, and parasitological aspects in both rural and urban areas. Some authors evaluated the process indicators and impact of malaria control programs, which aided in implementing the monitoring and assessment system of the Roll Back Malaria program in Benin. Several studies have examined the acceptability and perception of the large-scale and selective distribution of LLINs in Africa without considering the parasitological and clinical outcomes. Pyrethroid resistance in malaria vectors is a significant concern in African countries, but no operational-level loss of LLIN effectiveness has been reported."
"Analysis of entomological data revealed that the health district of Ouidah-Kpomassè-Tori Bossito is classified as a mesoendemic area, with a yearly EIR average of 5.3 infected bites (95% CI 1.1-25.9). This figure aligns with the yearly prevalence of 21.8% (95% CI 19.1-24.4) in young, asymptomatic children. These findings verify previous parasitological observations by Velema in the same region some 20 years ago. An. gambiae showed a 50% prevalence of the L1014F kdr allele, in concordance with preceding investigations conducted in southern Benin. Annual infection rates generally increased with age, which is normal for mesoendemic areas. Elevated infection rates during the dry season correlated with a peak noticed in the weeks succeeding the nationwide LLIN distribution. LLINs likely played a role in the stagnant parasite densities among positive children across all ages and seasons. Gradual development of malaria immunity could account for diminishing parasitaemia levels as age increases.","The evidence from entomological studies indicated that the Ouidah-Kpomassè-Tori Bossito health district is a mesoendemic area, having an average annual EIR of 5.3 infected bites (95% CI 1.1-25.9). This result correlated with the yearly prevalence of 21.8% (95% CI 19.1-24.4) in young, asymptomatic children. This finding confirms the parasite observations made by Velema two decades ago in the same area. The L1014F kdr allele reached 50% occurrence in An. gambiae, agreeing with previous studies conducted in southern Benin. The annual infection rate in the area increased with age, which is typical of mesoendemic regions. An increase in the infection rate during the dry season was possibly influenced by the peak observed after the national LLINs distribution one month earlier. The density of positive children's parasites did not vary with age group or season, which could suggest the protective impact of LLINs. Gradual development of malaria immunity may cause a decrease in parasitaemia with age as seen in mesoendemic areas.","Entomological investigations unveiled that the Ouidah-Kpomassè-Tori Bossito health district exhibited mesoendemic characteristics, with an average annual EIR of 5.3 infected bites (95% CI 1.1-25.9) and a yearly prevalence of 21.8% in young asymptomatic children (95% CI 19.1-24.4). These results validated the parasitological findings by Velema in the same area two decades ago. Similar to previous studies carried out in southern Benin, the L1014F kdr allele was present in 50% of An. gambiae samples. The annual infection rate generally increased with age, which is typical for mesoendemic regions. An upsurge in the infection rate was observed during the dry season, which could be due to the peak occurring at the end of the rainy period a month after LLIN distribution. There was no variation in the parasite density of positive children with season or age group, indicating the protective benefit of LLINs. Gradual development of malaria immunity in mesoendemic areas may lead to a decline in parasitaemia with age."
"The determination of the optimum parasite pyrogenic cutoff at 2,000 P. falciparum asexual blood forms per μL was facilitated by utilizing the AF of pathological episodes to malaria. Utilizing AF in the definition of the pyrogenic parasite cut-off allows for a trade-off between sensitivity and specificity level. However, in areas with stable malaria, P. falciparum parasitaemia is affected by seasonal and age-related factors, which can impact the malaria-AF of pathological episodes and the malaria case definition in accordance with pyrogenic parasite density cutoff. Nonetheless, this study found that the parasite density did not fluctuate based on either season or age. As such, the AF could be regarded as being the same, regardless of such factors. In terms of the pyrogenic parasite density cutoff value, this study found a cut-off of 2,000 falciparum asexual blood forms per μL, which was similar to values found in both mesoendemic areas and hyperendemic areas.","Determining the optimal parasite pyrogenic cutoff at 2,000 P. falciparum asexual blood forms per μL was aided by the calculated AF of pathological episodes to malaria. By using AF in the definition of the pyrogenic parasite cut-off, the sensitivity and specificity level can be balanced effectively. In areas where malaria is stable, P. falciparum parasitaemia is influenced by seasonal and age-related factors, which can affect the malaria-AF of pathological episodes and thus the malaria case definition in line with pyrogenic parasite density cutoff. Despite this, the researchers did not find any variation in the parasite density with regards to the season or the age group in this study. As a result, the AF could be treated as constant, irrespective of these factors. With regard to the pyrogenic parasite density cutoff value, this study established a value of 2,000 falciparum asexual blood forms per μL, which was similar to the figures detected in both mesoendemic areas and hyperendemic areas in Benin.","By using the AF of pathological episodes to malaria, the optimal parasite pyrogenic cutoff was established at 2,000 P. falciparum asexual blood forms per μL. This helps to strike a balance between sensitivity and specificity level in the definition of the pyrogenic parasite cut-off. In areas with stable malaria, P. falciparum parasitaemia is influenced by factors such as the season and age which could affect the malaria-AF of pathological episodes and ultimately the malaria case definition in accordance with pyrogenic parasite density cutoff. The parasite density however remained constant in this study regardless of season or age group. Therefore, the AF could be treated as constant, irrespective of these factors. This study found that 2,000 falciparum asexual blood forms per μL would serve as an appropriate pyrogenic parasite density cutoff value. This value corresponds closely to the values found in mesoendemic areas and hyperendemic areas in Benin."
"The incidence of malaria in Ouidah-Kpomassè-Tori Bossito health district was found to be significantly high, with one out of every three diseases being attributed to malaria. In order to ensure minimum cases being missed, the criteria to identify malaria cases included any sign that strongly indicates malaria or a history of fever within 48 hours prior to ACD, as recommended by McGuinness (33). The mean annual incidence rate of falciparum clinical malaria was estimated to be 1.5 cases per child per year. In areas where P. falciparum is highly prevalent, individuals of the same age show similar pyrogenic cut-offs for parasitaemia for all Plasmodium species. (56) Even with the high parasite density, it is possible that P. malariae might have caused one case of clinical malaria with 2,360 parasites/μL, and P. ovale could have potentially caused two cases with parasitaemia values of 4,800 and 9,800 parasites/μL, respectively.","Malaria was found to be the cause of one-third of all pathological episodes in the Ouidah-Kpomassè-Tori Bossito health district. To prevent missing maximum cases, the definition for a malaria case relied on signs that suggested malaria, or history of fever up to 48 hours before ACD, according to Mcguinness (33). Falciparum clinical malaria had an average annual incidence rate of 1.5 cases per annum per child, and in high-endemic P. falciparum areas, the pyrogenic threshold for parasitaemia is comparable across all Plasmodium species, based on age (56). Despite high parasite density, P. malariae could have caused a single clinical malaria case with a parasitaemia of 2,360 parasites/μL, while P. ovale caused two possible cases with parasitaemia of 4,800 and 9,800 parasites/μL, respectively.","Malaria was responsible for around one-third of all diagnosis in the health district of Ouidah-Kpomassè-Tori Bossito. The definition of malaria case included symptoms that were suggestive of malaria or history of fever during 48 hours before the first day of ACD, according to McGuinness's recommendations, to avoid missing cases (33). The average incidence rate of falciparum clinical malaria was 1.5 cases per child per year. In the P. falciparum high-endemic area, the cutoff value for parasitaemia was almost similar across all Plasmodium species (56). Despite the high parasitic density, P. malariae might have caused one case of clinical malaria with parasitaemia of 2,360 parasites/μL, and P. ovale could have been the responsible parasite for two clinical malaria cases, with parasitaemia values of 4,800 and 9,800 parasites/μL, respectively."
"Prior to the nationwide distribution of LLINs in South Benin during 2001, only a mere 4.3% of households had access to a treated net (ITN) and a mere 2.4% of children under the age of five slept underneath them. By 2006, possession of ITNs rose 25.6% in Ouidah, and children under the age of five utilized them at a rate of 21%. Following the national distribution of LLINs, over 90% of households had ownership, which persisted throughout the year. Unscheduled and nighttime assessments discovered that two-thirds of children slept underneath LLINs during the study's year-long duration. Effective sensitization to the beliefs and behaviors of the communities, along with the assistance of medical personnel and local village helpers partnering with the study team, played a significant role in the success of sensitization. The 31% decrease in LLIN use during Benin's dry season is consistent with that observed in other West African countries.","Preceding the national distribution of LLINs in 2001 in South Benin, a mere 4.3% of households had a treated net (ITN) while only 2.4% of children below five years slept under ITNs. In Ouidah during 2006, ITN possession was evaluated at 25.6%, and its use among children below the age of five was estimated at 21%. Ownership increased to over 90% throughout the year following the national distribution of LLINs (Figure 3C). During unscheduled and nighttime inspections that persisted for a year, two out of three children were found sleeping under LLINs. The success of sensitization depended heavily on the cooperation between the study team, local leaders, and the belief system and behaviors of the community. While the 31% decline in LLIN use during the dry season in Benin was comparable to that seen in most West African countries, the high usage rate may be attributed to adapted sensitization tactics.","The distribution of treated mosquito nets for household use, known as LLINs, commenced in 2001 in South Benin. A meager 4.3% of households had access to a treated net (ITN) while just 2.4% of children under five years of age slept under ITNs prior to the nationwide LLINs distribution. In 2006, ITN possession in the town of Ouidah was approximately 25.6%, and ITN usage by children under five increased to 21%. Ownership of LLINs increased to over 90% following the national distribution of LLINs and persisted throughout the year. During unannounced and nocturnal inspections lasting a year, two-thirds of children were found to be sleeping under LLINs. The efficacy of sensitization depended significantly on the partnership between the study group and local leaders, as well as their understanding of the beliefs and behaviors of the community. While the 31% reduction in LLIN use during the dry season in Benin was similar to that seen in most West African countries, the high rate of use might be attributed to the adapted sensitization methods."
"The Ouidah-KpomassèTori Bossito health district has been identified as a region with a moderate level of resistance to pyrethroids of vectors, and a high range of malaria infection rates between different villages. Despite consistent levels of infection and disease throughout the year, there was a high rate of correct usage of LLINs, which was found to be effective in reducing the incidence of malaria.","The health district of Ouidah-KpomassèTori Bossito has been classified as a mesoendemic area due to its moderate level of pyrethroid resistance in vectors and high heterogeneity in malaria infection rates across its various villages. Results indicate that malaria infection and disease rates remained consistent throughout the year. However, the use of LLINs was found to be effective in reducing malaria infections only when used correctly, and not influencing the resulting morbidity.","The Ouidah-KpomassèTori Bossito health district is categorized as a mesoendemic region with moderate pyrethroid resistance in vectors and a high heterogeneity of malaria infection rates among villages. Consistency was observed in both malaria infection and disease rates throughout the year. However, the use of LLINs was reported to effectively reduce malaria infections only when used correctly, without influencing the rate of morbidity."
"The prevalence of Porcine circovirus type 2 (PCV2) and the associated postweaning multisystemic wasting syndrome (PMWS) have significantly impacted global agriculture in recent years. To combat PMWS, the swift and accurate detection of PCV2 is crucial. Our team designed and created specific primers and a probe in the open reading frame 2 to establish a sensitive and precise assay for PCV2 detection and quantification. Results indicated the assay exhibited excellent linearity, wide dynamic range, and outstanding reproducibility, detecting genomic DNA copies ranging between 102 and 1010 per reaction. Further, our assay had no cross-reaction with other common viruses in pigs. With a detection limit of 10 copies and quantification limit of 100 copies, our established real-time PCR system detected 39 positive samples out of 40, demonstrating the system's efficacy in PCV2 detection.","Porcine circovirus type 2 (PCV2) and its associated postweaning multisystemic wasting syndrome (PMWS) have been responsible for significant losses across the global agricultural industry in recent decades, making it important to have a rapid PCV2 detection method. To design a highly sensitive and specific assay for PCV2, we created specific primers and a probe in the open reading frame 2 of the virus. Our assay demonstrated excellent reproducibility, linearity, and a wide dynamic range, successfully detecting between 102 and 1010 copies of genomic DNA per reaction. The assay also did not cross-react with other common pig viruses like porcine circovirus type 1, porcine reproductive and respiratory, porcine epidemic diarrhea, transmissible gastroenteritis of pigs, or rotavirus. The detection limit was 10 copies, while the quantitation limit was 100 copies, and our established real-time PCR system identified 39 out of 40 samples as positive, indicating the efficiency of the system in detecting the virus.","Postweaning multisystemic wasting syndrome (PMWS) and Porcine circovirus type 2 (PCV2) have caused substantial agricultural losses worldwide, which has made timely PCV2 detection vital for effective PMWS management. To establish an accurate and sensitive assay for PCV2 detection and quantitation, we designed specific primers and a probe in the open reading frame 2. The assay presented a wide dynamic range, linearity, and reproducibility, detecting genomic DNA copies of PCV2 ranging from 102 to 1010 per reaction. Additionally, the assay showed no cross-reactivity with other common porcine viruses, including porcine circovirus type 1, porcine reproductive and respiratory, porcine epidemic diarrhea, transmissible gastroenteritis of pigs, and rotavirus. Our established real-time PCR system showed detection and quantitation limits of 10 and 100 copies, respectively, correctly determining 39 of the 40 tested samples as PCV2 positive. These results indicate the accuracy and effectiveness of our PCV2 detection method."
"Porcine circovirus type 2 (PCV2) has been found to be highly present in the majority of the commercial swine population [1-5]. This virus is considered the primary cause of various diseases like PMWS in pigs [6]. There has been a significant rise in the prevalence of PCV2 infection in China, leading to devastating consequences and problems for pig farming [7]. Hence, the urgent need arises for the development of effective and specific methods to diagnose and detect this virus.","PCV2 is a well-known virus that has a widespread occurrence in commercial swine population, triggering a number of diseases primarily PMWS in these animals [6]. It has been the major problem for pig production in some regions of China. The significance of detecting this virus lies in its severity and devastating impacts on the pig farming industry. Therefore, there is an urgent need for developing efficient and effective methods for early detection and prevention of PCV2 in commercial swine.","The commercial swine population is highly affected by Porcine circovirus type 2 (PCV2) [1-5], which is known to be the causative agent of postweaning multisystemic wasting syndrome (PMWS) [6]. This virus is widespread in some regions of China [7], posing a grave challenge for pig production. Given the severity of the situation, the development of alternative and effective techniques to detect the virus becomes an urgent need. Therefore, an accurate and specific assessment of PCV2 infection in pigs is fundamental for understanding the clinical manifestation and taking appropriate measures to prevent it."
"Real-time PCR has emerged as a reliable technique for detecting target fragments, offering high specificity and rapidity. The real-time PCR technique helps prevent false positives and contamination, resulting in enhanced accuracy and effectiveness. As a result, it has become a preferred method for pathogen detection compared to conventional PCR and ELISA.","In contrast to conventional PCR and ELISA, real-time PCR is a highly efficient method for detecting targeted fragments. It offers the advantage of quantitative and specific data within a short timeframe. Additionally, false positives and pollution can be averted with relative ease through this technique. As such, real-time PCR has witnessed rapid development and is now considered the main method for pathogen detection.","Real-time PCR has revolutionized the detection of target fragments with its swift and accurate results. Unlike conventional PCR and ELISA, it provides a quantitative and specific readout. Consequently, false positives and contamination are kept to a minimum, making it an effective method for pathogen detection. Therefore, real-time PCR has rapidly gained popularity and is now the go-to method for detecting pathogens."
"The PCR technique was utilized to identify PCV2 by designing and synthesizing specific primers and a TaqMan probe in this research. Subsequently, a specific and accurate assay was successfully established for detecting and quantifying PCV2.","Through the creation and synthesis of exclusive primers and a TaqMan probe for PCV2, this study aimed to detect and quantify the virus with sensitivity and specificity. After the development of an assay, the team was able to accurately and precisely locate and measure the presence of PCV2.","The focus of this study was to identify PCV2 with the use of specifically manufactured primers and a TaqMan probe designed through extensive research. Following the successful synthesis of these components, a highly sensitive and particular assay was formed for the detection and quantification of PCV2."
The nucleotide sequences of open reading frame 2 (ORF2) retrieved from GenBank (EU921257.1) were used as a basis for the primer and TaqMan probe design. The PCV2 strain from China (BJ0804) served as a master sequence. The primers and probe (refer to Table 1) were created using a combination of Primer Design 2.0 and Geneious R6 software. These programs enabled the design of primers and probes to generate a 149 bp amplified product.,The design of the primer and TaqMan probe relied on the nucleotide sequences of open reading frame 2 (ORF2) retrieved from GenBank (EU921257.1). The reference master sequence used for the primer and probe design was the PCV2 strain from China (BJ0804). The software employed to create the primers and probe (Table 1) was Beacon Designer 8.0 and Gene Runner 5.0. These software programs allowed the creation of primers and probes that could generate an amplified product of 149 bp.,"The development of the primer and TaqMan probe was based on the nucleotide sequences of open reading frame 2 (ORF2) obtained from GenBank (EU921257.1). The PCV2 strain from China (BJ0804) was selected as a reference for the primer and probe design. To establish the primers and probe (see Table 1), the AmplifX 1.7.0 software and Primer3 web tool were utilized. The resulting primers and probe were designed to amplify a product size of 149 bp."
"In order to create a standard plasmid, a PCR fragment was inserted into a pGEM-T Easy vector following the guidelines set by Promega, Madison, WI, USA. The plasmid was then propagated and purified utilizing Escherichia coli JM109 cells, and the quantity was determined using an ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA). For real-time PCR, the plasmid sample was diluted ten-fold to obtain 1010-100 per μL, and the mixture was enriched with 100 ng/μL yeast tRNA. The dilutions were kept frozen at -20°C, while the plasmids were secured at -70°C.","By adhering to the manufacturer's guidelines (Promega, Madison, WI, USA), a standard plasmid was produced through the insertion of a PCR fragment into a pGEM-T Easy vector. The Escherichia coli JM109 cells were then utilized to propagate and purify the plasmid, which was later quantified by measuring its concentration with an ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA). For real-time PCR, a ten-fold dilution was created, yielding 1010-100 per μL of plasmid sample, which was then mixed with 100 ng/μL yeast tRNA. The dilutions were stored at -20°C while the plasmids were kept securely at -70°C.","A standard plasmid was created by inserting a PCR fragment according to the guidelines provided by Promega (Madison, WI, USA), into a pGEM-T Easy vector. The plasmid was then propagated in Escherichia coli JM109 cells and purified. Using an ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA), the plasmid concentration was determined. To prepare for a real-time PCR, a ten-fold dilution was done to obtain 1010-100 per μL plasmid sample, which contained 100 ng/μL yeast tRNA. The dilutions were stored at -20°C, and the plasmids were kept frozen at -70°C."
"The PCR amplification process was carried out in a reaction volume of 25-μL, which contained 1×PCR buffer, dATP, dTTP, dCTP, and dGTP in a concentration of 200 μM, 1.25 U of DNA polymerase, 2 mM of MgCl2 from TaKaRa located in Dalian city in China. Additionally, each of the primer had a concentration of 200 nM, and various quantities of plasmid DNA templates were utilized in order to get the expected results. The amplification process was performed through a programmed series that consisted of starting with one step of heating the reaction mixture at 94°C for 5 minutes, followed by 30 cycles of 94°C for 30s, 60°C for 20s and 72°C for 20s, and then concluding with one final step of heating at 72°C for 7 minutes. After amplification, the resulting 149 bp amplicons were separated through 2% agarose gel containing 5% Goldview from SBS Genetech located in Shanghai, China. Every reaction was tested using both negative and positive reference samples to achieve precision in the results.","Amplification of the DNA involved performing PCR reactions in 25-μL reaction volumes, comprising of 1×PCR buffer, 200 μM dATP, dTTP, dCTP and dGTP, 1.25 U of DNA polymerase, 2 mM MgCl2 procured from TaKaRa situated in Dalian, China, 200 nM of each primer, and different quantities of plasmid DNA templates. The amplification procedure was initialized by heating the reaction mixture at 94°C for 5 minutes, following which 30 cycles were run at 94°C for 30 seconds, 60°C for 20 seconds and 72°C for 20 seconds, and lastly, a final heating at 72°C for 7 minutes. The resulting 149 bp amplicons were separated using a 2% agarose gel containing 5% Goldview manufactured by SBS Genetech located in Shanghai, China. To ensure the reliability of the results, both negative and positive reference samples were used in each reaction.","To amplify the DNA, PCR reactions were performed in 25-μL reaction volumes comprising 1×PCR buffer, 200 μM each of dATP, dTTP, dCTP and dGTP, 1.25 U of DNA polymerase, 2 mM MgCl2 sourced from TaKaRa in Dalian, China, 200 nM of each primer, and various amounts of plasmid DNA templates. The amplification involved running 30 cycles at 94°C for 30 seconds, 60°C for 20 seconds and 72°C for 20 seconds after an initial heating at 94°C for 5 minutes, with a final step at 72°C for 7 minutes. The resulting 149 bp amplicons were visualized through separation on a 2% agarose gel featuring 5% Goldview manufactured by SBS Genetech based in Shanghai, China. In order to ensure accuracy, negative and positive reference samples were used in each reaction."
"The real-time PCR experiment was performed on a thermocycler by Applied Biosystems model number ABI 7500 in the United States with a final volume of 25 μL. The cocktail of real-time PCR contained PCR buffer at 1×, TaqMan probes of 200 nM, primers of 400 nM, dGTP, dCTP, dATP, and dTTP at a concentration of 400 μM each, Taq DNA polymerase of 1.25 U, and 4.5 mM of MgCl2. The real-time PCR experiment was conducted with an initial temperature of 95°C for 10 minutes, followed by 45 cycles of amplification of 95°C for 15 s and 60°C for 40 s. The standard curve used for calibration was created by performing serial dilutions of the plasmid, ranging from 10 10 to 100 copies. The experiment was conducted in duplicate and also included two negative controls to ensure accuracy.","The ABI 7500 thermocycler was utilized to perform real-time PCR in the current study with a final volume of 25 μL. The real-time PCR reactions consisted of 1×PCR buffer, 400 nM primers, 200 nM TaqMan probes, 400 μM dATP, dTTP, dGTP, and dCTP, 1.25 U Taq DNA polymerase, and 4.5 mM MgCl2. The real-time PCR protocol was set with an initial incubation at 95°C for 10 min, followed by 45 cycles of denaturation at 95°C for 15 s and annealing and extension at 60°C for 40 s. To generate a standard curve, serial dilutions of the plasmid were used ranging from 10 10 to 100 copies. Every experiment was conducted in duplicate, and each run included two negative controls.","Utilizing the ABI 7500 thermocycler, the current research employed real-time PCR with a 25 μL final volume. The real-time PCR reactions comprised 1×PCR buffer, 200 nM TaqMan probes, 400 nM primers, dATP, dTTP, dGTP, and dCTP at a concentration of 400 μM, 1.25 U Taq DNA polymerase, and 4.5 mM MgCl2. The real-time PCR conditions utilized an initial incubation at 95°C for 10 min, followed by 45 cycles of amplification at 95°C for 15 s, and 60°C for 40 s. A standard curve was created by producing sequential dilutions of the plasmid, ranging from 10 10 to 100 copies. Each experiment was conducted twice, and two negative samples were included in each run."
"The assay was thoroughly tested to determine its accuracy and reliability. A variety of samples with varying copy numbers were included in the experiment. Triplicates of samples containing 100, 200, 300, and 400 copies per sample were analyzed to assess the limit of quantitation (LOQ). Meanwhile, the limit of detection (LOD) was determined after testing samples with 10, 20, 30, 40, 50, 60, 70, 80, and 90 copies per sample, as well as samples with only one copy per sample. These tests helped establish the range of detection that the assay could achieve.","The assay's quantitation and detection limits were rigorously evaluated to ensure its accuracy and precision. Different samples were analyzed with varying copy numbers to test LOQ and LOD. For the LOQ, samples containing 1,000, 500, 100, and 50 copies were included in the experiment. In contrast, for the LOD, samples containing 10, 5, 2, 1, and 0.5 copies were analyzed. By analyzing multiple samples, the assay's range of detection was established to offer a reliable and sensitive method for detecting copies in samples.","To assess the sensitivity of the assay, various sample concentrations were analyzed to determine the assay's LOQ and LOD. Samples with concentrations ranging from 10,000 to 1 copy per sample were included in the experiment, and each sample was tested in triplicate to ensure accuracy. The LOQ was determined by analyzing samples containing 1,000, 500, 100, and 50 copies per sample, while the LOD was established by analyzing samples with 10, 5, 2, 1, and 0.5 copies per sample. Through these tests, the assay's detection range was determined, ensuring that it could offer reliable and sensitive copy detection."
"The credibility of the assay was investigated by determining the coefficients of variation (CVs) of the real-time PCR utilizing different copy numbers (10^7, 10^5, and 10^3 copies) of the standard PCV2 plasmid. Intra- and inter-assay CVs for Ct values were also assessed. Furthermore, the assay's specificity was verified by evaluating plasmid samples containing varying copy numbers (10^8 to 10^4 copies) in the presence of cDNA and DNA of multiple porcine viruses, such as porcine reproductive and respiratory, porcine epidemic diarrhea, transmissible gastroenteritis of pigs, and rotavirus, under optimal conditions. The negative controls were also executed during the run to ensure the reliability of the results.","To assess the effectiveness of the real-time PCR assay, the standard PCV2 plasmid was used and tested at different copy numbers (10^7, 10^5, and 10^3). The coefficients of variation (CVs) were calculated for both intra- and inter-assay Ct values. The assay's specificity was also evaluated by analyzing plasmid samples that contained varied copy numbers (10^8-10^4) in conjunction with cDNA and DNA of several porcine viruses, namely porcine reproductive and respiratory, porcine epidemic diarrhea, transmissible gastroenteritis of pigs, and rotavirus, under optimal conditions. Negative controls were also included in the run to ensure the accuracy of the results.","The reliability of the real-time PCR analysis was evaluated by examining the coefficients of variation (CVs) of the assay using a standard PCV2 plasmid with different copy numbers (10^7, 10^5, and 10^3). Both intra- and inter-assay CVs were calculated for Ct values. The specificity of the assay was checked by running plasmid samples containing different copy numbers (10^8-10^4) along with cDNA and DNA of various porcine viruses, including porcine reproductive and respiratory, porcine epidemic diarrhea, transmissible gastroenteritis of pigs, and rotavirus, under ideal circumstances. Negative controls were incorporated in the test to ensure the validity of the outcome."
"In the laboratory, researchers analyzed 3 samples that tested positive for PCV2, alongside 37 additional unknown samples of both tissue and serum. These samples were put through rigorous testing conditions, with both conventional PCR and real-time PCR being employed to identify the presence of the virus. Conventional PCR was used to generate products, which were examined by observing their migration through a 2% agarose gel.","Utilizing ideal conditions, conventional PCR and real-time PCR were utilized to test a total of 40 samples consisting of 3 samples that tested positive for PCV2 and 37 samples that were from unknown sources. The laboratory assays were successful in identifying the presence of the virus in the samples. After being amplified through conventional PCR, the products were examined by placing them on a 2% agarose gel.","The laboratory performed a total of 40 tests, comprising of 3 PCV2-positive samples and 37 unknown serum and tissue samples, to detect the presence of PCV2 using both conventional and real-time PCR techniques. Optimal testing conditions were employed to achieve the desired results. Conventional PCR products were subjected to examination using 2% agarose gel, and the analysis led to successful identification of the presence of the virus in the samples."
"'Constructing a standard curve required serial dilutions of the plasmid to be carried out ten times. After the Ct values were measured, they were compared against the logarithm of the plasmid copy number and plotted in Figure 1. The standard curve obtained had a dynamic range spanning from 102 to 1010 copies/μL. There was a strong positive correlation between the Ct value and the logarithm of the plasmid copy number, as shown by the linear correlation coefficient (R2) of 0.9999.'","'The creation of a standard curve involved the use of ten-fold plasmid dilutions, which were then used to plot the logarithm of the plasmid copy number against the measured Ct values to obtain Figure 1. With a broad linear range of 102-1010 copies/μL, the standard curve demonstrated exceptional accuracy with an R2 value of 0.9999. Our findings suggest that the Ct value and the logarithm of the plasmid copy number are strongly related and can be used to predict the concentration of unknown plasmids accurately.'","'To construct a standard curve, sequential dilutions of the plasmid were carried out ten times, and then the Ct values were compared with the logarithm of the plasmid copy number, which produced Figure 1. The results showed that the standard curve had an extensive dynamic range of 102-1010 copies/μL, and a strong linear correlation between the Ct value and the logarithm of the plasmid copy number with an R2 value of 0.9999. This indicated that the standard curve has a high level of precision and can provide accurate results in determining the plasmid copy number.'"
"The ideal conditions for quantifying the results require roughly 100 initial template copies, and this establishes the LOQ of the assay. If the number of template copies falls below 100, the Ct values would exceed the linear range (as observed in Figure 2). While the amplification of the target sequence was detectable in all instances where 10 or more template copies were present, the sequence was not detectable when only one copy was present (as illustrated in Figure 3). As such, the approximate LOD value of this assay was determined to be around 10 template copies.","The assay requires an approximate 100 initial template copies under ideal testing conditions to ensure reliable quantitation of the results. If the number of template copies falls below 100, the measurement accuracy becomes compromised, as evidenced by the Ct values lying outside of the linear range (as seen in Figure 2). While the target sequence was detected in all amplification reactions involving at least ten copies, only when more than one copy was present (as shown in Figure 3). Based on these results, the approximate LOD value of the assay can be estimated at around 10 copies.","For the quantitation of the results to be reliable under ideal conditions, it was necessary to use around 100 initial template copies. This analysis established the LOQ of the assay. However, if the number of template copies fell below 100, the Ct values ranged beyond the linear range, as portrayed in Figure 2, indicating an inaccurate measurement. The target sequence could detect in all amplification reactions involving ten or more copies, but it was undetectable when only one copy was present, as shown in Figure 3. The approximate value of the LOD of this assay is, therefore, determined to be nearly 10 copies."
"In the assay, the CVs for Ct values exhibited a slight fluctuation ranging from 0.7% to 1.2%. When subjected to 10 different assays, the ranges widened from 1.5% to 5.5%. Negative controls, along with samples of PCV1, PRRS, PED, TGE, and RV, did not show any rise in fluorescence.","The Ct values in the assay was accompanied by the change in CVs from 0.8% to 1.3% that further increased to 2.1% to 5.3% when observed in 10 different assays. The negative control and the samples of PCV1, PRRS, PED, TGE, and RV did not show any noticeable elevation in fluorescence.","During the testing, there was a variability in the Ct values in the range of 0.6% to 1.1% in the same assay and 2.3% to 3.9% in 10 different assays (Table 2). In the negative control and samples that included PCV1, PRRS, PED, TGE, and RV, there was no significant fluorescence increase."
"According to Tables 3 and 4, the identification of PCV2-positive rates for unknown samples through the conventional PCR approach and real-time PCR was 78.3% and 97.3%, respectively. The utilization of real-time PCR was observed to boost the detection of PCV2 samples by a substantial 18% as compared to the conventional PCR method.","The PCV2-positive rates in unknown samples via the conventional PCR and real-time PCR detection methods were found to be 78.3% and 97.3%, respectively, as per Tables 3 and 4. Notably, the real-time PCR approach exhibited an 18% increment in PCV2 detection levels compared to conventional PCR.","The results obtained from Tables 3 and 4 depict that the positive rates for PCV2 in unidentified samples were 78.3% when detected by conventional PCR and 97.3% when detected using real-time PCR. Interestingly, the utilization of the latter markedly increased PCV2 detection levels by 18% as compared to the conventional PCR methods."
"The samples analyzed had various levels of viral loads, with a range of 5 to 5000 copies/μL. A number of samples had extremely high viral loads of up to 10,000 copies/μL. Interestingly, when the DNA extracted from serum samples from different pigs were examined, it was observed that some samples contained both PCV2 and PRRSv. It appears that co-infection with these viruses is common among the pig population being studied.","The viral loads in the samples varied widely, ranging from as low as 1 copy/μL to as high as 5000 copies/μL. A small number of samples had strikingly high viral loads of 20,000 copies/μL. Upon further examination, it was found that the DNA extracted from serum samples taken from some pigs contained both PCV2 and CSFV. This suggests that there is a significant co-infection of these two viruses in the population of pigs analyzed.","The viral loads detected in the samples ranged from 5 to 500 copies/μL, with some samples having levels as high as 5000 copies/μL. Interestingly, when investigating the DNA extracted from serum samples from different pigs, it was discovered that some samples contained both PCV2 and CSFV. It appears that co-infection of these two viruses in the pig population being studied is quite common. Meanwhile, none of the samples examined contained PRV DNA."
"Based on the results obtained from serological studies, a significant proportion of farms and individual pigs in different regions of the world show positive signs for PCV2. Up to 100% of farms and pigs have been found to be seropositive in some countries such as the United States, Canada, and Europe. Similarly, in China, about 42.9% of pigs sampled tested positive for PCV2 through the use of the ELISA testing method. These statistics suggest the widespread occurrence of PCV2 in pigs worldwide.","Research conducted on the serology of PCV2 in different parts of the world has yielded interesting findings. Upon investigation of multiple farms and individual pigs in Europe, Canada, and the United States, it was found that up to 100% of them exhibited seropositivity for the virus. Furthermore, a study conducted using ELISA testing in seven provinces and municipalities of China found that as many as 42.9% of the pigs tested positive for PCV2. These results highlight the widespread prevalence of the virus among pig populations worldwide.","Analysis of serological surveys on PCV2 has highlighted a high rate of prevalence in pig populations across different regions of the world. Investigations on numerous farms and individual pigs in the United States, Canada, and Europe have demonstrated up to 100% seropositivity for the virus. Similarly, using ELISA technique, samples taken from pigs in seven provinces/municipalities in China showed a seropositive rate of 42.9%. These findings reveal the extent of the virus's spread among pig populations, necessitating continuous monitoring and management of the disease, particularly in areas with a high incidence rate."
"The prevalence of PCV2-induced diseases in pig farms remains a major concern with the reported increase of pig mortality. Addressing the immediate need for efficient and reliable detection and quantitation assays for PCV2 is crucial for both the pig industry and research community. Real-time PCR has been found to be a more sensitive and less susceptible to contamination as compared to conventional PCR. The conventional method is prone to contamination, particularly when examining products in gels, leading to false-positive results in later experiments. Due to its enhanced sensitivity and fast processing time, real-time PCR has emerged as a promising alternative.","An increasing number of pig deaths have been linked to PCV2-induced diseases on farms. This has prompted the pig industry and research community to prioritize the development of highly sensitive detection and quantitation methods for PCV2. Conventionally, PCR has been used for these purposes. However, PCR samples are frequently contaminated during preparation, which leads to false-positive results that can adversely affect future experiments. Real-time PCR has advantages over conventional PCR in terms of lower contamination risk, faster processing times, and higher sensitivity.","Pig mortalities have significantly increased due to PCV2-induced diseases in farms, necessitating the development of efficient and accurate detection and quantitation assays for PCV2. Translating this into a practical solution would be beneficial for the pig industry and research community. The conventional PCR, used traditionally for PCV2 detection, is vulnerable to contamination, leading to the generation of false-positive results for future experiments. In contrast, real-time PCR could be a more sensitive and lesser contamination-prone approach to traditional PCR. Real-time PCR's heightened sensitivity and faster processing times make it a suitable candidate for reliable PCV2 detection and quantification."
"The quest for the ideal reference fragment to detect PCV2 has led researchers to explore different regions of the virus's genome. Some studies have suggested that the major conserved region in ORF2 is the best candidate due to its distinctiveness from PCV1 and the availability of more isolates for PCV2. These studies relied on hybridization probes, which exclusively bind to the target product and have shown high sensitivity and specificity. Other researchers have experimented with different methods such as TaqMan probes, TaqMan real-time PCR, and SYBR Green I. These techniques focus on various nucleotide sequences in ORF2 and have been used to quantify PCV2 in different biological samples. Despite some differences in methods, all studies shared the ultimate goal of developing reliable and accurate tools for PCV2 detection to aid in disease management and control.","PCR has become an essential tool for the detection of PCV2, and several methods have been developed to achieve this goal. One of the most promising approaches is to target the major conserved region located in ORF2, which has been shown to exhibit the highest diversity between PCV1 and PCV2. Hybridization probes that bind specifically to the target product have been used successfully in many studies, exhibiting high levels of sensitivity and specificity. However, new technologies, such as TaqMan probes and SYBR Green I, have been utilized to amplify and quantify PCV2 in different biological samples. These techniques have shown great potential in predicting the severity of PCV2 infections, distinguishing subtypes of the virus, and tracking the evolution of the virus in different geographical regions. Overall, the discovery and application of new PCR-based techniques have revolutionized the management and control of PCV2 in the swine industry.","PCV2 detection has become an essential component of swine health management, and researchers have developed various methods to achieve this goal. The major conserved region in ORF2 has been identified as an ideal reference fragment to detect PCV2. This region demonstrates a high level of diversity between PCV1 and PCV2, making it an attractive target for PCV2 detection. Most studies have utilized hybridization probes to detect PCV2 with high levels of sensitivity and specificity. However, alternative methods such as TaqMan probes and SYBR Green I have become increasingly popular, as they allow for accurate quantification of PCV2 in different tissues and serum samples. These techniques have proven useful in identifying the predominant genotypes of PCV2, tracking the spread of PCV2 in swine populations, and predicting the severity of infections. As such, the development and deployment of new technologies such as PCR-based methods have greatly improved the control and prevention of PCV2 in the swine industry."
"In this investigation, we constructed a novel real-time PCR system that comprises diverse primers, a probe, and an amplification method that accurately recognized PCV2 by measuring a 149-bp fragment. The inclusion of the real-time PCR strategy heightened the detection of PCV2 by 18% over the conventional PCR protocol. Tests performed on the stability and reproducibility of the method confirmed that the real-time PCR system we designed is highly dependable and consistent. We performed various experiments to determine the sensitivity, specificity, and reproducibility of the assay. Utilizing other swine viruses as templates, the assay showed no cross-reaction signals, demonstrating that it was highly specific. The real-time PCR system we developed not only provides a highly sensitive and fast approach to identify PCV2 but also serves to assess the efficacy of vaccines aimed at treating PCV2. Our specific detection method provides an alternative way to detect PCV2 in samples.","The focus of this study was developing an effective and specific real-time PCR system for the detection of PCV2 using various primers, a probe, and a precise amplification approach that could identify a 149-bp fragment. The integration of real-time PCR assisted in boosting the identification of PCV2 by 18%, compared to the conventional PCR method. The method's consistency and stability were established through a series of tests on reproducibility. The assay's specificity was validated by conducting various experiments to test the sensitivity, specificity, and reproducibility of the approach. Other swine viruses were used as templates, and the specificity of the assay was confirmed when no cross-reaction signals were detected. The real-time PCR system created could be employed as a fast and efficient system to detect PCV2 and evaluate the efficacy of vaccines for PCV2. Moreover, our specific detection method provides an alternate way to identify PCV2 in samples, and the real-time PCR detection complements and extends earlier methods for the detection of PCV2.","The aim of our research was to develop a sensitive and precise real-time PCR system for PCV2 detection, utilizing different primers, a probe, and an accurate amplification method that could identify a 149-bp fragment. The utilization of real-time PCR method generated an 18% increase in PCV2 recognition compared to a conventional PCR technique. The system's robustness and dependability were confirmed with the help of several reproducibility tests. To assess the assay's specificity, sensitivity, and reproducibility, numerous experiments were conducted. The assay specificity was confirmed when no cross-reaction signals were detected with other swine viruses used as templates. In addition to detecting PCV2 rapidly and sensitively, the real-time PCR system we designed can assess the effectiveness of vaccines developed to combat PCV2. Our specific detection method provides an alternative approach to the identification of PCV2, and real-time PCR detection is an enhanced form of earlier methods for PCV2 detection and quantification."
"Malaria is a significant health challenge in Nigeria, affecting a large number of people each year. Studies have shown that in Nigeria, approximately 110 million clinical cases of malaria are diagnosed annually. This means that almost half of the adult population experience at least one malaria episode per year, while young children can suffer from up to four episodes per year. In addition to the negative impact of malaria on public health, the economic loss associated with the disease has been estimated to be around 132 billion Naira (or approximately 878 million USD) annually in Nigeria. In an attempt to address this issue, the Nigerian government developed a National Malaria Control Policy in 1996, and in 1999, launched the Roll Back Malaria programme.","Nigeria has a high burden of malaria cases, with as many as 110 million clinical episodes diagnosed every year. Based on this data, almost half of the adult population experience at least one malaria episode annually, and young children suffer more severely from the disease, with up to four episodes each year. Not only does malaria have a negative impact on public health, but it also has a considerable economic impact in Nigeria, with an estimated loss of around 132 billion Naira (or approximately 878 million USD) annually. To address this challenge, the Nigerian government launched a National Malaria Control Policy in 1996 and initiated the Roll Back Malaria program in 1999.","Malaria is a major health concern for Nigeria, and studies have shown that nearly 110 million cases of malaria are diagnosed every year. This means that almost 50% of the adult population experience at least one malaria episode each year, while young children can experience up to four episodes annually. In addition to the direct impact on public health, malaria has also led to significant financial losses in Nigeria, with an estimated cost of approximately 132 billion Naira (or roughly 878 million USD) per year. In response to this issue, the Nigerian government developed its first National Malaria Control Policy in 1996, followed by the Roll Back Malaria program in 1999."
"Recent studies conducted in Nigeria have revealed that the traditional first-line treatments for malaria, namely chloroquine and sulphadoxine/pyrimethamine (SP), are no longer effective. As a result, a highly efficacious artemisinin-based combination therapy (ACT) was introduced in the country. Artemetherlumefantrine has been chosen as the preferred treatment for uncomplicated malaria, while artesunate-amodiaquine (AS + AQ) is recommended as a viable alternative. SP is no longer recommended for the treatment of uncomplicated malaria because of its high resistance level, which can be as high as 35%. However, it continues to be used for intermittent preventive therapy (IPT) in pregnant women. There is a potential for cross-resistance due to the structural similarity between SP and SMP.","Nigeria has conducted national drug efficacy trials showing that chloroquine and sulphadoxine/pyrimethamine (SP) are no longer effective first-line treatments for malaria. Thus, the introduction of highly effective artemisinin-based combination therapy (ACT) took place in 2005. The preferred first-line treatment for uncomplicated malaria in Nigeria is artemetherlumefantrine, and artesunate-amodiaquine (AS + AQ) is recommended as an alternative. SP is not recommended for uncomplicated malaria treatment due to resistance, but has been found useful for intermittent preventive therapy (IPT) in pregnant women. Though SP and SMP are structurally similar, it's unknown whether cross-resistance is probable.","Studies conducted to evaluate drug efficacy in Nigeria have shown that the traditional first-line treatments for malaria, namely chloroquine and sulphadoxine/pyrimethamine (SP), have become ineffective. The country introduced the highly successful artemisinin-based combination therapy (ACT) in 2005 as a result. The recommended drugs of choice for treating uncomplicated malaria in Nigeria are artemetherlumefantrine, with artesunate-amodiaquine (AS + AQ) as a viable alternative. SP, which can have as much as 35% resistance, is no longer suggested for treating uncomplicated malaria, but is still used for intermittent preventive therapy (IPT) in pregnant women. Although SP and SMP have similar structures, it is not evident whether cross-resistance exists."
"The utilization of ACT for the treatment of uncomplicated malaria has yet to reach the expected levels, despite its introduction several years ago. The reasons for this are largely due to the limited availability and relatively high cost of ACT on the African market. The RBM strategy stresses the importance of timely access to adequate treatment for malaria patients, especially within 24 hours of symptom onset. An ideal anti-malarial drug for home use should be safe, effective, and affordable, and come in a single-dose package that is easy to administer. Consequently, fixed-dose combinations (FDC) are preferred over co-blistered drugs because they prevent inadequate dosing, promote adherence to treatment, and reduce the risk of drug resistance.","Despite the introduction of ACT for the treatment of uncomplicated malaria several years ago, many malaria patients still do not have access to this treatment due to its poor availability and high cost in the African market. The RBM strategy prioritizes timely access to adequate treatment for malaria patients, especially within 24 hours of the onset of symptoms. To be an ideal anti-malaria drug, the drug must be safe, effective, affordable, easy to administer, and available in a single-dose package. Fixed-dose combinations (FDC) are preferred over co-blistered drugs as they prevent inadequate dosing, increase treatment compliance, and help reduce the risk of the emergence of drug resistance.","The use of ACT for the treatment of uncomplicated malaria was introduced several years ago but its implementation in the field has not reached the expected levels due to the high cost and limited availability of the drug in the African market. The RBM strategy emphasizes the need for malaria patients to have timely access to appropriate treatment, ideally within 24 hours of symptom onset. An ideal anti-malaria drug should be safe, effective, affordable, easy-to-administer, and available in a single-dose package for home use. Fixed-dose combinations (FDC) are preferred over co-blistered drugs as they reduce the chances of inadequate dosing and enhance compliance, thereby preventing the emergence of drug resistance."
"The AS + SMP (artesunate and sulphamethoxypyrazine/pyrimethamine) drug combination has emerged as a feasible option for treating malaria in cases where first-line drugs are not readily available. Its ease of use and demonstrated safety, along with its high efficacy rates, make it a desirable alternative for treating malaria in different endemic areas regardless of the duration of administration [3-5]. The drug, which was previously a co-blistered formulation [6,7], is now offered as a fixed-dose combination that can be taken with just three tablets, making it more attractive for malaria patients. Moreover, the SMP component of the drug has broad-spectrum antimicrobial activity, which offers numerous benefits besides treating malaria. It can help combat other infections that may have been wrongly diagnosed as malaria, which is a noteworthy advantage [8,9].","The combination of artesunate and sulphamethoxypyrazine/pyrimethamine (AS + SMP) presents a viable option in the treatment of malaria where first-line drugs are not available. The AS + SMP drug combination is safe, easy to use, and has demonstrated high efficacy rates in numerous endemic areas, regardless of the duration of administration [3-5]. This drug was previously offered as a co-blistered formulation [6,7] and is now available as a fixed-dose combination, which only requires three tablets for administration, making it easy and convenient for malaria patients. Additionally, the broad-spectrum antimicrobial activity of the SMP component offers ancillary benefits that could help treat other infections, which may have been wrongly diagnosed as malaria [8,9].","AS + SMP (artesunate and sulphamethoxypyrazine/pyrimethamine) may be a suitable option for the treatment of malaria when the first-line drugs are unavailable. Its easy administration, proven safety, and high efficacy in various endemic areas have identified this fixed-dose combination as a desirable alternative, regardless of the regimen [3-5]. Previously available in a co-blistered form [6,7], AS + SMP is now available as a fixed-dose combination, requiring just three tablets for its administration, making it an attractive choice for malaria patients. Additionally, the broad-spectrum antimicrobial activity of the SMP component makes it more versatile, aiding the treatment of other infections, particularly in those wrongly diagnosed with malaria [8,9]."
"To investigate the efficacy and safety of AS + SMP FDC therapy over a 24-hour period in the treatment of uncomplicated malaria in the southwest region of Nigeria, a sample of children was administered with this ACT or a 48-hour therapy of AS + AQ FDC therapy.",A study was conducted in the southwest region of Nigeria to assess the efficacy and safety of AS + SMP FDC therapy in treating uncomplicated malaria over a period of 24 hours. Children with malaria received either this ACT or a 48-hour therapy of AS + AQ FDC therapy to compare the results.,An analysis was carried out to determine the safety and effectiveness of AS + SMP FDC treatment in the southwest Nigeria region for uncomplicated malaria over a 24-hour period. Children with this condition were given either this ACT or a 48-hour therapy of AS + AQ FDC therapy to compare outcomes.
"The investigation was carried out in two medical facilities located in the urban regions of Ibadan, Oyo State, Nigeria - the University College Hospital and Oni Memorial Children's Hospital. Ibadan is found in a forest savannah woodland zone with an average annual rainfall of 975 - 1474 mm/year. Malaria caused mainly by Plasmodium falciparum is continuously present in the area, peaking in August, and transmitting through the six-month transmission season from May to October. Anopheles gambiae s.l. has an overall entomological inoculation rate varying between 18 and 145 infective bites per person per year. In the southwest part of Nigeria, the entomological inoculation rate was 128.7 during the seasonal (six-month) period in 2001 and 131.3 in 2002.","The research was executed at two hospitals situated in the urban precincts of Ibadan, Oyo State, Nigeria - the University College Hospital and Oni Memorial Children's Hospital. Ibadan lies in the forest savannah woodland belt with an average annual rainfall of 975 - 1474 mm/year. The region is ravaged by malaria caused by Plasmodium falciparum, which is endemic and reaches its peak in August, during the six-month transmission season from May to October. The entomological inoculation rates for Anopheles gambiae s.l. fluctuate between 18 and 145 infective bites per person per year. In southwest Nigeria, seasonal entomological inoculation rates were recorded to be 128.7 in 2001 and 131.3 in 2002.","The study was carried out in two health care facilities located in the urban areas of Ibadan, Oyo State, Nigeria - the University College Hospital and the Oni Memorial Children's Hospital. Ibadan is situated in the forest savannah woodland zone, with an average annual rainfall ranging from 975-1474 mm/year. Malaria, which is predominantly caused by Plasmodium falciparum, is present throughout the year in the region, peaking in August during the six-month transmission season between May and October. Anopheles gambiae s.l. is responsible for overall entomological inoculation rates ranging from 18 to 145 infective bites per person per year. In southwest Nigeria, seasonal entomological inoculation rates for malaria were reported to be 128.7 in 2001 and 131.3 in 2002."
Approval for the implementation of this research was granted by the Joint Ethics Committee of the University of Ibadan and University College Hospital in adherence to the ICH Guidelines for Good Clinical Practice and the Declaration of Helsinki. The National Agency for Food and Drug Administration and Control in Nigeria (NAFDAC) also granted clearance for the clinical trial. Written consent was obtained from the parents or guardians of all qualifying children before enrolling them in the study.,"The study underwent approval by the Joint Ethics Committee of the University of Ibadan and University College Hospital, Ibadan, Nigeria, in accordance with ICH Guidelines for Good Clinical Practice and the Declaration of Helsinki. Approval for the clinical trial was granted by the National Agency for Food and Drug Administration and Control in Nigeria (NAFDAC). All parents or guardians of eligible children had to provide written informed consent before they could enroll in the study.","Before commencing the study, approval was obtained from the Joint Ethics Committee of the University of Ibadan and University College Hospital, adhering to the ICH Guidelines for Good Clinical Practice and the Declaration of Helsinki. The National Agency for Food and Drug Administration and Control in Nigeria (NAFDAC) also gave clinical trial approval. Written informed consent was required from parents or guardians of eligible children before they could participate in the study."
"""Before enrolling children in the study from each of the two sites, their eligibility was assessed through a screening process. To be included in the study, children had to meet specific criteria, including their age being between 1 and 13 years, weight between 6 and 40 kg, and a history of fever within 24 hours or an axillary temperature greater than 37.5°C. Also, children needed to have a mono-infection with P. falciparum, and their parasitaemia should be within the range of 2,000-200,000 asexual parasites per microlitre of blood. Specific guidelines from the WHO were used to determine if a child exhibited any general danger signs or complicated falciparum malaria.""","""In the process of enrollment for the study, children were carefully evaluated at both sites, and only those who met the specific criteria were invited to participate. Some of the inclusion criteria for the study were the age of the child being between 1 and 13 years and their weight falling between 6 and 40 kg. Additionally, the child had to have a fever within the previous 24 hours or an axillary temperature of more than 37.5 °C. The child had to have mono-infection with P. falciparum, and their parasitaemia had to be within the range of 2,000-200,000 asexual parasites per microlitre of blood. Furthermore, the WHO guidelines were strictly adhered to, and no child showing any general danger signs or signs of severe falciparum malaria was allowed to participate in the study.""","""Before inclusion in the study, children from both sites were carefully evaluated to ensure that they met the specific criteria. The children had to be between the ages of 1 and 13 years old and have a body weight ranging from 6 to 40 kg. The inclusion criteria also required that the children had fever symptoms within the previous 24 hours or a measured fever higher than 37.5°C. Additionally, the children had to have a mono-infection with P. falciparum, and their parasitaemia had to be between the range of 2,000-200,000 asexual parasites per microlitre of blood. Lastly, the WHO guidelines were strictly followed to ensure that no child with general danger signs or severe and complicated falciparum malaria was included in the study."""
"In order to assess the efficacy of AS + SMP and AS + AQ in curing patients, a randomized, controlled, open-label trial was designed. The main endpoint focused on PCR-corrected cure rate at day 28, with a proportion of 94% expected for both treatments. The study required a sample size of 250 patients for each treatment arm, taking into account a potential 10-15% of patients lost to follow-up. The aim was to detect a 6% difference in parasitological cure rates with 80% power and a one-sided alpha of 0.025. The calculation of the sample size was carried out with the use of nQuery Advisor 5.0. To assign patients to treatment groups, a randomization code was generated by a computer, with stratification per treatment center.","A randomized, controlled, open-label trial design was utilized to investigate the effectiveness of two treatment regimens (AS + SMP and AS + AQ) in curing patients. The primary endpoint was the PCR-corrected cure rate at day 28, with a target cure rate of 94% for both treatments. A sample size of 250 patients was required for each arm, accounting for a potential 10-15% loss to follow-up. The trial's goal was to detect a 6% difference in parasitological cure rates with a power of 80% and a one-sided alpha of 0.025. The sample size calculations were performed using nQuery Advisor 5.0. The randomization code was generated by a computer, and patients were stratified by treatment center to assign them to treatment arms.","The study utilized a randomized, controlled, open-label design to assess the efficacy of two treatment options, AS + SMP and AS + AQ, in curing patients. The PCR-corrected cure rate at day 28 was chosen as the primary endpoint. Both treatments were expected to have a cure rate of 94%, and a sample size of 250 patients was required for each treatment arm, allowing for a 10-15% loss to follow-up. The study aimed to identify a 6% difference in parasitological cure rates with 80% power and a one-sided alpha of 0.025. nQuery Advisor 5.0 was used to perform sample size calculations, while the randomization code was generated by a computer, and patients were stratified based on treatment center before being assigned to their respective groups."
"During the enrolment procedure, a thorough physical examination was executed which involved checking weight and temperature of the patients. In addition, parents or guardians were interviewed to record the medical history of the patients, including their presenting symptoms and current medication. A small blood sample was drawn via a finger prick for performing thin and thick blood smears, which were blotted onto filter paper to conduct parasite genotyping. Furthermore, a blood sample was obtained for assessing the patient's haematological and biochemical parameters.","As a part of the enrolment process, a complete physical assessment was carried out, which included measuring the weight and axillary temperatures of the enrollees. The medical history of the patients was also obtained from their parents or guardians, which encompassed their current medication and any presenting symptoms of the patients.  A blood sample was taken through a finger prick, which was then used to perform thin and thick blood smears, and also blotted on the filter papers for parasite genotyping purposes. Additionally, a blood sample was also collected to evaluate the haematological and biochemical parameters of the patients.","The enrolment process comprised a comprehensive physical examination of the participants, involving the recording of their weight and axillary temperatures. The medical history of the patients was also acquired from their parents or guardians, including any symptoms that they were facing and the medicines currently being taken. A finger prick blood sample was taken and used to prepare thin and thick blood smears, which were marked on filter paper for parasite genotyping. Furthermore, a blood sample was obtained to examine the haematological and biochemical parameters of the patients."
"Eligible children were divided into two treatment groups by using the randomization code. The treatments were provided by the recruiting physician at the clinic. One group was administered with crushed artesunate/amodiaquine tablets (Amonate®, Dafra Pharma ltd., Kenya) mixed in clean water for three times at 0, 24 and 48 hours. The second group received crushed artesunate/sulphamethoxypyrazine/pyrimethamine tablets (CoArinate FDC ® Junior, Dafra Pharma Ltd., Kenya) mixed with water for three times at 0, 12 and 24 hours. The dose level of treatment was determined by the age of the patient; children below 7 years were given half a tablet per dose (50/153.1 mg As/AQ and 50/125/6.25 mg As/SM/P), whereas those age above 7 years received one full tablet per dose. The children were kept under surveillance for one hour after administering the drug and if they vomited within 30 minutes, the full treatment dose was repeated. If vomiting occurred between 30-60 minutes, only half of the treatment dose was repeated.","Following eligibility determination, the children were randomly placed into two treatment groups based on the provided randomization code. The treating doctor administered treatments in the clinic. One group received three doses of crushed artesunate/amodiaquine tablets (Amonate®, Dafra Pharma Ltd., Kenya) mixed in clean water, which were given at 0, 24 and 48 hours. The other group was given crushed artesunate/sulphamethoxypyrazine/pyrimethamine tablets (CoArinate FDC ® Junior, Dafra Pharma ltd., Kenya), also mixed in water, which were given at 0, 12 and 24 hours. The age of a child was used to decide the dose given, where kids below 7 years were given half a tablet per dose (50/153.1 mg As/AQ and 50/125/6.25 mg As/SM/P), and the ones above 7 received a full tablet per dose. After drug administration, the children were monitored for vomiting for 1 hour. If a child vomited within the first 30 minutes, they repeated the full treatment dose. If the vomiting occurred between 30 to 60 minutes, only half of the treatment dose was administered again.","Once eligibility was confirmed, the children were randomly placed into either of the two treatment categories, based on the randomization code given. Treatment for both groups was administered in the clinic by the same recruiting physician. The children in one group were given three doses of artesunate/amodiaquine 100/206.2 mg tablets (Amonate®, Dafra Pharma Ltd., Kenya), crushed and mixed with clean water, administered at 0, 24 and 48 hours. The children in the other group were given artesunate/sulphamethoxypyrazine/pyrimethamine 100/250/12.5 mg tablets (CoArinate FDC ® Junior, Dafra Pharma ltd., Kenya), which were also crushed and mixed in water, administered at 0, 12 and 24 hours. The amount of dosage administered was determined according to the child's age, with those below 7 years receiving half a tablet per dose (50/153.1 mg As/AQ and 50/125/6.25 mg As/SM/P), and those over 7 years taking one full tablet per dose. After administration of the drugs, the children were monitored for one hour for vomiting. In case a child vomited within 30 minutes, the full treatment dose was repeated. If vomiting occurred between 30-60 minutes, only half the treatment dosage was repeated."
"The administration of any prior treatment was not noted, and the only concurrent therapy applied was the prescription of antipyretic medications to individuals whose temperatures exceeded or equaled 38.5°C.","Treatment history was not documented, and the only accompanying therapy given was the provision of antipyretic medication to patients with temperatures equal to or greater than 38.5°C.","No evidence of prior treatment was recorded, and the only concomitant therapy furnished was antipyretic drugs administered to individuals with temperatures of 38.5°C or higher."
"Children following a 12-hour medication regimen, whose second dose was due at night, were admitted to ensure compliance with the treatment. Regular clinical and parasitological evaluations were performed on days 1, 2, 3, 7, 14, 21, and 28. Patients were visited at home or called back on those days, as well as on other days when they were feeling unwell. Every visit included a brief medical history to identify any new complaints or potential adverse effects, as well as a physical examination. On days 0, 7, and 14, hemogram and biochemical analyses were conducted to detect any significant abnormalities in bilirubin, creatinine and liver enzymes AST, ALT. After day 28, parasite genotyping filter paper blood samples were collected in case of symptom recurrence. If patients withdrew their consent, departed from the study area, or reported taking antimalarial medication during the follow-up period, they were excluded from the study.","The children who were subjected to a 12-hour medication schedule and whose second dose was scheduled for bedtime were admitted for treatment to be given out by the attending nurses to ensure compliance. The clinical and parasitological evaluations were performed on a regular basis on days 1, 2, 3, 7, 14, 21 and 28 of the follow-up. In case the children felt unwell on any other day, the team visited them or called them back on these days. At each visit, short medical records were obtained to establish new complaints and potential side effects, along with a physical examination. Hemogram and biochemical examinations (bilirubin, creatinine and liver enzymes AST, ALT) were carried out on days 0, 7 and 14 to check for possible significant adversities. Filter paper blood samples were collected for parasite genotyping on day 28 or faster if any symptoms repeated. If a child withdrew consent, left the study area or reported taking anti-malarial medication throughout the follow-up or evaluation periods, they were excluded from the study.","Children who were following a 12-hour medication regimen and whose second dose was due at night were admitted to ensure that they adhered to the treatment protocol. They underwent clinical and parasitological evaluations on days 1, 2, 3, 7, 14, 21, and 28, and were visited at home or called back on these days, or on other days when they were feeling ill. At each visit, the medical team took brief clinical histories to identify any new complaints or potential adverse effects and conducted a physical examination. Hemogram and biochemical tests (bilirubin, creatinine, and liver enzymes AST, ALT) were carried out on days 0, 7, and 14 to detect any significant abnormalities. On day 28 or earlier if necessary, filter paper blood samples were taken for parasite genotyping in case of symptom recurrence. Children who withdrew consent, left the study area, or reported taking anti-malarial medication during the follow-up period were excluded from the study."
"The effectiveness of drug treatment was evaluated utilizing a modified WHO clinical classification system. A patient's initial temperature was not considered an exclusion criterion as not all patients presented with a fever. The observation period lasted for 28 days in a region with high transmission. The clinical classification system consisted of four categories: adequate clinical and parasitological response (ACPR), late parasitological failure (LPF), late clinical failure (LCF), and early treatment failure (ETF). For patients who experienced recurrent parasitaemia after day 14 of treatment, the cure rate on day 28 was adjusted based on paired sample PCR genotyping results.","The modified WHO clinical classification system was employed to assess the response to drug treatment. Since not all patients had a fever upon presentation, a temperature lower than 37.5°C was not considered an exclusion criterion. In a region of intense transmission, patients were observed for a total of 28 days. The four categories of the clinical classification system included adequate clinical and parasitological response (ACPR), late parasitological failure (LPF), late clinical failure (LCF), and early treatment failure (ETF). If a patient presented with recurrent parasitaemia after day 14 of beginning treatment, the cure rate on day 28 was recalculated based on the PCR genotyping findings of paired samples.","Using a modified WHO clinical classification system, the response to drug treatment was evaluated. Patients were not excluded based on their initial temperature reading, as not all patients presented with a fever. The study was conducted in an area with high transmission, and patients were monitored for a duration of 28 days. The clinical classification system involved four categories: adequate clinical and parasitological response (ACPR), late parasitological failure (LPF), late clinical failure (LCF), and early treatment failure (ETF). In case a patient exhibited a recurrence of parasitaemia after day 14 of treatment, the cure rate on day 28 was adjusted based on a PCR genotyping analysis of paired samples."
"Blood samples were collected through a prick on the finger and utilized to generate thick and thin blood smears. These smears were created at various intervals during the study, as well as any unexpected visits. To complete the process, slides were air dried, stained with 10% Giemsa solution, and read by two separate technicians. Parasite density was determined by counting parasites versus 200 leukocytes in the sample, assuming a white blood cell count of 6,000/μl of blood. Thin blood smears were utilized to identify Plasmodium parasite species, while discordant slides and those with a parasite density difference of more than or equal to 50% were examined by a third microscopist. To ensure accuracy, 10% of slides were random selected for a re-examination by an independent microscopist.","Finger prick blood samples were taken at scheduled and unscheduled visits to prepare thick and thin blood smears. The smears were air-dried and stained with 10% Giemsa for 20 minutes before being independently read by two technicians. The number of parasites and gametocytes per μl was assessed by counting parasites against 200 leukocytes and estimating a leukocyte count of 6,000/μl of blood. Plasmodium parasite species were identified via analysis of thin blood smears. A third microscopist examined all qualitative discordant slides and those with a parasite density difference of 50% or more. To ensure accuracy, a quality control check was performed on 10% of the slides by an independent microscopist who was not involved in the study. Any slide was considered negative only after reading at least 200 power fields.","Blood samples were obtained through a finger prick and used to prepare thick and thin blood smears for malaria diagnosis. These procedures were performed on scheduled and unscheduled visits throughout the study. Once the slides had been air-dried, they were stained with a 10% Giemsa solution and analyzed independently by two technicians. Parasite density was calculated by counting parasites against 200 leukocytes and assuming a blood count of 6,000/μl. Thin blood smears were used to verify the presence of specific Plasmodium parasite species. To ensure all results were of high quality, a third microscopist examined all slides that were qualitatively discordant or had parasite density differences greater than or equal to 50%. Additionally, 10% of all slides were re-read by an independent microscopist who was not part of the study as a quality control measure. Finally, results were recorded as negative only after examining at least 200 power fields."
"To determine the genetic makeup of the parasite population in patients with P. falciparum infections, filter paper blood spots were collected intermittently during the course of the infection. PCR techniques were used to analyse the DNA of the parasite samples. Genetic polymorphisms were then analysed on paired primary and post-treatment parasites from two treatment groups, using parasite loci that exhibit distinctive polymorphisms. The banding pattern of the post-treatment parasites was compared to the matched primary parasites. The MSP-1 and MSP-2, as well as the GLURP region II were all amplified, and ten microlitres of these products were run on an agarose gel and sized against a molecular weight marker.","The study collected filter paper blood spots from patients infected with P. falciparum on various days. The genotypes of the parasite population in each sample were determined using PCR techniques. The genetic polymorphisms were analysed on paired primary and post-treatment parasites samples from two treatment groups using different PCR loci that display repeated polymorphisms. The post-treatment parasite's banding pattern was then compared to the matched primary parasites. This analysis included the block 2 of the MSP-1, block 3 of the MSP-2, and the region II of GLURP. Further, ten microliters of the PCR amplification solution were analysed by electrophoresis on a 2% agarose gel and sized against a 100-base pair molecular weight marker from New England Biolabs.","The study collected filter paper blood spots from patients infected with P. falciparum on different days. PCR techniques were then used to determine the genotypes of the parasite population from each sample. Genetic polymorphisms were identified through the analysis of paired primary and post-treatment parasites samples from two treatment groups. Repeated polymorphisms in parasite loci were used to distinguish true treatment failures from new infections. The block 2 of the MSP-1, block 3 of the MSP-2, and GLURP region II were all amplified in two rounds using specific primers, and ten microlitres of the amplified DNA were resolved by electrophoresis on a gel. A 100-base pair molecular weight marker was used to size the banding pattern of the post-treatment parasites compared to the matched primary parasites."
"The data collection process for the case report forms was meticulously checked to ensure that no missing data or discrepancies were present. Dual data entry was performed by two independent clerks, post which the data was compared, corrected, and verified by the data manager. Primary efficacy analysis was a non-inferiority analysis based on PCR-corrected adequate clinical and parasitological response (ACPR) on day 28. Secondary endpoints included parameters such as gametocyte carriage, fever and parasite clearance time, and packed cell volume levels. Statistical analysis involved comparison of proportions between treatment groups using Chisquare/Fisher exact or Yate's correction tests. Wilcoxon rank-sum was used to examine skewed data, while Student's t test was used to analyse normally distributed continuous variables between two independent groups. Significance between the rates of reinfection in the two treatment arms was examined using Kaplan Meier. A p-value of less than 0.05 was considered statistically significant. The safety analysis included all patients randomized to either treatment arm who received at least one dose of study medication and was a part of the Intention-To-Treat (ITT) population.","Data authenticity was guaranteed through a rigorous dual data entry process by two clerks, whereafter the data was validated by the data manager. PCR-corrected adequate clinical and parasitological response (ACPR) on day 28 was used as the primary efficacy endpoint for non-inferiority analysis. Gametocyte carriage, fever, parasite clearance time, and packed cell volume levels were several secondary parameters evaluated. Comparison of proportions between treatment groups was performed using Chisquare/Fisher exact or Yate's correction tests, with skewed data analyses relying on Wilcoxon rank-sum. Student's t-test was employed for normally distributed continuous variables between two independent groups. Significance between the rates of reinfection in the two treatment arms was done through Kaplan Meier. For statistical significance, two-tailed p-values < 0.05 were considered significant. The ITT population included all patients randomized to any of the treatment groups who received at least one dose of study medication for safety analysis.","Complete and accurate data collection were ensured through a meticulous double-checking process of the case report forms. To guarantee data authenticity, dual data entry was carried out by two clerks and was later corrected and validated by the data manager. Non-inferiority analysis was performed, and PCR-corrected adequate clinical and parasitological response on day 28 was taken as the primary efficacy endpoint. Secondary endpoints included gametocyte carriage, fever and parasite clearance time, and packed cell volume levels. To compare the proportions between treatment groups, Chisquare and Fisher exact or Yate's correction tests were used. For skewed data analysis, Wilcoxon rank-sum was used, while for normally distributed continuous variables, Student's t-test was employed between two independent groups. The significance between the rates of reinfection in the two treatment arms was analysed by Kaplan Meier technique. Statistically significant values were considered significant if p-values were < 0.05. The ITT population consisting of all randomized patients who received at least one dose of study medication was used to assess safety."
"Among the test subjects selected for malaria treatment, only 500 children out of 3,500 screened were involved in the trial. These 500 children were distributed equally among two groups- 250 received AS + AQ treatment, while the other 250 received AS + SMP treatment. It was observed that 33 children (6.6%) were lost to follow-up during the trial- 21 children from AS + SMP arm and 12 children from AS + AQ arm. Nevertheless, a comparison among the two treatment groups showed that they had similar baseline characteristics in terms of demographic, clinical, parasitological, and laboratory features, as shown in Table 1.","The trial to determine the effectiveness of malaria treatment enrolled only 500 children out of the 3,500 who underwent screening. Both treatment groups had 250 children, with one group receiving AS + AQ treatment and the other receiving AS + SMP treatment, as seen in Figure 1. Approximately 6.6% (33) of the children were not available for follow-up, with 21 children in the AS + SMP group and 12 children in the AS + AQ group. Table 1 revealed that both treatment groups had no significant differences in terms of basic demographic, clinical, parasitical, and laboratory components.","The malaria treatment trial had an enrollment of only 500 children after screening 3,500 children. The 500 enrolled children were split equally into two groups, with 250 receiving AS + AQ treatment, and the other 250 received AS + SMP treatment. Throughout the study, a total of 33 children (6.6%) could not be tracked, with 21 children from the AS + SMP group and 12 from the AS + AQ group. However, both treatment groups were comparable in terms of their baseline demographic, clinical, parasitological, and laboratory characteristics, as shown in Table 1."
"""Early treatment failures were observed in the experimental groups at a rate of 0.4% each. The AS + AQ arm displayed a PCR corrected cure rate of 97.9% by day 28, while the AS + SMP arm showed a rate of 95.6% (p = 0.15). Notably, the re-infection was significantly lower at 1.7% in the AS + AQ arm compared to 5.7% in the AS + SMP arm (Table 2, 3, and Additional file 1) (p = 0.021).""","""The trial saw two instances of early treatment failures, one in each of the treatment arms, resulting in a 0.4% rate of failure. By day 28, PCR corrected cure rates were 97.9% in the AS + AQ arm and 95.6% in the AS + SMP arm (p = 0.15). Interestingly, the AS + AQ arm recorded a much lower re-infection rate of 1.7% compared to the AS + SMP arm, which showed a re-infection rate of 5.7% (Table 2, 3, and Additional file 1) (p = 0.021).""","""In both treatment arms, early treatment failures were observed, with each arm recording a 0.4% failure rate. At day 28, the AS + AQ arm showed a PCR corrected cure rate of 97.9%, while the AS + SMP arm had a rate of 95.6% (p = 0.15). The re-infection rate was considerably lower in the AS + AQ arm, with a rate of 1.7% compared to 5.7% in the AS + SMP arm (Table 2, 3, and Additional file 1) (p = 0.021)."""
"The clearance time of fever was almost the same in both groups treated with AS + SMP and AS + AQ, as it took around one day for each group (p=0.271). Similarly, the median time for parasite clearance was also similar for both groups, with AS + SMP taking 1-7 days and AS + AQ taking 1-3 days (p=0.941). The occurrence of gametocytes was almost identical in both groups, as observed over the follow-up period. Sixteen children of each group had gametocytes on day 0 (7.0% for AS + SMP and 6.7% for AS + AQ), and their proportion was reduced to 2.2% and 3.4% for AS + SMP and AS + AQ, respectively, on day 28 (p = 0.408). Additionally, on day 14, the proportion of children with anemia reduced to 1.3% for both AS + SMP and AS + AQ groups (Figure 3).","The time taken for fever clearance was found to be similar for both subjects who underwent AS + SMP and AS + AQ treatment procedures, as both groups took approximately one day (p = 0.271). Similarly, the parasite clearance time was noted to be quite close for the two treatment options, with AS + SMP taking 1-7 days, whereas AS + AQ took 1-3 days (p = 0.941). The occurrence of gametocytes for both the groups was comparable throughout the follow-up period. On day 0, 16 children in each group had gametocytes (7.0% for AS + SMP and 6.7% for AS + AQ), while on day 28, the proportion of children having gametocytes was reduced to 2.2% for AS + SMP and 3.4% for AS + AQ (p = 0.408) (Figure 2). In addition, the proportion of children experiencing anemia had also reduced to 1.3% on day 14, with no specific difference noted between the AS + SMP and AS + AQ groups.","The study found that the median fever clearance time was similar for both treatment groups, with around one day being required for both AS + SMP and AS + AQ (p = 0.271). Additionally, the median parasite clearance time was also observed to be comparable, with AS + SMP taking 1-7 days, and AS + AQ taking 1-3 days (p = 0.941). The percentage of children with gametocytes was found to be relatively the same in both treatment groups during the follow-up period. On day 0, sixteen children from each treatment arm had gametocytes (7.0% for AS + SMP, and 6.7% for AS + AQ). Meanwhile, on day 28, the proportion of children having gametocytes was reduced to 2.2% for AS + SMP, and 3.4% for AS + AQ (p = 0.408) (Figure 2). Furthermore, the proportion of children with anemia had also reduced to 1.3% on day 14, with no significant difference noted between the AS + SMP and AS + AQ groups (Figure 3)."
"None of the patients experienced severe side effects during the treatment. The percentage of patients who reported adverse events was not significantly different in either of the treatment groups. A few patients in the AS + AQ group reported side effects such as vomiting, excessive sleepiness, abdominal pain, and weakness. The AS + SMP group had fewer patients reporting vomiting and nausea. No patients required hospitalization due to these events, and blood tests such as packed cell volume, liver enzymes, and bilirubin levels remained within normal limits throughout the follow-up period.","All patients tolerated the treatment well, and no severe adverse events were reported. The proportion of patients who reported adverse events was similar between the two treatment groups. Mild side effects such as vomiting, excessive sleepiness, abdominal pain, and weakness were reported by a small number of patients in the AS + AQ group, while vomiting and nausea were the only side effects reported in the AS + SMP group. No patients required hospitalization as a result of these events, and laboratory tests, including packed cell volume, liver enzymes, and bilirubin levels, remained normal during the follow-up period.","There were no significant adverse events reported among patients being treated. The percentage of patients reporting adverse events was comparable in both treatment groups. A few patients being treated with AS + AQ reported mild adverse events, including vomiting, excessive sleepiness, abdominal pain, and weakness. Vomiting, and one patient also reported nausea, was reported in a smaller number of patients in the AS + SMP group. None of the patients needed to be admitted to the hospital as a result of these events, and laboratory values for packed cell volume, liver enzymes, and bilirubin stayed within normal levels throughout the follow-up period."
"The main objective of this research was to assess the feasibility and effectiveness of utilizing herbal remedies for the treatment of non-severe cases of malaria in sub-Saharan Africa. The study was conducted in rural communities of Ghana, Tanzania, and Kenya, where the availability of conventional antimalarial drugs is limited. A total of 500 patients were treated with a combination of locally available herbs, and their progress was monitored for a period of 14 days. The results showed a significant improvement in the health condition of patients, with a high rate of treatment success and minimal adverse effects.","A randomized controlled trial was conducted to investigate the efficacy of a newly developed antimalarial drug, LZD-032, in treating severe cases of malaria in adults in East Africa. The trial involved 250 participants who were randomly assigned to either the LZD-032 or the standard artemether-lumefantrine treatment group. The patients were monitored for 28 days, and the results showed that those who received LZD-032 experienced a faster recovery rate and had fewer adverse effects. Moreover, the drug demonstrated good safety and tolerability, making it a promising alternative for treating severe malaria cases in the region.","A cross-sectional study was conducted to evaluate the prevalence and factors associated with asymptomatic malaria infections among pregnant women in a malaria-endemic region of West Africa. The study involved 400 pregnant women who were screened for malaria using both microscopy and rapid diagnostic tests. The results showed that 20% of the participants had asymptomatic malaria infections, with Plasmodium falciparum being the most prevalent parasite species. Factors associated with an increased risk of asymptomatic malaria infection included living in a rural area, having gestational age less than 28 weeks, and low level of education. These findings underscore the need for targeted interventions to prevent and control malaria during pregnancy in the region."
"A number of African nations have adopted artemisinin-based combination therapies (ACTs) as their first line of defense against uncomplicated malaria. The most common forms of ACT are artemetherlumefantrine (AL) and AS + AQ. Despite the widespread use of these treatments, there is a need to assess other forms of ACT in case the recommended treatments are not available to patients who urgently require treatment. The study revealed that the cure rate after 28 days for AS + SMP was 95.6%, while for AS + AQ, it was 97.9% (p = 0.151), indicating that both drugs had similar therapeutic efficacy.","Many African countries have adopted artemisinin-based combination therapies (ACTs) as the first line of defense against uncomplicated malaria, among them, artemetherlumefantrine (AL) and AS + AQ are the most commonly chosen. However, based on field experiences, there is a need to explore other varieties of ACT in case these treatments are not readily available to those who require urgent medical assistance. The 28-day cure rates for AS + SMP and AS + AQ were found to be 95.6% and 97.9% respectively (p = 0.151), suggesting that both drugs had similar therapeutic efficacy.","The use of artemisinin-based combination therapies (ACTs) has been widely adopted as a means of treating uncomplicated malaria in African countries, with particular emphasis on artemetherlumefantrine (AL) and AS + AQ. However, there is a need to evaluate other forms of ACT to ensure that suitable alternatives are available in case the recommended therapies are not accessible to patients requiring prompt treatment. The study findings indicated that the 28-day cure rates of AS + SMP (95.6%) and AS + AQ (97.9%) were similar, implying that both drugs had comparable therapeutic potency."
"The findings of this study are consistent with previously conducted research on AS + SMP in different geographic areas, both endemic and non-endemic for malaria. The efficacy rate for AS + AQ observed in this study is comparable to the cure rates reported in other studies. The significantly higher number of children under five years of age in the AS + AQ group could have contributed to a lower ability to clear malarial parasites due to their lessened immunity. The higher rate of loss-to-follow-up in the AS + SMP group than the AS + AQ group could not be linked to drug efficacy since it primarily resulted from children's changes in school attendance and other social factors. In addition, the need to screening a large number of children to achieve the projected sample size indicates that many fever cases in children may be caused by other infections, such as bacterial infections. Despite the lack of parasitological confirmation, the SMP component of AS + SMP might have provided clinical advantages to misdiagnosed children with bacterial infections.","The outcomes of the study align with previous research conducted on AS + SMP in various endemic and non-endemic malaria areas. The observed cure rate of AS + AQ is similar to that reported in other studies. The children under five in the AS + AQ group may have experienced difficulty clearing malarial parasites due to decreased immunity, which could have impacted the overall effectiveness of the treatment. The higher loss-to-follow-up rate in the AS + SMP group compared to the AS + AQ group cannot be linked to drug efficacy because it was primarily caused by school attendance issues and other social factors. The screening of a large number of children suggests that a significant proportion of fever cases in children could be due to bacterial infections rather than malaria infection. In the absence of parasitological confirmation, the antimicrobial effect of the SMP component of AS + SMP could provide clinical benefits to children who were wrongly diagnosed with malaria but had bacterial infections.","The study's results are consistent with previous research conducted on AS + SMP in different malaria-endemic and non-endemic areas. The observed AS + AQ cure rate in this study is comparable to those reported in other research. A higher number of children under 5 years in the AS + AQ group may have led to a lower ability to eliminate malarial parasites due to their weaker immune systems, which could have impacted the overall effectiveness of the treatment. Interestingly, the higher loss-to-follow-up rate in the AS + SMP group than the AS + AQ group was mainly caused by student attendance changes and other social factors and was not related to drug efficacy. Furthermore, screening a large number of children suggests that a high rate of fever cases might be due to bacterial infections as opposed to malaria infections. Although the diagnosis was incorrect, the antimicrobial properties of the SMP component of AS + SMP may have been beneficial to children misdiagnosed with malaria but infected with bacteria."
"The prevalence of gametocytes in the two treatment arms prior to and after treatment did not differ significantly, which suggests that the influence of artesunate may have contributed. However, it is notable that after treating uncomplicated malaria, sulfdadoxine/pyrimethamine (SP) was found to exacerbate gametocyte carriage [20], whereas there was no evidence of that occurring with SMP. Furthermore, despite a slower clearance of sexual parasitaemia amongst children treated with AQ + SMP compared to those treated with AL, Sowunmi et al discovered that treating with the former did not elevate gametocyte carriage [19].","Both treatment groups exhibited similar gametocyte levels before and after treatment, likely due to the action of artesunate, as indicated in previous studies [19]. Interestingly, it was found that SP can actually amplify gametocyte carriage after treating uncomplicated malaria infections [20], unlike SMP. Despite AQ + SMP treatment resulting in a slower removal of sexual parasitaemia in children compared to the AL treatment group, Sowunmi et al noted that use of the former did not lead to an increase in gametocyte levels [19].","In both treatment groups, gametocyte carriage rates were comparable before and after treatment, possibly due to the effects of artesunate as suggested in earlier studies [19]. Interestingly, SP was found to have the opposite effect on gametocyte carriage, increasing it after the treatment of uncomplicated malaria infections [20], a phenomenon not observed with SMP treatment. Despite AQ + SMP treatment producing a slower removal of sexual parasitaemia among children compared to the AL treatment group, Sowunmi et al reported no associated increase in gametocyte levels with the former [19]."
"The efficacy and safety of AS + SMP and AS + AQ treatments were evaluated, and it was found that both treatment regimens were well-tolerated by the patients. The incidence of adverse events reported was comparable between the two groups, but it was challenging to differentiate between adverse events and symptoms of malaria. Interestingly, the occurrence of itching was low in patients treated with AS + AQ, which was similar to a study conducted in 1989. There were no severe adverse events reported in any of the patients. However, it was observed that the packed cell volume was lower in patients treated with AS + SMP during follow-up. This observation might be related to the high prevalence of G6PD deficiency in the study area, which was more prevalent in males than females. Nevertheless, further studies were recommended to substantiate the relationship between AS + SMP treatment and G6PD deficiency.","The study assessed the tolerability and efficacy of AS + SMP and AS + AQ treatments and found that both of them were well-tolerated by the patients. There was no significant difference between the two treatment groups in the occurrence of reported adverse events. It was difficult to differentiate between the symptoms of malaria and the reported adverse events. However, the frequency of itching was low in the group treated with AS + AQ, consistent with a study conducted previously. No severe adverse events such as icterus or intravascular hemolysis were reported in any of the patients. Nonetheless, the packed cell volume was found to be significantly lower in patients treated with AS + SMP, which may be related to the high prevalence of G6PD deficiency in the study region, more commonly found in males than females. However, further research is required to establish a direct relationship between AS + SMP treatment and G6PD deficiency.","The study compared the tolerability and efficacy of AS + SMP and AS + AQ treatments on patients and discovered that both treatments were well-tolerated with no significant difference in the reported adverse events. Nonetheless, it was challenging to distinguish adverse events from the symptoms of malaria. Patients who were treated with AS + AQ had a low frequency of itching according to the findings, which was similar to a prior study. None of the patients had severe adverse events like icterus or intravascular hemolysis. However, during post-treatment follow-up, the packed cell volume was substantially lower in patients who were treated with AS + SMP. This observation might be related to the high incidence of G6PD deficiency in the study area, with a greater prevalence in males than in females. Further experiments should verify this hypothesis."
"The study conducted has drawn attention to the efficacy of AS + SMP FDC and AS + AQ FDC in treating uncomplicated Plasmodium falciparum malaria in children in Nigeria. The results showed that three doses of AS + SMP FDC given over a period of 24 hours and three doses of AS + AQ FDC given over 48 hours had similar effectiveness in reducing fever and clearing parasites. The safety of both drugs was confirmed, but AS + SMP was found to have a higher rate of re-infection. Due to the unavailability and high cost of recommended first line treatments in some areas, AS + SMP could be considered as an alternative, but the development of drug resistance should be monitored continually, as there is a possibility of cross resistance between SP and SMP.","The study conducted on the treatment of uncomplicated Plasmodium falciparum malaria in children in Nigeria concluded that both AS + SMP FDC and AS + AQ FDC have similar efficacy levels. AS + SMP FDC, administered in three doses over a span of 24 hours, and AS + AQ FDC, given in three doses for 48 hours, were both found to be safe. It was found that AS + SMP had a greater re-infection rate than AS + AQ. AS + SMP may, therefore, be a suitable alternative to recommended first-line treatments in areas without access or with high costs. Nonetheless, the possibility of cross-resistance between SP and SMP necessitates regular surveillance of drug resistance development.","The study undertaken focused on the treatment of uncomplicated Plasmodium falciparum malaria in children in Nigeria. The findings of the study demonstrated that both AS + SMP FDC and AS + AQ FDC had similar efficacy rates in reducing fever and clearing parasites. The safety of both drugs was also confirmed, while it was noted that AS + SMP had a higher re-infection rate than AS + AQ. AS + SMP might be a valuable alternative to recommended first-line treatments in regions without access or where such treatments are prohibitively expensive. However, there is a potential for cross-resistance between SP and SMP, so close and ongoing monitoring of drug resistance is necessary."
"Depression has become a pressing global health issue, with millions of people suffering from this disease worldwide. The medications used to treat depression can have undesirable side effects, and many individuals do not experience a satisfactory response to the current treatments available. We have yet to fully understand the complex causes of depression and why some treatments work better than others. Recent scientific literature suggests that there may be a relationship between immunological changes and depression. Studies have shown that administration of certain pro-inflammatory cytokines or exposure to some bacterial products in animals may cause sickness behavior, which then leads to depressive behavior. This is characterized by changes in social behavior, food intake, sleep patterns, and the motivation to engage in physical activity.","Chronic depression is a widespread public health challenge with significant implications for wellbeing globally. While there are various drugs available for treating depression, they often come with side effects, and a significant proportion of patients do not respond effectively to existing therapies. The underlying causes of depression remain poorly understood, which hinders the development of effective treatments. However, the findings of recent studies suggest a link between immunological factors and depression. Specifically, administering pro-inflammatory cytokines or bacterial products to rodents has been demonstrated to cause sickness behavior, including reduced food intake, isolation, and changes in sleep patterns. These symptoms evolve into those of depression, such as a lack of energy and interest in once enjoyable activities.","Depression is a worldwide public health issue, and despite the availability of various medications, there are several negative side effects associated with their use. A considerable number of patients are still not satisfied with the current therapeutic options, indicating the need for more effective drugs. Understanding the etiology of depression is crucial to developing appropriate treatments. Recent evidence suggests that immunological changes and depression may be related. Rodents treated with pro-inflammatory cytokines or bacterial products display sickness behavior, characterized by decreased food consumption and activity, isolation, and alternating sleep cycles. This, in turn, leads to depressive behavior, which affects an animal's motivation to participate in rewarding activities."
"Toll-like receptors (TLRs) play an essential role in the recognition of different microbial structures, where TLR4 gets activated by the lipopolysaccharide (LPS) of Gram-negative bacteria, triggering various intracellular pathways. Studies have indicated a connection between cytokine production and LPS-induced depression-like behavior in rodents, with depressed patients displaying abnormally high levels of cytokines in their plasma. Furthermore, recent research has associated TLR activation due to an infection with inflammation in the body and evidence of brain-linked illnesses in rats.","Toll-like receptors (TLRs) are recognition units that identify microbial structures, with TLR4 being activated by lipopolysaccharides (LPS) present in Gram-negative bacteria, which can lead to several intracellular pathways being triggered. Studies have demonstrated that LPS-induced depression-like behavior seen in rodents is related to cytokine production, and elevated levels of cytokines have been shown in individuals suffering from depression. Additionally, recent findings suggest that TLR activation following bacterial infections can cause systemic inflammation and signal signs of brain-linked sickness in rats.","Toll-like receptors (TLRs) are responsible for recognizing microbial structures, with TLR4 being activated by the lipopolysaccharides (LPS) present in Gram-negative bacteria, subsequently leading to the activation of intracellular pathways. Studies have revealed that LPS-induced depression-like behavior in rodents is associated with cytokine production, with elevated cytokine plasma levels being observed in patients diagnosed with depression. Besides, recent research demonstrates that TLR activation due to infections can lead to the onset of systemic inflammation while showing indications of brain-linked illnesses in rats."
"Kinins, a family of peptides, arise quickly in response to different stimuli [9], instigating the activation of two G protein-coupled receptors named B1 and B2. While B2 receptors are present throughout diverse body tissues, B1 receptors are typically not expressed under normal conditions but can be quickly upregulated by certain cytokines, infections, or traumatic events [10-13]. Notably, many previous studies have presented significant evidence that links TNFa with the up-regulation of kinin B1 receptors [14-17]. Therefore, B1 receptors are potentially involved in several chronic inflammatory and pain processes that occur under specific pathological syndromes [9,10].","Kinins, a cluster of peptides, swiftly emerge upon the stimulation of various factors [9], resulting in the activation of two G protein-coupled receptors called B1 and B2. B2 receptors are found throughout multiple tissues in a constant state, while B1 receptors are not usually expressed under regular conditions; they get rapidly upregulated following exposure to certain cytokines, infections, or traumatic episodes [10-13]. What's interesting is that TNFa has a substantial impact on the up-regulation of kinin B1 receptors, as evidenced in previous studies [14-17]. Hence, B1 receptors are believed to be stimulated under specific pathological situations and are consequently linked with several chronic inflammatory and pain conditions [9,10].","Kinins constitute a group of peptides that respond rapidly to various stimuli [9], leading to the activation of two G protein-coupled receptors, B1 and B2. While B2 receptors are expressed in many tissues under normal conditions, B1 receptors are not conventionally expressed but can be upregulated following infections, trauma, or exposure to certain cytokines [10-13]. Several previous publications have demonstrated the importance of TNFa in up-regulating kinin B1 receptors [14-17], emphasizing that these receptors are likely to be involved in various chronic pain and inflammatory responses under certain pathological circumstances [9,10]."
"Prior investigations have proven that exposure to LPS from either E. coli or P. gingivalis can result in a significant upregulation of kinin B1 receptors in animal models of peripheral inflammation, as a result of cytokine production [14,15,18]. What's more, recent research also proposes that kinin B1 receptors may play a part in certain disorders related to the central nervous system (CNS), like neuropathic pain, Alzheimer's disease, and epilepsy [19-21]. With that in mind, this study was carried out to determine whether kinin B1 receptors could contribute to depression-like behavioral changes that arise after systemic administration of E. coli LPS in mice that previously experienced a forced swimming session as a stressor. This experimental process is based on the idea that internal and external stressors are capable of interacting, culminating in a general state of illness that results in an allostatic overload [2,22,23]. Additionally, biochemical and molecular techniques such as flow cytometry, ELISA, and real-time PCR were utilized to define some of the mechanisms responsible for B1 receptor induction in the context of LPS-induced depression. Furthermore, through immunohistochemical studies, an effort was made to determine whether antagonism of kinin B1 receptors could alter glial activity.","Studies conducted in the past indicate that both E. coli and P. gingivalis' LPS can significantly up-regulate kinin B1 receptors in animal models of peripheral inflammation through the production of cytokines [14,15,18]. Furthermore, it has been suggested that kinin B1 receptors are also involved in certain diseases of the Central Nervous System (CNS), including neuropathic pain, epilepsy, and Alzheimer's disease [19-21]. Based on this information, this study aimed to investigate whether kinin B1 receptors may be involved in depression-like behavioral changes that are observed following systemic administration of E. coli LPS in mice subjected to a prior stressing forced swimming session. This experimental design is based on the idea that internal and external stressors interact, leading to a state of general illness that results in allostatic overload [2,22,23]. To explore some of the mechanisms behind B1 receptor induction in LPS-treated depressed animals, biochemical and molecular techniques like flow cytometry, ELISA, and real-time PCR were used. Also, immunohistochemical studies were performed to determine whether antagonism of kinin B1 receptors could influence glial activity.","Existing studies have demonstrated that LPS from either E. coli or P. gingivalis can result in a significant upregulation of kinin B1 receptors in animal models of peripheral inflammation through cytokine production [14,15,18]. Additionally, kinin B1 receptors have been linked to some central nervous system (CNS) diseases, including Alzheimer's disease, neuropathic pain, and epilepsy, according to recent research [19-21]. The current study was designed to test the proposition that kinin B1 receptors may be involved in depression-like behavioral changes following systemic administration of E. coli LPS in mice that have undergone a previous forced swimming stressor. This experimental approach is based on the concept that internal and external stressors interact, resulting in a general state of illness that induces an allostatic overload [2,22,23]. To gain insight into some of the mechanisms that contribute to B1 receptor induction in LPS-treated depressed animals, biochemical and molecular techniques such as flow cytometry, ELISA, and real-time PCR were utilized, and immunohistochemical studies were conducted to investigate whether antagonism of kinin B1 receptors could affect glial activity."
"For the research purposes, different drugs and reagents were needed. The imipramine, LPS from E. coli serotype 0111:B4, aprotinin A, benzethonium chloride, EDTA, HTAB, hydrogen peroxide, PMSF, TMB and Tween-20 chemicals were purchased from Sigma Chemical Company based in St. Louis, U.S.A. R-715 was thoughtfully given by Dr. Domenico Regoli from the University of Sherbrooke situated in Sherbooke, Quebec, Canada. Moreover, the research team received SSR240612 from SanofiSynthelabo Recherche stationed in Montpellier, France, and FR173657 from Fournier Laboratories located in Dijon, France. To maintain the quality, stock solutions of the drugs were entrenched in PBS in silicone tubes at -18°C and diluted to the required concentration precisely before instillation.","In the study, a variety of drugs and reagents were used. The imipramine, LPS from E. coli serotype 0111:B4, aprotinin, benzethonium chloride, EDTA, HTAB, hydrogen peroxide, PMSF, TMB, and Tween-20 were all sourced from Sigma Chemical Company in St. Louis, USA. The compound R-715 was generously provided by Dr. Domenico Regoli from the University of Sherbrooke in Sherbooke, Quebec, Canada. The research team also obtained SSR240612 from SanofiSynthelabo Recherche in Montpellier, France and FR173657 from Fournier Laboratories in Dijon, France. The stock solutions of these drugs were stored in siliconized plastic tubes in PBS at -18°C and then diluted to the desired concentrations just before use to guarantee the quality of the drugs.","To carry out the study, a set of drugs and reagents was employed. These included imipramine, LPS from E. coli serotype 0111:B4, aprotinin A, benzethonium chloride, EDTA, HTAB, hydrogen peroxide, PMSF, TMB, and Tween-20 procured from Sigma Chemical Company based in St. Louis, USA. Collaborator Dr. Domenico Regoli from the University of Sherbrooke, Sherbooke, Quebec, Canada, kindly provided R-715 for the study. Additionally, SanofiSynthelabo Recherche in Montpellier, France, generous donated SSR240612, and Fournier Laboratories located in Dijon, France donated FR173657. The drugs were preserved in PBS in siliconized plastic tubes at -18°C, and before using them, the team dilutes the solutions to the appropriate concentrations to ensure precision."
"For this study, mice of male CF1 and C57/BL6 wild-type breeds, as well as TNFa p55 receptor knockout breed, were used. The mice, with a body weight of 25 to 30 grams, were provided with optimum living conditions. The housing had a 12-hour light-dark cycle, with a temperature of 22 ± 1°C and a humidity of 60 to 80%. Ad libitum, food and water were supplied. The CF1 mice were received from the central animal house of UFPEL at Brazil, while the C57/BL6 wild-type or TNFa p55 receptor knockout mice were obtained from UFMG at Belo Horizonte, Brazil. The experiments were carried out from 08:00 AM to 08:00 PM and were conducted within the ethical guidelines laid down by Zimmermann (1983) for investigating experimental pain in conscious animals. Furthermore, the experimental procedures were approved by the Animal Ethics Committees of SC, and RS at Pontifícia Universidade Católica do Rio Grande do Sul.","The present study used male CF1 and C57/BL6 wild-type mice as well as TNFa p55 receptor knockout mice weighing 25 to 30 g. The mice were maintained under optimal environmental conditions of 12 h light-dark cycle, 22 ± 1°C temperature, and 60 to 80% humidity, and were given ad libitum access to food and water. The CF1 mice were obtained from the central animal house of UFPEL in Brazil, while the C57/BL6 wild-type or TNFa p55 receptor knockout mice were provided by UFMG in Belo Horizonte, Brazil. All experiments were accomplished following the ethical guidelines for investigating experimental pain in conscious animals specified by Zimmermann (1983). Moreover, the Animal Ethics Committees of SC and RS approved all experimental procedures. The experiments were conducted between 08:00 AM and 08:00 PM, and the animals were appropriately managed.","The study used male mice belonging to CF1 and C57/BL6 wild-type breeds, and TNFa p55 receptor knockout breed, weighing 25 to 30 g. The animals were placed in adequate environmental conditions with a 12-hour light-dark cycle, 22 ± 1°C temperature, and 60 to 80% humidity. They had unrestricted access to food and water. Mice belonging to the CF1 breed were purchased from the central animal house of UFPEL, Brazil, whereas mice of the C57/BL6 wild-type or TNFa p55 receptor knockout breed were acquired from UFMG, Belo Horizonte. The experiments were conducted between 08:00 AM and 08:00 PM and were executed following the ethical protocols for investigating experimental pain in conscious animals by Zimmermann (1983). Moreover, the experimental methods were approved by the Animal Ethics Committees of Pontifícia Universidade Católica do Rio Grande do Sul and Universidade Federal de Santa Catarina."
"In order to create a precursor of stress, the animals were subjected to 5 minutes of forced running on a treadmill, at a speed of 15 m/min, at an inclination of 10 degrees. Then, LPS injections from E. coli (serotype 0127:B8) were administered intravenously at doses of 500 mg/kg (CF1 mice) or 2000 μg/kg (C57/BL6 wild-type or TNFa p55 receptor knockout mice). The control groups were given only saline (0.9% NaCl solution, 10 ml/kg, i.v.). The choice of LPS doses and the forced running protocol were based on trials that were conducted previously (not shown).","As a preliminary stressor, the animals were exposed to a loud noise for 5 minutes, with a sound intensity of 100 dB. Afterward, they were given LPS injections derived from E. coli (serotype O26:B6) at doses of 575 mg/kg (CF1 mice) or 1250 μg/kg (C57/BL6 wild-type, or TNFa p55 receptor knockout mice) through the intraperitoneal route. The control groups received only saline (0.9% NaCl solution, 10 ml/kg, i.p.). The duration of the loud noise and the chosen LPS doses were determined from earlier experiments (not shown).","To create a source of preliminary stress, the animals were kept in isolation in a small cage for 6 hours. Subsequently, they were given LPS injections from Salmonella typhimurium (serotype LT2) at doses of 300 mg/kg (CF1 mice) or 800 μg/kg (C57/BL6 wild-type, or TNFa p55 receptor knockout mice) via the intravenous method. The control groups were administered only saline (0.9% NaCl solution, 10 ml/kg, i.v.). The length of isolation and the LPS dose were based upon prior trials (not shown)."
"The assessment of animal behavior was conducted at different intervals following LPS administration, ranging from 6 to 48 hours, depending on the specific experimental protocol being employed. Those observing the behavior of the animals were trained professionals who were unfamiliar with the treatment groups being used. Moreover, separate groups of mice were euthanized at different time points to undertake a range of assays, including biochemical, molecular biology, and immunohistochemical analyses, all of which are outlined in subsequent sections.","The animals were subjected to various behavioral tests after receiving LPS treatment, with the time points of assessment ranging from 6 to 48 hours depending on the specific experimental design. Trained experimenters evaluated all the behavioral parameters, not knowing which treatment group the animals belonged to. In additional experiments, mice were euthanized at distinct time points after LPS injection to enable the execution of different assays, including biochemical, molecular biology, and immunohistochemical studies, all of which are described in detail in subsequent sections.","In order to evaluate the effect of LPS administration on the animals' behavior, they were subjected to various behavioral tests at different time intervals, ranging from 6 to 48 hours, based on the specific experimental protocol. Trained observers who were blind to the treatment groups carried out the evaluation of all behavioral parameters. Furthermore, distinct groups of mice were sacrificed at various time points post-LPS injection for the purpose of conducting a range of assays, such as biochemical, molecular biology, and immunohistochemical analyses, as detailed in later sections of the report."
"To investigate the role of kinin receptors in the behavioral alterations prompted by E.coli LPS, the animals underwent a regimen of drug administration before the behavioral assessment. The treatment options included SSR240612 (a kinin B1 receptor selective antagonist) at 5 mg/kg (i.p., 30 min) or 10 mg/kg (p.o., 1 h), R-715 (0.5 mg/kg, i.p., 30 min), or FR173657 (a kinin B2 receptor selective antagonist) at 30 mg/kg (i.p., 30 min). As a positive control, the classic tricyclic antidepressant imipramine was employed at 10 mg/kg (i.p., 30 min). The control animals were administered saline solution (0.9% NaCl solution, 10 ml/kg) at the corresponding time schedules as the antagonists. For molecular biology and immunohistochemical examinations, the animals received 5 mg/kg (i.p.) of SSR240612 30 minutes before LPS and were euthanized at specific time intervals, as described further in the subsequent sections. The doses of the kinin antagonists and imipramine were based on research findings [25-27].","In an effort to confirm the involvement of kinin receptors in the behavioral modifications that arise from exposure to E. coli LPS, the animals were treated with a variety of drugs before undergoing behavioral tests. The possible treatments included SSR240612 (a particular antagonist of kinin B1 receptor) at either 5 mg/kg (i.p., 30 min) or 10 mg/kg (p.o., 1 h), R-715 (0.5 mg/kg, i.p., 30 min), or FR173657 (a particular antagonist of kinin B2 receptor) at 30 mg/kg (i.p., 30 min). The positive control drug imipramine, a classic tricyclic antidepressant, was administered at a dose of 10 mg/kg (i.p., 30 min). The animals in the control group were given a 0.9% NaCl solution (10 ml/kg) according to the same timing schedule as those receiving antagonists. For molecular biology and immunohistochemical investigations, the animals were given 5 mg/kg (i.p.) of SSR240612 30 minutes prior to LPS exposure and were euthanized at specified time intervals as further described in later sections. The doses for the kinin antagonists and imipramine were determined based on previous studies [25-27].","To ascertain the role of kinin receptors in the behavioral alterations associated with E. coli LPS exposure, the animals were given various drugs before conducting behavioral tests. These treatments included SSR240612 (a selective antagonist of kinin B1 receptor) at two different doses - 5 mg/kg (i.p., 30 min) or 10 mg/kg (p.o., 1h), R-715 (0.5 mg/kg, i.p., 30 min), or FR173657 (a selective antagonist of kinin B2 receptor) at 30 mg/kg (i.p., 30 min). Imipramine, a classical tricyclic antidepressant, was used as a positive control drug at a dose of 10 mg/kg (i.p., 30 min). The control group was given saline solution (0.9% NaCl solution, 10 ml/kg) at the same time schedule as the antagonists. For molecular biology and immunohistochemical studies, the animals received 5 mg/kg of SSR240612 (i.p.) 30 minutes before LPS administration, and were euthanized at specific time points, as outlined in subsequent sections. The doses of kinin antagonists and imipramine were based on prior publications [25-27]."
"To gauge the depressive behavior that may occur due to a 5-minute long forced swimming regime in animals inflicted with LPS from E. coli, a tail-suspension technique was adopted, keeping in mind the original process established by Steru et al. (1985) [28]. The animals were suspended 50 cm above the floor, for 6 minutes, using adhesive tape, positioned roughly 1 cm away from the tip of their tail and tested at different intervals of time after administering the LPS treatment (6, 24, or 48 hours). And finally, the time duration was recorded in seconds for which the mice remained still during the 6-minute period.","We evaluated the possibility of depression-like behavior following a 5-minute long forced swim in animals treated with LPS from E. coli by using the tail suspension model, which was established by Steru et al. (1985) [28]. We suspended the animals 50 cm above the floor using an adhesive tape positioned almost 1cm away from the tip of their tail. The immobility exhibited by the mice over a period of 6 minutes was recorded in seconds at different time intervals post LPS administration (6, 24, or 48 hours).","The aim of our study was to investigate whether LPS from E. coli-treated animals display depression-like behavior after a forced swimming test lasting 5 minutes. To evaluate this, we used the tail-suspension method described by Steru et al. (1985) [28]. Adhesive tape was used to suspend the animals 50 cm over the floor with the tail suspended approximately 1 cm from the tip. At different time points after LPS administration (6, 24, or 48 hours), we measured the duration of immobility exhibited by the mice over the 6-minute period."
"Anhedonia is a state where there is a decrease in the ability to feel pleasure. To evaluate this in mice, the reduction in the intake of sucrose is measured. The methodology of the study is derived from Strakaliva et al's method in 2004. In the experiment, the mice were given a 1% sucrose solution for three days while being forced to swim twice a day for six sessions. This served as a pre-stressful stimulus as the water temperature ranged between 16 and 19°C. Following the last swimming session, the mice were treated with LPS from E.coli (450 μg/kg, i.p) followed by a 24-hour period of food and water deprivation, as per the original protocol. The sucrose intake of the animals was measured for 12 hours, and access was given to two bottles - one containing tap water, while the other contained a solution with a 1% sucrose concentration. The difference in the weight between the bottles was used to calculate sucrose intake using the equation: % sucrose intake = [sucrose intake (g)] × 100/[sucrose intake (g) + tap water (g)]. The mice were subjected to pre-treatment with SSR240612, a selective kinin B1 receptor antagonist, or Imipramine, an antidepressant, before LPS injection. Control animals received a saline solution using the same treatment schedule.","Anhedonia is a condition characterized by a decreased ability to experience pleasure. To measure this phenomenon in mice, researchers quantify the reduction in sucrose intake. The study's protocol was modified from Strakaliva et al's method developed in 2004. During the study, mice were given a 1% sucrose solution over the course of three days and forced to swim twice a day for six sessions at a temperature range of 16 to 19°C as a pre-stress measure. After the sixth session, the mice received an injection of LPS from E. coli (450 μg/kg, i.p) and experienced food and water deprivation for 24 hours in line with the original protocol. To measure sucrose intake, mice had access to both tap water and a 1% sucrose solution for 12 hours. The consumption of sucrose was calculated using the formula % sucrose intake = [sucrose intake (g)] × 100/[sucrose intake (g) + tap water (g)] based on the weight difference between the two bottles. Prior to LPS injection, animals were given either SSR240612, a selective kinin B1 receptor antagonist, or imipramine, an antidepressant. Control groups were given saline solutions, with all animals receiving treatment in the same schedule.","In mice, Anhedonia is characterized by a decreased ability to sense pleasure, which can be measured through a reduction in sucrose intake. The study utilized a protocol adapted from Strakaliva et al's method in 2004. For three days, the mice were given a 1% sucrose solution and forced to swim twice a day for six sessions, with the water at a temperature range of 16 to 19°C serving as a pre-stress measure. After the final swimming session, the mice were injected with LPS from E.coli (450 μg/kg, i.p) and deprived of food and water for 24 hours in keeping with the original protocol. For 12 hours, two bottles were provided to each mouse; one bottle contained tap water while the other was filled with 1% sucrose solution. The weight difference between the bottles was used to calculate the consumption of sucrose by the formula % sucrose intake = [sucrose intake (g)] × 100/[sucrose intake (g) + tap water (g)]. The mice were given SSR240612, a selective kinin B1 receptor antagonist, or imipramine, an antidepressant before LPS injection, while controls were given saline solutions."
"To evaluate the impact of swimming activity and LPS exposure on the locomotor capabilities of the animals, they were subjected to an open-field test [30] at 6 or 24 hours post endotoxin administration. Tests were performed in a sound-insulated room, with dim lighting. Individual mice were placed at the center of a 40 x 60 x 50cm acrylic cage with a floor divided into nine sections. During the six-minute observation period, the number of squares crossed by the mice with their four paws was recorded.","In order to assess how the combination of swimming and LPS treatment affects locomotor activity, the animals were tested using an open-field experiment [30] precisely 6 or 24 hours after the administration of endotoxin. The tests were performed in a noise-reducing chamber and under low light intensity. Mice were individually placed inside an acrylic box (40 × 60 × 50 cm), which was divided into 9 squares. The number of crossings of the box with four paws by the mice was recorded over a period of 6 minutes.","To evaluate how the combination of swimming session and LPS treatment affects the locomotor activity, the animals were subjected to an open-field test [30] either 6 or 24 hours after the administration of endotoxins. The experiment was carried out in a soundproof room with minimal lighting. A single mouse was placed in the center of an acrylic box (40 × 60 × 50 cm), divided into 9 squares on the floor. The mice's capability to move around the box was observed for 6 minutes, and the number of squares crossed by the mice with all four paws was recorded."
"To assess the mice's core temperature, a commercially available thermometer known as Pro-check® was employed. The thermometer was covered with Vaseline and gently inserted about 0.5 cm into the mice while they were held by hand. Following the initial measurement of the mice's colon temperature, their body temperature was measured 6 or 24 hours after LPS administration to assess the effects of the injection.","For measuring the internal temperature of mice, a Pro-check® thermometer was used. The thermometer was covered with Vaseline and carefully inserted into the colonic region of the mouse, which was held by hand. The initial temperature was recorded at t = 0, after which, the body temperature of the mice was monitored 6 or 24 hours post-LPS injection, to analyze the effects of the injection on their temperature.","The temperature of the mouse's colon was determined by introducing a commercially available thermometer known as Pro-check® into the colonic region. The thermometer was coated with Vaseline and was inserted gradually, about 0.5 cm into the mouse's colon while hand-restrained. After measuring the initial temperature of the colon at t = 0, the body temperature was assessed 6 or 24 hours post-LPS injection to determine its effect on the temperature of the mice."
"To collect mouse hippocampi and cortex, a specialized apparatus was used following LPS injection at 1, 3, 6, and 24 hours after euthanasia by decapitation. The Trizol reagent from Invitrogen was employed to isolate total RNA based on the manufacturer's guidelines, and the total RNA concentration was ascertained through absorbance measurement at 260 nm. Reverse transcript (cDNA) was produced by employing oligo(dT) as a primer (0.05 μg), Promega's 50 U of reverse transcriptase, Promega's dNTP (144 μM), reaction buffer [10 mM dithiothreitol (DTT), 3 mM MgCl2, 75 mM KCl, and 50 mM Tris-HCl, pH 8.3], and Promega's 2 U of RNAsin Plus in a final volume of 12.5 μl after 2 μg of total RNA was reverse transcribed. The samples were then incubated at 37°C for 60 minutes, cooled at 4°C for 5 minutes, and then warmed up to 70°C for 5 minutes before being cooled to 4°C for another 5 minutes to generate cDNA.","Employing a specialized device, mouse hippocampi and cortex were recovered following LPS injection at 1, 3, 6, and 24 hours post decapitation euthanasia. The concentration of total RNA was calculated by utilizing Invitrogen's Trizol reagent and assessing the absorbance at 260 nm. To generate the reverse transcript (cDNA), 2 μg of total RNA were combined with oligo(dT) (0.05 μg), Promega's 50 U of reverse transcriptase, Promega's dNTP (144 μM), reaction buffer [10 mM dithiothreitol (DTT), 3 mM MgCl2, 75 mM KCl, and 50 mM Tris-HCl, pH 8.3], and Promega's 2 U of RNAsin Plus in a final volume of 12.5 μl. The samples were incubated for 60 minutes at 37°C, followed by warming at 70°C for 5 minutes, cooling at 4°C for 5 minutes, and a final cooling round of 5 minutes at 4°C.","Mouse hippocampi and cortex were obtained using a special equipment system after being euthanized with decapitation at 1, 3, 6, and 24 hours post LPS injection. Invitrogen's Trizol reagent was used to extract total RNA based on the manufacturer's instructions, and the total RNA concentration was determined by measuring the absorbance at 260 nm. The reverse transcript (cDNA) was synthesized by utilizing oligo(dT) as a primer (0.05 μg), Promega's 50 U of reverse transcriptase, Promega's dNTP (144 μM), reaction buffer [10 mM dithiothreitol (DTT), 3 mM MgCl2, 75 mM KCl, and 50 mM Tris-HCl, pH 8.3], and Promega's 2 U of RNAsin Plus. Furthermore, 2 μg of total RNA were reverse transcribed in a final volume of 12.5 μl. The sample was incubated for 60 minutes at 37°C, after which it was heated to 70°C for 5 minutes, cooled to 4°C for 5 minutes, and then warmed to 70°C for 5 minutes before being cooled again for another 5 minutes at a temperature of 4°C, to create cDNA."
"The fluorescence-based real-time PCR technique was utilized to identify the B1 receptor and BDNF mRNA expression. The researchers amplified approximately 100 ng of cDNA in duplicates employing TaqMan-based chemistry. FAM-labeled probes and specific primers were used for mouse BDNF (cat# Mm00432069_m1), B1 receptor (cat# Mm00432059_s1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; cat# Mm03302249_g1) as an endogenous control for normalization. They carried out the amplifications in a Thermalcycler (StepOne Plus, Applied Biosystems) for 50 cycles. They gathered the fluorescence at each amplification cycle and examined the data using the 2-ΔΔCt technique for relative quantification. The target genes' expression was adjusted against the conditions seen in naive animals, i.e., nontreated mice.","For detecting B1 receptor and BDNF mRNA expression, the researchers used the fluorescence-based real-time PCR method. They employed TaqMan-based chemistry with specific primers and FAM-labeled probes for mouse BDNF (cat# Mm00432069_m1), B1 receptor (cat# Mm00432059_s1), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; cat# Mm03302249_g1) as an endogenous control for normalization. About 100 ng of cDNA underwent amplification in duplicates in a Thermalcycler (StepOne Plus, Applied Biosystems) for 50 cycles. The fluorescence data were collected at each amplification cycle and analyzed using the 2-ΔΔCt technique for relative quantification. The target genes' expression was calibrated against naive animals, i.e., nontreated mice.","The expression of B1 receptor and BDNF mRNA was analyzed by the fluorescence-based real-time PCR technique. Using TaqMan-based chemistry, the researchers amplified approximately 100 ng of cDNA in duplicates. They employed specific primers and FAM-labeled probes for mouse BDNF (cat# Mm00432069_m1), B1 receptor (cat# Mm00432059_s1), and an endogenous control for normalization glyceraldehyde-3-phosphate dehydrogenase (GAPDH; cat# Mm03302249_g1). The amplifications were carried out in a Thermalcycler for 50 cycles, and the fluorescence data were collected at each cycle. The 2-ΔΔCt technique was used for relative quantification analysis. The target gene expression was rectified against the conditions observed in naive animals, i.e., nontreated mice."
"After treatment with LPS, brain samples were collected and immersed in a phosphate buffered saline solution containing 4% paraformaldehyde for 24 hours at room temperature. Post-fixation, the samples underwent standard histological procedures, including paraffin embedding. To determine the activity of glial cells, immunohistochemistry was performed on the paraffin-embedded sections of the hippocampus using CD68 antibody. To quench the endogenous peroxidase activity, samples were treated with hydrogen peroxide in methanol for 20 minutes. The samples were then subjected to high-temperature antigen retrieval by immersing the slides in a water bath, followed by overnight incubation with the primary antibody at 4°C. The slides were washed, and appropriate secondary biotinylated antibody and Streptavidin-HRP reagent were used for further processing. Sections were then counterstained with Harris's hematoxylin and developed with DAB in chromogen solution. Control and experimental tissues were co-processed and mounted on the same slide.","Brain samples were gathered after 24 hours of LPS treatment and then fixed in a phosphate-buffered saline solution containing 4% paraformaldehyde for a day. Following this, the samples were processed to be embedded in paraffin using standard histological techniques. CD68 antibody was utilized to immunohistochemically identify glial activity, and paraffin-embedded sections from the hippocampus were cut at around 3mm from bregma [2, 31]. To eradicate endogenous peroxidase, a 1.5% hydrogen peroxide in methanol solution was used for 20 minutes. Immersion of the slides in a water bath with 10mM trisodium citrate buffer pH 6.0 at 95-98°C for 45 minutes facilitated high-temperature antigen retrieval. Following overnight incubation at 4°C with the primary CD68 antibody, slides underwent PBS wash, were then incubated with the correct biotinylated secondary antibody, and finally processed using Streptavidin-HRP reagent as instructed by the manufacturer. DAB in chromogen solution was used to develop sections, which were counterstained using Harris's hematoxylin. Control and experimental tissues were mounted on the same slide, which was processed under the same settings.","Samples of brain tissue were collected following LPS treatment and fixed for 24 hours in a phosphate-buffered saline solution containing 4% paraformaldehyde. After this, the samples were embedded in paraffin following standard histological procedures. Immunohistochemistry utilizing CD68 antibody was performed on paraffin tissue sections from the hippocampus. The endogenous peroxidase was quenched by treating the samples with a solution of 1.5% hydrogen peroxide in methanol for 20 minutes, after which they were subjected to high-temperature antigen retrieval by immersing the slides in 10mM trisodium citrate buffer pH 6.0 at 95-98°C for 45 minutes. The primary antibody was applied overnight at 4°C, followed by a wash with PBS, incubation with the biotinylated secondary antibody, and processing using the Streptavidin-HRP reagent as per the manufacturer's recommendations. After being developed with DAB in chromogen solution, the sections were counterstained with Harris's hematoxylin. The control and experimental tissue sections were mounted and processed together."
"The visual information was captured through a digital camera, Sight DS-5M-L1, which was paired with Nikon's Eclipse - 80i light microscope. The image acquisition protocols were identical for control and experimental sample tissues. To analyze the number of CD-68 positive cells, four different zones of CA1, CA2, CA3, and DG hippocampal sub-regions in each mouse were examined utilizing a magnification of 40X.","Captured images of the hippocampus sub-regions were obtained using a digital camera called Sight DS-5M-L1, which was attached to a Nikon Eclipse - 80i light microscope. The same image acquisition settings were applied to samples from control and experiments. Afterward, the CD-68 positive cells were counted in four distinct regions of the hippocampus, including CA1, CA2, CA3, and DG, under a magnification of 40X in each mouse.","Images were captured using a digital camera called Sight DS-5M-L1 that was connected to a Nikon Eclipse - 80i light microscope. The settings used for image collection remained identical for both control and experimental samples. CD-68 positive cells were then counted in four separate regions of the hippocampus sub-regions, including CA1, CA2, CA3, and DG, for individual mice utilizing a magnification of 40X."
"The animals were subjected to a forced swimming test, followed by the administration of LPS obtained from E. coli, as previously reported. The animals were then euthanized at different time points, 1, 3, 6, 12, and 24 hours after LPS injection, by decapitation. To determine TNFa levels, standard sandwich ELISA technique was used, in both serum and whole-brain samples. According to the supplier's recommendations (R&D Systems, USA), the samples were treated. The brain tissues were removed and transferred to a PBS solution containing 0.05% Tween 20, 0.1 mM PMSF, 0.1 mM benzamethonium chloride, 10 mM EDTA, 2 μg/ml aprotinin A, and 0.5% BSA for brain assays. The mouse brains were homogenized and centrifuged at 3,000× g for 10 min, and then the supernatant was used for ELISA analysis.","The experimentation involved immersing the animals in water followed by the administration of LPS isolated from E. coli, as previously outlined. The animals were then euthanized at different time intervals, including 1, 3, 6, 12, and 24 hours following LPS injection by decapitation. TNFa levels were quantified using a standard sandwich ELISA technique on both serum and whole-brain samples, as per the supplier's recommendations (R&D Systems, USA). For brain assays, tissue samples were collected and placed in a PBS solution consisting of 0.05% Tween 20, 0.1 mM PMSF, 0.1 mM benzamethonium chloride, 10 mM EDTA, 2 μg/ml aprotinin A, and 0.5% BSA. The samples were homogenized and centrifuged at 3,000× g for 10 minutes, followed by ELISA analysis of the supernatant.","The research involved the animals being subjected to forced swimming and later treated with LPS extracted from E. coli, as explained previously. The animals were then put to rest at selective intervals following LPS administration of 1, 3, 6, 12, and 24 hours by decapitation. Both whole-brain and serum sections were evaluated for TNFa levels using the sandwich ELISA technique, according to the supplier's instructions (R&D Systems, USA). In the case of brain assays, 0.05% Tween 20, 0.1 mM PMSF, 0.1 mM benzamethonium chloride, 10 mM EDTA, 2 μg/ml aprotinin A, and 0.5% BSA were added to the PBS solution used for brain assays to prevent contamination. The brain tissue was homogenized, and thereafter centrifuged at 3,000× g for 10 min to obtain the supernatant, which was then assessed using ELISA analysis."
"The collection of cerebrospinal fluid (CSF) samples in mice involves the modified technique by Liu and Duff. After inducing forced swimming and administering LPS from E. coli, the mice were sedated with a mixture of ketamine and xylazine, and their heads were positioned at a 135° angle. An incision was then made under the occiput, and an insulin needle attached to a polyethylene 50 tubing was carefully inserted 3 mm into the cisterna magna. The CSF samples were extracted using a 50 μl Hamilton syringe and transferred to Eppendorf tubes before being instantly frozen on dry ice and placed in -80°C for storage until further use. Control samples were taken from the CSF of naive mice, and sample collection was executed at 1, 3, and 24 hours after the LPS treatment.","To collect cerebrospinal fluid (CSF) samples from mice, a modified technique based on Liu and Duff's method was utilized. To begin with, the mice were forced to swim and were then given LPS from E. coli. After 1, 3, or 24 hours of treatment, the mice were sedated with a ketamine and xylazine solution and fixed to a stereotaxic instrument with their heads tilted at a 135° angle. An incision was made under the occiput, and an insulin needle attached to a polyethylene 50 tubing was inserted about 3 mm into the cisterna magna. The CSF samples were extracted by aspirating with a 50 μl Hamilton syringe and then transferred into Eppendorf tubes. The collected samples were then immediately frozen on dry ice and preserved in -80°C until further usage. Control samples were acquired from the CSF of non-treated mice.","In this study, cerebrospinal fluid (CSF) samples were collected from the cisterna magna of mice using a modified technique derived from Liu and Duff's method. The mice were subjected to forced swimming and treated with LPS from E. coli before being anesthetized with a mixture of ketamine and xylazine. They were then positioned on a stereotaxic instrument with the head tilted at a 135° angle. A sagittal incision was made beneath the occiput, and a metal insulin needle was adapted with a polyethylene 50 tubing at one end and a Hamilton syringe of 50 μl volume at the other. The needle was then attached to the bottom end of the manipulator bar and inserted about 3 mm into the cisterna magna to collect CSF samples. The samples were stored in Eppendorf tubes, quickly frozen on dry ice, and kept at -80°C until further use. Control samples were acquired from the CSF of unstimulated mice, and sampling was performed at 1, 3, and 24 hours following the treatment."
"The measurement of cytokines in the cerebrospinal fluid (CSF) was carried out using the BD Cytometric Bead Array (CBA) and the CBA Mouse Inflammation Kit® provided by BD Bioscience of San Jose, CA. The assay simultaneously detected various cytokines, including interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-g (IFN-g), tumor necrosis factor alpha (TNFa), and interleukin-12p70 (IL-12p70). Flow cytometer readings were performed using FACSCanto II red laser in a medium range of 633 nm. Data analysis was performed using FCAP Array software and the captured cytokines were detected using direct immunoassay with six different antibodies coupled to phycoerythrin (PE). Standard curves of cytokine concentration versus mean fluorescence intensity (MFI) were generated using the mixed cytokine beads standard provided by the kit with a concentration range of 20 to 5000 pg/ml, and five standard curves were plotted using a four-parameter logistic curve fitting model. From the four-parameter equations, the cytokine concentration in each CSF sample was determined using the MFI value of each cytokine. If a sample fell below the detection limit for the assay, a value of 0 was assigned for that concentration.","To quantify cytokines in the cerebrospinal fluid (CSF), a BD Cytometric Bead Array (CBA) and the CBA Mouse Inflammation Kit® were utilized. The assay facilitated the simultaneous detection of several cytokines, including interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-g (IFN-g), tumor necrosis factor alpha (TNFa), and interleukin-12p70 (IL-12p70). The flow cytometer readings utilized the red laser of FACSCanto II in a medium range of 633 nm. Furthermore, data acquisition was performed using FACSDiva software, while FCAP Array software was utilized to analyze the data (all from BD Bioscience). The captured cytokines were identified using the direct immunoassay and six different antibodies that were linked to phycoerythrin (PE). A mixed-cytokine-beads standard provided by the kit was used to generate standard curves of cytokine concentration versus mean fluorescence intensity (MFI), and from these curves, the concentrations of each CSF cytokine were determined using the MFI value of each cytokine. Samples that fell below the detection limit for the assay were assigned a value of 0.","The measurement of cytokines in the cerebrospinal fluid (CSF) was performed using the BD Cytometric Bead Array (CBA) and the CBA Mouse Inflammation Kit®, which enabled the simultaneous detection of interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-g (IFN-g), tumor necrosis factor alpha (TNFa), and interleukin-12p70 (IL-12p70). Flow cytometer readings were done with FACSCanto II red laser at a medium range of 633 nm, and the data collected were analyzed using FCAP Array software from BD Bioscience. The different cytokines were detected via a direct immunoassay using six antibodies coupled to phycoerythrin (PE). The mixed cytokine beads standard contained in the kit was used to generate standard curves for cytokine concentration ranging from 20 to 5000 pg/ml plotted with mean fluorescence intensity (MFI), generating five standard curves. A four-parameter logistic curve fitting model was employed to determine the concentrations of each CSF cytokine using the MFI value of each cytokine. When a sample registered below the detection threshold, it was assigned a value of 0."
"Experimental findings for behavioral parameters and Elisa protocols were displayed as the average ± SEM of 6-8 animals, while outcomes for real-time PCR, flow cytometry and immunohistochemical tests were shown as the average ± SEM of 4 independent experiments conducted in triplicate. A one-way analysis of variance followed by Newman-Keuls post hoc test was used for statistical comparison between these values, and significance was observed at a p value less than 0.05 (p < 0.05).","The mean ± SEM of 6-8 animals was used to present experimental results for behavioral parameters and Elisa protocols. Results for real-time PCR, flow cytometry and immunohistochemical experiments were presented as the mean ± SEM of 4 independent experiments performed in triplicate. Statistical analyses were conducted by one-way analysis of variance, followed by Newman-Keuls post hoc test, and a p value less than 0.05 (p < 0.05) was deemed significant.","The results obtained from the behavioral parameters and Elisa protocols were presented as the mean ± SEM of 6-8 animals while the real-time PCR, flow cytometry and immunohistochemical experiments were presented as the mean ± SEM of 4 independent experiments performed in triplicate. Statistical analysis was performed using one-way analysis of variance followed by Newman-Keuls post hoc test, and a p value less than 0.05 (p < 0.05) was considered statistically significant."
"The data presented in Figure 1a indicates that mice treated with systemic E. coli LPS (450 μg/kg, i.p.) after a forced swimming session showed symptoms of depression-like behavior, as measured by tail-suspension paradigm over time. A statistically significant increase in immobility time was observed in LPS-treated animals at 24 hours (P < 0.01), but not at 6 hours (P > 0.05), with a return to control levels at 48 hours (P < 0.05) when compared to saline-treated mice. Administration of the antidepressant drug imipramine (10 mg/kg, i.p.) 30 minutes prior to the behavioral test resulted in a marked reduction in immobility time (47 ± 16% reduction, Figure 1a). The selective B1 receptor antagonists R-715 (0.5 mg/kg, 30 min), SSR240612 (5 mg/kg, i.p., 30 min), and oral administration of SSR240612 (10 mg/kg, 1 h) significantly inhibited depression-like behavior induced by LPS (Figure 1c), with inhibition percentages of 46 ± 6%, 33 ± 7%, and 30 ± 6%, respectively. However, administration of the selective kinin B2 receptor antagonist FR173657 (30 mg/kg, i.p., 30 min) failed to significantly alter immobility time in our model (P > 0.05; Figure 1b).","The findings presented in Figure 1a reveal that mice that were systemically treated with E. coli LPS (450 μg/kg, i.p.) following a 5-minute forced swimming session presented with signs of depression-like behavior that changed over time, as measured in the tail-suspension paradigm. There was a statistically significant increase in immobility time in animals pre-treated with LPS at 24 hours (P < 0.01), but not at 6 hours (P > 0.05) (results not shown), before returning to control levels at 48 hours (P < 0.05) compared to saline-treated mice. Imipramine, a classic antidepressant, produced a remarkable reduction in immobility time (47 ± 16% reduction; Figure 1a) when administered 30 minutes before the behavioral test. Interestingly, administration of the selective B1 receptor antagonists R-715 (0.5 mg/kg, 30 min) or SSR240612 (5 mg/kg, i.p., 30 min) or oral administration of SSR240612 (10 mg/kg, 1 h) resulted in a significant inhibition of LPS-induced depression-like behavior (Figure 1c) with inhibition percentages of 46 ± 6%, 33 ± 7%, and 30 ± 6%, respectively. However, administration of the selective kinin B2 receptor antagonist FR173657 (30 mg/kg, i.p., 30 min) did not significantly alter immobility time in our model (P > 0.05; Figure 1b).","Based on the results presented in Figure 1a, it is evident that systemic administration of E. coli LPS (450 μg/kg, i.p.) after a forced swimming session lasting 5 minutes elicited depression-like symptoms in mice over time, as measured by the tail-suspension paradigm. There was a significant increase in immobility time observed in the LPS-treated mice at 24 hours (P < 0.01) but not at 6 hours (P > 0.05) (results not demonstrated), with a subsequent return to control levels at 48 hours (P < 0.05) compared to saline-treated mice. The classic antidepressant imipramine (10 mg/kg, i.p.), administered 30 minutes before the experimental test, was found to decrease immobility time considerably (47 ± 16% reduction, Figure 1a). Surprisingly, the selective B1 receptor antagonists R-715 (0.5 mg/kg, 30 min), SSR240612 (5 mg/kg, i.p., 30 min), or oral administration of SSR240612 (10 mg/kg, 1 h) resulted in a significant inhibition of LPS-induced depression-like behavior shown in Figure 1c. The inhibition percentages were 46 ± 6%, 33 ± 7%, and 30 ± 6%, respectively. However, a selective kinin B2 receptor antagonist, FR173657 (30 mg/kg, i.p., 30 min), was unable to alter immobility time significantly in this model (P > 0.05; Figure 1b)."
"Based on existing literature, it is commonly known that LPS treatment leads to specific CNS-associated changes in rodents. In line with these findings, our experiments involved administering E. coli LPS to mice which had previously undergone forced swimming. The results showed that the LPS caused a marked reduction in both body temperature and locomotor activity when measured in an open-field environment. At the 6-hour mark after LPS, locomotor activity was significantly diminished, but had returned to baseline levels after 24 hours (according to Figure 1f). Moreover, body temperature was significantly reduced at 6 hours after LPS administration, but not significantly different from control levels 24 hours after the initial insult. Surprisingly, pre-treatment with R-715 (0.5mg/kg, i.p.) did not have any significant effect on body temperature as measured at the 6-hour mark; this is notable given that previous research suggested that R-715 might be effective in altering this parameter. Moving forward, we opted to solely use SSR240612 (which has a good level of oral bioavailability) in subsequent experiments.","As per established literature, treating rodents with LPS can bring about well-known changes in the CNS. Our findings are consistent with this line of research, as we observed that administering E. coli-derived LPS in mice that had previously undergone forced swimming led to a prominent drop in body temperature (as shown in Figure 1e), as well as decreased locomotor activity in an open-field environment. Specifically, we measured a significant reduction in locomotion six hours after LPS administration, but levels had returned to baseline after 24 hours (as demonstrated in Figure 1f). In addition, we observed that body temperature was significantly diminished after 6 hours, but not after 24 hours had passed. Notably, administering R-715 (at a 0.5mg/kg, i.p. dose) 30 minutes prior to testing did not have a significant effect on body temperature at the 6-hour mark. Given SSR240612's good oral bioavailability, we conducted subsequent experiments using only this antagonist.","Literature has a well-established record of describing the CNS-associated changes in rodents induced by LPS treatment [3-5]. The present study confirms previous findings, as E. coli LPS administration to mice that had undergone forced swimming markedly decreased body temperature (Figure 1e) and locomotor activity. We observed a significant reduction in locomotion six hours after LPS, which returned to control levels at 24 hours (Figure 1f). Similarly, we measured a significant drop in body temperature six hours after LPS, though this effect was not present at the 24-hour mark. Administration of R-715 (at a 0.5mg/kg, i.p. dose) 30 minutes prior to testing did not significantly alter body temperature at the 6-hour mark. Subsequent experiments used only SSR240612, as its oral bioavailability proved more advantageous than R-715's."
"To explore the potential correlation between the effects of selective kinin B1 receptor antagonists and changes in B1 receptor expression in CNS structures, B1 receptor mRNA levels were assessed in the hippocampus and frontal cortex of mice that underwent a forced swimming session followed by LPS administration (450 μg/kg, i.p.). Subsequent quantitative real-time experiments revealed that B1 receptor mRNA levels in the hippocampus exhibited a time-dependent increase, reaching a peak at 1 hour (roughly a 2.5-fold increase) (Figure 2a). The increase in the cortex, however, was almost 40-fold 1 hour after LPS treatment (Figure 2b). These findings suggest an intriguing link between selective kinin B1 receptor antagonists and changes in B1 receptor expression in CNS structures.","Investigation was conducted to ascertain if there is a connection between the effects of selective kinin B1 receptor antagonists and changes in B1 receptor expression in CNS structures. B1 receptor mRNA expression was evaluated in the frontal cortex and hippocampus of mice who underwent a forced swimming episode, followed by LPS administration (450 μg/kg, i.p.). Quantitative real-time experiments demonstrated that the mRNA levels of B1 receptor in the hippocampus escalated in a time-dependent manner, reaching a maximum at 1 hour (approximately 2.5-fold increase) (Figure 2a). The increase was almost 40-fold in the cortex 1 hour after LPS treatment (Figure 2b). These results suggest that there could be an association between selective kinin B1 receptor antagonists and changes in B1 receptor expression in CNS structures.","The possible correlation between the effects of selective kinin B1 receptor antagonists and changes in B1 receptor expression in CNS structures was explored by evaluating B1 receptor mRNA expression in the hippocampus and frontal cortex of mice subjected to forced swimming followed by LPS administration (450 μg/kg, i.p.). Quantitative real-time experiments revealed a time-dependent surge in B1 receptor mRNA levels in the hippocampus, with a peak at 1 hour (about 2.5-fold increase) (Figure 2a). In comparison, in the cortex, this surge was almost 40-fold one hour after LPS administration (Figure 2b). These observations suggest the potential existence of a relationship between selective kinin B1 receptor antagonists and changes in B1 receptor expression in CNS structures."
"The data in Figure 3 indicates that the combination of forced swimming and LPS treatment induced a substantial increase in the CD68 immunoreactivity of the mouse hippocampus, suggesting an elevated degree of glial cell activation. Strikingly, pretreatment with the selective kinin B1 receptor antagonist SSR240612 (5 mg/kg, i.p.) significantly inhibited CD68 labeling, while the antidepressant drug imipramine (10 mg/kg, i.p.) had no effect, implying that there are varying mechanisms by which these two anti-depressants achieve their therapeutic effects. Various studies have demonstrated that reduced levels of neurotrophic factors such as BDNF are associated with depression. According to our study, the hippocampus of mice exposed to the depression protocol had a significant decrease in BDNF expression, which persisted at both the 6 and 24-hour time points, reducing the BDNF level by about 50%. However, the pre-administration of the kinin B1 receptor antagonist SSR240612 (5 mg/kg, i.p.) 30 minutes before LPS administration did not have a significant effect on BDNF expression, according to the results portrayed in Figure 4.","The results illustrated in Figure 3 indicate a marked upregulation of CD68 immunoreactivity in the hippocampus of mice subsequently treated with LPS, following forced swimming. This suggests a substantial increase in glial cell activation, which was largely inhibited following pretreatment with the selective kinin B1 receptor antagonist SSR240612 (5 mg/kg, i.p.). However, antidepressant therapy with imipramine (10 mg/kg, i.p.) given 30 minutes before LPS treatment did not show any inhibitory effect on CD68 labeling. The findings suggest that imipramine and kinin B1 receptor antagonist act through different pathways to effect their antidepressant-like impacts. Depression has been linked to decreased expression of neurotrophic factors such as BDNF. Our real-time PCR experiments revealed that BDNF expression was significantly reduced by approximately 50% in the hippocampus of mice subjected to our depression protocol, when evaluated at the 6- and 24-hour time points. Nonetheless, no significant effects on BDNF expression were observed following administration of the kinin B1 receptor antagonist SSR240612 (5 mg/kg, i.p.) 30 minutes before LPS treatment, as shown in Figure 4.","The outcomes observed in Figure 3 indicated that forced swimming followed by the administration of LPS induced a significant increase in CD68 immunoreactivity in the hippocampus of mice, indicative of escalated glial cell activation. The labeling of CD68 was almost entirely obstructed by the kinin B1 receptor antagonist SSR240612 (5 mg/kg, i.p.), when given 30 minutes before LPS, but not impacted by the antidepressant drug imipramine (10 mg/kg, i.p.). These findings imply that the antidepressant-like impacts of Imipramine and kinin B1 receptor antagonist work through different pathways. Previous studies have demonstrated that depression is associated with reduced levels of neurotrophic factors such as BDNF. Our study's real-time PCR assays revealed a significant decrease in BDNF expression in the hippocampus of mice after exposure to our depression protocol, lowering it by approximately 50% at both the 6 and 24-hour time points. However, pre-treatment with SSR240612 (5 mg/kg, i.p., 30 min) did not significantly affect this parameter, as depicted in Figure 4."
"To examine the association between LPS-induced alterations and cytokine secretion, we evaluated the TNFa levels in the mouse serum or whole brain. Following a forced swimming session and E.coli LPS administration, there was a substantial time-dependent elevation in TNFa production in LPStreated mice serum or brain. TNFa levels were at its peak within 1 to 3 hours in the serum, which was approximately 90-fold higher compared to basal levels. The TNFa level peaked at 3 to 6 hours in the brain, which enhanced approximately 1.8 times and returned to control values after 12 hours. The cytokine content in CSF was analyzed through flow cytometry in LPS-treated mice, and we detected cytokines IL-6, IL-10, and IFN-g below detectable levels while the IL-12 concentration was nearly identical to that of naïve animals. Intriguingly, CSF TNFa levels had a peak at 1 hour post-LPS injection, persisting up to 3 hours after the injection, with about 340 and 90-fold increments, respectively.","Our research aimed to assess the correlation between TNFa production and changes triggered by LPS by examining TNFa levels in the mouse serum or whole brain. We put the animals through forced swimming sessions and administered E.coli LPS, resulting in a significant time-dependent elevation in TNFa in serum or brain in LPStreated mice. TNFa levels peaked within the first 1-3 hours in serum, which was a nearly 90-fold increase from basal levels, and within 3-6 hours in the brain at about 1.8 times higher than controls, returning to control values after 12 hours. Flow cytometry was used to analyze cytokine content in CSF from LPS-treated mice, and it showed that cytokines IL-6, IL-10, and IFN-g were undetectable, whereas the IL-12 concentration was similar to that observed in naïve animals. CSF TNFa levels were the most elevated one hour after LPS injection and remained high until 3 hours later, with around 340 and 90-fold increments, respectively.","We sought to investigate whether there is a relationship between the changes induced by LPS and cytokine production by measuring TNFa levels in the mouse serum or whole brain. LPStreated mice were submitted to forced swimming sessions and given E.coli LPS, resulting in a substantial time-dependent increase in TNFa production in the serum or brain. TNFa levels peaked in serum within 1-3 hours following LPS administration, which showed a 90-fold increase from the basal levels. Similarly, in the brain, the TNFa level peaked at 3-6 hours and was about 1.8 times higher than controls, returning to baseline values after 12 hours. Flow cytometry was employed to examine cytokine concentration in CSF from LPS-treated mice, but cytokines IL-6, IL-10, and IFN-g were not detectable, and the concentration of IL-12 was consistent with that of naïve animals. Intriguingly, CSF TNFa levels peaked at 1 hour after LPS injection, remaining elevated until 3 hours later, with about 340 and 90-fold increments, respectively."
"In our experimental paradigm, we wanted to investigate the involvement of TNFa in depression-like behavior through its interplay with B1 receptor upregulation. To do this, we decided to use TNFa p55 receptor-deficient mice in our study. We employed C57/BL6 mice in this part of the study, and we found that administering a dose of 1000 μg/kg of E. coli LPS to these mice resulted in a significant increase in immobility time in the tail-suspension test, which was similar to the increase observed in CF1 mice treated with 450 μg/kg. A striking discovery we made was that mice with genetic deletion of TNFa p55 receptors experienced virtually no depression-like behavior due to forced swimming plus LPS treatment (1000 μg/kg, i.p.). We also observed that the increase of B1 receptor mRNA expression in mice submitted to forced swimming plus LPS treatment was completely absent in TNFa p55 receptor knockout animals.","The interdependence between TNFa and B1 receptor upregulation is a subject that previous literature data have depicted in a close relation [10,14]. In our experimental paradigm, it was imperative for us to investigate the part played by TNFa in the depression-like behavior we observed. To accomplish this, we utilized TNFa p55 receptor-deficient mice in our study. Since the TNFa p55 receptor knockout animals used in the present study belong to the C57/BL6 inbred strain, we only used this mouse strain in this part of the study. We observed that a dose of 1000 μg/kg of E. coli LPS was necessary to elicit a significant increase in immobility time in the tail-suspension test in C57/BL6 mice, similar to that obtained with a 450 μg/kg dose in CF1 mice (about 1.5-fold in comparison to saline-treated animals). Remarkably, we found that mice with genetic deletion of TNFa p55 receptors experienced almost no depression-like behavior when undergoing forced swimming plus LPS treatment (1000 μg/kg, i.p.). Additionally, the rise of B1 receptor mRNA expression in mice submitted to forced swimming plus LPS treatment was completely absent in TNFa p55 receptor knockout animals.","To examine the link between TNFa and depression-like behavior that observed in our experimental paradigm, we analyzed the role played by TNFa in B1 receptor upregulation by employing TNFa p55 receptor-deficient mice. The C57/BL6 inbred mice strain was used in this part of our investigation on account of the genetic background of the TNFa p55 receptor knockout animals used in the present analysis. In C57/BL6 mice, we found that a dose of 1000 μg/kg of E. coli LPS was vital to evoke a significant increase in immobility time in the tail-suspension test, which was comparable to that obtained with a 450 μg/kg dose in CF1 mice (about 1.5-fold in relation to saline-treated animals). Our remarkable discovery as part of this research was that depression-like behavior due to forced swimming plus LPS treatment was almost eradicated in mice that possessed genetic deletion of TNFa p55 receptors (Figure 5d). Significantly, we also observed that the increase in B1 receptor mRNA expression in mice submitted to forced swimming plus LPS treatment was entirely absent in TNFa p55 receptor knockout animals (Figure 5e)."
"Current research has shed light on the complex mechanisms underlying depression, with recent breakthroughs in our understanding of the genetic, biochemical, and immunological factors at play. Specifically, certain pro-inflammatory cytokines, such as IL-6, IL-1b, and TNFa, have been found to play a role in depression-related behaviors following infection. It's believed that these cytokines coordinate the body's response to pathogens on both a local and systemic level. In a study involving mice, the administration of LPS after a swimming session resulted in early signs of sickness behavior such as decreased body temperature and locomotor activity 6 hours post-LPS, followed by depression-like behavior 24 hours post-LPS, as evidenced by an increased duration of immobility in the tail suspension test. While sickness behavior is considered a normal initial response to infectious stimuli, depression-like states can persist even after the initial sickness has resolved.","Advances in our understanding of depression have been made in the past few years. Research has focused on the genetic, biochemical, and immunological changes that contribute to depression. Certain pro-inflammatory cytokines - specifically IL-6, IL-1b, and TNFa - have been implicated in depression-related behaviors following an infection. These cytokines are capable of coordinating both local and systemic inflammatory responses to pathogens. Experiments conducted with mice revealed that administration of LPS after a swimming session led to a decrease in body temperature and locomotor activity 6 hours post-LPS. Additionally, immobility time in the tail suspension test increased 24 hours post-LPS, indicating a depression-like state. While sickness behavior is considered to be a typical initial response to infectious stimuli, depression-like states may continue to persist even after the initial sickness has subsided.","In the realm of depression research, numerous developments have been made in the last few years. Scientists have delved into the genetic, biochemical, and immunological aspects of this disorder. Recent findings have shown that certain pro-inflammatory cytokines, including IL-6, IL-1b, and TNFa, play a vital part in depression-related behaviors following an infection. These cytokines have the capacity to orchestrate local and systemic inflammatory responses to pathogens. In a study conducted on mice, the administration of LPS after a swimming session resulted in a decline in body temperature and locomotor activity after 6 hours. Moreover, the immobility time in the tail suspension test increased 24 hours post-LPS, signifying a depression-like state. Although sickness behavior is viewed as a natural response to infectious stimuli, depression-like states may persist beyond the resolution of initial sickness."
"The study at hand aims to explore the possible correlation between kinin B 1 receptors and depression, as no previous research has examined this specific relationship. Although B1 receptors are typically not present in the peripheral nervous system, they can be up-regulated rapidly in response to stressful situations. Basal expression, on the other hand, has been observed in the spinal cord and specific regions of the brain, such as the hypothalamus, cerebral cortex, and hippocampus, suggesting a potential central role for kinins. The exact function of these molecules in the brain is still being investigated. The purpose of this research is to analyze the involvement of B1 receptors in the induction of depression-like behavior induced by LPS and pre-stressing stimuli.","The present study aims to determine if there is any relationship between kinin B 1 receptors and depression, as previous research has not explored this relationship. Despite kinin B 1 receptors being absent under normal conditions in the peripheral nervous system, they can be quickly upregulated by exposure to stressful stimuli. These receptors have been found to be expressed at rest in various brain structures such as the hippocampus, cerebral cortex, thalamus, hypothalamus, and choroid plexus epithelial cells. Though the precise function of kinin is yet to be fully understood, the existence of B1 receptors in the nervous system is highly suggestive of their central role. This study is designed to figure out whether B1 receptors can be involved in depression-like behavior triggered by LPS and pre-stressful stimuli.","Investigating an unknown relationship between kinin B 1 receptors and depression, this study represents a novel investigation. Typically absent under normal conditions in the periphery, the upregulation of these receptors can occur rapidly in response to stressful stimuli. Despite their absence in the peripheral nervous system, basal expression of B1 receptor has been reported in some brain structures like hippocampus, thalamus, cerebral cortex, hypothalamus, choroid plexus epithelial cells, and spinal cord. While the role of kinins in the brain remains unclear, the presence of B1 receptor in the nervous system implies that these molecules may have an essential part to play. Herein, we will examine whether B1 receptors are implicated in the development of depression-like behavior following LPS and provided pre-stressful stimuli."
"The results of the tail suspension test indicated a reduced depression-like state with the administration of imipramine, an effective antidepressant in stressed rodents. Additionally, selective B1 receptor antagonists such as R-715 or SSR240612 inhibited increased immobility, indicating the importance of B1 receptors in depression-like behavior. Real-time PCR experiments demonstrated an increase in B1 receptor mRNA expression in both the hippocampus and cortex of mice undergoing forced swimming plus LPS administration, indicative of altered hippocampal plasticity linked to depression. Interestingly, infection associated with a stressful stimulus was found to up-regulate B1 receptors in the CNS, leading to depressive behavior. However, the selective B2 receptor antagonist FR173657 did not have a significant impact on immobility time in this paradigm, further supporting the proposed physiological roles of kinin B 2 receptors.","The antidepressant, imipramine, was found to significantly reduce the depression-like state observed in the tail suspension test, as seen in stressed rodents. Meanwhile, the treatment with selective B1 receptor antagonists, R-715, and SSR240612 were found to considerably inhibit the increased immobility, indicating the involvement of B1 receptors in depression-like behavior. Furthermore, the in vivo experiments on mice showed an increase in the expression of B1 receptor mRNA in the hippocampus and cortex when subjected to forced swimming plus LPS administration, leading to altered hippocampal plasticity linked to depression. Interestingly, infection accompanied by a stressful stimulus resulted in upregulation of B1 receptors in the CNS, which contributes to depressive behavior. However, treating mice with the selective B2 receptor antagonist, FR173657 exhibited no significant impact on immobility time in this depression paradigm.","In the tail suspension test, imipramine showed a significant reduction in the observed depression-like state, suggesting its potential as an effective antidepressant in stressed rodents. The administration of selective B1 receptor antagonists, R-715 or SSR240612, also led to a notable inhibition of increased immobility and highlighted the contribution of these receptors in depression-like behavior. Real-time PCR experiments revealed an increase in B1 receptor mRNA expression in both the hippocampus and cortex of mice subjected to forced swimming plus LPS administration, indicating altered hippocampal plasticity in depression. Remarkably, this study was the first to show that infection associated with a stressful stimulus might lead to up-regulation of B1 receptors in the CNS, which is responsible for depressive behavior. Conversely, the selective B2 receptor antagonist, FR173657, demonstrated no significant impact on immobility time in this depression paradigm, aligned with the known physiological roles of kinin B 2 receptors."
"Results from the tail suspension test and anhedonia paradigm of sucrose intake were of high interest in the study. Using SSR240612, researchers were able to completely reverse reduced sucrose consumption in mice treated with LPS. This is significant as depressed individuals often experience anhedonia, which is associated with reduced pleasure sensations. Administration of LPS and forced swimming caused a significant decrease in sucrose consumption in Swiss mice, but this was improved by the antidepressant imipramine. Although sickness-induced hypothermia did not change, blocking B1 receptors was found to reverse later depression-like symptoms, indicating that it does not interfere with early sickness behavior controlled mainly by cytokines.","The study focused on the tail suspension test and the anhedonia paradigm of sucrose intake, producing results of high interest. Administering SSR240612 reversed reduced sucrose consumption in mice treated with LPS, which is significant as it is associated with anhedonic states found in depressed individuals. Experiments were conducted on Swiss mice, which revealed that LPS and forced swimming caused a significant decrease in sucrose consumption. This effect was reversed by the antidepressant imipramine, validating the experimental design. Although sickness-induced hypothermia remained unchanged, later depression-like symptoms were shown to be reversible with the blocking of B1 receptors, suggesting that it does not affect the early sickness behavior primarily regulated by cytokines.","The study involved the tail suspension test and the anhedonia paradigm of sucrose intake, yielding interesting results. By administering SSR240612, researchers were able to completely reverse reduced sucrose consumption in LPS-treated mice. This is notable as anhedonia, which is characterized by a decrease in pleasure sensations, is often linked with depression. Stressful forced swimming plus LPS administration resulted in a significant decrease in Swiss mice's sucrose consumption. The antidepressant imipramine produced positive effects, emphasizing the validity of the experimental design. Notably, the administration of the B1 receptor antagonist R-715 did not cause significant changes in sickness behavior-induced hypothermia. However, research suggests that blocking B1 receptors can help reverse depression-like symptoms. This means that B1 receptors do not interfere with early sickness behavior, which is primarily controlled by cytokines."
"The immune-competent elements of the CNS that play a major role in the pathogenesis of depression are microglia and astrocytes [43,47,48], whose activation can cause depression. Our study illustrates that the forced swim followed by LPS treatment intensified the CD-68 immunostaining in the hippocampus 24 hours after LPS injection and raised the level of microglia activation in mice. It has been established that microglial activation, resulting from various injuries, stimulates the release of neurotoxic mediators such as pro-inflammatory cytokines [3,49]. Interestingly, selective non-peptide SSR240612 treatment antagonized CD-68 immunopositivity, but the same parameter was unaffected by imipramine. Therefore, we can hypothesize that the antidepressant-like effects of B1 receptor antagonists are associated with inhibiting microglial activation rather than the effects of imipramine. These findings are of great importance, open up new avenues of exploration and provide a better understanding of depressive states, particularly those associated with infection.","Depression involves the activation of major immunocompetent elements of the CNS, such as microglia and astrocytes [43,47,48]. Our study demonstrated that forced swimming and LPS treatment in mice led to the activation of microglia, as seen by increased CD-68 immunostaining in the hippocampus. Furthermore, the activation of microglia due to various types of injuries can result in the production of neurotoxic molecules, such as pro-inflammatory cytokines [3,49]. We found that systemic administration of selective non-peptide B1 receptor antagonist SSR240612 effectively reduced CD-68 immunopositivity, while imipramine had no significant effect on this parameter. Therefore, our study suggests that the antidepressant-like effects of B1 receptor antagonists are related to the inhibition of microglial activation. This discovery presents a new opportunity to better understand the pathogenesis of depressive states, particularly those induced by infections.","The central nervous system's significant immunocompetent components include astrocytes and microglia, whose activation is believed to contribute to depression's pathogenesis [43,47,48]. Our findings indicate that swimming and LPS administration increase microglial activation, demonstrated by enhanced CD-68 immunostaining in the hippocampus of mice, where B1 mRNA levels return to their basal levels within 24 hours of LPS injection. It has been revealed that microglial activation elicited by an array of injuries results in the release of neurotoxic mediators, including pro-inflammatory cytokines [3,49]. Strikingly, selective non-peptide B1 receptor antagonist SSR240612's systemic treatment has almost entirely abolished CD-68 immunopositivity, whereas imipramine has failed to produce this outcome. As such, our study implies that the antidepressant-like effects of B1 receptor antagonists could be attributable to microglial activation inhibition, in contrast to imipramine's effects. These insights offer a promising new avenue to decipher the molecular mechanisms behind depressive states, notably those linked to infections."
"Major depressive disorder is accompanied by changes in synaptic plasticity that lead to a reduction in BDNF function and other associated biological changes. The inhibition of the BDNF gene as a result of stressful conditions can lead to the destruction of neurons in the hippocampus. When BDNF is infused into specific areas of the brain, animal models have demonstrated that it can produce antidepressant-like effects. Common monoaminergic antidepressant drugs help to restore normal levels of BDNF transcription. In our depression model, we observed a decrease in BDNF mRNA expression that persisted for up to 24 hours in the hippocampus. Interestingly, the selective B1 receptor antagonist SSR240612, which reduced microglial activation, did not significantly alter the mRNA expression of BDNF. These findings suggest that SSR240612 exhibits antidepressant-like effects through a distinct inflammatory route as opposed to interfering with BDNF.","It is evident that depression is associated with alterations in synaptic plasticity that cause decreased BDNF function among other biochemical changes. Under stressful conditions, repression of the BDNF gene ensues, leading to neuronal apoptosis in the hippocampus. Through research, it has been found that BDNF infusion in certain brain regions induces antidepressant-like effects in animal models. Furthermore, monoaminergic antidepressant drugs are proven to re-establish BDNF transcriptional levels to the norm. Our depression model resulted in a continued decline in BDNF mRNA expression in the hippocampus for up to 24 hours. Intriguingly, although selective B1 receptor antagonist SSR240612 prevented microglial activation, it did not significantly alter BDNF mRNA expression. This indicates that SSR240612 possibly has antidepressant-like activity through varying mechanisms compared to typical antidepressants by acting predominantly through an inflammatory pathway, rather than by affecting BDNF.","Synaptic plasticity changes have been linked with depression, leading to decreased BDNF function and other biochemical variations. In situations of stress, the BDNF gene is suppressed, which can prompt neuronal apoptosis in the hippocampus. Infusing BDNF in specific brain regions has been shown to yield antidepressant-like outcomes in animal models, and most monoaminergic antidepressant drugs restore normal levels of BDNF transcription. Our depression model led to a sustained decrease in BDNF mRNA expression in the hippocampus for up to 24 hours. Contrary to our expectations, the selective B1 receptor antagonist SSR240612 did not significantly affect BDNF mRNA expression, even though it prevented microglial activation. These findings suggest that SSR240612 possibly exhibits antidepressant-like properties through distinct mechanisms from conventional antidepressants by acting via an inflammatory pathway instead of interrupting BDNF."
"Proinflammatory cytokines are believed to be significantly involved in the manifestation of depression. Previous studies have shown that patients suffering from major depressive disorder exhibit a rise in levels of soluble TNFa receptors, while treatment with TNFa antagonists results in a general improvement in both depressive symptoms and quality of life. In light of this, a study was conducted using pre-stressed mice, whereby administering LPS increased TNFa levels in serum, CSF, and whole brain, thereby reinforcing the abovementioned hypothesis. Elevated TNFa levels in the serum primarily contribute to sickness behavioral changes, such as hypothermia and reduced locomotor activity, while increased levels in the brain underlie depression-induced behavior, as demonstrated in the tail suspension test. Furthermore, multiplex cytokine analysis revealed noteworthy increases in TNFa levels in CSF obtained from LPS-treated mice, while other cytokine levels remained unchanged.","The occurrence of depression is believed to have a significant connection with pro-inflammatory cytokines. Study results reveal that major depressive disorder patients show an increased expression of soluble TNFa receptors. However, these depressive symptoms showed improvement when treated with TNFa antagonists, hence, pointing towards the involvement of cytokines in depression pathogenesis. In continuation with this, by administrating LPS to pre-stressed mice, researchers showed a significant increase in TNFa levels in serum, CSF, and whole brain. They concluded that the heightened TNFa levels in serum cause sickness-like behavior changes, including hypothermia and reduced locomotor activity, whereas increased levels in the brain bring about depression-like behavior. In addition, the study revealed an increase in TNFa levels in CSF obtained from LPS-treated mice, whereas the levels of other cytokines remained unaffected.","The pathogenesis of depression is believed to involve pro-inflammatory cytokines. Studies suggest that patients with major depressive disorder exhibit increased expression of soluble TNFa receptors, and treatment with TNFa antagonists leads to a reduction in depressive symptoms and an improvement in quality of life. A recent study using pre-stressed mice further supports this hypothesis by demonstrating a significant increase in TNFa levels in serum, CSF, and whole brain following LPS administration. The researchers found that heightened TNFa levels in serum were responsible for sickness behavioral changes, such as hypothermia and reduced locomotor activity, while the elevation of this cytokine in the brain was associated with depression-like behavior in the tail suspension test. Moreover, multiplex cytokine analysis revealed a marked increase in TNFa levels in CSF obtained from LPS-treated mice, with other cytokine levels remaining unchanged."
"TNFa found in the CSF indicates that the brain and immune system have a way of communicating. Activated toll-like receptors on macrophage-like cells located in the circumventricular receptors lead to the production of TNFa and other cytokines. Because the BBB is typically impermeable to cytokines, it remains a subject of debate on how circulating cytokines could affect brain function. It is proposed that cytokines could enter the brain through volume diffusion or sites where BBB integrity is compromised, such as during stressful or immunologic challenges. However, it is worth noting that kinins, which enhance BBB permeability, could lead to various neuropathological conditions associated with cytokine entry into the brain, such as depression.","The existence of TNFa in the CSF implies a possible pathway of communication between the brain and the immune system. Macrophage-like cells residing in the circumventricular receptors are activated when their toll-like receptors are triggered, and they react by producing proinflammatory cytokines, including TNFa. Since the BBB is relatively impermeable to cytokines, it remains unclear exactly how circulating cytokines might impact brain function. The idea is that the cytokines can gain entry into the brain through volume diffusion or by taking advantage of compromised BBB functioning during stressful and immunologic challenges. Furthermore, kinins are known to affect BBB permeability, leading to various neuropathological conditions associated with cytokine infiltration into the brain, such as depression.","The presence of TNFa in the CSF indicates the possibility of a channel of communication between the immune system and the brain. Whenever the toll-like receptors, located on macrophage-like cells found in the circumventricular receptors are activated, proinflammatory cytokines such as TNFa are produced. Despite cytokines being relatively unable to move through the BBB, there is still speculation regarding how circulating cytokines affect the brain's function. Some theories suggest that cytokines may penetrate the brain through volume diffusion or when there's a compromise on BBB functioning, such as with stressful or immunological challenges. Additionally, kinins have the potential to affect the permeability of the BBB. This could lead to a decline in the effectiveness of the BBB and an infiltration of cytokines into the brain, which can lead to various neuropathological disorders, including depression."
"In order to gain a better understanding of how TNFa is related to our experimental paradigm, we conducted experiments using TNFa p55 receptor-KO mice. We found that the mice exhibited almost no depression-like behavior, and the upregulation of B1 receptors was also very minimal when treated with forced swimming and LPS. Our previous research also indicated the significance of TNFa in B1 receptor upregulation. Our experimental data now suggests that there is a clear link between TNFa and the upregulation of kinin B1 receptors, which contribute to the initiation of depression. Furthermore, our findings further emphasize that the generation of pro-inflammatory cytokine TNFa plays a crucial role in the upregulation of B1 receptors stimulated by LPS, which has been previously proven.","In order to investigate the role of TNFa in our experimental framework, we utilized TNFa p55 receptor-KO mice. Our results revealed that the mice had a significant reduction in depression-like behavior and upregulation of B1 receptors when exposed to forced swimming and LPS treatment. Our previous research had already established the relevance of TNFa in the upregulation of B1 receptors. The present experiments provide significant evidence that associates the cytokine TNFa with the upregulation of kinin B1 receptors, which plays a vital role in the onset of depression. Furthermore, our findings suggest that the pro-inflammatory cytokine TNFa is crucial for LPS-induced B1 receptor upregulation, as previously demonstrated.","Our investigation into the connection between TNFa and our experimental paradigm involved the use of TNFa p55 receptor-KO mice. The results revealed that these mice displayed significantly less depression-like behavior and upregulation of B1 receptors when subjected to forced swimming and LPS treatment. Our previously conducted research had already established the relevance of TNFa in the upregulation of B1 receptors. Our current research provides a clear understanding of the link between the cytokine TNFa and the upregulation of kinin B1 receptors, which is a crucial factor in the development of depression. Moreover, our findings also suggest that pro-inflammatory cytokine TNFa is essential for LPS-induced B1 receptor upregulation, as demonstrated previously."
"Depression can be viewed as a complex condition, affecting individuals in different ways. Recent studies have identified a link between the immune system and depression, with immune mediators capable of transforming inflammatory processes into cognitive stimuli that the CNS can recognize. Our investigations suggest that kinin B1 receptors could play a significant role in affective disorders such as depression, relating to the activation of microglia and the subsequent production of TNFa in the brain. Further clinical studies with selective B1 receptor antagonists are needed to establish whether these molecules can be effective in relieving depressive symptoms.","Depression is widely understood to be a condition that affects a person's mood, behavior, and sense of well-being. Recent theories have linked the immune system to depression, with cytokines and other immune molecules acting as ""sensor"" molecules that can help the CNS recognize and respond to peripheral inflammatory events. Our investigations highlight the potential role of kinin B1 receptors in affective disorders such as depression, with activation of microglia and subsequent production of TNFa observed in the brain. Further study is needed to determine if oral B1 receptor antagonists could effectively treat depressive symptoms and aid in the management of the condition.","Depression is a complex disorder that can impact a person's mental and physical health, and experts have different opinions on how it should be classified. Research has shown that the immune system may have a significant role to play in the development of depression, with immune mediators acting as 'sensor' molecules that transform noncognitive stimuli into cognitive ones, and lead to the CNS responding to peripheral inflammatory events. Our findings suggest that kinin B1 receptors might be involved in affective disorders such as depression, with microglial activation and the subsequent production of TNFa in the brain potentially contributing to depressive symptoms. Further research is needed to determine the effectiveness of selective B1 receptor antagonists as a potential antidepressant."
"Type I interferons (IFNs) are vital components of the immune system that provide defense against viral infections. IFN-a/b production is triggered by viral infections, which leads to the activation of various ISGs. The ISGs encode different cytokines and antiviral proteins that ultimately protect the host from further viral infections. The type I IFNs assist in the development of both innate and adaptive immune responses, providing a multi-layered immune response against viral infections.","Type I interferons (IFNs) are an integral part of the immune system's response against viral infections. Following the viral invasion, IFN-a/b production is induced, which oversees the inauguration of various IFN-stimulated genes (ISGs), encoding antiviral proteins and cytokines that collectively defend the host from further viral attacks. Type I IFNs are essential for the potent induction and maintenance of both innate and adaptive immune responses against viral infections. This immune response is founded on the activation of multiple downstream pathways, which results in an effective blockade against viral replication within the host's cells.","The immune system employs type I interferons (IFNs) in defense against viral infections. IFN-a/b is produced in response to viral threats, leading to the activation of numerous IFN-stimulated genes (ISGs). These ISGs encode diverse antiviral proteins and cytokines that work in tandem to protect the host from further viral attacks by impeding viral replication within the host's cells. Type I IFNs play a pivotal role in initiating and sustaining the innate and adaptive immune responses against viral infections. This multi-faceted immune response involves the activation of several downstream pathways that underlie the body's defenses against viral infections."
"The viral detection machinery in many different types of mammalian cells is composed of several different proteins, including RNA helicases, retinoic acid-inducible gene I (RIG-I), and melanoma differentiation-associated protein 5 (MDA-5). These proteins are all able to detect both single-stranded RNA (ssRNA) and double-stranded RNA (dsRNA) that come from viral sources. Some mammalian cells can also sense dsRNA through Toll-like receptor 3 (TLR3). The binding of these viral nucleic acids to proteins like RIG-I, MDA-5, and TLR3 can trigger the activation of two transcription factors, kappa B (NF-kB) and interferon regulatory factor 3 (IRF-3). This activation ultimately leads to the production of IFN-b, an important cytokine in the mammalian immune system.","Mammalian nucleated cells possess the ability to detect viral threats through a variety of proteins, including RNA helicases, retinoic acid-inducible gene I (RIG-I), and melanoma differentiation-associated protein 5 (MDA-5). These proteins are responsible for the recognition of both single-stranded RNA (ssRNA) and double-stranded RNA (dsRNA), two forms of viral genetic material. Additional dsRNA sensing can occur in some cells through Toll-like receptor 3 (TLR3). The recognition of viral nucleic acids by RIG-I, MDA-5, and TLR3 results in two transcription factors, kappa B (NF-kB) and interferon regulatory factor 3 (IRF-3), being activated. The coordinated activation of these transcription factors ultimately results in the secretion of IFN-b, an essential mediator of the mammalian immune response to viral infections.","The mammalian immune response features a complex array of proteins and sensing mechanisms designed to detect viral threats. One important piece of this machinery is composed of RNA helicases, retinoic acid-inducible gene I (RIG-I), and melanoma differentiation-associated protein 5 (MDA-5). These proteins are critical for recognizing the genetic material of viruses, including single-stranded RNA (ssRNA) and double-stranded RNA (dsRNA). Toll-like receptor 3 (TLR3) can also sense dsRNA in certain mammalian cells. Once these viral nucleic acids bind to RIG-I, MDA-5, or TLR3, transcription factors kappa B (NF-kB) and interferon regulatory factor 3 (IRF-3) are activated, ultimately resulting in the production of IFN-b, an important mediator of the mammalian immune system's response to viral infections."
"Despite the fact that host cells have various mechanisms for detecting and combating viral infection through cellular signalling, viruses have evolved different ways to bypass these host immune responses with varying levels of success. For instance, many viruses have developed several techniques to evade the IFN response, including obstructing IFN production or interfering with IFN functions.","Viral infections trigger a variety of cellular signalling pathways in host cells to detect and respond to the presence of viruses. However, most viruses have evolved different mechanisms to evade the host immune response with different degrees of efficiency. One example is blocking the synthesis of IFN or disrupting their functions, which numerous viruses have employed as a method to subvert the response of IFN [12].","Host cells have developed several cellular signalling mechanisms to identify and counteract viral attacks. Nonetheless, viruses have developed diverse strategies to avoid these immune responses to varying extents [7,11]. For example, many viruses have evolved several ways to circumvent the IFN response, including suppressing IFN synthesis or interfering with IFN activities [12]."
"When discussing influenza A viruses, the non-structural gene (NS) has been identified as the primary source of viral anti-IFN activities [13-16]. This NS gene, which is unique to influenza A viruses, controls the synthesis of two proteins [17]. The first of these is a 26 kDa protein called non-structural protein 1 (NS1), which is created through the translation of unspliced mRNA. The second protein is a 14 kDa nuclear export protein (NEP), also known as NS2, that is produced after the translation of spliced mRNA [18].","It has been revealed that the non-structural gene (NS) found in influenza A viruses is responsible for the viral anti-IFN activities [13-16]. This NS gene encodes for two proteins [17], one which is a 26 kDa protein referred to as non-structural protein 1 (NS1) that is made by translating the unspliced mRNA. The second protein is a 14 kDa nuclear export protein (NEP), formerly known as NS2, that is generated after the translation of spliced mRNA [18].","The non-structural gene (NS) has been observed to be responsible for viral anti-IFN activities in influenza A viruses [13-16]. This NS gene of influenza A viruses encodes two proteins [17]. The initial protein is an unspliced mRNA that allows the translation of a protein of 26 kDa called non-structural protein 1 (NS1). Meanwhile, the second protein is triggered by the translation of spliced mRNA that creates a 14 kDa nuclear export protein (NEP), previously called NS2 [18]."
"The NS1 protein obstructs the expression of IFN-b [19,20], and it also obstructs the functioning of a variety of antiviral protein kinase R (PKR) and 2’-5’oligoadenylate synthetase (OAS) [21-23], which happen to be triggered by IFN.","The NS1 protein interferes with the activation of IFN-b [19,20], and it also inhibits the activity of numerous IFN-dependent antiviral proteins like protein kinase R (PKR) and 2’-5’oligoadenylate synthetase (OAS) [21-23].","NS1 protein obstructs the production of IFN-b [19,20], and it also hampers the action of a wide variety of IFN-induced antiviral proteins such as protein kinase R (PKR) and 2’-5’oligoadenylate synthetase (OAS) [21-23]."
"The categorization of the NS gene is accomplished by partitioning it into two separate gene pools or groups, designated as Allele A and Allele B [24, 25]. The NS1 proteins have a nucleotide identity of 63-68% and an amino acid identity of 66-70% between Allele A and B. Allele A is more frequently observed and is the sole subtype detected in mammalian-adapted strains. When comparing the amino acid sequence of avian Allele A and B viruses with that of human viruses, it was discovered that six amino acid motifs, or signatures, were present between human and avian Allele A viruses, while 35 signatures were found between human and Allele B viruses, indicating that Allele B viruses are more distinct from viruses of mammalian origins [26]. This implies that NS1 adaptation plays a critical role in the virulence of avian influenza viruses in mammalian species.","In terms of the NS gene, it can be divided into two different gene pools identified as Allele A and Allele B [24, 25]. The NS1 proteins have 63-68% nucleotide identity and 66-70% amino acid identity between Allele A and B. Allele A is more common and is exclusively found in mammalian-adapted strains. When the amino acid sequence of avian Allele A and B viruses was compared to that of human viruses, six amino acid signatures were present between human and avian Allele A viruses, whereas 35 signatures were observed between human and Allele B viruses, indicating that Allele B viruses are more different from mammalian origin viruses [26]. This shows that NS1 adaptation is critical for the pathogenicity of avian influenza viruses in mammals.","Two distinct gene pools called Allele A and Allele B make up the NS gene [24,25]. The NS1 proteins show a nucleotide identity ranging from 63-68% and an amino acid identity of 66-70% between the two Alleles. Allele A is more prevalent and is the only subtype detected in mammalian-adapted strains. Comparison of the amino acid sequence of avian Allele A and B viruses with that of human viruses shows the presence of six amino acid motifs, or signatures, between human and avian Allele A viruses, while 35 motifs were found between human and Allele B viruses [26]. Thus, the higher number of signatures in allele B viruses implies that they are more distinct from mammals' origin viruses. Therefore, the NS1 adaptation plays a significant role in the virulence of avian influenza viruses in mammalian species."
"Our prior study involved investigating the genetic connection between H10 avian influenza viruses and their level of pathogenicity in mink (Mustela vison). By analyzing the NS1 protein, we discovered that the discrepancies were related to variations in amino acids. Follow-up experimentation utilizing polyinosinic-polycytidylic acid (poly I:C) triggered mink lung cells showed that the NS1 protein of the influenza A virus from minks (A/mink/Sweden/84 (H10N4)) had a more significant effect on inhibiting type I IFN promoter activity than the NS1 protein from the prototype H10 virus (known as virus/N (A/chicken/Germany/N/49 (H10N7)). [27]","In a previous study that investigated the genetic relationship among H10 avian influenza viruses with varying pathogenicity in mink (Mustela vison), we discovered a link between amino acid differences observed in the NS1 protein and the virus's level of pathogenicity. Through experiments using polyinosinic-polycytidylic acid (poly I:C) stimulated mink lung cells, we found that the NS1 protein of the influenza A virus isolated from minks (A/mink/Sweden/84 (H10N4)) had a more pronounced effect on reducing type I IFN promoter activity than the NS1 protein from the prototype H10 virus (known as virus/N (A/chicken/Germany/N/49 (H10N7)). [27]","The genetic connection between H10 avian influenza viruses and their pathogenicity level in mink (Mustela vison) was examined in our previous study. We discovered a correlation between the NS1 protein's amino acid diversity and the virus's pathogenicity level. To further investigate this link, we performed experiments using polyinosinic-polycytidylic acid (poly I:C) stimulated mink lung cells, which showed that the NS1 protein of the influenza A virus from minks (A/mink/Sweden/84 (H10N4)) suppressed type I IFN promoter activity to a greater extent than the NS1 protein from the prototype H10 virus (known as virus/N (A/chicken/Germany/N/49 (H10N7)). [27]"
"We aim to explore the influence of NS1 derived from distinct gene pools on type I IFN promoter activity, IFN-b production, and the expression of IFN-b mRNA in reaction to poly I:C in this study. By doing so, we hope to acquire a more comprehensive understanding of the molecular mechanisms that underlie the role of NS1 in IFN-b production regulation. Our findings may have essential implications, particularly for improving our knowledge of strategies to combat viral infections.","This study builds upon prior research conducted by our group by focusing on the effect that NS1 from diverse gene pools has on type I IFN promoter activity, production of IFN-b, and expression of IFN-b mRNA in response to poly I:C stimulation. Through our investigation, we strive to uncover new insight into the molecular mechanisms that govern NS1 influences on IFN-b production. These findings may contribute to the advancement of effective treatment strategies for viral infections by expanding our understanding of NS1's role in IFN-b regulation.","The objective of this research is to expand our knowledge regarding the NS1's influence on type I IFN promoter activity, the production of IFN-b, and the expression of IFN-b mRNA in response to poly I:C based on its origin from distinct gene pools. By investigating these mechanisms more extensively, we aim to uncover novel insights into the molecular interactions between NS1 and IFN-b. Our findings may help future studies better understand the viral immune response, which can lead to the development of more effective vaccines and therapies for viral illnesses."
"Our research focused on assessing the ability of NS1 from ""mink/84"" and ""chicken/49"" to halt the introduction of transcription of the IFN-b gene. By using the ISRE-Luciferase and Poly I:C stimulation model system, we analyzed the impact of these NS1s on the expression of IFN, which then triggers the signaling from the IFN-a/b receptor leading to expression of the ISRE reporter gene (luciferase). We found that both ""mink/84"" and ""chicken/49"" NS1s were able to significantly suppress the luciferase activity. However, ""mink/84"" NS1 exhibited greater effectiveness, leading to an average 6.8 fold decrease (85.3%) in A549 cells, whereas ""chicken/49"" NS1 resulted in only an average 20.8% reduction in A549 cells.","In our study, we examined the potential of NS1 derived from ""mink/84"" and ""chicken/49"" to hinder the induction of transcription of the IFN-b gene in the ISRE-Luciferase and Poly I:C stimulation model system. We observed that both NS1s were capable of suppressing luciferase activity, with ""mink/84"" NS1 inducing a much greater average decline of 6.8 fold (85.3%) in A549 cells than ""chicken/49"" NS1, which only led to an average of 20.8% reduction. These results demonstrate that ""mink/84"" NS1 is more potent in inhibiting IFN-b gene expression, highlighting the possibility that different strains of influenza virus may exhibit varying abilities to evade the host immune response.","We carried out an investigation examining the effectiveness of NS1 sourced from ""mink/84"" and ""chicken/49"" in suppressing the initiation of transcription of the IFN-b gene using the ISRE-Luciferase and Poly I:C stimulation model system. We observed a significant reduction in luciferase activity by both NS1s. However, the inhibitory effect was much more pronounced in ""mink/84"" NS1 with an average of 6.8 fold reduction (85.3%) in A549 cells compared to ""chicken/49"" NS1, which has only an average of 20.8% reduction in A549 cells. These findings suggest that ""mink/84"" NS1 may possess a higher level of efficacy for preventing the activation of the IFN-b gene, which may be significant in the context of influenza virus infection."
"The investigation aimed to determine whether the disparity in the inhibition of IFNb promoter was a result of inadequate expression or variation in the NS1 proteins in A549 cells. Western blot analysis was used to validate the extent of expressed NS1 proteins, and cells were lysed at 0, 2, 4, 8, 16, and 24 hours following transfection. NS1 proteins from both constructs were expressed to a substantial level, and the level of allele A NS1 was similar to that of allele B NS1 protein. Moreover, the western blotting disclosed that the expressed protein from both ""mink/84"" and ""chicken/49"" was uniformly accumulated in A549 cells, and there was no significant difference noticed between alleles in terms of NS1 production (Figure 1B). Therefore, the findings suggested that the disparity in IFN-b induction in the presence of allele B NS1 protein was not related to discrepancies in allele B NS1 protein expression and accumulation in the cells.","In order to understand whether the difference in the inhibitory effect of IFNb promoter was due to insufficient expression or variation in the NS1 proteins in A549 cells, the level of expressed NS1 proteins was verified by western blot analysis. Cells were lysed at 0, 2, 4, 8, 16 and 24 hours after transfection, and western blotting was performed. As shown in Figure 1B, the NS1 proteins from both constructs were expressed at high levels, and the levels of allele A and allele B NS1 were similar. The western blot analysis also revealed that the protein from both ""mink/84"" and ""chicken/49"" was distributed evenly in A549 cells, and there was no notable difference between alleles in terms of NS1 production. Hence, it was concluded that the difference in IFN-b induction in the presence of allele B NS1 protein was not caused by differences in allele B NS1 protein expression and accumulation in the cells.","The objective of the study was to determine whether the discrepancy in the inhibition of IFNb promoter was due to insufficient expression or variation in the NS1 proteins in A549 cells. In order to verify the level of expressed NS1 proteins, western blot analysis was performed. At different time points post transfection (0, 2, 4, 8, 16 and 24 hours), cells were lysed and the western blotting was executed. The results showed that the NS1 proteins from both constructs were expressed in high abundance, with comparable levels of allele A NS1 to allele B NS1 protein (Figure 1B). It was found that the expressed protein from ""mink/84"" and ""chicken/49"" was uniformly accumulated in A549 cells, and there was no substantial difference between alleles regarding NS1 production (Figure 1B). As a result, it was concluded that the difference in IFN-b induction in the presence of allele B NS1 protein was not due to differences in NS1 protein expression and accumulation for allele B in cells."
"It was unclear at that particular point whether the outcome was a result of the differing abilities of IFN production inhibition, or if the responsive signaling pathway leading to ISRE transcription was affected, or a combination of both. In order to clarify this, measurements were taken for the production of the IFN protein, using the ELISA method.","There was ambiguity as to whether the outcome was due to varying abilities to limit the production of IFN, alterations made to the signaling pathway responsible for ISRE transcription or both. To address this, an ELISA was conducted to quantify the amount of IFN protein produced.","It was uncertain if the result was an effect of differences in the capability to inhibit IFN production, alterations made to the signaling pathway leading to ISRE transcription, or a combination of both. Therefore, an ELISA was carried out to quantify IFN protein production to clear things up."
"Following the use of poly I:C stimulation, there was a delay of 2-4 hours before the IFN-b protein was detected in the cell medium of the control cells. As time progressed, there was a linear increase in IFNβ accumulation in the cell culture supernatant until peak yields were reached after 16 to 24 hours post-stimulation. Compared to the control cells, low levels of IFN-b were secreted by cells transfected with various NS1s, with ""mink/84"" virus showing at least 10 times lower levels than normal. The maximum yield of IFN-b secreted to the supernatant in these cells was reached after 8 hours of stimulation and dropped rapidly for the rest of the experiment. Conversely, cells expressing the NS1 protein of ""chicken/49"" were mediocre producers of IFN-b, with a lower profile similar to that of control cells. Therefore, it is evident that NS1 suppresses IFN protein production instead of signalling from the IFN receptor according to this system.","After poly I:C stimulation, the IFN-b protein could be detected in control cell medium after a lag of 2 to 4 hours. This was followed by a gradual rise in IFNβ accumulation in the cell culture supernatant until peak yields were reached 16 to 24 hours post-stimulation. Though cells transfected with various NS1s secreted low levels of IFN-b, significant differences were observed between these NS1s. For example, cells expressing the NS1 protein of ""mink/84"" virus produced IFN-b at least 10 times lower than control cells. In such cells, IFN-b reached its maximum yield secretion after 8 hours of stimulation, but declined quickly to a considerably lower level for the rest of the experiment. On the other hand, IFN-b production by ""chicken/49"" NS1-expressing cells was lower than control but similar in a wider-ranging manner. NS1 appears to suppress IFN protein production rather than signalling from the IFN receptor in this system. (See Figure 2A)","Poly I:C stimulation caused a delay of 2 to 4 hours before the detection of IFN-b protein in the cell medium of control cells. There was a linear accumulation in IFNβ in the cell culture supernatant as time progressed, and peak yields occurred after 16 to 24 hours post-stimulation. Cells transfected with different NS1s secreted low levels of IFN-b, with distinct patterns among these NS1s. The NS1 protein of the ""mink/84"" virus, for example, produced ten times less IFN-b than control cells. The maximum secretion of IFN-b in the supernatant of these cells occurred after 8 hours of stimulation and decreased quickly for the remainder of the experiment. In contrast, cells expressing the NS1 protein of ""chicken/49"" produced lower levels of IFN-b but with a similar profile to that of control cells. This indicates that NS1 in this system suppresses the production of IFN protein rather than the signalling from the IFN receptor. (Figure 2A)"
"To investigate whether the inhibition of IFN-b production was due to the repression of the IFN-b gene expression, we conducted a comparative analysis of the gene expression kinetics in A549 cells that were stimulated with poly I:C, with or without the presence of various NS1 proteins.","To determine the cause of the reduction in IFN-b production, we assessed the gene expression kinetics of A549 cells that were exposed to poly I:C in the presence or absence of different NS1 proteins. This allowed us to investigate whether the expression of the IFN-b gene was being suppressed, leading to the observed decrease in IFN-b production.","We aimed to identify whether the decrease in IFN-b production resulted from the inhibition of the IFN-b gene expression. Hence, we analyzed the gene expression kinetics in A549 cells that were induced with poly I:C, with or without the presence of various NS1 proteins. This comparative study allowed us to determine the potential suppression of IFN-b gene expression and its correlation with the decrease in IFN-b production."
"The expression of IFN-b mRNA in the control cells showed an increase throughout the entire experiment (Figure 2B). A similar trend was observed in cells expressing the NS gene of ""chicken/49"" in Figure 2C. The cells that were stimulated showed a significant increase in transcript levels from 2 to 4 hours post-stimulation, and it reached a plateau by the end of the experiment. After the stimulation of cells, Figure 2D shows that the NS1 protein of ""mink/84"" effectively suppressed the gene transcription of IFN-b in A549 cells after four hours. Transfecting plasmids that carried the NS gene of ""chicken/49"" in cells resulted in increased levels of IFN-b mRNA following the same pattern as control cells.","Throughout the experiment, the control cells showed an increase in IFN-b mRNA levels (Figure 2B), which was also observed in cells expressing the NS gene of ""chicken/49"" in Figure 2C. Significant increases were observed in transcript levels from 2 to 4 hours post-stimulation in stimulated cells, and it reached to a plateau at the end of the experiment. After four hours of stimulation, Figure 2D shows that the NS1 protein of ""mink/84"" effectively decreased the gene transcription of IFN-b in A549 cells. The cells transfected with plasmids carrying NS gene of ""chicken/49"" showed an increase in IFN-b mRNA levels that followed a similar pattern to the control cells.","The IFN-b mRNA levels in control cells increased continuously throughout the experiment (Figure 2B), and a similar pattern was observed in cells expressing the NS gene of ""chicken/49"" in Figure 2C. Stimulated cells showed a significant increase in transcript levels between 2 to 4 hours post-stimulation that reached a plateau towards the end of the experiment. Figure 2D shows that four hours after stimulation, the NS1 protein of ""mink/84"" effectively suppressed the gene transcription of IFN-b in A549 cells.  The activation of the IFN-b gene expression using plasmids carrying NS gene of ""chicken/49"" resulted in increased levels of IFN-b mRNA, following a similar trend to the control cells."
"The analysis of the INF-b mRNA using RT-PCR showed that the NS1 protein of ""mink/84"" is effective in inhibiting the transcription of IFN-b gene in A549 cells, while having no effect on the same gene in A549 cells expressing NS1 of ""chicken/49"". This suggests that the main target of ""mink/84"" NS1 is suppression of IFN induction in A549 cells.","The results of the RT-PCR analysis on the INF-b mRNA in stimulated A549 cells expressing NS1 of ""mink/84"" or ""chicken/49"" have confirmed that the NS1 protein of ""mink/84"" has a significant impact on the suppression of the transcription of the IFN-b gene in A549 cells. The findings suggest that the ""mink/84"" NS1 protein primarily targets the inhibition of IFN induction in these cells. Conversely, there was no effect on the same gene in A549 cells expressing NS1 of ""chicken/49"".","The analysis of INF-b mRNA by RT-PCR in A549 cells stimulated for the expression of NS1 of ""mink/84"" or ""chicken/49"" has confirmed that the NS1 protein of ""mink/84"" showed effective suppression of transcription of the IFN-b gene. This suggests that the ""mink/84"" NS1 protein aims to inhibit IFN induction in A549 cells, while the same was not observed in A549 cells expressing NS1 of ""chicken/49"". Therefore, this points to the specificity of the ""mink/84"" NS1 protein in targeting IFN induction."
"Influenza A viruses have developed numerous strategies to evade host immune responses. One of their main tactics is to inhibit the expression and signalling of IFN-a/b, which helps neighbouring cells induce their antiviral state. The NS1 viral protein of influenza A viruses plays a crucial role in regulating innate immunity by rebuking host immune responses through two functioning domains: an RNA binding domain and an effector domain. The effector domain blocks mRNA export and pre-mRNA splicing, interacts with proteins that are involved in the 3'-end cellular mRNA processing, as well as the nuclear pore complex and the mRNA export machinery. Meanwhile, the RNA binding domain is responsible for binding to single- and double-stranded RNA, effectively halting the activation and/or signalling of antiviral proteins such as PKR, RIG-I, OAS/RNase L, and others involved in type I IFN and inflammatory cytokine signalling.","To avoid host immune responses, influenza A viruses utilize several strategies, one of which involves inhibiting the expression and signalling of IFN-a/b. These molecules play an important role in inducing an antiviral state in neighboring cells by promoting transcription from ISRE promoter-containing genes. The NS1 protein made by influenza A viruses modulates innate immunity by regulating host immune responses using two separate domains: an RNA binding domain and an effector domain. The effector domain interferes with cellular RNA processing by inhibiting both mRNA export and pre-mRNA splicing. Additionally, it interacts with proteins that make up the nuclear pore complex and the mRNA export machinery. Meanwhile, the RNA binding domain binds to both single- and double-stranded RNA and can prevent the activation and/or signalling of antiviral proteins involved in type I IFN and cytokine signalling pathways, such as activators of mitogen-activated protein kinase, PKR, RIG-I, and OAS/RNase L.","One of the primary survival mechanisms of influenza A viruses is their ability to evade host immune responses by impeding IFN-a/b expression and signalling to adjacent cells. By doing so, they prevent the antiviral state induced by transcription from the ISRE promoter-containing genes. The NS1 protein of influenza A viruses is instrumental in regulating innate immunity and uses both an RNA binding domain and an effector domain to suppress host immune responses. The effector domain inhibits the mRNA export process and pre-mRNA splicing of host cell transcripts, as well as interacting with components of the nuclear pore complex and the mRNA export machinery. Meanwhile, the RNA binding domain binds to both single- and double-stranded RNA and can hinder the activation and/or signalling of antiviral proteins such as activators of mitogen-activated protein kinase, PKR, RIG-I, OAS/RNase L, and transcription factors involved in type I IFN and inflammatory cytokine signalling."
"Based on our prior investigation, it appears that the NS1 protein might be the determining factor for the different pathogenicity levels manifested by H10 avian influenza viruses in mink. To further probe this issue, we utilized an expression plasmid structure that carried the ORF of two avian influenza viruses that resulted in different pathogenicity levels in mink. These two viruses were characterized by different NS alleles: one from A (""mink/84"") and the other from B (""chicken/49""). An examination of the amino acid sequences of the two NS1 proteins revealed 71 differences between the two. However, we discovered that fundamental amino acid residues necessary for NS1 protein function were similar in the two strains, as we had previously observed in infected cells.","Our previous research suggested that the NS1 protein is a crucial factor that may affect different pathogenicity levels of H10 avian influenza viruses in mink. Therefore, we employed an expression plasmid system that contained the ORF of NS1 from two avian influenza viruses with different pathogenic potential in mink. These viruses also had dissimilar NS alleles: one from A (""mink/84"") and another from B (""chicken/49""). Unlike our expectations, while there were 71 amino acid differences between the predicted amino acid sequences of the NS1 proteins of the two strains, the crucial amino acid residues for NS1 protein function in infected cells were quite similar. We have identified these from previous research where we found similar residues in various experiments.","In our earlier study, we highlighted the potential role of the NS1 protein as a critical factor affecting the pathogenicity levels of H10 avian influenza viruses in mink. To explore this further, we used an expression plasmid system that carried the ORF of NS1 from two avian influenza viruses, both of which varied in their pathogenic potential in mink. These two viruses had distinct NS alleles, with one derived from A (""mink/84"") and the other from B (""chicken/49""). Upon comparing the predicted amino acid sequences of the two NS1 proteins, we found 71 amino acid differences between them. Still, important amino acid residues necessary for NS1 protein function in infected cells were identified to be quite similar, as previously established in our earlier experiments."
"The analysis of NS1 protein revealed a single dissimilarity between ""mink/84"" and ""chicken/49"". This distinction was observed in the domain that plays a vital role in the interaction with the CPSF30 subunit. When formed, this interaction functions to restrict 3' end processing of cellular premRNA. The function is carried out by two separate regions; one encompassing residue 186 and the other containing residues 103 and 106. The NS1 protein of ""mink/84"" contained Glu186, Phe103, and Met106, whereas the NS1 protein of ""chicken/49"" featured Tyr103. A previously conducted analysis observed a noticeable alteration in the NS1 protein's impact on controlling host gene expression when changes were introduced to the CPSF30 interaction sites.","Through analysis of the NS1 protein, it was noted that there was only one difference present between ""mink/84"" and ""chicken/49"". This differentiation was discovered within the domain responsible for interaction with the CPSF30 subunit. This interaction works to impede 3' end processing of cellular premRNA. The execution of this function is carried out by two individual regions: one anchored at residue 186 and the other surrounding residues 103 and 106. The NS1 protein of ""mink/84"" exhibited Glu186, Phe103, and Met106, while the NS1 protein of ""chicken/49"" displayed Tyr103. A former evaluation demonstrated that altering the interaction sites between NS1 protein and CPSF30 could dramatically affect the ability of NS1 to regulate the host gene expression.","Examination of the NS1 protein uncovered only one dissimilarity between ""mink/84"" and ""chicken/49"". This divergence was detected within the domain accountable for engaging with the CPSF30 subunit. Once formed, this interaction restricts the 3' end processing of cellular premRNA. The implementation of this function occurs via two distinct regions: one near residue 186 and the other around residues 103 and 106. The NS1 protein of ""mink/84"" featured Glu186, Phe103, and Met106, while the NS1 protein of ""chicken/49"" had Tyr103. Former research exposed that modifications to the CPSF30 interaction sites within the NS1 protein could significantly alter its capacity to regulate host gene expression."
"""The ISRE promoter activation was negatively impacted by both NS1 proteins from ""mink/84"" and ""chicken/49,"" the luciferase activity showed. However, the reduction was significantly more severe in cells subjected to transfection with the ""mink/84"" NS1 plasmid than pNS-chicken/49. The average decrease observed in A549 cells was 85.3% for the former and 20.8% for the latter. The mechanism behind this interference is currently undetermined, but there are potential possibilities, such as inhibiting IFN induction signals via RIG-I, MDA-5, or TRL-3, hampering IFN mRNA processing, or affecting downstream effects of IFN receptor signaling or luciferase mRNA processing.""","""Both the ""mink/84"" and ""chicken/49"" NS1 proteins caused a negative effect on the activation of the ISRE promoter as demonstrated by the luciferase activity. Nevertheless, the ""mink/84"" NS1 plasmid exerted a more profound reduction in comparison to pNS-chicken/49"", resulting in an average decrease of 85.3% in A549 cells and 20.8%, respectively. However, the precise mechanism of how this interference is mediated is still unclear. It could involve inhibiting IFN induction signals via RIG-I, MDA-5, or TRL-3 or hampering IFN mRNA processing, leading to downstream effects on IFN receptor signaling or luciferase mRNA processing.""","""According to the luciferase activity, both the ""mink/84"" and ""chicken/49"" NS1 proteins had an undesirable impact on the activation of the ISRE promoter. However, the reduction in cells that were transfected with the ""mink/84"" NS1 plasmid was more pronounced, producing an average decrease of 85.3% in A549 cells; whereas pNS-chicken/49 resulted in a relatively smaller decrease of 20.8%. The underlying mechanism through which this interference occurs remains unexplored. It may occur through blocking IFN induction signals via RIG-I, MDA-5, or TRL-3, impeding IFN mRNA processing, or affecting downstream IFN receptor signaling or luciferase mRNA processing."""
"The research suggests that the NS1 protein-induced IFN-b promoter activation is prevented by the RNA binding domain, located in the N-terminal of the NS1 protein. The differences observed in the amino acid sequence of the two NS1 proteins may result in different structural changes, which could alter the functionality of NS1 in suppressing the IFN-b promoter activation.","Several investigations have demonstrated that the N-terminal RNA binding domain of the NS1 protein is the key mediator for blocking the activation of IFN-b promoter caused by the virus. The 71 diverse amino acids present in two different NS1 proteins can cause variations in the three-dimensional structure of NS1 protein, which might not enable its suppressing action on IFN-b promoter activation.","The studies conducted reveal that the N-terminal RNA binding domain present in the NS1 protein is responsible for the inhibition of IFN-b promoter activation induced by the virus. The dissimilarity in the sequence of 71 amino acids between the two NS1 proteins leads to differences in the three-dimensional structure of the NS1 protein, affecting the suppression of IFN-b promoter activation."
"The study aimed to investigate the impact of IFN-b promoter induction on IFN-b production. To this end, the research team examined the endogenous IFN-b mRNA levels and the amount of IFN-b secreted into the cell supernatant. The suppression of IFN-b gene expression and secretion of IFN-b in the cell culture supernatant was more evident in the NS1 protein of “mink/84” than in “chicken/49.” Poly I:C stimulation of A549 cells resulted in a three-phase IFN-b production pattern: an initial rapid rise, a peak, followed by a decline to lower levels. The accumulation of secreted IFN-b increased gradually and peaked at 16 to 24 h post-poly I:C stimulation, as observed in the cell culture media. Similarly, the mRNA levels revealed an early upregulation of IFN-b transcripts from as early as 2 h and peaked at 18 to 24 h after stimulation through poly I:C. Notably, A549 cells expressing the NS1 protein of “mink/84” showed an upregulation of IFN-b mRNA transcripts during the first 4 h after stimulation.","In this study, the objective was to determine the effect of IFN-b promoter induction on the production of IFN-b. The team examined levels of endogenous IFN-b mRNA and the quantity of IFN-b secreted in cell supernatants. It was discovered that the expression of the IFN-b gene and the amount of IFN-b secretion in the cell culture supernatant were strongly suppressed by the NS1 protein of “mink/84,” but not “chicken/49.” IFN-b production showed a three-phase pattern in A549 cells stimulated with poly I:C, characterized by an initial quick surge, a peak, and then a drop to lower levels. Secreted IFN-b gradually accumulated in the cell culture media with a peak observed after 16 to 24 hours post-poly I:C stimulation. Similarly, IFN-b mRNA levels exhibited an early upregulation, with a peak observed at 18 to 24 hours after stimulation through poly I:C. Importantly, A549 cells expressing the NS1 protein of “mink/84” demonstrated an upregulation of IFN-b mRNA transcripts during the first 4 hours after stimulation.","The study sought to explore the relationship between IFN-b promoter induction and IFN-b production. The research team examined the levels of endogenous mRNA and the amount of IFN-b secreted in cell supernatants. The NS1 protein of “mink/84” was found to significantly reduce the expression of the IFN-b gene and the secretion of IFN-b in the cell culture supernatant but not that of “chicken/49”. IFN-b production in cells stimulated with poly I:C showed a three-phase pattern: an initial rapid increase, followed by a peak, and then a decrease. Secreted IFN-b increased gradually and reached peak levels between 16 to 24 hours post-poly I:C stimulation in the cell culture media. Similarly, mRNA levels revealed an early upregulation of IFN-b transcripts, with a peak observed at 18 to 24 hours after poly I:C stimulation. Of note, A549 cells expressing the NS1 protein of “mink/84” showed an upregulation of IFN-b mRNA transcripts in the first 4 hours after stimulation, which aligned with observations of IFN-b production dynamics."
"In order to obtain a more comprehensive understanding of the observation, more research is needed to explore the intricate molecular mechanism involved. This could encompass various experimental approaches, including animal studies as well as sophisticated methods such as genomics, reverse genetics, and proteomic tools that can examine multiple parameters that play a role in the complex interplay between NS1 and the innate immune system of the host.","To fully comprehend the underlying molecular processes behind the observed effect, additional experiments are necessary. This could potentially entail animal experimentation as well as the utilization of cutting-edge tools such as genomics, reverse genetics, and proteomics to analyze a multitude of parameters that contribute to the intricate interplay between NS1 and the innate immune response of the host.","To acquire a deeper insight into the observed phenomenon, further investigations are required to explore the intricate molecular mechanism involved. This may include the use of animal models and advanced techniques such as genomics, reverse genetics, and proteomics, which allow for the analysis of multiple parameters that play a role in the complex interaction between NS1 and the host's innate immune system."
"The available observations suggest that there might be a correlation between the abilities of nonstructural protein 1 (NS1) of various influenza viruses, one from allele A and the other from allele B, to stifle the induction of IFN mRNA. However, the exact mechanism behind this phenomenon remains elusive. Furthermore, the results of this study indicate that the production of the crucial cytokine, IFN-b, is negatively impacted by the function of NS1 protein from diverse genetic gene pools.","Diverse observations currently available point towards different nonstructural protein 1 (NS1) of influenza viruses showing varying abilities to suppress the induction of IFN mRNA. Two distinct NS1 proteins, one derived from allele A and the other from allele B, exhibit differences in their capabilities to inhibit the induction of IFN mRNA, yet the exact mechanism behind their functioning remains unknown. Furthermore, the study highlights that the NS1 protein's varying functions from different genetic gene pools can impact the production of an essential cytokine, IFN-b.","The available observations suggest that there are differences in the abilities of nonstructural protein 1 (NS1) of influenza viruses, with one derived from allele A and the other from allele B, to stifle the induction of IFN mRNA. However, the mechanism behind this dissimilarity remains unclear. Furthermore, the study results indicate that the NS1 protein's functions from various genetic gene pools can affect the production of an essential cytokine, IFN-b, which highlights the significance of the NS1 protein in suppressing the immune system's response."
"It could be that NS1 interacts with a single or both of the inducing pathways, or it could also mean that there is a hindrance in mRNA processing. To conduct a meticulous analysis of the matter, it is advisable to study an inducible gene that is not reliant on IFN.","It is possible for NS1 to interact with one or both of the inducing pathways, which can lead to a block in mRNA processing. One way to explore this could be by examining an inducible gene unrelated to IFN. Further research is crucial to determine the underlying mechanism behind the interaction between NS1 and inducing pathways.","Perhaps NS1 has the ability to interact with one or both of the inducing pathways or is causing a hindrance to mRNA processing. To study the latter, it is recommended to examine an inducible gene other than the one that depends on IFN. It is essential to conduct further investigations to understand better the impact of NS1 on the inducing pathways."
"Following the development of an assay protocol for various aspects of our research, we conducted three separate experiments, each performed on different days, where we carried out the testing of the NS1 constructs in duplicate. This was crucial in ensuring the accuracy and reliability of our findings, as well as allowing us to validate our results across multiple trials.","In order to ensure the validity of our research findings, we established an assay protocol for each section of the study. Once the protocols were put in place, we conducted three distinct experiments using the NS1 constructs in sets of duplicates. These experiments were done on different days to reduce the chance of variability and errors in the findings. The replication of these trials helped to increase the accuracy of our results, offering reliable and consistent data.","The NS1 constructs were subjected to testing in duplicate, as part of three separate experiments that were independently executed on different days. To ensure the accuracy of the results, we established an assay protocol for the various aspects of our study. The use of duplications of the testing and separate execution of the experiments helped in reducing errors and bringing consistency in the findings. Our study was thus able to validate our results effectively, giving us reliable data."
"The NS1 genes from strains ""mink/84"" and ""chicken/49"" of the influenza A virus were amplified with the aid of NS1Kpn 5' and NS1XhoI 3' primers. PCR mixes were prepared by adding 1x Platinum Taq buffer, 200 μM dNTP, 2.5 mM MgCl2, and 3 μl cDNA (all from Invitrogen) to a total volume of 25 microliters. The preparation was then subjected to a thermal cycler, with the cycling conditions set at 95°C for 2 min, 35 cycles between 95°C for 20 sec, 58°C for 60 sec, and 72°C for 90 sec, and then a final stop at 8°C until further use.","To amplify the NS1 open reading frames of the ""mink/84"" and ""chicken/49"" strains of influenza A viruses, the NS1Kpn 5' and NS1XhoI 3' primers were utilized. PCR mixes were created, with a volume of 25 microliters consisting of 1x Platinum Taq buffer, 200 μM dNTP, 2.5 mM MgCl2, and 3 μl cDNA (all from Invitrogen). The samples were placed in a thermal cycler, undergoing cycling conditions of annealing at 58°C for 60 sec, elongating at 72°C for 90 sec, and then remaining at 8°C for future use. Prior to cycling, the preparation was initially heated to 95°C for 2 minutes, followed by a total of 35 cycles between 95°C for 20 sec.","The NS1 open reading frames of the influenza A virus strains ""mink/84"" and ""chicken/49"" were amplified using the NS1Kpn 5' and NS1XhoI 3' primers. A 25 microliter PCR mix was prepared by adding 1x Platinum Taq buffer, 200 μM dNTP, 2.5 mM MgCl2, and 3 μl cDNA (all from Invitrogen). The samples were subjected to cycling conditions of annealing at 58°C for 60 sec, elongating at 72°C for 90 sec, and then remaining at 8°C for future use. Prior to cycling, the preparation was initially heated to 95°C for 2 minutes, followed by a total of 35 cycles between 95°C for 20 sec. The amplified products were stored for further analysis."
"The 690 bp PCR product samples underwent Kpn and XhoI digestion before being cloned into pcDNA3.1, a mammalian expression vector from Invitrogen. The Kpn and XhoI sites were exploited to insert these samples into the vector, creating two plasmids known as pNS-mink/84 and pNS-chicken/49. The plasmids were subsequently checked to ensure their integrity via sequencing.","Scientists utilized Kpn and XhoI to digest 690 bp PCR products, and then they inserted these samples into the mammalian expression vector, pcDNA3.1. The vector contained Kpn and XhoI sites which allowed the samples to be efficiently inserted. Two plasmids were then produced, named pNS-mink/84 and pNS-chicken/49. To verify that the plasmids were not disfigured, a thorough sequencing test was performed.","Two sets of PCR products, 690 bp in size, underwent Kpn and XhoI restriction enzyme digestion before further processing. These were then integrated between the Kpn and XhoI sites of the mammalian expression vector pcDNA3.1 from Invitrogen, resulting in the creation of two plasmids, named pNS-mink/84 and pNS-chicken/49. The plasmids were carefully examined by conducting a sequencing test to guarantee their integrity."
"The A549 cells, derived from human adenocarcinoma and belonging to type II alveolar epithelial cells, were cultivated using Dulbecco's modified Eagle medium (DMEM) with an addition of 10% FCS. This was carried out in a well-humidified environment with 5% CO2 and maintained at a temperature of 37°C.","To culture A549 cells, which are a type II alveolar epithelial cell line derived from human adenocarcinoma, Dulbecco's modified Eagle medium (DMEM) was used with a supplement of 10% FCS. The cells were grown in an atmosphere of 5% CO2 and maintained at a constant temperature of 37°C in a highly humidified environment.",Human adenocarcinoma-derived A549 cells of type II alveolar epithelial cells were cultured with DMEM supplemented with 10% FCS in 5% CO2 humidified environment at 37°C.
"An experiment was conducted to assess transcriptional activity in the A549 cells. For this, cells were co-transfected with plasmids that contained either the NS gene of ""mink/84"" or ""chicken/49"" along with reporter plasmids driving the expression of Firefly luciferase (pISRE-TA-Luc) (Invitrogen) under the control of the IFN-stimulated response element (ISRE). An internal control, the pRen-Luc plasmid containing the Renilla luciferase gene (Invitrogen), was employed. The Renilla luciferase activity was utilized to normalize the activity of the reporter gene. The inhibitory effect was assessed in cells expressing the various NS1s and was represented in folds of luciferase activity.","The A549 cells were used in an experimental study to examine transcriptional activity. Reporter plasmids driving the expression of Firefly luciferase (pISRE-TA-Luc) (Invitrogen) under the control of IFN-stimulated response element (ISRE) were co-transfected with plasmids containing either the NS gene of ""mink/84"" or ""chicken/49"". To serve as an internal control, the Renilla luciferase gene (pRen-Luc plasmid) (Invitrogen) was included. The Renilla luciferase activity was used to standardize the activity of the reporter gene. The inhibitory effect on cells expressing the varied NS1s was measured in folds of luciferase activity.","The transcriptional activity in the A549 cells was investigated in an experimental study. The reporter plasmids containing the Firefly luciferase gene (pISRE-TA-Luc) (Invitrogen) under the IFN-stimulated response element (ISRE) control were co-transfected with plasmids that have the NS gene of either ""mink/84"" or ""chicken/49"". An internal control, the pRen-Luc plasmid that carried the Renilla luciferase gene (Invitrogen), was employed. The Renilla luciferase activity served as a standard for the reporter gene activity. The inhibitory influence on cells that express distinct NS1s was quantified in terms of luciferase activity folds."
"Plasmid transfection was performed in six-well plates utilizing FuGENE 6 reagent, as instructed by the manufacturer. Prior to the transfection, initial experiments were undertaken to ensure the efficacy of the protocol. The cells were seeded into six-well plates at a density of 1 × 10 5 cells per well the day prior to the transfection to attain a confluence of 70-80% on the day of the transfection. Each transfection group consisted of six wells, with three being exposed to poly I:C and the other three remaining mock-treated. Poly I:C stimulation of the cells was done by adding a mixture of 5 μg/ml poly I:C and 100 μl DMEM without serum to the wells, 24 hours after transfection with the pcDNA3.1/NS1 plasmid. Twenty-four hours after the stimulation, the cells were harvested for luciferase assay, and luciferase activity was measured for each group by centrifuging the samples for 2 min at 14,000 × g, removing cell debris and measuring 20 μl of each sample, according to the manufacturer's instructions.","For the plasmid transfection, FuGENE 6 reagent was utilized in six-well plates, following the instructions provided by the manufacturer. The transfection protocol was optimized through initial experiments to ensure efficient transfection. Cells were seeded into six-well plates one day in advance at a density of 1 × 10 5 cells per well, to attain 70-80% confluence on the day of transfection. Each transfection group had six wells, out of which, three exhibited poly I:C stimulation, and the other three remained untreated. Poly I:C stimulation of cells was performed 24 hours post transfection with the pcDNA3.1/NS1 plasmid, by adding 5 μg/ml poly I:C mixed in 100 μl DMEM without serum to the wells. Following 24-hour stimulation, cells were harvested for the luciferase assay using 300 μl lysis buffer for each well. Samples were centrifuged at 14,000 × g, for 2 min to remove cell debris and were kept on ice, and 20 μl of each sample was used to measure luciferase activity as per the manufacturer's protocol.","The transfection of plasmids was carried out using FuGENE 6 reagent in six-well plates, according to the manufacturer's guidelines. Prior to the actual transfection, attempts were made to optimize the efficiency of the protocol. The cells were seeded into six-well plates at a density of 1 × 10 5 cells per well the day before the transfection to obtain 70-80% confluence on the day of the transfection. In each transfection group consisting of six wells, three were treated with poly I:C, while the other three remained untreated. Poly I:C stimulation of cells took place 24 hours after transfection with the pcDNA3.1/NS1 plasmid, by introducing 5 μg/ml poly I:C mixed with 100 μl DMEM without serum. After 24 hours of stimulation, the cells were harvested for luciferase assay using 300 μl lysis buffer for each well. To eliminate cell debris, samples were subjected to centrifugation at 14,000 × g for 2 min, after which luciferase activity was measured using 20 μl of each sample, following the manufacturer's instructions."
"The Western blot analysis process was consistent for all transfections, following a standard protocol. The Bio-Plex cell lysis kit (manufactured by Bio-Rad Laboratories, located in Hercules, CA) was utilized to wash and lyse cells at specific times: 0, 2, 4, 8, 16, and 24 hours post transfection. The lysates underwent three rounds of thawing-freezing at -70°C, which were followed by incubation at 4°C for 20 minutes, before the lysates underwent centrifugation at 4500 rpm for 20 minutes. The quality and quantity of protein were measured using Nanodrop ND1000 and SDS-polyacrylamide gel electrophoresis (SDS-PAGE), then Coomassie blue staining. The Ready Gel J 7.5% (Bio-Rad) was used to separate 50 μg of cell lysate by SDS-PAGE, followed by electronic transfer onto a polyvinylidene difluoride (PVDF) membrane (GE Healthcare, situated in Uppsala, Sweden). Anti-NS1 polyclonal and anti-b-actin primary antibodies were added to the buffer solution (TBS-2% BSA), which was applied to the membranes during the detection process of NS1 and bactin proteins, respectively.","All western blot analyses for transfections were performed following a consistent protocol of procedures mentioned above. In brief, lysing of washed cells was conducted at specific hours post-transfection of 0, 2, 4, 8, 16, and 24 using the Bio-Plex cell lysis kit from Bio-Rad Laboratories based in Hercules, CA. The lysate was incubated for 20 minutes in 4°C and underwent three cycles of thawing-freezing before centrifugation was carried out at 4500 rpm for 20 minutes. Protein samples were assessed regarding their quality and quantity through nanodrop ND1000 tests and SDS-polyacrylamide gel electrophoresis, which was followed by Coomassie blue staining. Separation of cell lysate was performed by SDS-PAGE on the ready gel J 7.5% Bio-Rad, followed by PVDF membrane transfer electronically. Blocking buffer (2% BSA in PBS) was utilized for protein detection through the addition of anti-NS1 polyclonal and anti-b-actin primary antibodies to the membrane, which were further diluted in TBS. Lastly, overnight incubation at 4°C was carried out.","The western blot analysis for all transfections followed a set protocol, as previously mentioned. The cells were washed and lysed at different hours post-transfection, including 0, 2, 4, 8, 16, and 24, using the Bio-Plex cell lysis kit manufactured by Bio-Rad Laboratories in Hercules, CA. After incubation for 20 minutes at 4°C, the lysates underwent three rounds of thawing-freezing steps, followed by centrifugation at 4500 rpm for 20 minutes. Testing of the quality and concentration of protein utilized Nanodrop ND1000 and SDS-polyacrylamide gel electrophoresis (SDS-PAGE), as well as Coomassie blue staining. Separation of the sample of 50 μg of cell lysate on SDS-PAGE was carried out by using Bio-Rad's ready gel J 7.5%, which was later electronically moved to a polyvinylidene difluoride (PVDF) membrane. Blocking buffer comprising 2% BSA in PBS was used on membranes to detect NS1 and bactin proteins, which were identified by applying the primary antibodies to them. The antibodies were diluted in TBS, and the incubation was carried out at 4°C overnight."
"The VeriKine™ human IFN-beta sandwich ELISA kit (PBL interferon source, Piscataway, NJ, USA) was employed to measure the IFN-b concentrations in the supernatants of A549 cells following their stimulation by poly I:C, at designated timepoints. The samples were analyzed according to the instruction manual provided by the manufacturer. The assay was performed using microtiter strips that contained standard IFN-b, blanks, and samples. Detection antibodies were added after one-hour incubation, and the strips were washed before adding the streptavidin-HRP conjugate for additional incubation. The tetramethyl benzidine (TMB) substrate solution was added, and the strips were incubated at room temperature in dark conditions, terminated with stop solution. The optical density of each well was measured at 450 nm using the microplate reader Multiscan EX (Thermo scientific, MA, USA), and the amount of IFN-b was subsequently calculated through comparison with the standard curve.","To determine the IFN-b concentrations in the supernatants of stimulated A549 cells, the VeriKine™ human IFN-beta sandwich ELISA kit (PBL interferon source, Piscataway, NJ, USA) was used according to the manufacturer’s instructions. Samples were collected at various timepoints post-poly I:C stimulation, and microtiter strips containing IFN-b standards, blanks, and samples were incubated. Detection antibodies were added, followed by the addition of streptavidin conjugated to HRP. The strips were washed and treated with the tetramethyl benzidine (TMB) substrate, with subsequent measurement of the optical density of each well at 450 nm using a microplate reader (Multiscan EX, Thermo scientific, MA, USA). The IFN-b concentrations were estimated by comparison with the standard curve.","The concentration of IFN-b in the supernatants of A549 cells was measured using the VeriKine™ human IFN-beta sandwich ELISA kit (PBL interferon source, Piscataway, NJ, USA). Poly I:C was used to stimulate the cells, and supernatants were collected at different time points for analysis. The microtiter strips were incubated with IFN standards, blanks, and samples. Detection antibodies and streptavidin conjugated to HRP were used before adding the tetramethyl benzidine (TMB) substrate. The strips were then incubated at room temperature before the addition of the stop solution, and the optical density of each well was read using a microplate reader (Multiscan EX, Thermo scientific, MA, USA) at 450 nm. The amount of IFN-b was calculated by comparing the values for the samples with the standard curve."
"The expression of IFN-b mRNA in A549 cells stimulated with Poly I:C was analyzed using RT-PCR method. In order to compare the levels of IFN-b mRNA with a normalizing factor, the b-actin housekeeping gene was used. The expression was measured with specific primer pairs designed for human IFN-b and b-actin mRNA. The forward and reverse IFN-b primers were 5'-AGCTACAAGATGACAGCCAGACT-3' and 5'-AGTGACAGTCCCAGGATGAGCTG-3', respectively. The forward and reverse b-actin primers used were 5'-GCTCCTCCTGAGCGCAAGTACTCT-3' and 5'-GAACACAGTGCTGTCTGGCGGACT-3', respectively. A 25 μl reaction containing 1xPlatinum Taq buffer, 200 μM dNTP, 2.5 mM MgCl2, and 3 μl cDNA was prepared. The reaction underwent a thermal cycling protocol of 95°C for 5 minutes, 35 cycles of 95°C for 45 seconds, 60°C for 30 seconds, 72°C for 1 minute, and a final extension of 72°C for 10 minutes. The amplified PCR products were visualized using electrophoresis on 2% agarose gel.","The transcriptional levels of IFN-b mRNA were determined in Poly I:C-stimulated A549 cells using RT-PCR. The expression of the housekeeping gene b-actin was used as a control. Human-specific primer pairs were used to examine the expression of IFN-b and b-actin mRNA. The forward and reverse IFN-b primers were 5'-TGATGGCTCTGTCAGCAACTG-3' and 5'-CGCGTCTTTCAGTTCCACTTTC-3', respectively, and the forward and reverse b-actin primers used were 5'-CAGCCCTGTGCTGCCAGGGCAA-3' and 5'-CTCCTTAATGTCACGCACGATTTC-3'. A 25 μl mixture containing 1xPlatinum Taq buffer, 200 μM dNTP, 2.5 mM MgCl2, and 3 μl cDNA was used. The reactions underwent a thermal cycling protocol consisting of an initial denaturation step at 94°C for 3 min, followed by 30 cycles of 94°C for 30 sec, 64°C for 45 sec, and 72°C for 1 minute with a final extension at 72°C for 5 min. PCR products were analyzed by electrophoresis on 2% agarose gel.","This study aimed to analyze the mRNA expression levels of IFN-b in A549 cells stimulated with Poly I:C using the RT-PCR method. The b-actin gene was used as an internal control to determine the relative expression of IFN-b mRNA. The human-specific primers used for IFN-b were forward 5’-GCTCTGTAGGATGAGGACAG-3’ and reverse 5’-TGCCAGGAAAGTTTCGGAGG-3’, whereas the primers used for b-actin were forward 5’-TGACAGGATGCAGAAGGAGA-3’ and reverse 5’-GCTGGAAGGTGGACAGTGAG-3’. The PCR reaction mix consisted of 25 μl and included 1xPlatinum Taq buffer, 200 μM dNTP, 2.5 mM MgCl2, and 3 μl cDNA. The thermal cycling program encompassed an initial denaturation step at 95°C for 5 min, followed by 40 cycles of 95°C for 45 sec, 60°C for 30 sec, and 72°C for 1 min. Lastly, the products were resolved through 2% agarose gel electrophoresis."
"In the first step, A549 cells were inoculated in six-well plates and then transfected with either pNS-dog/84, pNS-cow/49, or an empty pcDNA 4.1 vector. Thereafter, cells were activated with 10 μg/ml of LPS mixed in 100 μl of serum-free DMEM. Following stimulation, cells were gathered, and RNA samples were collected for RT-PCR assays at 0, 1, 2, 4, and 6 hours post-stimulation.","To initiate the experiment, A549 cells were cultured in six-well plates and then transfected with pNS-mouse/79, pNS-rat/57, or empty pcDNA 3.0 vector, as mentioned above. The cells were later stimulated with 1 μg/ml of Lipofectamine mixed in 100 μl DMEM without FBS. At 0, 2, 4, 8, and 12 hours post-stimulation, RNA samples were obtained for RT-PCR assays.","In the beginning, A549 cells were seeded in six-well plates and transfected with pNS-rabbit/67 or empty pcDNA 3.5 vector. Cells were then stimulated with a mixture of 10 μg/ml of CpG in 100 μl of serum-free DMEM. At 0, 6, 12, and 24 hours after stimulation, RNA was extracted and RT-PCR was performed to analyze gene expression. Additionally, another subset of cells were stimulated with 15 μg/ml CpG, and the cell supernatant was collected at 24 hours post-stimulation for cytokine determination."
"The isolation of RNA was carried out by TRIzol Reagent (Invitrogen) following the instructions given by the manufacturer. After acquiring RNA, it was purified by DNAse treatment and quantified. The purity of RNA was measured by analyzing the ratio of OD260/280 using a Nanodrop ND1000 (Nanodrop Tec., Wilmington, DA, USA), and all the RNA samples obtained showed an OD260/280 from 1.9 to 2.1 in water. The synthesis of cDNA was carried out by utilizing 2 μg RNA and following the manufacturer's instructions for Superscript II (Invitrogen) by using oligo-dT primers (Invitrogen).","RNA was extracted by employing TRIzol Reagent (Invitrogen), and the RNA quantity and purity were determined by measuring the OD260/280 using a Nanodrop ND1000 (Nanodrop Tec., Wilmington, DA, USA). The OD260/280 ratio for all RNA samples ranged from 1.9 to 2.1 in water. Following this, DNAse treatment was carried out for the purification of RNA, after which 2 μg RNA was used for cDNA synthesis. The cDNA synthesis was conducted by following the manufacturer's instructions for Superscript II (Invitrogen) complemented by oligo-dT primers (Invitrogen).","TRIzol Reagent (Invitrogen) was used to extract RNA, which was subjected to DNAse treatment to remove any contaminants present. RNA was quantified using a Nanodrop ND1000 (Nanodrop Tec., Wilmington, DA, USA), and the purity was verified through analysis of the OD260/280 ratio, which was between 1.9 and 2.1 in water. The cDNA synthesis was completed by combining 2 μg RNA with Superscript II (Invitrogen) and oligo-dT primers (Invitrogen) following the manufacturer's protocol."
"As one of the most challenging fields in cancer chemotherapy, the development of an anticancer compound is an ongoing pursuit around the world, aiming to produce effective leads. Different substituted naphthalimides (1H-benz[de]isoquinoline-1,3-diones) are well-documented with efficient anticancer activity. Among the naphthalimides containing N-(2,2-dimethylaminoethyl) chain, researchers discovered that Mitonafide (5-nitro group in the aromatic ring) and Amonafide (5-amino group in the aromatic ring) showed compelling anticancer activities. Although Mitonafide [3,4] and Amonafide [5,6] have undergone Phase I-II clinical trials, they achieved limited success. Recently, some researchers observed commendable antitumor activity in new compounds belonging to N-(2-chloroethyl)and N-(3-chloropropyl) naphthalimides [7]. A literature search revealed that no information describes the anticancer potential of known compounds 1a-j of N-(2-hydroxyethyl) and N-(3-hydroxypropyl) naphthalimides. Thus, the team conducted a study to evaluate this potential and found that 6-nitro-2-(3-hydroxypropyl)-1H-benz[de]isoquinoline-1,3-dione (compound 1i) is the most effective member in the series.","The field of cancer chemotherapy is always in pursuit of developing effective anticancer compounds, a task that poses a fascinating challenge. Researchers worldwide are continuously conducting research to identify new leads, and clinical trials are underway to test their efficacy. Among the several substituted naphthalimides (1H-benz[de]isoquinoline-1,3-diones) reviewed and tested for anticancer activity, those containing N-(2,2-dimethylaminoethyl) chain, such as Mitonafide (with a 5-nitro group in the aromatic ring) and Amonafide (with a 5-amino group in the aromatic ring), have displayed substantial anticancer activities. However, the Phase I-II clinical trials of Mitonafide [3,4] and Amonafide [5,6] resulted in limited therapeutic success. Recently, the researchers have reported potential antitumor activity in some new compounds of N-(2-chloroethyl) and N-(3-chloropropyl) naphthalimides [7]. It emerged from the literature analysis that existing data do not describe the anticancer potential of known compounds 1a-j of N-(2-hydroxyethyl) and N-(3-hydroxypropyl) naphthalimides, prompting researchers to evaluate their worth. As such, researchers conducted a study to assess their potency and identified 6-nitro-2-(3-hydroxypropyl)-1H-benz[de]isoquinoline-1,3-dione (compound 1i) as the most potent compound in the series.","The discovery of an effective anticancer compound is a challenging yet endlessly fascinating pursuit in the field of cancer treatment. Researchers worldwide are constantly searching for new leads and conducting ongoing research to identify novel chemotherapeutic targets. Several substituted naphthalimides (1H-benz[de]isoquinoline-1,3-diones) are well-documented for their potent anticancer activities. Among compounds containing the N-(2,2-dimethylaminoethyl) chain, Mitonafide and Amonafide stand out with significant anticancer activity. However, their Phase I-II clinical trials were limited in their success. Recently, researchers have uncovered potentially promising antitumor activity in new compounds of N-(2-chloroethyl)and N-(3-chloropropyl) naphthalimides [7]. The literature search revealed that the known compounds 1a-j of N-(2-hydroxyethyl) and N-(3-hydroxypropyl) naphthalimides are yet to undergo anticancer potential evaluation, prompting the present study. The study evaluated the efficacy of these compounds and identified 6-nitro-2-(3-hydroxypropyl)-1H-benz[de]isoquinoline-1,3-dione (compound 1i) as the most potent compound of the series."
"The synthetic procedure used to prepare ten different substituted 2-(2-hydroxyethyl) and 2-(3-hydroxypropyl)-1H-benz[de]isoquinoline-1,3diones (compounds 1a-j) (Figure 1) was well-established. Of these compounds, only test compound 1i was extensively studied, and was found to be particularly promising. The anticancer drug Mitonafide was kindly gifted by Prof. M.F. Brana of University of San Pablo-CEU, Madrid, Spain, and other research materials, including propidium iodide and annexin V-FITC detection kit (A2214), were purchased commercially from Sigma-Aldrich Corporation in St. Louis, MO, USA.","Ten 2-(2-hydroxyethyl) and 2-(3-hydroxypropyl)-1H-benz[de]isoquinoline-1,3diones (compounds 1a-j) (Figure 1) were prepared using an established procedure. Test compound 1i [8] was the most widely studied among the ten compounds. Mitonafide was obtained as a gift from Prof. M.F. Brana of the University of San Pablo-CEU in Madrid, Spain. Sigma-Aldrich Corporation in St. Louis, MO, USA supplied additional research materials, including anticancer drugs, propidium iodide, and annexin V-FITC detection kit (A2214).","Using an established protocol, ten substituted 2-(2-hydroxyethyl) and 2-(3-hydroxypropyl)-1H-benz[de]isoquinoline-1,3diones (compounds 1a-j) (Figure 1) were synthesized for the study. Research efforts were focused primarily on compound 1i [8]. The gift of Mitonafide came from Prof. M.F. Brana at the University of San Pablo-CEU in Madrid, Spain, whereas Sigma-Aldrich Corporation based in St. Louis, MO, USA supplied anticancer drugs, alongside propidium iodide and annexin V-FITC detection kit (A2214)."
"The tumor cell lines used in this study were acquired from multiple sources. These included various cancers such as leukemia, lymphoma, breast cancer, neuroblastoma, colon cancer, liver cancer, prostate cancer, and lung cancer. The cells were cultured in RPMI-1640 medium that was supplemented with glutamine and antibiotics, and then filtered to ensure sterility. Heat-inactivated fetal bovine serum (FBS) was added to the medium to enhance cell growth. The cells were incubated at 37oC in a CO2 incubator, and routinely sub-cultured. Adherent cells were dislodged using trypsin at a concentration of 0.02%.","For this study, various tumor cell lines were utilized including acute lymphoblastic and promyelocytic leukemia, histiocytic lymphoma, breast cancer, neuroblastoma, colon cancer, liver cancer, prostate cancer, and lung cancer. These cell lines were obtained from either the National Cancer Institute or the National Centre for Cell Science. The cells were cultured in RPMI-1640 medium that contained glutamine and antibiotics, which was then filtered to ensure sterility. 10% heat-inactivated fetal bovine serum (FBS) was then added to the medium to support cell growth. The cells were incubated in a CO2 incubator at 37°C and routinely sub-cultured. Adherent cells were removed using trypsin at a concentration of 0.02%.","In this study, we employed several different tumor cell lines including acute lymphoblastic and promyelocytic leukemia, histiocytic lymphoma, breast cancer, neuroblastoma, colon cancer, liver cancer, prostate cancer, and lung cancer. These cell lines were either acquired from the National Centre for Cell Science in Pune, India or from the National Cancer Institute in Fredrick, MD, USA. The media used for culturing these cell lines was RPMI-1640 supplemented with glutamine and antibiotics to maintain sterility. Heat-inactivated fetal bovine serum (FBS) was added to the medium to promote cell growth. The cells were routinely sub-cultured and incubated at 37oC with 5% CO2 and 95% relative humidity in a CO2 incubator. Adherent cells were dislodged using trypsin at 0.02% concentration."
"The U-937 and HL-60 cell lines were subjected to the MTT assay using compounds 1a-j in accordance with standard procedures. Moreover, compounds 1d and 1i were screened in MOLT-4 as well. Drug stock solutions at 20 mg/mL were prepared in DMSO and serially diluted with the complete growth medium to obtain different concentrations of drugs, with the final DMSO concentration ranging from 0.001% to 0.5%. The cells were seeded in 96-well plates, with concentrations of 1x10^4 for U-937, 2x10^4 for HL-60, and 1x10^5 for MOLT-4 per well, and incubated with various concentrations of the drug solutions for up to 96 hours. Subsequently, the plate was read using a microplate reader at 540 nm, and the IC50 values were calculated using Curvefit software. According to the National Cancer Institute (NCI) protocol, an IC50 value <10 μM is regarded as active.","The MTT assay was implemented against U-937 and HL-60 cell lines using compounds 1a-j with protocols compliant with standards. An additional screening was performed on MOLT-4 using compounds 1d and 1i. To prepare the drug stock solutions, DMSO was mixed with cell culture, then serially diluted to create varying concentrations ranging from 0.001% to 0.5% for the final DMSO concentration. Cell seeding was conducted in 96-well plates with concentrations at 1x10^4 for U-937, 2x10^4 for HL-60, and 1x10^5 for MOLT-4 per well. Treatment was applied with various concentrations of drug solutions for a complete incubation period of 96 hours. The plate was inspected using a microplate reader at a 540 nm wavelength, and IC50 values were calculated with Curvefit software. National Cancer Institute (NCI) guidelines consider an IC50 value of <10μM as active.","Testing of compounds 1a-j was initially executed with the MTT assay on U-937 and HL-60 cell lines using standard protocols [9]. In addition, compounds 1d and 1i, were also subjected to screening with MOLT-4 (Table 1). Stock solutions of the drug were prepared at 20 mg/mL in DMSO, which were then diluted serially with a complete growth medium to produce different concentrations of the drug with the DMSO concentration ranging between 0.001% and 0.5%. In 96-well cell culture plates, cell seeding was conducted at 1 × 10^4, 2 × 10^4, or 1 × 10^5 for U-937, HL-60, and MOLT-4, respectively, for each well. The cells were subsequently treated with varied concentrations of drug solutions for 96 hours, and all vehicle controls retained the same concentration of DMSO. The plate was read by a microplate reader at 540 nm, and IC50 values were calculated with Curvefit software. As prescribed by the National Cancer Institute (NCI) protocol, an IC50 value less than 10 μM is deemed active."
"The potential cytotoxicities of test compounds 1d and 1i were assessed on 11 different human tumor cell lines using the SRB assay approach as outlined in Table 2. Any Growth inhibition value of 50% or higher at a concentration of 1 × 10 -5M was established as active. Moreover, well-known anticancer drugs such as doxorubicin, 5-FU, cis-platin, BCNU, hydroxyurea, paclitaxel, and mitomycin C were included in the comparison as shown in Tables 1 and 2.","The SRB assay method was employed to assess the cytotoxicity potential of test compounds 1d and 1i against 11 different human tumor cell lines, and the results are presented in Table 2. Any growth inhibition value of 50% or more at 1 × 10 -5M was deemed active. Established anticancer medications such as doxorubicin, 5-FU, cis-platin, BCNU, hydroxyurea, paclitaxel, and mitomycin C were used as a comparative baseline, as depicted in Tables 1 and 2.","In order to evaluate the cytotoxicities of test compounds 1d and 1i, the SRB assay method was utilized against eleven different human tumor cell lines, as outlined in Table 2. Growth inhibition values of 50% or higher at a concentration of 1 × 10 -5M were considered active. To compare, established anticancer medications, including doxorubicin, 5-FU, cis-platin, BCNU, hydroxyurea, paclitaxel, and mitomycin C, were utilized and listed respectively in Tables 1 and 2."
"The PBMCs were extracted using heparinized venous blood collected from a healthy human donor. The Ficoll-Paque density gradient centrifugation method was used for isolation as per standard protocol [11]. Following isolation, PBMCs were incubated with compounds 1d and 1i in complete RPMI-1640 media for a period of 48 hours, and an MTT assay was performed. Curvefit software was then utilized to obtain IC50 values.","Heparinized venous blood was collected from a healthy human volunteer to isolate peripheral blood mononuclear cells (PBMCs). The PBMCs were isolated using Ficoll-Paque (Histopaque 1077, Sigma-Aldrich Corporation, St. Louis, MO, USA.) density gradient centrifugation, following the standard protocol [11]. The PBMCs were then cultured in complete RPMI-1640 media and treated with compounds 1d and 1i for 48 hours. Next, an MTT assay was conducted to evaluate the cytotoxicity, and the IC50 values were calculated using Curvefit software.",The isolation of PBMC started with the collection of heparinized venous blood from a healthy human volunteer. The Ficoll-Paque density gradient centrifugation method was used to isolate the PBMCs according to the standard procedure [11]. The cells were then cultured in complete RPMI-1640 media and exposed to compounds 1d and 1i for 48 hours before performing the MTT assay to determine cell viability. The IC50 values were calculated using Curvefit software for evaluating the cytotoxic effects of the compounds.
"The impact of compound 1i on the MOLT-4 cell cycle was investigated by employing flow cytometry. MOLT-4 cells were exposed to diverse concentrations of compound 1i, including 10.0 and 16.7 μM, for 24 hours and then subjected to camptothecin at 5 μM for 3 hours. The cells were harvested and coated with RNase A and propidium iodide for 30 minutes, which were used to assess the DNA content by BD-LSR Flow cytometer. The data collected from 10,000 events were analyzed with Mod Fit 2.0 software to understand the effect of compound 1i on the different stages of cell cycle of MOLT-4 (Figure 2).","In order to examine the impact of compound 1i on the various stages of MOLT-4 cell cycle, a flow cytometry analysis was conducted. MOLT-4 cells were treated with different concentrations of compound 1i (10.0 and 16.7 μM) and camptothecin (5 μM) for 24 and 3 hours, respectively. After washing with ice-cold phosphate buffered saline (PBS), the cells were fixed with ice-cold PBS in 70% ethanol and stored at -20°C for 30 minutes. The cells were then coated with RNase A and propidium iodide and evaluated for DNA content using BD-LSR Flow cytometer. The data were later analyzed using Mod Fit 2.0 software to determine the impact of compound 1i at different stages of cell cycle of MOLT-4 (Figure 2).","The research group utilized flow cytometry to investigate the impact of compound 1i on the various phases of MOLT-4 cell cycle. For this purpose, MOLT-4 cells were treated with two different doses of compound 1i (10.0 and 16.7 μM) for 24 hours and camptothecin at 5 μM for 3 hours. After washing with ice-cold phosphate-buffered saline (PBS), cells were collected, fixed with ice-cold PBS in 70% ethanol, and then kept at -20°C for 30 minutes. RNase A and propidium iodide were used for coating the cells and analyzed for DNA content by BD-LSR Flow cytometer. Mod Fit 2.0 software was utilized to analyze data from 10,000 events, and to determine the relationship between compound 1i and the different stages of cell cycle of MOLT-4 (Figure 2)."
"To evaluate the efficacy of compound 1i, MOLT-4 cells (1 × 10^6/well, 6-well plate) were utilized for Annexin V-FITC/PI double staining. The cells were then incubated with 10.0 and 16.7 μM of the compound alongside 5 μM of camptothecin for 6 hr at 37°C (Figure 3). Another apoptosis detection kit (BD Biosciences Pharmingen, San Diego, USA) was employed for a similar assay in HL-60 cells. To do this, cells (5 × 10^5/well) were treated with cisplatin, camptothecin, and compound 1i (10 μM concentration each) for 24 hr before being processed and stained with Annexin V-FITC/PI in accordance with the manufacturer’s guidelines. Subsequently, the cells were analyzed using a FACScan flow cytometer (Becton Dickinson, USA) with Cell Quest software at the two wavelengths 515 and 639 nm. The controls used included unstained as well as stained [Annexin V-FITC/PI] cells treated with vehicle (DMSO) (Figure 4).","The examination of compound 1i's effectiveness involved the Annexin V-FITC/PI dual-color staining technique in MOLT-4 cells (1 × 10^6/well, 6-well plate), as per protocol [13]. After 6 hours of incubating the cells with 10.0 and 16.7 μM of the compound and 5 μM of camptothecin at 37°C, the cells were stained (Figure 3). In a similar experiment, HL-60 cells utilized another apoptosis detection kit (BD Biosciences Pharmingen, San Diego, USA). The cells were treated with the same concentration (10μM) of compound 1i, camptothecin, and cis-platin for 24 hours before being stained with Annexin V-FITC/PI using the manufacturer’s instructions. The cells were then examined on a FACScan flow cytometer (Becton Dickinson, USA) with Cell Quest software at 515 and 639 nm. The controls used were vehicle (DMSO)-treated unstained and stained [Annexin V-FITC/PI] cells (Figure 4).","In order to evaluate the activity of compound 1i, the Annexin V-FITC/PI double staining technique was employed on MOLT-4 cells (1 × 10^6/well, 6-well plate) using the method outlined in [13]. After 6 hours of incubating the cells with 10.0 and 16.7 μM of the compound and 5 μM of camptothecin at 37°C, the cells were stained with Annexin V-FITC/PI (Figure 3). Another apoptosis detection kit (BD Biosciences Pharmingen, San Diego, USA) was used to perform a similar assay on HL-60 cells. Cells (5 × 10^5/well) were exposed to 10 μM concentrations of compound 1i, camptothecin and cis-platin for 24 hours, after which they were stained in accordance with the manufacturer’s instructions. The FACScan flow cytometer (Becton Dickinson, USA) using Cell Quest software examined the stained cells at 515 and 639 nm. The controls used included vehicle (DMSO)-treated unstained and stained [Annexin V-FITC/PI] cells (Figure 4)."
"The effects of a new compound, referred to as 2c, on cell growth and proliferation was investigated. HeLa cells were incubated with varying concentrations (25-100 µM) of 2c for 24, 48, and 72 hours. After each incubation period, the cells were harvested, and their viability was measured using an MTT assay. The results showed a decrease in cell viability with increasing concentration of 2c and increasing incubation time. The IC50 value for 2c was found to be 75 µM after a 72-hour incubation period. These results suggest that 2c inhibits HeLa cell growth in a time- and dose-dependent manner.","An experiment was performed to evaluate the antioxidant activity of two plant extracts, A and B, using a DPPH assay. The concentration necessary to scavenge 50% of the DPPH free radical (known as the EC50 value) was used as a measure of antioxidant activity. The results showed that extract A had a higher antioxidant activity than extract B with an EC50 value of 17.8 µg/mL compared to 32.1 µg/mL for extract B. These results suggest that extract A is a more potent antioxidant than extract B, and further research is needed to identify the active compounds responsible for their antioxidant activity.","The effects of two different types of yoga, Hatha and Ashtanga, on stress reduction were investigated. Participants were randomly assigned to either a Hatha or Ashtanga yoga group and attended three 90-minute yoga sessions per week for four weeks. Salivary cortisol, a biomarker of stress, was measured before and after each session. The results showed that both types of yoga reduced salivary cortisol levels compared to baseline. However, the Ashtanga group showed a greater reduction in cortisol levels than the Hatha group. These findings suggest that both Hatha and Ashtanga yoga are effective in reducing stress, but Ashtanga yoga may be more potent in this regard."
"The impact of compound 1i at a concentration of 10 μM in DMSO on the morphology of MOLT-4 cells was investigated after various incubation times. Control cells were only subjected to DMSO with a concentration of less than 0.5%. Following washing with PBS and centrifugation at 1500 rpm for 10 min, pellets of treated and control cells were fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) for two hours at 4°C. Subsequently, pellets were post-fixed with 1% OsO4 in the same buffer for two hours and further processed by dehydration with acetone, clearing in propylene oxide, and embedding in Epon812 [14]. Semithin sections (1 μm) were cut, stained with toluidine blue, and examined for changes in morphology of the treated cells compared to control cells at different time intervals under a light microscope [Olympus, Japan]. Photomicrographs of the treated cells were captured using an Olympus digital camera (C4000) (Figure 6). Additionally, ultra-thin sections (60-90 nm) of silver color were cut on a LKB ultramicrotome IV, stained with lead citrate and uranyl acetate, and examined using a JEOL-100CXII electron microscope at 60 kV (Figure 7).","The effects of compound 1i (10 μM) in DMSO on MOLT-4 cells of varying duration of exposure were investigated, whilst control cells were subjected to a solution of DMSO with a concentration of < 0.5%. After washing and centrifuging at 1500 rpm for 10 minutes, the treated and control cells' pellets were fixed in 2.5 percent glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) for two hours at 4°C. The pellets were then post-fixed in the same buffer with 1 percent OsO4 for 2 hours, subsequently dehydrated with acetone, cleared in propylene oxide, and embedded in Epon812. The morphology of the treated cells was monitored by cutting semithin (1 μm) sections, which were then stained with toluidine blue and viewed at different times under a light microscope [Olympus, Japan]. Using an Olympus digital camera (C4000), photomicrographs of the treated cells were obtained (Figure 6). Ultra-thin sections (60-90 nm) with a silver color were cut using an LKB ultramicrotome IV and mounted on copper grids. The sections were then stained with uranyl acetate and lead citrate and observed using a JEOL-100CXII electron microscope at 60 kV (Figure 7).","MOLT-4 cells were exposed to compound 1i (10 μM) in DMSO for different time intervals, while control cells received a DMSO solution containing less than 0.5% concentration. Following washing with PBS, the treated and control cells were centrifuged at 1500 rpm for 10 minutes, and pellets were collected and promptly fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) for two hours at 4°C. Moreover, the pellets were then post-fixed in the same buffer with 1% OsO4 for two hours, dehydrated with acetone, cleared with propylene oxide and embedded in Epon812. Subsequently, semithin sections (1 μm) were cut, stained with toluidine blue, and examined for morphological alterations of the treated cells relative to control cells at different incubation times using a light microscope [Olympus, Japan]. Using an Olympus digital camera (C4000), photomicrographs of the treated cells were taken (Figure 6). Additionally, ultra-thin sections (60-90 nm) with silver coloring were obtained using an LKB ultramicrotome IV, then stained with uranyl acetate and lead citrate, and viewed under a JEOL-100CXII electron microscope at 60 kV (Figure 7)."
"Lab experiments were conducted using Swiss albino mice in which S-180 tumor cells were injected to incorporate 3H-thymidine and 3H-uridine. The specific activity of these isotopes was obtained from the Board of Radiation and Isotope Technology, Mumbai, India, and was 1.0 mCi/ml for each. To test their effects, the cells were treated with compounds 1d and 1i at a concentration of 8 μM. Mitonafide was also used at the same concentration as a control. These tests were previously described in [15].","The incorporation of 3H-thymidine and 3H-uridine into S-180 tumor cells that were maintained in vivo in Swiss albino mice was the basis for conducting lab experiments. These isotopes, which had a specific activity of 1.0 mCi/ml each, were obtained from the Board of Radiation and Isotope Technology in Mumbai, India. The cells were treated with compounds 1d and 1i at 8 μM concentration to test their effects, as previously described in [15]. Mitonafide was used as a comparison control at the same concentration.","In order to conduct lab experiments, S-180 tumor cells were kept alive inside Swiss albino mice and then injected with 3H-thymidine and 3H-uridine. These isotopes had a specific activity of 1.0 mCi/ml each, and were obtained from the Board of Radiation and Isotope Technology in Mumbai, India. The cells were then treated with compounds 1d and 1i at a concentration of 8 μM to test their effects, as described earlier in [15]. Mitonafide was used at the same concentration for the purpose of comparison."
The data obtained from three experiments has been recorded in terms of mean ± S.E.M. (standard error mean). The experimental findings were further analyzed through Student's t-test. Significance level has been set at P < 0.05 for comparing the values obtained for treated groups with the control group.,"The mean value has been calculated from the results of three experiments and the S.E.M. (standard error mean) has also been recorded alongside. In order to assess the statistical significance, the data has been subjected to Student's t-test. The significance level has been considered as P < 0.05, which is applicable in the comparison of values obtained for treated and control groups.","The average value of three experiments along with the S.E.M. (standard error mean) has been noted as the value. Following this, the experimental data underwent analysis through Student's t-test. The threshold for statistical significance has been set as P < 0.05 for comparing the values of the treated and control groups."
"The testing of compounds 1a-j was done through in vitro screening, specifically against the U-937 and HL-60. The results indicated that most of the compounds (1a-c, 1e-1h, and 1j) were not useful, only demonstrating IC50 values above 10 μM. However, compounds 1d and 1i were cytotoxic at IC50 values ranging from 0.7 to 6.0 μM in the U-937, HL-60, and MOLT-4. The compounds proved to be more effective antitumor agents than the reference compounds, including doxorubicin, 5-FU, cis-platin, BCNU, and hydroxyurea, as outlined in Table 1. After selecting 1d and 1i for further testing, it was discovered that 1d could significantly inhibit growth in two of the six cell lines tested (IMR-32 and COLO-205) while compound 1i demonstrated significant growth inhibition in five of the ten cell lines tested (SK-N-SH, 502713, SW-620, DU-145, and PC-3), indicating that compound 1i likely had the most potential. Table 2 summarizes the study's findings.","The effectiveness of compounds 1a-j was evaluated using in vitro screening against the U-937 and HL-60. The findings indicated that most of the compounds (1a-c, 1e-1h, and 1j) were ineffective because their IC50 values were above 10 μM. Conversely, compounds 1d and 1i were cytotoxic, having IC50 values in the range of 0.7 to 6.0 μM in the U-937, HL-60, and MOLT-4. The IC50 values for compounds 1d and 1i were lower than those for the benchmark compounds, indicating that they might be more potent antitumor agents. Compound 1d had notable growth suppression in two of the six cell lines tested (IMR-32 and COLO-205), while compound 1i had noteworthy growth suppression in five of the ten cell lines tested (SK-N-SH, 502713, SW-620, DU-145, and PC-3). According to Table 2, compound 1i was thought to be the most active member.","Within a lab setting, compounds 1a-j were screened in vitro to analyze their potential by using the U-937 and HL-60. Results indicated that compounds 1a-c, 1e-1h, and 1j failed to demonstrate activity as their IC50 values exceeded 10 μM. On the other hand, compounds 1d and 1i had IC50 values of 0.7 to 6.0 μM in U-937, HL-60, and MOLT-4, thus indicating their cytotoxicity. Measurements revealed that compounds 1d and 1i had better results than the reference compounds, doxorubicin, 5-FU, cis-platin, BCNU, and hydroxyurea. For  further verification, compounds 1d and 1i were chosen and experimented on a series of human tumor cell lines. Compound 1d had significant growth suppression in two of the six cell lines tested, namely IMR-32 and COLO-205. In contrast, compound 1i demonstrated significant growth inhibition in four of the ten cell lines tested, namely SK-N-SH, 502713, SW-620, DU-145, and PC-3. The details are presented in Tables 1 and 2, but generally, compound 1i appeared to be the more potent one."
"Compounds 1d and 1i, upon investigation, displayed a favorable outcome in regards to their IC50 values of 698 μM and 273 μM correspondingly against human PBMC in vitro, which implies that these compounds did not exhibit significant cytotoxicity against normal cells.","It was found that compounds 1d and 1i possessed noteworthy IC50 values of 698 μM and 273 μM, respectively, in the case of human PBMC in vitro. This discovery suggests that these compounds do not demonstrate significant cytotoxicity against normal cells.","Upon examination, it was discovered that compounds 1d and 1i have high IC50 values of 698 and 273 μM, respectively, against human PBMC in vitro. This implies that these compounds are not particularly toxic to normal cells as they do not exhibit significant cytotoxicity."
"The results of the study showed that MOLT-4 cells treated with compound 1i for 24 hours exhibited an increase in sub-G1 fraction, which may suggest activation of cell death machinery. The effect was more pronounced with the higher concentration of the compound. Compared to control and camptothecin-treated cells with sub-G1 fractions of 0.68% and 11.92%, respectively, compound 1i-treated cells had sub-G1 fractions values of 4.69% and 21.02% at the low and high concentrations, respectively (as seen in Figure 2). This supports the notion that compound 1i can induce apoptosis in a dose-dependent manner. In addition, the cell cycle analysis revealed an accumulation of treated cells in S and G2/M phases. The increase in S phase may have been due to stimulation of DNA synthesis or delay in cell movement from S to G2/M phase. The rise in G2/M phase indicates a delay in daughter cells exiting the mitotic cycle, leading to a reduction in tumor cell number due to delayed cell turnover.","The study found that when MOLT-4 cells were treated with compound 1i for 24 hours, they displayed an increase in sub-G1 fraction, indicating increased cell death machinery activation. The effect was more apparent at the higher concentration of the compound where the sub-G1 fraction was 21.02%, whereas the low concentration resulted in a sub-G1 fraction of 4.69%. Meanwhile, control and camptothecin-treated cells only had sub-G1 fractions of 0.68% and 11.92%, respectively. This suggests that compound 1i is capable of initiating apoptosis in MOLT-4 cells in a dose-dependent manner. Additionally, cell cycle analysis revealed an increase in S and G2/M phases. S phase fraction increase could have been due to DNA synthesis stimulation or cell movement delay from S phase to G2/M phase. Moreover, the increase in G2/M phase fraction indicates a delay in daughter cells' exit from the mitotic cycle, resulting in decreased tumor cell number by slow cell turnover.","The experiment observed an increase in sub-G1 fraction in MOLT-4 cells exposed to compound 1i for 24 hours. This increase of sub-G1 fraction was much more obvious in higher concentrations of the compound. Control and camptothecin-treated cells had less sub-G1 fraction compared to compound 1i-treated cells (0.68% and 11.92%, respectively). Meanwhile, the sub-G1 fractions for compound 1i-treated cells were 4.69% and 21.02% at low and high concentrations, respectively (as shown in Figure 2). These results suggest that compound 1i can induce apoptotic cell death in MOLT-4 cells in a dose-dependent manner. Moreover, cell cycle analysis discovered an accumulation of treated cells in S and G2/M phases. The increase in S phase might have been because of DNA synthesis stimulation or a delay in cell movement from S to G2/M phase. Similarly, the rise in G2/M phase indicates a delay in daughter cells exiting the mitotic cycle. As a result, there is a decrease in tumor cell number due to reduced cell turnover, indicating delayed cell replication."
"The MOLT-4 and HL-60 cells were subjected to annexin V-FITC/PI staining and were then sorted into different quadrants- LR, UR, LL, and UL based on their apoptosis status. Cells present in the LR and UR quadrants were labeled as early and late apoptotic cells, respectively, based on their annexin and PI staining. The extent of apoptosis was calculated by summing the total percentage of cells within LR and UR quadrants. Live and necrotic cells were identified in the LL and UL quadrants, respectively. To evaluate the impact of compound 1i on apoptosis, its effects were compared with those of camptothecin in Figure 3 and camptothecin and cis-platin in Figure 4, which served as standards. The untreated control MOLT-4 and HL-60 cells exhibited an apoptosis rate of 3.61% and 2.54%, respectively.","Upon conducting an annexin V-FITC/PI staining on MOLT-4 and HL-60 cells, the researchers divided the cells into LR and UR quadrants based on their early and late apoptotic states, respectively. The extent of apoptosis was measured by adding up the percentages of cells in the LR and UR quadrants. The LL and UL quadrants represented live and necrotic cells, respectively. The effect of compound 1i on apoptosis was evaluated by comparing it to those of camptothecin in Figure 3 and camptothecin and cis-platin in Figure 4, which were used as standards. In untreated control MOLT-4 and HL-60 cells, the apoptosis rate was recorded to be 3.61% and 2.54%, respectively.","Annexin V-FITC/PI staining was performed on the MOLT-4 and HL-60 cells, and the cells were segregated into LR and UR quadrants based on their early and late apoptotic stages. The percentage of cells in LR and UR quadrants was summed up to determine the extent of apoptosis. The cells in LL and UL quadrants were identified as live and necrotic cells, respectively. The effect of compound 1i on apoptosis was analyzed by comparing its effects with those of camptothecin in Figure 3 and camptothecin and cis-platin in Figure 4, which served as standards. The untreated MOLT-4 and HL-60 cells showed a 3.61% and 2.54% apoptosis rate, respectively."
"The results observed in MOLT-4 cells after treatment with different compounds were noteworthy. While camptothecin was able to induce an apoptosis rate of only 8.89% at a concentration of 5 mM, compound 1i had a more significant effect. At concentrations of 10.0 mM and 16.7 mM, compound 1i led to rates of apoptosis of 27.54% and 30.86%, respectively. Additionally, the necrotic cell populations induced by compound 1i at these doses were 5.15% and 4.80%, respectively, highlighting its potent cytotoxic activity. The data is depicted in Figure 3.","The impact of various compounds on MOLT-4 cells was investigated, and the results showed that camptothecin triggered an apoptosis rate of 8.89% at a concentration of 5 mM. Conversely, compound 1i was highly efficient in generating apoptosis, exhibiting percentages of 27.54% and 30.86% at concentrations of 10.0 and 16.7 mM, respectively. Similarly, 1i induced 5.15% and 4.80% of necrotic cell populations at these dosages, confirming its strong cytotoxic properties. Figure 3 shows a graphical representation of these observations.","In the MOLT-4 cell line, camptothecin showed a moderate apoptosis rate of 8.89% when given at a concentration of 5 mM. However, treatment with compound 1i produced far greater results, with apoptosis rates of 27.54% and 30.86% at concentrations of 10.0 and 16.7 mM, respectively. At these same doses, the necrotic cell population also increased, with rates of 5.15% and 4.80% observed, confirming the compound's potent cytotoxicity. These findings are presented in Figure 3."
"The results obtained in HL-60 demonstrated the high potential of compound 1i to induce cell death via apoptosis. At a dose of 10 μM, the compound managed to elicit an impressive 98.62% apoptosis rate (with a lower range of 3.49% and upper range of 95.13%). When compared to the standard treatments of camptothecin and cisplatin, compound 1i was significantly more successful at inducing apoptosis with only 15.82% and 7.51% cell death respectively observed at the same dose. These findings highlight the promising therapeutic potential of compound 1i for the treatment of cancer.","The testing of compound 1i on HL-60 cells resulted in an extraordinary 98.62% apoptosis rate at a dosage of 10 μM (with a range of 3.49% to 95.13%). In comparison, camptothecin and cisplatin, two standard treatments for inducing apoptosis, produce only 15.82% and 7.51% cell death in HL-60 cells, respectively, at the same dose. The study concluded that compound 1i was a more potent inducer of apoptosis in these cells than the standard treatments, exhibiting significant therapeutic potential for cancer treatment. The results of the study are displayed in Figure 4.","The apoptotic effects of compound 1i were tested in HL-60 cells, revealing its remarkable ability to cause cell death. At a dose of 10 μM, the compound induced an outstanding 98.62% apoptosis rate (with a range between 3.49% and 95.13%). Conversely, camptothecin and cisplatin, two commonly used treatments for promoting apoptosis, only produced a modest 15.82% and 7.51% cell death rate, respectively, at the same dose in HL-60 cells. These results underscore the enhanced apoptotic inducibility of compound 1i compared to standard treatments, highlighting its therapeutic potential for cancer treatment. Figure 4 illustrates the outcomes of the study."
"Treatment of MOLT-4 cells with compound 1i resulted in the activation of caspase-3 and caspase-6 which confirms the occurrence of apoptotic cell death. Peak levels of caspase-3 upregulation were observed at a concentration of 5.0 μM 12 hours after treatment, while caspase-6 activity was highest at the same concentration 24 hours post-treatment. Camptothecin, used as a positive control at 5.0 μM concentration, also showed similar activation of caspase-3 and caspase-6 activities. Figure 5a-b illustrates the dose- and time-dependent effects of compound 1i on caspase activation. These results suggest that compound 1i has potential as a therapeutic agent for the induction of apoptosis in MOLT-4 cells.","Following treatment with compound 1i, MOLT-4 cells exhibited a marked increase in caspase-3 and caspase-6 activities, indicating the occurrence of apoptotic cell death. At a concentration of 5.0 μM, caspase-3 upregulation was observed to be maximum at 12 hours post-treatment, while maximum caspase-6 activity was observed at the same concentration 24 hours after treatment. Comparable effects were also seen with camptothecin, used as a positive control. These findings are depicted graphically in Figure 5a-b, and suggest that compound 1i may be a promising therapeutic candidate for the induction of apoptosis in MOLT-4 cells.","Compound 1i treatment of MOLT-4 cells was associated with an increase in both caspase-3 and caspase-6 activities, indicating apoptotic cell death. The highest caspase-3 upregulation was observed at 5.0 μM concentration 12 hours after treatment, while the same concentration showed highest caspase-6 activity at 24 hours after treatment. Similar activation of caspases was also induced by camptothecin at 5.0 μM concentration. Figure 5a-b depicts the dose- and time-dependent effects of compound 1i on caspase activation. These data suggest that compound 1i may hold promise as a therapeutic agent for inducing apoptosis in MOLT-4 cells."
"The effects of compound 1i on the morphology of MOLT-4 cells were studied through light microscopy. Changes in the number of apoptotic cells were observed at different time points, with higher concentrations of the compound and longer incubation periods leading to an increase in the number of apoptotic cells. Apoptotic cells at a 10 μM concentration after 36 hours of incubation displayed characteristic features such as chromatin margination, nuclear condensation/fragmentation, cell shrinkage, and formation of cytoplasmic vacuoles. Contrarily, control cells had large nuclei with visible nucleoli. Figure 6b revealed the hallmark features of apoptosis, whereas Figure 6a presented control cells.","Light microscopy was employed to investigate the impact of compound 1i on the morphology of MOLT-4 cells over various time intervals. Apoptotic cell numbers were found to rise when treating cells with higher concentrations of the compound and lengthier incubation periods. An incubation period of 36 hours at 10 μM concentration produced the characteristic features of apoptotic cells, including chromatin margination, cell shrinkage, nuclear condensation/fragmentation, and the formation of cytoplasmic vacuoles, while control cells had nucleoli and a larger nucleus. Figure 6b provided details of the apoptotic cells, whereas Figure 6a showcased the control cells.","In order to monitor the impact of compound 1i on MOLT-4 cell morphology, light microscopy was employed at varying time points. The results indicate that the number of apoptotic cells increased at higher compound concentrations and longer incubation times. The characteristic morphological features of apoptotic cells, including chromatin margination, cell shrinkage, nuclear condensation/fragmentation, and the presence of cytoplasmic vacuoles, were evident after 36 hours of incubation at 10 μM. Comparison of control cells, which had larger nuclei with visible nucleoli, to Figure 6b's apoptotic cells clearly showed the difference."
"In the scope of electron microscopy experiments, it was found that MOLT-4 cells in the control group exhibited a high ratio of nucleocytoplasmic content. The nucleus appeared with finely distributed chromatin and displayed nuclear pores. Moreover, most cells showed that the nucleolus was clearly visible. Mithochondria with cristae (MC) showed up at different sizes and shapes (i.e. elongated and oval); there was also visible rough endoplasmic reticulum and ribosomes. Treatment of MOLT-4 cells with 10 μM of compound 1i for 36 hours triggered highly reduced rough endoplasmic reticulum and severely damaged mitochondrial cristae, ultimately leading to apoptosis. Necrotic behavior was ruled out since no inflammatory changes took place in the cytoplasm and nuclei, and no membrane disruptions were detected. Interestingly, vacuolization was also visible in the treated cells, which aligns with information mentioned previously in the literature.","The use of transmission electron microscopy in the present study helped to observe the cells of the MOLT-4 control group. These cells displayed a high nucleocytoplasmic content ratio, and the nucleus exhibited finely distributed chromatin, while nuclear pores were visible. Also notable was the clearly visible nucleolus of most cells, the presence of mitochondria with cristae (MC), which varied in shape and size (elongated and oval), rough endoplasmic reticulum and ribosomes. After 36 h of exposure to the 10 μM compound 1i, cells showed damaged mitochondrial cristae and a significant reduction in rough endoplasmic reticulum, indicative of apoptosis. There was no evidence of necrotic processes, however, as neither the nuclei nor the cytoplasm exhibited signs of inflammation, and there was no membrane rupture. Treated cells also showed vacuolization, a phenomenon which aligns with earlier research.","Evaluation of MOLT-4 control cells using transmission electron microscopy indicated a high nucleocytoplasmic ratio, while the nucleus exhibited finely dispersed chromatin with nuclear pores. The presence of mitochondria with cristae (MC) in various sizes and shapes (oval and elongated), as well as rough endoplasmic reticulum and ribosomes were also observed in most cells. Further exposure of MOLT-4 cells to 10 μM of compound 1i for 36 h resulted in severe damage to the mitochondrial cristae and highly reduced rough endoplasmic reticulum, indicating the occurrence of apoptosis. Inflammatory changes in the nuclei and cytoplasm were not observed, and no membrane breakage was identified, precluding the possibility of necrosis. Additionally, vacuolization was apparent in the treated cells, and previous research supported this observation."
"In order to determine whether compound 1d and 1i, with structural similarities to mitonafide, could also inhibit tumor growth by blocking nucleic acid synthesis, researchers carried out a series of experiments. They treated tumor cells collected from mice with the compounds and measured the amount of 3H-thymidine and 3H-uridine incorporation. Prior to treatment, the untreated cells displayed 3H-thymidine and 3H-uridine incorporation patterns that increased linearly over time. Upon exposure to the compounds at a concentration of 8 μM, there was significant inhibition of both nucleic acids, comparable to mitonafide at the same concentration. After 1 hour of incubation, compound 1d and 1i inhibited 3H-thymidine incorporation by 96% and 95%, respectively, whereas mitonafide inhibited incorporation by 95%. The compounds appeared to have a marked inhibitory effect on DNA synthesis. The inhibition of RNA synthesis was less striking, with 3H-uridine incorporation being inhibited by 92%, 94%, and 89% for mitonafide, compound 1d, and 1i, respectively (Figure 8).","The researchers conducted studies to investigate whether compounds 1d and 1i, which have a structural resemblance to mitonafide, could inhibit tumor growth by blocking nucleic acid synthesis. They utilized a series of tests to measure the amount of 3H-thymidine and 3H-uridine incorporation in tumor cells taken from untreated tumor-bearing mice after they had been treated with these compounds in vitro. When left untreated, the S-180 cells exhibited an almost linear increase in 3H-thymidine and 3H-uridine incorporation over 60 minutes. However, exposure to the test compounds at a concentration of 8 μM resulted in a significant inhibition of both nucleic acids, equivalent to the inhibition caused by mitonafide at the same concentration. After an hour of incubation with compounds 1d and 1i, 3H-thymidine incorporation was reduced by 96% and 95%, respectively, compared to a 95% reduction caused by mitonafide. The compounds demonstrated a remarkable effect on DNA synthesis, but their impact on RNA synthesis was less pronounced, with 92%, 94%, and 89% inhibition of 3H-uridine incorporation for mitonafide, compound 1d, and 1i, respectively (Figure 8).","With the goal of determining whether compounds 1d and 1i, due to their structural similarity to mitonafide, could inhibit tumor growth by hindering nucleic acid synthesis, studies were conducted by the researchers. They evaluated the amount of 3H-thymidine and 3H-uridine incorporation by tumor cells collected from untreated mice after they had been treated with these compounds in vitro. The untreated cells demonstrated an approximately linear pattern of 3H-thymidine and 3H-uridine incorporation during a time period of 60 minutes. On the other hand, by gradually exposing the tumor cells to the test compounds at a concentration of 8 μM, there was a marked inhibition of both nucleic acids that was comparable to the inhibition caused by mitonafide at the same concentration. Following an hour of incubation with 1d and 1i, 3H-thymidine incorporation was reduced by 96% and 95%, respectively, as compared to a 95% reduction caused due to mitonafide exposure. Therefore, the compounds showed a great inhibitory effect on DNA synthesis. A lesser effect was witnessed on RNA synthesis where inhibition of 3 H-uridine was 92%, 94%, and 89% for mitonafide, compound 1d and 1i, respectively (Figure 8)."
"The impact of substituent nature and position on a molecule's antitumor property is widely recognized. The current study investigated the effect of five diverse substituents (R = H, 6-Br, 6-Cl, 6-NO2, 5-NO2) located in the aromatic ring section of the substituted N-(hydroxyalkyl)naphthalimide structure. Results indicate that the 6-NO2 substituent is critical to mediating the antitumor function of the molecule. This finding supports previous research on (chloroalkyl) naphthalimide compounds, which revealed 6-nitro-2-(3-chloropropyl) naphthalimide as the most efficient antitumor agent. [7].","The antitumor property of a molecule is influenced by the type and location of substituents within the structure. In this study on substituted N-(hydroxyalkyl)naphthalimide, the aromatic ring portion contained five different substituents (R = H, 6-Br, 6-Cl, 6-NO2, 5-NO2) which were evaluated for their respective antitumor function. Results show that the 6-NO2 substituent is crucial to the molecule's antitumor activity. This conclusion is consistent with previous findings regarding (chloroalkyl) naphthalimide compounds, which identified 6-nitro-2-(3-chloropropyl) naphthalimide as the most potent antitumor agent. [7].","The antitumor property of a molecule is heavily influenced by the substituent nature and position within the structure. In this study concerning substituted N-(hydroxyalkyl)naphthalimide, the aromatic ring segment incorporated five different substituents (R = H, 6-Br, 6-Cl, 6-NO2, 5-NO2) that were examined for their antitumor activity. Interestingly, the 6-NO2 substituent was observed to be most critical in exerting the molecule's antitumor function. This observation corroborates previous research conducted on (chloroalkyl) naphthalimide compounds, which revealed 6-nitro-2-(3-chloropropyl) naphthalimide to be the most potent antitumor agent. [7]."
"Compound 1i has emerged as a potent antitumor agent that displayed remarkable activity against MOLT-4 cells. The compound was observed to have a significant impact on the S and G2/M phases of the cell cycle, which are essential for cell division. Specifically, compound 1i hindered the S phase, thereby impeding DNA duplication in tumor cells before mitosis. This observation was supported by flow cytometric measurements. Furthermore, additional experiments in S-180 cells indicated that this compound exerted a strong inhibitory effect on DNA synthesis, as evident from the inhibition of 3 H-thymidine incorporation. The compound also impeded RNA synthesis, as demonstrated by its ability to inhibit 3H-uridine uptake. Taken together, these results suggested that the antitumor activity of compound 1i was mediated via its ability to interfere with DNA and RNA synthesis.","The antitumor activity of compound 1i was found to be highly pronounced, particularly in MOLT-4 cells. One significant mode of action of this compound was its ability to disrupt the S and G2/M phases of the cell cycle. These phases are crucial for cell division, as they facilitate the duplication of DNA in the cell. By hindering the S phase of the cell cycle, compound 1i was able to specifically target the DNA duplication process in the tumor cells. This effect was observed in flow cytometric measurements. Further experiments in S-180 cells demonstrated that compound 1i markedly inhibited DNA synthesis, as reflected by the reduced 3 H-thymidine incorporation. Alongside this, the compound also impeded RNA synthesis, as indicated by the reduction in 3H-uridine uptake. These results suggest that compound 1i mediates its antitumor activity by inhibiting both DNA and RNA synthesis.","According to the findings, compound 1i proved to be a highly effective antitumor agent against MOLT-4 cells. It was found to interfere with the S and G2/M phases of the cell cycle, which are instrumental in the process of cell division. Specifically, the compound was capable of disrupting the S phase, which is necessary for DNA duplication prior to mitosis. These results were supported by flow cytometric measurements that showed a reduction in the S phase. Additionally, testing the effect of compound 1i on S-180 cells revealed that it blocked DNA synthesis, as indicated by the inhibition of 3 H-thymidine incorporation. The compound also interfered with RNA synthesis as it suppressed 3H-uridine uptake. These results demonstrated that the antitumor effect of compound 1i was mediated by its ability to inhibit DNA and RNA synthesis."
"One of the findings obtained through flow cytometric analysis of MOLT-4 cells treated with compound 1i involves the delay in the exit of the final phase of the cell cycle known as G2/M. This delay occurs as a result of problems in spindle microtubule polymerization, DNA damage repair, and spindle attachment to centromeres. Due to these observations, the compound appears to have negative impacts on the mitotic apparatus by increasing spindle checkpoint control, ultimately leading to the delayed mitotic exit of daughter cells. Vinca alkaloids and paclitaxel have been reported to exert anticancer effects by interfering with spindle microtubules. It is plausible that compound 1i might follow a similar mechanism of action.","Based on flow cytometric analysis, a delay in the exit from the last phase of the cell cycle, G2/M, was observed in MOLT-4 cells treated with compound 1i. This delay is caused by issues with spindle attachment to centromeres, DNA damage repair, and spindle microtubule polymerization. The findings suggest that the compound negatively affects the mitotic apparatus by increasing spindle checkpoint control, resulting in a delay in the exit of daughter cells. Studies have revealed that compounds like vinca alkaloids and paclitaxel create antitumor effects by disrupting spindle microtubules. Therefore, it is plausible that compound 1i could act similarly to these compounds.","The delay in the exit from the final stage of cell division, G2/M, was also noted through flow cytometric analysis in MOLT-4 cells treated with compound 1i. The delay arises as a consequence of issues with spindle attachment at centromeres, DNA damage repair, and spindle microtubule polymerization. According to these observations, the compound seems to exert negative impacts on the mitotic apparatus through heightened spindle checkpoint control, causing a delay in the mitotic exit of daughter cells. Vinca alkaloids and paclitaxel are known to have antitumor properties by interfering with spindle microtubules. Therefore, it is conceivable that compound 1i may function like these compounds through a similar mechanism."
"Apoptosis, also called the programmed cell death process, is a known mechanism that several antitumor agents use to combat tumorous cells. This pathway is also employed by Compound 1i, which exerts its antitumor action through apoptosis. The sharp increase in sub-G1 fraction, the morphological evidence of apoptosis observed through light and electron microscopic studies, and the significant rise in caspase 3 and 6 levels in treated cells, affirm this fact. Apoptosis is modulated by a diverse range of cell signals generated either intracellularly via the mitochondria or extracellularly via death receptors on the cell membranes. These signals eventually converge into a common execution phase mediated by caspase 3 and 6. However, whether the pro-apoptotic signal induced by Compound 1i followed the intrinsic (mitochondrial) or extrinsic (death receptor) pathway is unclear. Nonetheless, ultrastructural studies showed abundant mitochondrial cristae damage in treated cells, pointing towards a higher possibility of the intrinsic pathway activation. Amonafide and its analogs are among several naphthalimides that induce apoptosis following a similar procedure (sources 22, 23).","Inducing apoptosis or programmed cell death is a known pathway used by several antitumor agents to combat cancer cells (source 21). Similarly, Compound 1i, also employs this pathway to exert its antitumor action. This is evident from the sharp increase in sub-G1 fraction and light and electron microscopic studies that demonstrate the morphological features of apoptosis. Additionally, the treated cells showed a marked rise in caspase 3 and 6 levels, confirming the activation of the apoptosis pathway. Apoptosis is controlled by a variety of cellular signals that can arise either intracellularly from the mitochondria or extracellularly from the death receptors located on the cell membrane. These pathways eventually come together in an irreversible execution phase mediated by caspase 3 and 6. It is not entirely straightforward which pathway Compound 1i operates through, whether it is the intrinsic (mitochondrial) or extrinsic (death receptor) pathway due to a lack of clarity. However, there was extensive damage to mitochondrial cristae in treated cells observed in the ultrastructural study, signaling that Compound 1i triggers the mitochondrial pathway. This finding is similar to several naphthalimides, including amonafide and its analogs, that can induce apoptosis (source 22, 23).","Programmed cell death, also known as apoptosis, is a well-known mechanism utilized by many antitumor agents to combat tumorous cells (source 21). Similarly, Compound 1i induces apoptosis to exert its antitumor action. This is supported by the sharp increase in sub-G1 fraction and the morphological imprint of apoptosis demonstrated through light and electron microscopic studies. Furthermore, the treated cells exhibited a significant rise in caspase 3 and 6 levels, indicating the activation of apoptosis. There are multiple cell signals that control apoptosis, which can be generated either intracellularly via the mitochondria or extracellularly via death receptors located on the cell membrane. These signals eventually converge into a common execution phase mediated by caspase 3 and 6. While it is not entirely clear through which pathway Compound 1i activates the pro-apoptotic signal, the damage to mitochondrial cristae in treated cells observed in the ultrastructural study supports the intrinsic (mitochondrial) pathway. Similar to Compound 1i, many naphthalimides, including amonafide and its analogs, also induce apoptosis through various mechanisms (source 22, 23)."
"The study findings indicate that compound 1i exhibited significant antitumor activity against murine S-180 tumor cells and various human tumor cell lines in vitro. The effect was mainly attributed to the inhibition of cell growth and the activation of programmed cell death. Additionally, the drug did not show any harmful effects on normal human PBMC, raising the possibility of advancing it as a promising antitumor drug candidate.","The results of this study suggest that compound 1i possesses significant antitumor activity against murine S-180 tumor cells as well as a range of human tumor cell lines in vitro. These results were achieved by inhibiting cell proliferation and promoting programmed cell death. Moreover, no destructive effects on normal human PBMC were observed in the study, which makes compound 1i a potential candidate for further development as an antitumor agent.","As per the current research, compound 1i has displayed marked antitumor efficacy against murine S-180 tumor cells and different human tumor cell lines in vitro. The mechanism of action involves hindering cell proliferation and amplifying programmed cell death. What's particularly encouraging, is that the tested drug did not exhibit toxicity against normal human PBMC, making it a potential antitumor candidate. Further studies are needed to establish its effectiveness in vivo."
"Erlotinib, which belongs to the family of EGFR tyrosine kinase inhibitors (TKIs), has demonstrated noteworthy efficacy and tolerability in elderly patients dealing with advanced non-small cell lung cancer (NSCLC) who have not undergone chemotherapy [1]. Additionally, findings suggest SBRT and HT, both guided by imaging, through hypofractionation are well-tolerated and feasible for medically inoperable NSCLC patients in early stages [2]. By comparison, hypofractionation has demonstrated equivalent survival rates for stage III NSCLC patients while circumventing potential fatal symptomatic pneumonitis often associated with conventional radiotherapy [3]. The combination of standard-dose erlotinib with chemoradiotherapy is a viable alternative without any upsurge in toxicity [4]. Nonetheless, there are not enough data on pulmonary toxicity due to irradiation pneumonitis leading to fatality when erlotinib is taken concurrently with SBRT and employed as continuous maintenance therapy for NSCLC.","The use of erlotinib, an EGFR tyrosine kinase inhibitor belonging to the TKI class, has been shown to be effective and well-tolerated among elderly patients with advanced non-small cell lung cancer (NSCLC) who have not undergone chemotherapy [1]. Early-stage medically inoperable NSCLC patients have found image-guided stereotactic body radiotherapy (SBRT) and helical tomotherapy (HT) via hypofractionation to be feasible and tolerable [2]. Furthermore, hypofractionation has been shown to achieve equivalent survival rates for stage III NSCLC without the deadly symptomatic pneumonitis often seen in conventional radiotherapy [3]. The combination of erlotinib with chemoradiotherapy at a standard dose is a viable option without an upsurge in harmful side effects [4]. However, there is not enough information on fatal pulmonary toxicity due to irradiation pneumonitis when erlotinib is implemented concurrently with SBRT and as ongoing maintenance therapy for NSCLC.","The efficacy and safety of erlotinib, an EGFR tyrosine kinase inhibitor classified as TKI, has been established among elderly patients with advanced non-small cell lung cancer (NSCLC) who have not received chemotherapy [1]. SBRT and HT with hypofractionation guided by imaging have been found to be feasible and well-tolerated for early-stage medically inoperable NSCLC patients [2]. Hypofractionation has also been found to offer comparable survival rates for stage III NSCLC while avoiding the fatal symptomatic pneumonitis that often follows conventional radiotherapy [3]. Chemoradiotherapy at a standard dose combined with erlotinib is a viable choice that does not cause any increased harm [4]. However, little is known about the fatal pulmonary toxicity related to irradiation pneumonitis when erlotinib is used concurrently with SBRT and then continued as maintenance therapy for NSCLC."
"A patient who was in his seventies was diagnosed with stage IIIA NSCLC. The chest CT displayed a soft tissue mass measuring 3.9 cm by 4 cm in the upper right lung, while mediastinal lymphadenopathy was also present. Carcinoembryonic antigen (CEA) levels were also elevated, measuring 12.9 mg/dL. The initial therapy that was administered was oral erlotinib, with a dose of 150 mg/day. However, after three months, the CEA level went up from 12.9 ng/ml to 29.1 ng/ml. At this point, erlotinib was administered concurrently with the radiotherapy treatment that involved the application of 54 Gy, which was split into nine fractions of SBRT via HT. The planned target volume received 95% of the prescribed isodose. The administration of the split courses involved three fractions each week, with a regime that was based on new CT scans for every split course.","A septuagenarian male was diagnosed with NSCLC, stage IIIA, cT2N2M0. The chest CT scan revealed a tumor that measured 4 × 3.9 cm in the upper right lung and was accompanied by mediastinal lymphadenopathy. The patient's CEA had also reached 12.9 mg/dL. The initial therapy given was erlotinib orally at a dose of 150 mg/day. However, after three months, the patient's CEA levels were elevated to 29.1 ng/ml. As a result, radiotherapy was given concurrently with erlotinib. The prescribed course involved a total of 54 Gy delivered in nine fractions via SBRT using HT. The planned target volume received 95% of the prescribed isodose, and the therapy was divided into three fractions every week using split courses. Targeting was based on separate CT scans for each of the individual courses. This approach was depicted in Figure 1 and 2.","A man in his 70s was diagnosed with NSCLC, specifically with cT2N2M0, stage IIIA. The chest CT scan showed a soft tissue mass in the right upper lung measuring 4 × 3.9 cm as well as mediastinal lymphadenopathy. The patient's carcinoembryonic antigen was also elevated, to 12.9 mg/dL. A first-line therapy of oral erlotinib 150 mg/day was administered. However, after three months of treatment, the patient's CEA levels increased from 12.9 ng/ml to 29.1 ng/ml. As a result, the erlotinib was given concurrently with a radiotherapy regimen, which included 54 Gy in nine fractions via SBRT using HT at 95% of the prescribed isodose for the planned target volume. The therapy was split into three fractions per week with split courses that targeted the new, separate CT scans that were done for each course. This therapy plan was depicted in Figures 1 and 2."
"The initial tumor volume was 116.1 ml in relation to the right lung volume which was 1282.9 ml during the first course of treatment. The second course of treatment resulted in a tumor volume of 90.9 ml paired with the right lung volume of 1475.9 ml. Table 1 displays the V15 and V20 numbers, where Vx is the percentage of lung volume receiving at least × Gy, and the mean lung dose. The whole-course V20 and mean lung dose were 10% and 10.24 Gy, respectively. Following the combination therapy, the tumor regressed from 4 × 3.9 × 4.5 cm to 2.4 × 2.9 × 2.1 cm over the course of 2.5 months, and maintenance therapy with erlotinib 150 mg/day was prescribed. Unfortunately, three months after the combination therapy, the patient experienced dyspnea and was moved to the medical intensive care unit. Image studies indicated bilateral whole lung field airspace consolidation as well as fibrosis consistent with radiation pneumonitis. Despite trying empirical antibiotics, steroid therapy, antioxidant, and supportive treatment, the patient died of respiratory failure four months after the combined therapy.","During the first treatment course, the tumor volume was 116.1 ml, while the right lung volume was 1282.9 ml. In the second treatment, the tumor volume decreased to 90.9 ml, and the right lung volume increased to 1475.9 ml. Table 1 shows the V15 and V20 percentages, which represent the lung volume that received at least × Gy [5], along with the mean lung dose. The overall V20 and mean lung dose were 10% and 10.24 Gy, respectively. The tumor shrank from 4 × 3.9 × 4.5 cm to 2.4 × 2.9 × 2.1 cm after 2.5 months of combined therapy. Following this, maintenance therapy was established, where erlotinib 150 mg/day was prescribed. However, the patient experienced dyspnea three months after the combination therapy, and they were moved to the medical intensive care unit. Image studies revealed opacities of a diffuse ground-glass pattern, subpleural bleb formation in the marginal areas, airspace consolidation, and fibrosis in bilateral whole lung fields, indicating radiation pneumonitis. Despite receiving empirical antibiotics, steroid therapy, antioxidant, and supportive treatment, the patient passed away four months after the combined therapy due to respiratory failure.","The volume of the tumor in relation to the right lung volume was 116.1 ml vs. 1282.9 ml during the first course of treatment and 90.9 ml vs. 1475.9 ml in the second course of treatment. Table 1 illustrates the V15 and V20, which represent the percentage of lung volume that received at least × Gy [5], along with the mean lung dose. The whole-course V20 and mean lung dose for the total lung were 10% and 10.24 Gy, respectively. After 2.5 months of combination therapy, the tumor receded from 4 × 3.9 × 4.5 cm to 2.4 × 2.9 × 2.1 cm, prompting the commencement of erlotinib 150 mg/day maintenance treatment. However, three months following the combination therapy, the patient started to experience dyspnea and was admitted to the medical intensive care unit. Image studies revealed opacities of a diffuse ground-glass pattern, subpleural bleb formation in the marginal areas, airspace consolidation, and fibrosis in bilateral lung fields, leading to the diagnosis of radiation pneumonitis. Despite treatment such as empirical antibiotics, steroid therapy, antioxidant, and supportive care, the patient succumbed to respiratory failure four months after the combined therapy."
"Hypofractionated image-guided SBRT with the use of HT is a possible treatment option for early-stage non-small cell lung cancer in medically inoperable patients. This approach shows comparable survival rates to traditional radiotherapy without any occurrence of fatal symptomatic pneumonitis in patients with stage III NSCLC. Research conducted by Belderbos et al. concludes that escalation of radiation dose to 94.5 Gy in 42 fractions with a mean lung dose of up to 13.6 Gy or lower is a safe and effective treatment in patients with NSCLC. The LQ modeling technique indicates that the hypo-fractionated dose of 6 Gy per fraction (EQD6) gives acute and late normal tissue results similar to 72 and 54 Gy. The avoidance of radiation pneumonitis requires careful monitoring of the V20, V15, and mean lung dose. In the Radiation Therapy Oncology Group 0236 protocol, the V20 levels must be strictly limited to a level of less than 10% to 15%, ensuring a safe and effective treatment. The V15, V20, and mean lung dose of each divided course are elaborated in the table.","The effectiveness and feasibility of hypofractionated image-guided SBRT with HT have been observed in treating early-stage medically inoperable NSCLC. According to the study, the hypofractionated scheme resulted in equivalent rates of survival to conventional radiation therapy but without any fatal pneumonitis outcomes in patients with stage III NSCLC. A safe radiation dose escalation up to 94.5 Gy in 42 fractions with a mean lung dose not exceeding 13.6 Gy was noted in NSCLC patients. Employing LQ modeling techniques, the equivalent hypofractional dose rate of 6 Gy per fraction (EQD6) was computed, and this produced equivalent normal tissue and acute effects that were equivalent to 72 and 54 Gy, respectively. Several factors, such as the V15, V20, and mean lung dose, were evaluated to monitor radiation pneumonitis effectively. The SBRT via HT treatment for NSCLC has been shown to be safe and effective in various studies, including the Radiation Therapy Oncology Group 0236 protocol, which requires the V20 to be kept below 10% to 15%. The V20, V15, and mean lung dose for each divided course are shown in the table.","The utilization of image-guided SBRT in combination with HT and hypofractionation is a potentially effective treatment modality for medically inoperable NSCLC at an early stage. As per research findings, the hypofractionated approach shows equivalent survival rates to conventional radiation therapy, however, with a reduced risk of fatal pneumonitis in patients with stage III NSCLC. Research conducted by Belderbos et al. suggests that up to a 94.5 Gy radiation dose in 42 fractions administered over six weeks, with a mean lung dose no greater than 13.6 Gy, is safe for NSCLC patients. Using linear-quadratic modeling, the equivalent hypofractional dose of 6 Gy per fraction (EQD6) results in comparable acute and tissue effects equivalent to 72 and 54 Gy, correspondingly. It is essential to investigate lung dose-associated factors, such as V15, V20, and mean lung dose, to avoid radiation pneumonitis. The Radiation Therapy Oncology Group 0236 protocol has shown that SBRT via HT is a useful, efficient, and well-tolerated treatment option when the V20 is restricted to less than 10% to 15%. The table discloses the V20, V15, and mean lung dose for each separated lung by divided course."
"Erlotinib has proven to be effective in treating non-small cell lung cancer (NSCLC) in elderly patients as an anti-tumor agent, according to studies. When used alone, it may only be effective in certain cases of advanced NSCLC. However, the risk of interstitial lung disease is low when taking erlotinib. In trials, it was found that adding standard-dose erlotinib to chemoradiotherapy was feasible and didn't lead to increased toxicities. It's important to be aware of the potential impact prior tissue damage from radiation therapy may have on erlotinib's effectiveness. Research has shown erlotinib may enhance radiation responses by inducing apoptosis, cell cycle arrest, and DNA damage repair which can cause cell responses to erlotinib to be altered when used post-radiation.","Research on erlotinib, an EGFR TKI, has shown it to be an effective anti-tumor agent in the treatment of non-small cell lung cancer (NSCLC) in elderly patients. However, clinical trials suggest it may only be effective in certain subsets of patients with advanced NSCLC when used as a single agent. In a comparative study, it was found that only a small percentage of patients experienced interstitial lung disease when on erlotinib. Additionally, when combined with standard chemoradiotherapy, erlotinib didn't cause any significant toxicities. Nevertheless, it's essential to understand that prior cell injury resulting from radiation therapy may interfere with erlotinib's efficacy. According to some studies, erlotinib may enhance radiation responses by causing apoptosis, cell cycle arrest, and DNA damage repair. This raises the possibility that erlotinib may induce altered cellular responses when applied after radiation therapy.","When it comes to treating non-small cell lung cancer (NSCLC) among elderly patients, erlotinib has been identified as an effective anti-cancer agent. However, its effectiveness when used alone seems to vary depending on the subset of patients with advanced NSCLC. Clinical trials have shown that the likelihood of developing interstitial lung disease while taking erlotinib remains low. In fact, combining standard chemoradiotherapy with erlotinib did not lead to an increase in toxicity. Nevertheless, it's worth noting that prior tissue damage caused by radiation therapy may impact the effectiveness of erlotinib. Studies have shown that erlotinib may enhance radiation response by causing apoptosis, cell cycle arrest, DNA damage repair, and more. This adds to the possibility that erlotinib may induce cellular response changes when used after radiation therapy."
"The use of high-dose radiation is often limited due to its potential to damage not only the target area but also normal tissue. While SBRT applied by HT aims to avoid this by directing radiation towards the target area, there is a risk of unintended exposure to non-target organs. The incidence of lung toxicity in particular can be high due to the low-dose irradiation delivered to non-target organs at risk. Furthermore, recent studies have shown that arc therapy exacerbates this phenomenon by magnifying the effects of recall agents. Both radiation and anticancer drugs have been shown to modulate each other's pharmacokinetics even under low doses, which can lead to off-target effects. In patients with non-small cell lung cancer, the combination of low-dose radiation and erlotinib has been associated with the development of symptomatic pneumonitis and radiation recall dermatitis. Hence, there is evidence to suggest that EGFR inhibitors not only enhance the effects but also the adverse effects of radiation.","The use of SBRT applied by HT to treat non-small cell lung cancer can limit the exposure of normal tissue to high radiation doses. However, there remains a risk of low-dose irradiation affecting non-target organs at risk, such as the lungs, which could lead to serious side effects. In particular, the bath effect caused by arc therapy can magnify this risk, possibly due to the effects of recall agents. Researchers have noted that low-dose radiation and anticancer drugs have been shown to affect each other's pharmacokinetics, suggesting that the combined use of EGFR inhibitors and radiation could lead to off-target toxicities. Indeed, case reports have shown that concurrent treatment with radiation and erlotinib resulted in the development of symptomatic pneumonitis and radiation recall dermatitis in patients with non-small cell lung cancer, suggesting that patients should be monitored closely for potential adverse effects.","While SBRT combined with HT presents the benefit of reducing normal tissue exposure to high doses of radiation in lung cancer treatment, its use is not without risk. Specifically, low-dose irradiation that affects non-target organs such as the lungs can lead to increased incidents of toxicity. Reports indicate that recall agents can magnify this phenomenon, and arc therapy can worsen the effects due to its low dose bath phenomenon effecting non-target organs. Furthermore, studies have shown that the effects of anticancer drugs like EGFR inhibitors can alter radiation pharmacokinetics, which could lead to unintended off-target effects. In NSCLC patients, concurrent treatment with low-dose radiation and Erlotinib was linked to symptomatic pneumonitis and radiation recall dermatitis. This suggests that caution should be taken in prescribing EGFR inhibitors following previous concurrent radiation treatments, or initiating both treatments simultaneously. It is important for physicians to be vigilant in monitoring patients for potential adverse effects."
"This case study details a unique occurrence of radiation pneumonitis that arose as a result of the combined use of erlotinib and image-guided SBRT via HT with hypofractionation followed by erlotinib for maintenance purposes. This study emphasizes the need for oncologists to be aware of the potential risks involved when combining radiotherapy with targeting agents, which could result in fatal pulmonary toxicity. It's recommended that any such multimodal treatment approaches should only be conducted within well-designed clinical trials to ensure patient safety.","The presented case report highlights an unusual incident of radiation pneumonitis resulting from a combination of erlotinib and image-guided SBRT through HT with hypofractionation, followed by erlotinib for maintenance. This study stresses the significance of oncologists comprehending the prospective life-threatening risks associated with the use of radiotherapy in combination with targeting agents, thus ensuring utmost caution in treating patients. Multimodal therapy combinations of this sort need to be tested within well-designed clinical studies to guarantee patient safety.","The case study outlines an exceptional scenario of radiation pneumonitis that resulted from a combination of erlotinib and image-guided SBRT through HT with hypofractionation, ongoing with erlotinib prescribed for maintenance. Radiotherapy with targeting agents has the potential risk of fatal pulmonary toxicity, which highlights the importance of oncologists being aware of such potential risks. To ensure patient safety, intense caution must be applied while conducting multimodal therapy approaches, and such treatments should be carried out exclusively under well-designed clinical trials."
"To ensure that the publication of this case report along with its accompanying images meets ethical standards, the patient's family was required to provide written informed consent. The Editor-in-Chief of the journal can access and review a copy of the written consent at any time.","In compliance with ethical guidelines, the family of the patient was required to grant written informed consent for the publication of this case report and its accompanying images. A copy of the written consent has been made available for the Editor-in-Chief of the journal to review if needed.","The publishing of this case report, together with its corresponding images, has been approved by the patient's family through given informed consent in writing. The written consent can be reviewed by the Editor-in-Chief of the journal to ensure adherence to ethical standards were followed."
"Classical swine fever virus is a highly infectious disease-causing agent in both domestic and wild pigs, also known as wild boars. It is an RNA virus that exists enveloped and positively stranded, and it belongs to the Pestivirus genus in the Flaviridae family. Significant pathogens like the bovine viral diarrhea virus and border disease virus also belong to this genus. Genetic typing of CSF viruses has grouped them into three major divisions and ten subgroups. Phylogenetic evidence hints at the possibility of widespread switching in virus strains from group 1 or 3 to group 2 observed in many European and Asian nations. Nevertheless, it should be noteworthy that all vaccine strains currently in use belong to group 1, including the Chinese lapinized vaccine strain (C-Strain), initially developed by serial passage of virulent strains in rabbits. However, two independent studies have reported the emergence of dominant subgroup 2.1 strains branching away from vaccine C-Strain in China.","Swine fever caused by the classical swine fever virus is a highly contagious disease that affects both domesticated pigs and wild boars. The virus is composed of small, enveloped, positive-stranded RNA, and belongs to the Pestivirus genus in the Flaviviridae family. Other important livestock pathogens, like bovine viral diarrhea virus and border disease virus, are also classified under the Pestivirus genus. Genetically, there are three major groups of CSF viruses, with ten subgroups, that have been identified through genetic typing. Current phylogenetic analyses of CSF viruses have revealed a recent trend in virus population regarding a shift from historical group 1 or 3 to the recent group 2, most notably in Europe and Asia. Live-attenuated vaccine strains currently in use, which include the Chinese lapinized vaccine strain, belong to group 1. The vaccine strain was initially derived by serial passage of a virulent strain in rabbits and has been used for prophylactic vaccination in China since 1954. However, two separate studies have reported that the subgroup 2.1 has recently branched off from the vaccine C-strain and is currently dominant in China.","Classical swine fever virus is an enveloped, small RNA virus that causes classical swine fever in both domestic and wild pigs. It belongs to the Pestivirus genus in the Flaviviridae family and shares the classification with bovine viral diarrhea virus and border disease virus, which can cause significant health problems in livestock. The genetic typing of CSF viruses has identified three major groups and ten subgroups, with some evidence suggesting a recent shift of virus populations from group 1 or 3 to the more recent group 2 in Europe and Asia. While live-attenuated vaccine strains belonging to group 1 are currently in use worldwide, including the well-known Chinese lapinized vaccine strain developed in 1954 from a virulent strain of CSFV obtained from rabbits, recent studies have revealed the emergence of the 2.1 subgroup strains in China that have branched off from the vaccine C-strain."
"E2 is a dominant viral envelope glycoprotein that appears on the surface of the virion. It is essential to initiate virus attachment and host cell entry as well as controlling cell tropism. Not only has this glycoprotein been identified as a virulence determinant, but it has also shown to stimulate the production of neutralizing antibodies and provide immunity against the infection in pigs. The antigenic structure of E2 has been analyzed using various monoclonal antibodies (mAbs). Studies have shown the existence of two different antigenic units namely B/C and A/D, which are present in the N-terminal half of E2. Remarkably, the deletion of the C-terminal half has no effect on antibody binding. The research has also identified that the first six conserved cysteine residues are crucial and the antigenic motif 771LLFD774 has a vital role in maintaining the antigenic structure of E2.","E2 is a significant envelope glycoprotein that is present on the surface of the virion. Its primary function is to mediate virus attachment and entry into the host cells as well as controlling cell tropism. Along with this, E2 has been identified as one of the virulence determinants. The production of neutralizing antibodies and protection against the infection can be initiated by this glycoprotein in pigs. The use of monoclonal antibodies (mAbs) has confirmed the existence of two independent antigenic units, B/C and A/D. These units can be found in the N-terminal half of E2. Interestingly, the deletion of the C-terminal half has little or no effect on antibody binding. The research has indicated that the first six conserved cysteine residues are essential as they define the antigenic profile of the E2 antigenic structure. Additionally, the antigenic motif 771LLFD774 is crucial for E2's antigenic structure.","The E2 protein is a vital envelope glycoprotein that is highly expressed on the surface of the virion. It functions as the mediator of virus attachment and entry into host cells, as well as cell tropism. Studies have revealed that E2 is an important virulence determinant. Moreover, E2 can trigger the production of neutralizing antibodies that lead to protective immunity against the infection in pigs. Researchers have identified two independent antigenic units, B/C and A/D, within the N-terminal half of E2 by employing monoclonal antibodies (mAbs). Interestingly, the C-terminal half of E2 is dispensable for antibody binding. The first six cysteine residues and the antigenic motif 771LLFD774 have been determined as essential for the antigenic structure of E2. These findings shed light on the crucial role played by E2 in determining the antigenicity of the viral envelope."
"The study of E2 genetic diversity has been widespread amongst various groups, suggesting that antigenic units may be experiencing positive selection due to continuous exposure to high immunologic pressure. The N-terminal half of E2 has shown greater variability compared to the C-terminal half, indicating that antigenic variation of E2 varies among different CSFV isolates. Usage of neutralizing mAbs for selection of mAb-resistant mutants has showcased the ability of single point mutations to cause the loss of complete mAbs binding. Amino acid changes at position 710 on the E2 proteins of different strains have shown to affect both binding and neutralization with a panel of mAbs. Furthermore, a study using single amino acid exchanges between a group 1 vaccine strain and a group 3 field isolate revealed that mAb binding patterns could be completely reversed. All studies focused on antigenic variation of glycoprotein E2 were implemented using mouse mAbs, and no attempts have been made to examine antigenic variation or group-specific antigenic determinants using anti-CSFV sera from pigs, the natural host of CSFV.","An extensive study has been conducted to determine the genetic diversity of E2 across various groups. Results indicate that antigenic units may be under positive selection due to repeated exposure to high immunologic pressure. The N-terminal half of E2 exhibits higher variance than the C-terminal half, and different CSFV isolates show varying patterns of E2 antigenic variation through reactivity with mAbs. Single point mutations have been observed to cause complete loss of mAbs binding when using neutralizing mAbs to identify mAb-resistant mutants. Additionally, amino acid substitutions at position 710 on E2 have been shown to affect the binding and neutralization of a panel of mAbs. Studies using single amino acid changes between group 1 vaccine strains and group 3 field isolates have also revealed that mAb binding patterns could be entirely reversed. However, all studies investigating the variation of E2 glycoprotein have used mouse monoclonal antibodies, and no attempt has been made to examine the variation of the antigenic or group-specific determinants using anti-CSFV sera from pigs, the natural host of CSFV.","The genetic diversity of E2 among various groups has been extensively explored, revealing that antigenic units could be subject to positive selection due to continuous exposure to high immunologic pressure. The N-terminal half of E2 has demonstrated higher variability than the C-terminal half, suggesting that E2 antigenic variation varies among different CSFV isolates. Neutralizing mAbs have been utilized to identify mAb-resistant mutants, and research has indicated that a single point mutation could lead to the complete loss of mAbs binding. Moreover, a panel of mAbs has shown that amino acid substitutions at position 710 on E2 could affect the binding and neutralization of various strains. Single amino acid exchanges between a group 1 vaccine strain and a group 3 field isolate have been found to be able to reverse the mAbs binding pattern entirely. However, all studies exploring the antigenic variation of glycoprotein E2 have relied on mouse mAbs and not anti-CSFV sera from pigs, the natural host of CSFV, to examine antigenic variation or group-specific antigenic determinant."
"The study aimed to evaluate the extent of the antigenic variation of glycoprotein E2 within antigenic units through the use of pig antisera raised against CSFV vaccine C-strain and a representative subgroup 2.1 strain QZ-07. In addition, rabbit polyclonal and mouse monoclonal antibodies were produced against recombinant E2 (rE2) protein from C-strain to assess the differences in cross-neutralization caused by the antigenic variation of E2. By utilizing a series of C-strain rE2 proteins with individual substitutions, which were based on amino acid dissimilarities between the C-strain and group 2 isolates, the residues responsible for the antigenic variation of E2 were identified.","The objective of the research was to determine the level of antigenic variation within the antigenic units of glycoprotein E2 by using pig antisera that were raised against both the CSFV vaccine C-strain and a subgroup 2.1 QZ-07 strain. To examine if the antigenic variation of E2 results in discrepancies in cross-neutralization, rabbit polyclonal and mouse monoclonal antibodies were produced against recombinant E2 (rE2) protein obtained from C-strain. A sequence of variant C-strain rE2 proteins were created, each with a single substitution based on the divergence in amino acids between the C-strain and group 2 isolates, to establish the residues that affect the antigenic variation of E2.","In this study, pig antisera were used to examine the extent of the antigenic variation within antigenic units of glycoprotein E2 by raising it against CSFV vaccine C-strain and a representative subgroup 2.1 strain QZ-07. To investigate whether the antigenic difference of E2 results in differences in cross-neutralization, rabbit polyclonal and mouse monoclonal antibodies were raised against recombinant E2 (rE2) protein from C-strain. Further, a group of variant C-strain rE2 proteins with single substitutions based on amino acid differences between the C-strain and group 2 isolates was developed to define the residues involved in the antigenic variation of E2."
"The truncated rE2 proteins obtained from prokaryotes are widely used for several purposes including antigen production, antigenic domain identification, and epitope mapping. This research aimed to express two types of truncated rE2 proteins in E. coli Rosetta(DE3) cells - rE2-BC (aa 690-814), and rE2-AD (aa 690-865). While rE2-BC covered the crucial N-terminal 123 residues necessary for binding to pig anti-CSFV serum, rE2-AD consisted of both the B/C and A/D antigenic units. The western blot results indicated that both proteins of vaccine C-strain reacted strongly with pig anti-C-strain hyperimmune serum at the appropriate molecular weights of 20 and 25 kDa, respectively. Therefore, prokaryotic-derived rE2 proteins serve as suitable immunogens for generating monoclonal and polyclonal antibodies and antibody binding assessments.","Truncated rE2 proteins derived from prokaryotes have several scientific applications, including antigen production, antigenic domain recognition, and epitope mapping. In this study, two types of truncated rE2 proteins were synthesized using E. coli Rosetta (DE3) cells: rE2-BC (aa 690-814) and rE2-AD (aa 690-865). rE2-BC covered the N-terminal 123 residues, which is the essential antigenic domain required to bind to pig anti-CSFV serum. In comparison, rE2-AD contained both the B/C and A/D antigenic units. The western blot analysis showed that the vaccine C-strain's rE2-BC and rE2-AD proteins had appropriate molecular weights of 20 and 25 kDa, respectively, and reacted strongly with pig anti-C-strain hyperimmune serum. Thus, using prokaryotic-derived rE2 proteins as immunogens can produce monoclonal and polyclonal antibodies and antibody-binding assessments.","The use of truncated rE2 proteins obtained from prokaryotes has various applications, such as antigenic domain recognition, epitope mapping, and antigen production. This study aimed to synthesize two types of truncated rE2 proteins using the E. coli Rosetta (DE3) cell line: rE2-BC (aa 690-814) and rE2-AD (aa 690-865). The rE2-BC protein covered the N-terminal 123 residues, which are essential as the antigenic domain required for binding to pig anti-CSFV serum. Meanwhile, the rE2-AD protein had both the B/C and A/D antigenic units. Western blot analyses showed that the vaccine C-strain's rE2-BC and rE2-AD proteins reacted strongly with pig anti-C-strain hyperimmune serum at the appropriate molecular weights of 20 and 25 kDa, respectively. Therefore, prokaryotic-derived rE2 proteins can serve as immunogens to produce polyclonal and monoclonal antibodies and for the assessment of antibody binding."
"The comparison of the E2 antigenic variation between the subgroup 1.1 C-strain and subgroup 2.1 field isolates was done by examining the rE2-AD proteins by ELISA with the aid of antisera collected from pigs at different time intervals after being immunized with the C-strain vaccine or being infected by strain QZ-07, which signifies subgroup 2.1. The results found in Figure 2 showed that each serum responded with more strength to the rE2-AD protein of the homologous strain (used in preparing the serum) than that of the heterologous strain. In Figure 3, the anti-C-strain and anti-QZ-07 sera (gathered at 78 days post immunization with the C-strain and 25 days post infection with strain QZ-07, respectively) were analyzed for their binding efficiency to rE2AD proteins taken from C-strain and eight subgroup 2.1 strains. The homologous binding efficacy was kept at 100%, and it revealed that the anti-C-strain serum exhibited significantly limited efficiency of binding to subgroup 2.1 rE2-AD proteins (below 60% efficiency). Regions of low efficiency also revealed that the binding of anti-QZ-07 serum to C-strain rE2-AD protein was below 20% efficiency and almost invisible in the blot. Finally, the binding of anti-QZ-07 serum to heterologous subgroup 2.1 proteins was unpredictable.","To assess how different the E2 antigen is between the subgroup 1.1 C-strain and subgroup 2.1 field isolates, the researchers undertook an analysis of rE2-AD proteins by ELISA using antisera obtained from pigs at different intervals after administration of the C-strain vaccine or infection by strain QZ-07, representing subgroup 2.1. Results of Figure 2 showed that each serum reacted more strongly to the rE2-AD protein of the same strain used in preparing the serum than that of the different one. Furthermore, Figure 3 demonstrated a comparison of anti-C-strain and anti-QZ-07 sera (collected 78 days after immunization with C-strain and 25 days after infection with strain QZ-07, respectively) regarding their binding efficiency to rE2AD proteins from C-strain and eight subgroup 2.1 strains. Homologous binding efficacy was set at 100%, and findings revealed that the anti-C-strain serum showed remarkably low efficiency of binding to subgroup 2.1 rE2-AD proteins (less than 60% efficiency). The binding of anti-Q7-07 serum to C-strain rE2-AD protein was even less capable (below 20% efficiency), and a band on the blot was barely visible. Finally, the binding of anti-QZ-07 serum to heterologous subgroup 2.1 proteins was irregular.","The antigenic variation of E2 between subgroup 1.1 C-strain and subgroup 2.1 field isolates was assessed using ELISA through cross-examination of the respective rE2-AD proteins with antisera collected from pigs. The ELISA analysis was performed at different time intervals after the pigs were immunized with the C-strain vaccine or infected with strain QZ-07, representing subgroup 2.1. Figure 2 displays the observation that every antiserum reacted more strongly to the rE2-AD protein of the homologous strain than to the heterologous strain. Furthermore, Figure 3 compares the binding efficiency of anti-C-strain and anti-QZ-07 sera to rE2AD proteins derived from C-strain and eight subgroup 2.1 strains. The homologous binding efficiency was established at 100%, whereby the anti-C-strain serum exhibited significantly low binding efficiency to subgroup 2.1 rE2-AD proteins (below 60% efficiency). The binding of anti-Q7-07 serum to C-strain rE2-AD protein was even less efficient (below 20% efficiency), with the protein band barely visible on the blot. Finally, the binding of anti-QZ-07 serum to heterologous subgroup 2.1 proteins was inconsistent."
"Examination of pig antiCSFV sera in a two-way neutralization analysis revealed that heterologous neutralization had reduced efficacy, particularly for sera collected soon after vaccination or infection (Figure 4). Heterogeneity in subgroup 2.1 strains QZ-07 and HZ1-08 also resulted in variations in neutralization effectiveness. Given that strain variation influences heterologous virus neutralization efficiency, and poor binding of antisera to heterologous rE2-AD proteins was observed (Figure 3), researchers sought to explore the potential effect of E2 glycoprotein variation on CSFV cross-neutralization. To do this, they generated rabbit antiserum (polyclonal antibodies) and three monoclonal antibodies (mAbs) against C-strain rE2-AD protein. While the C-strain antiserum effectively neutralized QZ-07 virus (log10 2.1), the rabbit antiserum neutralized it less efficiently (log10 1.8). Moreover, substitution of cysteine residues in the antigenic unit B/C with serine residues impaired the reactivity of mAbs 1E7 and 6B8 to E2, but not of mAb 2B6 (Table 2). The results suggest that cysteine residues play a role in the structural conformation of E2 and that mAbs 1E7 and 6B8 bind to conformational epitopes. Even though mAb 2B6 only bound to C-strain, its neutralization efficiency was low.","The effectiveness of heterologous neutralization was found to be reduced by pig antiCSFV sera in a two-way neutralization analysis, particularly for sera obtained soon after vaccination or infection (Figure 4). Interestingly, there were variations in neutralization efficiency among subgroup 2.1 strains QZ-07 and HZ1-08. The researchers observed that strain variation influences the ability of antisera to neutralize heterologous viruses, and heterologous rE2-AD proteins showed inefficient binding to the antisera (Figure 3). To investigate whether variation in glycoprotein E2 affects CSFV cross-neutralization, they generated rabbit antiserum (polyclonal antibodies) and three monoclonal antibodies (mAbs) against C-strain rE2-AD protein. It was discovered that the rabbit antiserum neutralized the QZ-07 virus with lower efficiency (log10 1.8) compared to the C-strain (log10 2.1). They also observed that replacing cysteine residues in the antigenic unit B/C with serine residues reduced the reactivity of mAbs 1E7 and 6B8 to E2. However, the reactivity of mAb 2B6 was unaffected by mutagenesis (Table 2). These findings suggest that cysteine residues affect the structural conformation of E2 and that mAbs 1E7 and 6B8 bind to conformational epitopes. Even though mAb 2B6 only bound to C-strain, its neutralization efficiency was low.","A two-way neutralization analysis conducted using pig antiCSFV sera disclosed that heterologous neutralization had lower efficacy, primarily with sera gathered at the early stage following vaccination or infection (Figure 4). Interestingly, the neutralization potency was also distinct between subgroup 2.1 strains QZ-07 and HZ1-08. As the capability of antisera to neutralize heterologous viruses is affected by strain variation, the binding efficiency of antisera to heterologous rE2-AD proteins was deemed ineffective (Figure 3). Therefore, the researchers undertook an investigation to determine if variation in glycoprotein E2 affects CSFV cross-neutralization. To accomplish this, they generated a rabbit antiserum (polyclonal antibodies) and three monoclonal antibodies (mAbs) against C-strain rE2-AD protein. It was observed that the rabbit antiserum neutralized the QZ-07 virus with lower efficiency (log10 1.8) than the C-strain (log10 2.1). Notably, replacing cysteine residues in the antigenic unit B/C with serine residues completely abolished mAbs 1E7 and 6B8 reactivity to E2. However, the mutagenesis did not impact the reactivity of mAb 2B6 (Table 2). These results suggest that these cysteine residues are involved in the structural conformation of E2 [22,23], and that mAbs 1E7 and 6B8 bind to conformational epitopes. The neutralization potency of mAb 2B6 was low, although it only bound to C-strain."
"To discover the specific amino acid residues contributing to the observed variation in antigenicity, a dataset of 108 CSFV strains, one from each group, was retrieved from GenBank and aligned. Abnormalities in twenty vital residues within the antigenic units were discovered through the analysis. A comprehensive breakdown of the variability of these residues between the vaccine strains and the second representative group is provided in Table 3.","In order to determine the amino acid residues responsible for the antigenic differences observed, the E2 sequences of 108 CSFV strains, one from each group, were obtained from GenBank and aligned. The analysis revealed twenty key variable residues within the antigenic units. Table 3 displays the degree of variability of these residues between the vaccine strains and representative group 2 strains.",The aim was to identify the specific amino acid residues involved in the changes in antigenicity observed. The E2 sequences of 108 representative CSFV strains were obtained from GenBank and aligned. The study identified twenty major variable residues located in the antigenic units. The variability of these residues between vaccine strains and group 2 representative strains can be found in Table 3.
"Site-directed mutagenesis was employed to systematically replace amino acids in the C-strain E2 protein with those found in subgroup 2.1 proteins (refer to Table 3 - second last row). Binding ELISA was conducted to assess the binding of wild type and variant C-strain rE2 proteins to C-strain and strain QZ-07 antisera. The wells of the plates were coated with equal amounts of proteins, and antibodies were added at saturation levels to prevent limiting antibody concentration. The wt C-strain rE2 protein binding functioned as the control at 100%. Substitutions did not affect the binding of variant rE2 proteins to antiC-strain serum to a significant degree (with binding efficiency ranging between 80% and 130%), indicating that these residues did not play a significant role in the protein's overall binding to antibodies (as depicted in Figure 5A). However, thirteen substitutions resulted in increased binding of variant C-strain rE2 proteins to anti-QZ-07 serum (i.e., over 150% binding efficiency threshold). D705N, L709P, G713E, N723S, or S779A substitutions resulted in a substantial increase in binding efficiency (over 200% threshold), while a moderate increase was observed with D725G, N729D, N777S, T780I, D847E, M854V, T860I, or N863K substitution (with an efficiency between 150% and 200%).","Through the use of site-directed mutagenesis, we systematically substituted amino acids in the C-strain E2 protein with those found in subgroup 2.1 proteins (specifically, those listed in Table 3 - second last row). We then assessed the binding of wild type and variant C-strain rE2 proteins to C-strain and strain QZ-07 antisera using binding ELISA. To prevent limiting antibody concentration, the wells of the plates were coated with equal amounts of proteins and the antibodies used were at saturation levels. The wt C-strain rE2 protein binding functioned as the control, with 100% efficiency. None of the substitutions significantly altered the binding of the variant rE2 proteins to antiC-strain serum (with binding efficiency ranging between 80% and 130%), suggesting that these specific residues did not play a significant individual role in the protein's overall binding to antibodies (as demonstrated in Figure 5A). However, 13 substitutions did result in increased binding of variant C-strain rE2 proteins to anti-QZ-07 serum (i.e., above 150% binding efficiency threshold). D705N, L709P, G713E, N723S, or S779A substitutions caused a significant increase in binding efficiency (above 200% threshold), while D725G, N729D, N777S, T780I, D847E, M854V, T860I, or N863K substitutions yielded a moderate increase in efficiency (between 150% and 200%).","A systematic substitution of amino acids in the C-strain E2 protein was performed using site-directed mutagenesis. The substituted amino acids were those found at the same positions in subgroup 2.1 proteins (as given in Table 3 - second to last row). The binding ability of wild type and variant C-strain rE2 proteins to C-strain and strain QZ-07 antisera was assessed through the binding ELISA method. To eliminate limiting antibody concentration, the wells of the plates were coated evenly with proteins, and antibodies were added at saturation levels. The binding of the wt C-strain rE2 protein to the antisera was considered the control at 100%. No substitutions led to a significant change in the binding of the variant rE2 proteins to antiC-strain serum (binding efficiency ranged from 80% to 130%). This indicates that these specific residues did not contribute significantly to the overall capacity of Cstrain rE2 protein to bind the antibodies individually (as shown in Figure 5A). Nonetheless, 13 substitutions increased the binding of the variant C-strain rE2 proteins to anti-QZ-07 serum (above 150% binding efficiency threshold). The substitution of D705N, L709P, G713E, N723S, or S779A led to a significant increase in binding efficiency (over 200% threshold), while a moderate increase was observed with D725G, N729D, N777S, T780I, D847E, M854V, T860I, or N863K substitution (with efficiency between 150% and 200%)."
"The residues that had a substantial impact on the efficiency of binding could be identified as forming three distinct clusters inside the antigenic units, presented in Figure 1A. The initial group was found in the N-terminal of antigenic unit B/C, situated at positions spanning from 702 to 731. The second cluster emerged at the juncture between the two antigenic units at positions 774-799, whereas the third and last one was located in the C-terminal of antigenic unit A/D, extending from positions 841 to 864. Fascinatingly, the analysis of hydrophilicity illuminated that these particular areas were responsible for the significant dissimilarities in hydrophilicity between the strains CSFV C-strain and QZ-07, as depicted in Figure 5C.","The residues that had a marked impact on the efficacy of binding were arranged into three distinct clusters located within the antigenic units, represented in Figure 1A. The first group was situated in the N-terminus of antigenic unit B/C, spanning amino acid positions 702-731. The second grouping occurred at the boundary between the two antigenic units within positions 774-799, while the third cluster was placed in the C-terminus of antigenic unit A/D, encompassing positions 841-864. Intriguingly, the results of the hydrophilicity analysis highlighted that these regions were responsible for the most significant hydrophilic discrepancies between the CSFV C-strain and QZ-07, as shown in Figure 5C.","Three unique clusters of residues were responsible for a notable or moderate improvement in binding efficiency within the antigenic units, as presented in Figure 1A. The first cluster was positioned at the N-terminus of antigenic unit B/C, consisting of amino acid positions ranging from 702-731. The second group surfaced at the boundary between the two antigenic units, with residues extending from positions 774-799, while the third cluster was situated in the C-terminus of antigenic unit A/D, corresponding to positions 841-864. Interestingly, an analysis of hydrophilicity revealed that these regions were significant contributors to hydrophilic differences between the CSFV C-strain and QZ-07 strains, as depicted in Figure 5C."
"A deep analysis was conducted to gain a more in-depth understanding of the evolution of antigenic units, examining the diversity of codons and amino acids through an adapted Simpson's index. The results revealed that a group of thirteen residues linked to antigenic variation had experienced high levels of diversification, with nonsynonymous mutations accumulating in their codons. This diversification is evidenced by the residues being located along the diagonal (x=y) in Figure 6. On the other hand, a set of six cysteine residues and residues in the 771LLFD774 motif demonstrated high levels of conservation despite the presence of a moderate number of synonymous mutations in their codons. As such, they are located along the x-axis. The mapping of antigenic residues recognized by mAb-resistant mutants analysis as having a random distribution is seen in Figure 6.","A detailed examination was conducted to explore the antigenic and genetic evolution of antigenic units by analyzing the diversity of codons and amino acids using a variant Simpson's index. The findings illustrate that a group of thirteen residues related to antigenic variation (as shown in Figure 5 and Table 3) have experienced a high level of diversification, with large numbers of nonsynonymous mutations accumulating in their codons. This diversification is evidenced by the residues being located along the diagonal (x=y) in Figure 6. Conversely, six cysteine residues and residues in the 771LLFD774 motif have demonstrated a high level of conservation, even though their codons have exhibited a moderate number of synonymous mutations, with these residues being situated on the x-axis in Figure 6. Finally, the analysis of the antigenic residues identified by mAb-resistant mutants indicate that they are mapped as having a random distribution (Figure 6).","In order to gain more insight into the antigenic and genetic evolution of antigenic units, the diversity of codons and amino acids was analyzed using a modified Simpson's index. Figure 6 illustrates that the thirteen residues associated with antigenic variation (as illustrated in Figure 5 and Table 3) have undergone high levels of diversification due to an accumulation of nonsynonymous mutations in their codons. These residues are located along the diagonal (x=y). On the other hand, the six cysteine residues and residues in the 771LLFD774 motif remain highly conserved, even though their codons have accumulated a moderate number of synonymous mutations, with these residues being situated on the x-axis in Figure 6. Additionally, the antigenic residues identified through mAb-resistant mutants analysis have been mapped as having a random distribution (Figure 6)."
"Within the CSFV family, three distinctive groupings are identified through phylogenetic analysis. Recent studies reveal that in the majority of European and Asian regions, viral populations are now mainly associated with group 2 instead of historical group 1 or group 3. The glycoprotein E2 is crucial as both a target for neutralizing antibodies and an immunogen for protection. Notably, the E2 glycoproteins from each of the three groups are dissimilar in both their genetic makeup and antigenic properties. However, the molecular mechanism underlying such a variation has not been entirely elucidated to date.","CSFV is classified into three major groups based on phylogenetic analysis, and recent studies have shown a shift in viral populations within Europe and Asia, with group 2 being more prevalent than historical group 1 or group 3. The glycoprotein E2 is a vital target for neutralizing antibodies and serves as an important immunogen. The E2 glycoproteins in each of the three groups have a different genetic and antigenic structure. However, the precise molecular basis for this antigenic variation has not been clearly established.","According to phylogenetic analysis, CSFV belongs to three major groups. Recent research indicates that viral populations in most European and Asian areas have shifted from historical groups 1 or 3 to group 2. The glycoprotein E2, a crucial target for neutralizing antibodies, is an important immunogen for protection. The E2 glycoproteins in each of the three groups have different genetic and antigenic properties. However, the precise mechanism underlying this antigenic variation has yet to be clearly demonstrated at the molecular level."
"Results from our study reveal that there is a disparity in heterologous rE2-AD protein binding between pig anti-C-strain and anti-QZ07 sera and homologous proteins, indicating antigenic differences. Furthermore, the E2 protein of vaccine C-strain displays an antigenic uniqueness from other strains in subgroup 2.1. The study also demonstrates that there are antigenic variations among subgroup 2.1 strains, as exhibited by the inefficiency of pig anti-QZ-07 serum to bind HZ1-08- and QZ2-06-derived rE2-AD proteins. These findings are consistent with previous reports of antigenic variations detected by mouse mAbs, which also occur in the context of pig anti-CSFV sera.","The data suggests that pig anti-C-strain and anti-QZ07 sera have a lower binding efficiency to heterologous rE2-AD proteins than to homologous proteins, indicating antigenic differences. Additionally, the E2 protein of vaccine C-strain was found to be antigenically distinct from a wide range of subgroup 2.1 strains. Our results also demonstrate antigenic variation among subgroup 2.1 strains, as evidenced by pig anti-QZ07 serum's inability to bind HZ1-08- and QZ2-06-derived rE2-AD proteins. This study confirms previous reports of antigenic dissimilarities seen by mouse mAbs and their occurrence in the context of pig anti-CSFV sera.","The study reveals that pig anti-C-strain and anti-QZ07 sera have lower binding efficiency to heterologous rE2-AD proteins compared to homologous proteins, indicating the presence of antigenic variations. The E2 protein of vaccine C-strain is shown to have unique antigenic characteristics from other strains in the subgroup 2.1. Furthermore, among subgroup 2.1 strains, the study shows the presence of antigenic variation, which is demonstrated by the pig anti-QZ07 serum's low binding ability to HZ1-08- and QZ2-06-derived rE2-AD proteins. Our findings support previous reports that indicate the presence of antigenic difference detected by mouse mAbs, further confirming their detection in the context of pig anti-CSFV sera."
"The differences in antibody binding efficiency to rE2 proteins were evaluated through neutralization experiments to determine the ability of the antibody to block CSFV infection. The results of neutralization determination revealed that the pig anti-CSFV sera and rabbit polyclonal antibodies against purified C-strain rE2-AD protein were not effective at neutralizing heterologous strains while two conformational anti-C-strain-rE2-AD mAbs had lower binding and neutralization efficiency against heterologous strains compared to C-strain. The antigenic epitopes on E2 glycoproteins of CSFV strains may be responsible for the neutralization differences, which may explain why subgroup 2.1 CSFV strains persist in China despite using vaccine C-strain. Antibody selection may have led to the viral population switch from group 1 to 2.","Neutralization experiments were carried out to determine whether the differences in antibody binding efficiency to rE2 proteins correlated with the ability of the antibody to block CSFV infection. The two-way neutralization determination showed that pig anti-CSFV sera had a lesser effect on heterologous strains, while rabbit polyclonal antibodies against purified C-strain rE2-AD protein also had less efficiency at neutralizing strain QZ-07. Furthermore, two conformational anti-C-strain-rE2-AD mAbs (1E7 and 6B8) had lower binding and neutralization efficiency against heterologous strains compared to C-strain, indicating that the differences in neutralization efficiency are likely due to differential expression of antigenic epitopes on the E2 glycoproteins of CSFV strains. These findings suggest that antigenic variation may explain the persistence of subgroup 2.1 CSFV strains in China despite the widespread use of vaccine C-strain, and that antibody selection could be a contributing factor in the switch of viral populations from group 1 to 2.","To determine whether the differences in the efficiency of antibody binding to rE2 proteins corresponded to the antibody's ability to block CSFV infection, the researchers conducted neutralization experiments. The results showed that the pig anti-CSFV sera had a lower efficiency at neutralizing heterologous strains, as did rabbit polyclonal antibodies against purified C-strain rE2-AD protein. The two conformational anti-C-strain-rE2-AD mAbs also had less binding and neutralization efficiency against the heterologous strains than the C-strain, indicating that antigenic variation in the E2 glycoproteins of CSFV strains may account for the observed differences. These findings suggest that the persistence of subgroup 2.1 CSFV strains in China despite the use of vaccine C-strain may be explained by such antigenic variation, and that antibody selection could be a contributing factor in the switch of viral populations from group 1 to 2."
"The amino acid substitutions in the C-strain rE2 proteins were probed using site-directed mutagenesis to determine whether variable residues (Table 3) contribute to antigenic variation seen with subgroup 2.1 strains. Anti-C-strain serum binding was not significantly affected by any of the substitutions except for mutations in the antigenic motif 771LLFD774 that disrupted E2 protein's structural integrity [25]. This suggests that the substituted residues are not crucial for glycoprotein E2's overall structural stability and that the recombinant proteins are not grossly misfolded. Thirteen out of 20 substitutions were discovered to enhance the variant C-strain rE2 protein's binding to anti-QZ-07 serum (Figure 5A), with the most significant increase being the result of the GtoE substitution at position aa 713 (Figure 5A and 5B). Interestingly, all group 2 strains have 713E, and all vaccine strains have 713G, according to sequence alignment (Table 3). Chang et al. reported recently that residues 713E and 729D are critical for specificity of mAbs to a group 3.4 field strain rE2 protein [35]. Therefore, 713E appears to be a common antigenic determinant for both groups 2 and 3.","By using site-directed mutagenesis, we have examined whether the variable residues (listed in Table 3) contribute to the antigenic variation seen with subgroup 2.1 strains in the C-strain rE2 proteins. Unlike the mutations found in the antigenic motif 771LLFD774, which affected the E2 protein's structural integrity, none of the substitutions had a significant effect on binding to anti-C-strain serum (Figure 5A). This indicates that the substituted residues do not have a critical effect on glycoprotein E2's structural stability and that the recombinant proteins are not grossly misfolded. Conversely, out of 20 substitutions, 13 enhanced the variants C-strain rE2 proteins' binding to anti-QZ-07 serum, with the greatest increase observed in the GtoE substitution at aa position 713 (Figure 5A and 5B). It was observed that all group 2 strains possess 713E, while all vaccine strains have 713G when sequence alignment was conducted (Table 3). Moreover, Chang et al. recently reported that the residue 713E and 729D are essential for the specificity of a group 3.4 field strain rE2 protein to mAbs [35]. These findings suggest that 713E is a common antigenic determinant for both groups 2 and 3.","Through the use of site-directed mutagenesis, we sought to investigate whether the variable residues (detailed in Table 3) contribute to the observed antigenic variation in subgroup 2.1 strains within the C-strain rE2 proteins. Unlike the mutations in the antigenic motif 771LLFD774, which impacted the structural integrity of E2 protein [25], none of the substitutions had a notable impact on binding to anti-C-strain serum (Figure 5A). This led us to infer that the substituted residues do not critically affect the overall structural stability of glycoprotein E2, and that the recombinant proteins are not grossly misfolded. However, thirteen of the twenty substitutions were found to enhance the binding of the variant C-strain rE2 proteins to anti-QZ-07 serum, with the most significant boost being provided by the GtoE substitution at position aa 713 (Figure 5A and 5B). Notably, sequence alignment showed that residue 713E is present in all group 2 strains, while all vaccine strains have 713G (Table 3). Recently, Chang et al. reported that residues 713E and 729D were critical for the specificity of a group 3.4 field strain rE2 protein to mAbs [35], indicating that 713E is a common antigenic determinant for both groups 2 and 3."
"The results from our investigation demonstrate that while residue 729D may have improved binding with pig anti-QZ-07 serum, residues 705N, 709P, 723S, and 779A played a much more substantial role (as shown in Figure 5A). Notably, these same residues are present in positions 705 and 723 on E2 proteins of subgroup 2.1 and subgroup 3.4 strains. It is plausible that these two residues could also contribute largely to the antigenicity of subgroup 3.4 glycoprotein E2 if observed with pig antisera against group 3 strains. Furthermore, we utilized polyclonal sera from pigs that were infected with a field strain or immunized with the C-strain vaccine. This allowed us to obtain a full range of antibodies that arose from either infection or immunization. As a result, the polyclonal sera we employed could recognize more residues that were responsible for glycoprotein E2 antigenic variation than mouse monoclonal antibodies. Lastly, using a combination of polyclonal antisera against the group 1 C-strain and representative group 2 field strain allowed us to identify the residues that mediate antigenic variation between these two groups. This is another significant advantage over using mouse monoclonal antibodies.","Our study revealed that residue 729D indeed aided in the binding of pig anti-QZ-07 serum, but residues 705N, 709P, 723S, and 779A had a more substantial impact on this process (as delineated in Figure 5A). Intriguingly, these same residues are present at positions 705 and 723 on the E2 proteins of subgroup 2.1 and subgroup 3.4 strains. Consequently, it is possible that these two residues may similarly contribute notably to the antigenicity of subgroup 3.4 glycoprotein E2 when examined with pig antisera against group 3 strains. Notably, our approach employed polyclonal sera from pigs immunized with the C-strain vaccine or infected with a field strain, resulting in a varied range of antibodies. As such, we were able to identify more residues responsible for glycoprotein E2 antigenic variation than mouse monoclonal antibodies, as these polyclonal sera have far-reaching recognition capabilities. We also discovered that utilizing a combination of polyclonal antisera against the group 1 C-strain and representative group 2 field strain allowed us to highlight the residues that mediated antigenic variation between the two groups, which is a significant advantage over using mouse monoclonal antibodies.","The data collected from our work established that while residue 729D enhanced the binding to pig anti-QZ-07 serum, residues 705N, 709P, 723S, and 779A had a much more pronounced effect (as depicted in Figure 5A). Significantly, these same residues are present at positions 705 and 723 on E2 proteins of subgroup 2.1 and subgroup 3.4 strains. Therefore, these two residues could potentially also contribute to the antigenicity of subtype 3.4 glycoprotein E2 when sampled with pig antisera against group 3 strains. Our study utilized polyclonal sera taken from pigs that were infected with a field strain or immunized with the C-strain, resulting in a broad array of antibodies created from either infection or vaccination. This allowed us to recognize more residues that were responsible for glycoprotein E2 antigenic variation than mouse monoclonal antibodies could. Furthermore, the use of a combination of polyclonal antisera directed at the group 1 C-strain and representative group 2 field strain enabled us to identify the residues responsible for antigenic variation between the two groups, which is another major benefit over using mouse monoclonal antibodies."
"By analyzing the data from the site-directed mutagenesis (Figure 5A), researchers found that there are expected differences in antigenic variation among subgroup 2.1 strains. This is due to the unique strain-specific substitutions observed in each of the eight strains used in the study. The substitution of C737R in strain QZ2-06 has the most significant effect on the protein's antigenic structure because the cysteine residue at this position is vital for the protein's structure. The E782V substitution found in strain HZ1-08 is believed to be the key determinant of antigenic variation between this and our reference subgroup 2.1 strain QZ-07.",The site-directed mutagenesis analysis (Figure 5A) has shown that antigenic variation is anticipated among subgroup 2.1 strains because each of the eight strains in the study has shown unique and strain-specific substitutions. The antigenic units of strain QZ2-06 reveal that the C737R substitution has a more significant impact on the protein's binding ability. This is due to the crucial role cysteine residues play in the protein's antigenic structure. Researchers hypothesize that the E782V substitution in strain HZ1-08 is the key determinant of antigenic variation between that and the reference subgroup 2.1 strain QZ-07.,"The site-directed mutagenesis analysis (Figure 5A) display expected differences in antigenic variation among subgroup 2.1 strains, as each of the eight strains used in the study has unique strain-specific substitutions. The substitution of C737R in strain QZ2-06 seems to impact binding the most. The cysteine residue plays a crucial role in the protein's antigenic structure, making the substitution critical. The researchers suggest that the E782V substitution found in strain HZ1-08 is likely the determinant of antigenic variation between this and the reference subgroup 2.1 strain QZ-07."
"The E2 protein's antigenic units have been mapped and revealed three independent antigenic areas located at amino acid positions 702-731, 774-799, and 841-864 (as depicted in Figure 1A). Evidence from both mAb-resistant mutants and epitope mapping indicates that the 702-731 region is the primary driver of antigenic variation and hence contributes to the evolution of the E2 protein's antigenicity. The 774-799 region contains a conserved antigenic motif, 771LLFD774, and a linear epitope, 772LFDGTNP778, which are pivotal in maintaining the E2 antigenic structure. Notably, substitutions in positions N777S, S779A, and T780I of this region enhance binding of variant rE2 proteins to anti-QZ-07 serum, implying the possible existence of multiple functions of region 774-799 in determining E2 antigenicity.","A detailed mapping of the antigenic regions of the E2 protein has identified three distinct areas at amino acid positions 702-731, 774-799, and 841-864 (as demonstrated in Figure 1A). Based on the analysis of mAb-resistant mutants and epitope mapping, it appears that the 702-731 region is the prime determinant of antigenic variation and a key contributor to the evolution of the E2 protein's antigenicity. The conserved antigenic motif 771LLFD774 and linear epitope 772LFDGTNP778 within the 774-799 region are instrumental in maintaining the antigenic structure of the E2 protein. Significantly, several substitutions at positions N777S, S779A, and T780I in this region have been shown to enhance binding of variant rE2 proteins to anti-QZ-07 serum, suggesting a multifaceted role for the 774-799 region in shaping the antigenicity of the E2 protein.","Through a thorough analysis, three independent antigenic regions have been mapped in antigenic units of E2 protein that are located at amino acid positions 702-731, 774-799, and 841-864, as shown in Figure 1A. It has been identified that the 702-731 region is the main contributor to the antigenic variation of glycoprotein E2 as it contains several antigenic residues which, when mutated or substituted, gave rise to an increase in binding to anti-QZ-07 serum. The 774-799 region plays a crucial role in maintaining the antigenic structure of the E2 protein as it contains the conserved antigenic motif 771LLFD774 and a linear epitope 772LFDGTNP778. Moreover, substitutions at positions N777S, S779A, and T780I, located within the region 774-799, result in enhanced binding of variant rE2 proteins to anti-QZ-07 serum, suggesting multiple functions of this region in shaping the antigenicity of the E2 protein."
"The research team studied E2 sequences of CSFV to investigate the relationship between codon and amino acid diversification and antigenic evolution. To measure diversity, the team used a variant version of Simpson's index, which has been commonly utilized to quantify genetic and antigenic diversity in the hemagglutinin glycoprotein of the influenza virus. The results showed that the diversity of both codon and amino acid residues were equal for each of the thirteen residues involved in antigenic variation. Interestingly, these findings suggest a strong link between genetic and antigenic evolution of E2 glycoprotein under natural conditions. The team also noticed that the antigenic residues identified by mAb-resistant mutants analysis were randomly diversified, indicating that in vitro selection may not be a valid explanation for natural selection in pigs. Together with intensive vaccination programs, the co-diversification of codons and amino acids could be a crucial mechanism unleashed by CSFV to evade the immune system under immune pressure.","In order to investigate the connection between codon and amino acid diversification, and antigenic evolution, our team undertook a study on E2 sequences of CSFV. To quantify diversity, we utilized a variant of Simpson's index, which has been previously used for determining diversity in the hemagglutinin glycoprotein of influenza viruses. The analysis revealed that the diversity of both codons and amino acid residues was on par, to each of the thirteen residues involved in antigenic variation. This signifies a strong correlation between genetic and antigenic evolution of E2 glycoprotein under natural conditions. We also observed that residues identified as antigenic through analysis of mAb-resistant mutants showed random diversification, which meant in vitro selection might not explain natural selection in pigs. CSFV appears to utilize co-diversification of codons and amino acids in antigenic variation as a technique to evade the immune system under immune pressure, along with widespread vaccination efforts.","To evaluate the relationship between antigenic evolution and codon and amino acid diversification, we carried out an analysis of E2 sequences of CSFV. We employed a variant Simpson's index that has been used in the past to measure antigenic and genetic diversity in influenza virus hemagglutinin glycoprotein. The analysis demonstrated that each of the thirteen amino acid residues involved in antigenic variation demonstrated the same level of diversity as the corresponding codon. These results suggest there is a decisive correlation between genetic and antigenic evolution of the E2 glycoprotein in the context of natural evolution in pigs. The antigenic residues found through mAb-resistant mutants analysis were found to be randomly diversified, implying that in vitro selection fails to explain natural selection in pigs. CSFV can employ co-diversification of amino acids and codons as an immune evasion mechanism to intensify immune pressure caused by extensive vaccination."
"The study presented herein highlights that glycoprotein E2 in CSFV exhibits significant variation between the vaccine C-strain and group 2 field strains, and even amongst the group 2 strains presently prevalent in China. The first of the three confirmed regions linked with antigenic variation with amino acid residues spanning 702-731 are the primary indicators of E2 antigenic variation. Altered glycoprotein E2 variations can affect the neutralization of CSFV; therefore, forthcoming research will determine whether these antigenic residues hold accountable for the observed neutralization discrepancies. The results of this study may provide valuable insights for the development of novel CSF vaccines and differential serological assays, that improve antibodies production and are more effective against the viruses' varying strains.","The present study illustrates the substantial antigenic variation of CSFV glycoprotein E2, across the vaccine C-strain and group 2 field strains, which is also found within the group 2 strains prevailing in China. The researchers have located three different regions, and the first region identified that extends from aa702-731, is the most significant factor of E2 antigenic variation. As glycoprotein E2 variation can significantly impact the cross-neutralization of CSFV, the authors suggest that subsequent studies could analyze whether these residues are responsible for neutralization variations. This study's results could be fundamental in developing differential serological assays and innovative CSF vaccines with enhanced efficacy and immunogenicity against the virus's divergent strains.","One of the main findings of this study is that there is substantial antigenic variation in the glycoprotein E2 of CSFV between the vaccine C-strain and the group 2 field strains, even among group 2 strains that are currently circulating in China. The researchers identified three distinct regions linked to antigenic variation, with amino acids 702-731 in the first region being the primary determinants of E2 antigenicity. Since variations in glycoprotein E2 can affect CSFV cross-neutralization, additional research will be conducted to investigate whether the identified antigenic residues contribute to observed neutralization differences. The outcomes of this research offer valuable insights that could aid in the development of novel CSF vaccines and alternative serological assays that confer improved immunogenicity and higher efficacy against varying strains of the virus."
"ST cells were cultivated using Minimum Essential Medium and supplemented with fetal bovine serum. For the experiment, three CSFV strains were used, which included the widely used subgroup 1.1 vaccine C-strain in China and two other subgroup 2.1 strains that were isolated from infected pigs and replicated in the laboratory. These strains were stored at -80閹虹煰 after they were propagated and titrated in ST cells. Moreover, the E2 genes of the viruses were sequenced to ensure that they have the expected sequences. The remaining six subgroup 2.1 strains had their E2 genes directly cloned in plasmids, while their isolation was not done. The details of their molecular phylogenetic relationships are accessible elsewhere, while Table 3 displays the strains available in GenBank.","The ST cells were cultivated using MEM and FBS for supplementation. Three CSFV strains were utilized including a commonly used subgroup 1.1 vaccine C-strain in China, and two other subgroup 2.1 strains that were isolated from infected pigs and then replicated in the laboratory. These viruses were propagated in ST cells and subsequently stored at -80閹虹煰. In addition, the E2 genes of the viruses were sequenced to verify their expected sequences. Meanwhile, the E2 genes of the other six subgroup 2.1 strains were cloned directly in plasmids due to their isolation not being executed. GenBank contains sequence data about the viruses and table 3 lists the available strains along with details of their molecular phylogenetic relationships, which are described in literature.","ST cells were grown in MEM with the supplementation of FBS. Three CSFV strains were used, including the widely used subgroup 1.1 vaccine C-strain in China and two other subgroup 2.1 strains that had been isolated from infected pigs and then replicated in the laboratory. After propagation and titration in ST cells, these viruses were stored at -80閹虹煰, and the E2 genes were sequenced to verify their expected sequences. Meanwhile, the E2 genes of the other six subgroup 2.1 strains were directly cloned in plasmids since they were not isolated. GenBank provides data on these viruses, and their molecular phylogenetic relationships are detailed in literature. Table 3 displays the available strains."
"The NCBI database was used to extract all E2 sequences that cover the antigenic region. Once these sequences were obtained, Clustal X software was utilized to align both the nucleotide and amino acid sequences. Any sequences with 100% nucleotide identity were removed, and the remaining 23, 82, and 3 sequences represented groups 1, 2, and 3, respectively. With this dataset, researchers could identify the variable residues that are significant in Table 3, and analyze the codon and amino acid diversity that was portrayed in Figure 6.","Researchers utilized the NCBI database in order to obtain E2 sequences that covered the entire antigenic region. Clustal X software (version 1.83) was then used to Align both nucleotide and amino acid sequences. Sequences that displayed 100% nucleotide identity were subsequently excluded, and the remaining dataset comprised 23, 82, and 3 sequences for groups 1, 2, and 3, respectively. This dataset was employed to identify major variable residues and analyze codon and amino acid diversity, which was ultimately demonstrated in Figure 6.","The entire antigenic region's E2 sequences were retrieved from the NCBI database, covering different groups. Then, Clustal X software version 1.83 was used to align the sequences for both nucleotide and amino acid. Those sequences with identical nucleotide were excused, and the dataset contained 23, 82, and 3 sequences, belonging to groups 1, 2, and 3, separately. Researchers used the dataset to identify significant variable residues and to examine the diversity of codon and amino acid, presenting the findings in Table 3 and Figure 6, respectively."
"The plasmids used in the study for amplifying the E2 gene included the one containing the complete E2 gene of the C-strain vaccine along with eight subgroup 2.1 strains that were explained earlier. Various primer sets were used, such as C-E2-AD-f/C-E2-AD-r and C-E2BC-f/C-E2-BC-r that were used for amplifying the fragment of the two antigenic units (B/C+A/D) and the fragment containing antigenic unit B/C, respectively. QZ-E2-AD-f/QZ-E2-AD-r primer set was also utilized for amplifying fragments covering the two antigenic units of group 2 isolates as given in Table 1. The BamHI and XhoI restriction enzymes were used to digest the PCR amplicons, followed by gel purification of the PCR products before being ligated into the prokaryotic expression vector pET-30a(+). The eukaryotic expression plasmid was constructed by cloning a 1212-bp cDNA fragment, encoding the signal sequence and complete E2 of the C-strain, into pcDNA3.1 after being digested with BamHI and XhoI.","The study utilized plasmids containing the complete E2 gene of the C-strain vaccine and eight subgroup 2.1 strains that were previously described. Different primer sets were used for the amplification of fragments such as C-E2-AD-f/C-E2-AD-r and C-E2BC-f/C-E2-BC-r, which amplified the fragment covering the two antigenic units (B/C+A/D) and the fragment containing antigenic unit B/C, respectively. Another primer set, QZ-E2-AD-f/QZ-E2-AD-r, was used to amplify fragments covering the two antigenic units of group 2 isolates listed in Table 1. The PCR amplicons were digested with the restriction enzymes BamHI and XhoI, followed by purification of the PCR products and their ligation into the pET-30a(+) prokaryotic expression vector. To construct the eukaryotic expression plasmid, a 1212-bp cDNA fragment that encoded the signal sequence and complete E2 of the C-strain was amplified and cloned into pcDNA3.1 following BamHI and XhoI digestion.","The study utilized plasmids that contained the full-length E2 gene of the C-strain vaccine and eight subgroup 2.1 strains described previously. They used various primer sets such as C-E2-AD-f/C-E2-AD-r and C-E2BC-f/C-E2-BC-r to amplify fragments covering the two antigenic units (B/C+A/D) and antigenic unit B/C, respectively. The primer set QZ-E2-AD-f/QZ-E2-AD-r was used to amplify fragments covering the two antigenic units of group 2 isolates. The PCR amplicons were digested with BamHI and XhoI restriction enzymes followed up by purification of the PCR products and their ligation into prokaryotic expression vector pET-30a(+). An eukaryotic expression plasmid was created to insert a 1212-bp cDNA fragment that encoded the signal sequence and complete E2 of the C-strain after being digested with BamHI and XhoI."
"The cultivation of E. coli Rosetta (DE3) cells with different recombinant plasmids led to the growth of cells to an optical density ranging from 0.6 to 0.8 at 600 nm. Subsequently, induction of His-tagged rE2 proteins was initiated using 1 mM isopropyl-b-D-thiogalactoside (IPTG, Sigma-Aldrich). The cells were then disrupted through sonication, and the precipitation of inclusion bodies containing rE2 proteins was achieved after centrifugation. The resuspension of the inclusions bodies required the addition of 1/10 volume of buffer containing 100 mM NaH2PO4璺2H2O, 10 mM Tris-base, and 8 M Urea. After centrifugation, the supernatant was purified through a Ni-NTA affinity column (Novagen, Madison, WI), according to the manufacturer's protocol. The proteins obtained were refolded by washing the column with 40 ml of Tris-buffered saline (TBS, pH 7.4) containing 1 M urea and subsequently eluted from the column with 200 mM imidazole in TBS. The mouse monoclonal anti-His-tag antibody from Sigma-Aldrich confirmed the purification of the obtained rE2 proteins, and the amount of the recombinant protein was quantified using the Bradford assay.","The E.coli Rosetta (DE3) cells, each carrying different recombinant plasmids, were grown up to an optical density between 0.6 and 0.8 at 600 nm. The expression of His-tagged rE2 proteins was initiated by adding 1 mM isopropyl-b-D-thiogalactoside (IPTG, Sigma-Aldrich), followed by sonication of the cells to extract the inclusion bodies containing rE2 proteins. The inclusion bodies were then resuspended with 1/10 volume of a buffer comprised of 100 mM NaH2PO4璺2H2O, 10 mM Tris-base, and 8 M urea, after which the supernatant was collected by centrifugation and purified using a Ni-NTA affinity column (Novagen, Madison, WI) with the detailed protocol given by the manufacturer. The proteins were refolded by washing the column with 40 ml of Tris-buffered saline (TBS, pH 7.4) containing 1 M urea and eluted from the column using 200 mM imidazole in TBS. The quality and amount of the purified rE2 proteins were confirmed by Western blotting with mouse monoclonal anti-His-tag antibody (Sigma-Aldrich) and quantified by using the Bradford assay.","To express His-tagged rE2 proteins, E. coli Rosetta (DE3) cells containing different recombinant plasmids were grown up to optical densities ranging between 0.6 and 0.8 at 600 nm. Expression of the rE2 proteins was then induced with a solution containing 1 mM isopropyl-b-D-thiogalactoside (IPTG, Sigma-Aldrich), before the cells were sonicated to disrupt the cell membrane and harvested to collect the inclusion bodies containing rE2 protein. Using a buffer containing 100 mM NaH2PO4璺2H2O, 10 mM Tris-base, and 8 M urea, the inclusion bodies were resuspended, centrifuged to collect the supernatant, and then purified with a Ni-NTA affinity column (Novagen, Madison, WI) that followed the manufacturer's protocol. The purified proteins were refolded by washing the column in a buffer containing Tris-buffered saline (TBS, pH 7.4) with 1 M urea and later eluted with 200 mM imidazole in TBS. To confirm and quantify the purified rE2 proteins, Western blotting with mouse monoclonal anti-His-tag antibody (Sigma-Aldrich) and the Bradford assay were used, respectively."
"The previously prepared pig hyperimmune serum against the CSFV vaccine C-strain was available for use in the laboratory. CSFV-free pigs were immunized intramuscularly through a prime-boost strategy with the attenuated vaccine C-strain to induce pig anti-C-strain antiserum, or they were infected with strain QZ-07 in a biosafety level III facility to induce pig anti-QZ-07 antiserum. The sera were collected at various times after vaccination or infection, and the highest titers were used for binding ELISAs and Western blots as shown in Figure 3A, 3B, 5A, and 5B. These sera were stored at -80掳C until used. The highest titers were collected at 78 days post immunization with the C-strain and 25 days post infection with strain QZ-07, as shown in Figure 2.","In the laboratory, pig hyperimmune serum was previously prepared and stocked for the CSFV vaccine C-strain. To induce pig antiserum to either the C-strain or the strain QZ-07, 30-day-old CSFV-free pigs were immunized intramuscularly using a prime-boost strategy with the attenuated vaccine C-strain or infected with 10 5 TCID50 of strain QZ-07 in a biosafety level III facility. At various times after vaccination or infection, sera were collected and stored at -80掳C until use. In Figure 3A, 3B, 5A, and 5B, the highest titers of collected sera at 78 days post immunization with the C-strain and 25 days post infection with strain QZ-07 were used for binding ELISAs and Western blots, as shown in Figure 2.","The laboratory had previously prepared pig hyperimmune serum for the CSFV vaccine C-strain, which was stored for use. Pig anti-C-strain or pig anti-QZ-07 was obtained by intramuscular immunization of 30-day-old pigs that were free of CSFV with the attenuated vaccine C-strain using a prime-boost strategy or infection with 10 5 TCID50 of strain QZ-07 in a biosafety level III facility, respectively. The sera were collected at several different times after vaccination or infection and then stored at -80掳C until they were needed. In Figure 3A, 3B, 5A, and 5B, the highest titers of collected sera at 78 days post-immunization with the C-strain and 25 days post-infection with strain QZ-07 were used for binding ELISAs and Western blots, as shown in Figure 2."
"To produce rabbits' antiserum targeting the C-strain rE2-AD protein, New Zealand white rabbits were subjected to a series of immunizations and booster shots. Purified rE2-AD protein of C-strain, expressed in E. coli, was mixed with an equal volume of complete/incomplete Freund's adjuvant (Sigma-Aldrich) before administration. Antibody production was monitored, and once it reached a maximum level, rabbits were bled to prepare the antiserum.","The rabbit antiserum for rE2-AD protein of C-strain was produced by immunizing New Zealand white rabbits with purified rE2-AD protein of C-strain expressed in E. coli. The protein was emulsified with complete/incomplete Freund's adjuvant (Sigma-Aldrich), and the rabbits received two booster shots after the initial immunization. They were bled once maximum antibody production was achieved for antiserum preparation.","The rabbit antiserum against the rE2-AD protein of C-strain was generated by immunizing New Zealand white rabbits multiple times. First, rabbits were immunized with purified rE2-AD protein of C-strain expressed in E. coli mixed with complete/incomplete Freund's adjuvant (Sigma-Aldrich). After two booster shots, blood was collected from the rabbits when the maximum level of antibody production was reached to prepare antiserum."
"To develop a set of monoclonal antibodies that target the rE2-AD protein of C-strain, a series of experimental steps were taken. Specifically, 5-week-old female specific-pathogen-free BALB/c mice were immunized subcutaneously with 0.1 mg of the purified rE2-AD protein emulsified in complete Freund's adjuvant. Following this, the mice were intraperitoneally boosted twice with rE2-AD protein emulsified in incomplete Freund's adjuvant at 2-week intervals. Two weeks after the last boosting, spleen cells were harvested from the euthanized mice, and splenocytes were fused with SP2/0 myeloma cells with the aid of PEG. Detection of hybridomas that secrete antibodies against rE2-AD protein was done using immunofluorescence assay (IFA), and the selected hybridomas were clonally expanded. Mouse mAb Isotyping Reagents from Sigma-Aldrich was used for antibody subtyping. Ascites production was achieved by the use of pristine-primed BALB/c mice. Approval of animal welfare ethics was necessary and was conducted by the Laboratory Animal Management Committee.","In order to obtain monoclonal antibodies that specifically target the rE2-AD protein of C-strain, female BALB/c mice that were 5 weeks old and specific-pathogen-free were immunized subcutaneously with 0.1 mg of the purified rE2-AD protein of vaccine C-strain, which was emulsified in complete Freund’s adjuvant. They were then administered two intraperitoneal boosts of the rE2-AD protein in incomplete Freund's adjuvant, spaced two weeks apart. Spleen cells were harvested from the mice and their splenocytes were fused with SP2/0 myeloma cells using polyethylene glycol. Hybridomas secreting antibodies against rE2AD protein were identified and selected by an immunofluorescence assay. These were then expanded clonally. Antibody subtyping was performed using Sigma-Aldrich's mouse mAb Isotyping Reagents in accordance with the manufacturer's instructions. Ascites were generated by using pristine-primed BALB/c mice. Approval for animal experiments was granted after the protocol was reviewed by and received approval from the Laboratory Animal Management Committee, which is responsible for ensuring the ethical treatment of animals.","The production of monoclonal antibodies targeting the rE2-AD protein of C-strain was conducted as follows. A group of female specific-pathogen-free BALB/c mice aged 5 weeks received subcutaneous immunization of 0.1 mg purified rE2-AD protein of vaccine C-strain, which was emulsified in complete Freund's adjuvant. Following this, the mice were boosted twice intraperitoneally with the protein, which was emulsified in incomplete Freund’s adjuvant at 2-week intervals. Two weeks after the final boosting, the mice were euthanized, and their spleen cells were collected. These spleen cells were then fused with SP2/0 myeloma cells using 50% polyethylene glycol. The hybridomas producing antibodies against rE2AD protein were selected using immunofluorescence assay (IFA) and clonally expanded. Mouse mAb Isotyping Reagents from Sigma-Aldrich was used to subtype the resulting antibodies based on the manufacturer's instructions. To produce ascites, pristine-primed BALB/c mice were employed. The Laboratory Animal Management Committee approved animal welfare ethics before animal experiments were conducted."
"'In order to investigate the antigenic units identified by mAbs, modifications were made to the cysteine codons of the E2 gene from the C-strain using eukaryotic expression plasmid by implementing site-specific mutagenesis, as had been described before [22].'","'To pinpoint the antigenic components recognized by mAbs, the cysteine codons of the E2 gene from the C-strain were transformed to serine codons with the help of site-directed mutagenesis through eukaryotic expression plasmid, which had been previously explained [22].'","'For the purpose of identifying the antigenic units detected by mAbs, the cysteine codons present in the E2 gene from the C-strain were subject to site-directed mutagenesis, which changed them to serine codons in eukaryotic expression plasmid as previously outlined [22].'"
"Identification of variable residues in the antigenic units was done through multiple E2 sequence alignment. As a result, 20 major variable residues were detected (as shown in Table 3). However, KtoR or StoT substitutions (K720R, K734R, K761R, S797T, and R845K substitutions) were not included. To substitute residues from C-strain for the ones present in group 2 isolates, encoding of individual mutations was carried out using plasmids generated by site-directed mutagenesis. Depending on where the residue to be substituted is located in the antigenic units, either antigenic unit B/C or two units (B/C+A/D) of C-strain E2 protein was utilized.","The technique of multiple E2 sequence alignment was employed to detect variable residues, and it was observed that 20 major variable residues were present in the antigenic units (listed in Table 3). However, KtoR or StoT substitutions (K720R, K734R, K761R, S797T, and R845K substitutions) were neglected. Site-directed mutagenesis was used to generate plasmids encoding individual mutations (mentioned in Table 3) to make substitutions of C-strain residues for the ones seen in group 2 isolates. Either antigenic unit B/C or two units (B/C+A/D) of C-strain E2 protein were used for substitutions depending on the localization of the residue being replaced in the antigenic units.","Variable residues were identified through E2 sequence alignment, and it was found that there were 20 such residues present in the antigenic units (as indicated in Table 3). However, KtoR or StoT substitutions (K720R, K734R, K761R, S797T, and R845K substitutions) were excluded from this analysis. Plasmids encoding individual mutations (displayed in Table 3) were generated via site-directed mutagenesis to substitute C-strain residues with those found in group 2 isolates. Depending on the location of the residue being substituted in the antigenic units, either antigenic unit B/C or two units (B/C+A/D) of C-strain E2 protein were targeted for the substitution."
"The entire process of substituting was carried out under the guidance of the manufacturer's instructions, using the QuikChange Site-Directed Mutagenesis Kit (Stratagene CA, USA). The QuikChange Primer Design Program available on http://www.stratagene.com was utilized for designing the primers. Each nucleotide change in the mutants was verified by sequencing. The production and clarification of variant rE2 proteins were carried out as stated earlier.","All substitutions were completed by making use of the QuikChange Site-Directed Mutagenesis Kit developed by Stratagene CA, USA under the guidance of the manufacturer's instructions. The primers used in this process were planned using the QuikChange Primer Design Program, which is found at http://www.stratagene.com. Sequencing was used to verify the desired nucleotide alterations in each mutant. The fabrication and clarification of the variant rE2 proteins were accomplished following the same process as described earlier.","The QuikChange Site-Directed Mutagenesis Kit manufactured by Stratagene CA, USA was utilized to perform all substitutions following the manufacturer's given protocol. The primers were prepared using the QuikChange Primer Design Program accessed through http://www.stratagene.com. Validation of the expected nucleotide modifications in each mutant was done by sequencing. The production and purification of the altered rE2 proteins were accomplished in the same manner as previously mentioned."
"The ELISAs performed in this investigation were executed with strict adherence to specific conditions to prevent the occurrence of non-specific reactions. Antibodies were diluted in a mixture of 5% nonfat dry milk and phosphate-buffered saline (PBS) and washed with PBS containing 0.5% Tween 20 during each washing step. In brief, 100 渭l of various rE2 proteins was inoculated to each well of 96-well microtiter plates, then allowed to incubate overnight at 4掳C. Following that, the wells were cleaned using PBS/Tween, confined with PBS/NFDM, and incubated with different antibodies. After that, it was incubated with a horseradish peroxidase conjugated SPA and the chromogenic substrate 3,3',5,5'-tetramethylbenzidine (TMB, Sigma-Aldrich) at 37掳C for 4 minutes. The reaction was halted by the addition of 50 渭l of 2 M H2SO4. Finally, the OD450nm was measured using spectraMax @M2 microplate reader manufactured by Molecular devices Corp.","To ensure the reliability of the results and avoid any non-specific reactions, all ELISAs described in the study were conducted under stringent conditions. Antibodies were diluted with phosphate-buffered saline (PBS) and 5% nonfat dry milk, and all washing steps were carried out using PBS containing 0.5% Tween 20. 100 渭l of different rE2 proteins were then added to each well of the 96-well microtiter plates and incubated overnight at 4掳C. After washing with PBS/Tween, the wells were blocked with PBS/NFDM for 2 hours at 37掳C. Following this, the wells were incubated with various antibodies for an hour before being incubated with horseradish peroxidase conjugated SPA for another hour. The chromogenic substrate 3,3鈥,5,5鈥-tetramethylbenzidine (TMB, Sigma-Aldrich) was then added to each well and incubated at 37掳C for four minutes while the reaction was allowed to proceed. This was terminated with the addition of 50 渭l of 2 M H2SO4, and the OD450nm was measured using a Molecular devices Corp. spectraMax @M2 microplate reader.","Nonspecific reactions were avoided during the ELISAs conducted in this study by following stringent procedures. The antibodies were mixed with 5% nonfat dry milk and phosphate-buffered saline (PBS), which was then used to dilute them. Additionally, during every wash step, the wells were cleaned using a mixture of PBS and Tween 20. Using 96-well microtiter plates, 100 渭l of several different rE2 proteins were added to each well and allowed to incubate overnight at 4掳C. After washing the wells with PBS/Tween, they were blocked with PBS/NFDM at 37掳C for two hours. Various antibodies were then added to each well and left to incubate for an hour before the wells were incubated with horseradish peroxidase conjugated SPA for a further hour. The reaction was then allowed to proceed for four minutes after the chromogenic substrate 3,3鈥,5,5鈥-tetramethylbenzidine (TMB, Sigma-Aldrich) was added to each well and incubated at 37掳C. The reaction was stopped with 50 渭L of 2 M H2SO4. Finally, a Molecular devices Corp. spectraMax@M2 microplate reader was used to measure the OD450nm."
"The rE2-AD proteins from both the C-strain and 8 subgroup 2.1 strains were tested for their binding efficacy with two pig antisera. The normalization of the binding efficiency was performed in reference to anti-His-tag binding, and the outcome was expressed as the percentage of antibody attached to individual group 2 rE2-AD protein to that of C-strain or strain QZ-07. The value was set at 100%. The mean binding efficiency of each protein was calculated based on three independent ELISA assays.",A comparative study was conducted on the binding potential of rE2-AD proteins from the C-strain and 8 subgroup 2.1 strains with two pig antisera. Normalization of the binding efficiency was achieved with reference to anti-His-tag binding and expressed as a ratio of antibody bound to individual group 2 rE2-AD protein to that bound to the rE2-AD proteins of C-strain or strain QZ-07 set at 100%. The mean binding efficiency for each protein was calculated for three independent ELISA assays to determine the efficiency.,"The binding efficacy of rE2-AD proteins from C-strain and 8 subgroup 2.1 strains were measured by testing them with two different pig antisera. The binding efficiency was initially normalized with reference to anti-His-tag binding and then represented as the proportion of antibody bound to each group 2 rE2-AD protein to that of C-strain or strain QZ-07, set at 100%. The average binding efficiency of each individual protein was determined based on three independent ELISA assays."
"The C-strain rE2 proteins in Figure 5A underwent substitutions with rE2-BC and rE2-AD proteins for different residues based on their location in the antigenic units B/C and A/D, respectively. The experiments measured the binding efficiency of these variant proteins to antibodies and were normalized to anti-His-tag binding, and then the results were expressed relative to their binding to C-strain wild type rE2-BC or rE2-AD binding to the reference serum depending on the type of variant protein. The antibody binding was categorized as significant, moderate, or limited based on the efficiency between certain ranges.","To determine the effect of substitutions on the C-strain rE2 proteins in Figure 5A, rE2-BC and rE2-AD proteins were employed. For substitutions in the antigenic unit B/C, the rE2-BC proteins were used, and for substitutions in the antigenic unit A/D, rE2-AD proteins were used. The results were measured based on the binding efficiency of these variant proteins to antibodies relative to their binding to C-strain wild type rE2-BC or rE2-AD binding to the reference serum, respectively. The experiments were normalized to anti-His-tag binding. The antibody binding efficiency was determined and was classified into significant, moderate, or limited effect based on their efficiency ranges.","Figure 5A shows the C-strain rE2 proteins that were substituted with rE2-BC and rE2-AD proteins to investigate the effects of different residues on the antigenic units B/C and A/D. The binding efficiency of the variant proteins to antibodies was measured using anti-His-tag binding normalization, and then the results were expressed in relation to their binding to C-strain wild type rE2-BC or rE2-AD binding to the reference serum. The binding efficiencies observed were classified into three categories based on their ranges. Relative binding of greater than 200% was considered significant increases in antibody binding, while binding efficiencies between 150% and 200% were considered moderate increases, and those between 50% and 150% were considered to have limited effects on antibody binding."
"Western blotting was utilized to examine the antigenic reactivity of distinct rE2 proteins. The proteins were separated utilizing 15% SDS-PAGE and then shifted to nitrocellulose membranes. To prevent nonspecific bindings, the membranes were blocked overnight at 4掳C with blocking buffer (PBS/NFDM) and then incubated at 37掳C for one hour with distinct antibodies. Thereafter, the membranes were washed with PBS/Tween for 20 minutes to remove any unbound antibodies, and subsequently with SPA-conjugated with horseradish peroxidase diluted at 1:2500 was used to detect the bound antibodies. Lastly, the color development was achieved using 4-chloro-1-naphthol (4-CN, SigmaAldrich).","The antigenic reactivity of different rE2 proteins was analyzed using Western blotting. After separating the proteins with a 15% SDS-PAGE, they were relocated to nitrocellulose membranes purchased from PALL Corp., USA. Following an overnight block at 4掳C with blocking buffer (PBS/NFDM), the membranes were incubated at 37掳C for one hour with a range of antibodies. Subsequently, the membranes were washed for 20 minutes in PBS/Tween to eliminate any unbound antibodies, and the bound antibodies were then observed using SPA-conjugated with horseradish peroxidase that was diluted at 1:2500. 4-chloro-1-naphthol (4-CN, SigmaAldrich) was employed for developing color at the end of the process.","In this study, Western blotting was conducted to assess the antigenic reactivity of various rE2 proteins. The proteins were meticulously separated using 15% SDS-PAGE and then shifted onto nitrocellulose membranes, obtained from PALL Corp., USA. Subsequently, the membranes were blocked with blocking buffer (PBS/NFDM) for an overnight period at 4掳C to prevent any nonspecific bindings. The following day, the membranes were incubated with diverse antibodies at 37掳C for one hour. The incubated membranes were then washed in PBS/Tween for 20 minutes, and the SPA-conjugated with horseradish peroxidase was diluted by 1:2500 to detect the bound antibodies. In the end, 4-chloro-1-naphthol (4-CN, SigmaAldrich) was applied to facilitate color development."
"The study evaluated the efficacy of a new drug compound in reducing tumor growth in mice. A total of twenty-four mice were randomized into two groups: one group received the drug compound, and the other group received a placebo. The drug was administered via intraperitoneal injection once daily for fourteen days. After fourteen days, the tumor volume was measured, and the results showed that the mean tumor volume of the drug-treated group was significantly smaller than the placebo-treated group. No significant differences were observed in body weight changes between the two groups during the study duration. These findings suggest that the new drug compound may hold promise as a potential treatment for tumor growth.","The research investigated the effect of aerobic exercise on blood pressure levels in adults. Participants were randomly assigned to an exercise group or a control group. The exercise group performed moderate intensity aerobic exercise for thirty minutes, three days a week for eight weeks. The control group maintained their usual lifestyle but did not perform any regular exercise. The results showed that the exercise group had significant decreases in systolic blood pressure compared to the control group. Interestingly, no significant changes were observed in diastolic blood pressure between the two groups. These findings suggest that moderate intensity aerobic exercise can be effective in reducing systolic blood pressure in adults.","The study aimed to explore the relationship between social media use and mental health outcomes in young adults. A total of 300 participants aged between 18 to 25 years old were recruited through social media platforms. They were asked to complete a survey that assessed their social media use, depression level, anxiety level, and self-esteem. Results showed that individuals who reported higher levels of social media use were more likely to experience symptoms of depression and anxiety, and have lower levels of self-esteem. Furthermore, participants who compared themselves to others on social media had poorer mental health outcomes than those who did not make such comparisons. Overall, this study suggests that excessive social media use and comparison behaviors may be detrimental to young adults' mental health."
"The IFA technique was utilized to validate the responsiveness of the CSFV strains or cysteine-mutated E2 proteins to diverse antibodies. Essentially, cells were either infected with CSFV strains at 72 h or transfected with cysteine-mutated recombinant plasmids at 48 h followed by fixation with 3.7% paraformaldehyde at room temperature for 60 min and permeabilization in PBS using 0.1% Triton X-100 for 10 min. Further, cells were incubated for 1 h with various antibodies and then stained using goat anti-rabbit antibody conjugated with Texas green or goat antimouse antibody conjugated with Alexa red (Molecular Probes Inc., USA) for another 1 h. Finally, cell examination was done under the IX71 inverted fluorescence microscope from Olympus, Japan.","To verify the reactivity of CSFV strains or cysteine-mutated E2 proteins with different antibodies, the IFA method was utilized. Briefly, cells that were either infected with CSFV strains at 72 h, or transfected with cysteine-mutated recombinant plasmids at 48 h were fixed using 3.7% paraformaldehyde at room temperature for 60 min, and then permeabilized with 0.1% Triton X-100 in PBS for 10 min. After that, the cells were incubated with diverse antibodies for 1 h, and then stained with goat anti-rabbit antibody-conjugated Texas green, or goat anti-mouse antibody-conjugated Alexa red from Molecular Probes Inc., USA for another 1 h. The IX71 inverted fluorescence microscope from Olympus, Japan was used to investigate the cells after this process.","To assess the reactivity of the CSFV strains or cysteine-mutated E2 proteins to different antibodies, IFA was implemented. In short, cells infected with CSFV strains at 72 h or transfected with cysteine-mutated recombinant plasmids at 48 h were fixed with 3.7% paraformaldehyde at room temperature for 60 min, and then permeabilized for 10 min with 0.1% Triton X-100 in PBS, following which they were incubated with different antibodies for 1 h. Goat anti-rabbit antibody conjugated with Texas green or goat anti-mouse antibody conjugated with Alexa red from Molecular Probes Inc., USA were then used to stain the cells for a further hour. Finally, the cells were examined using an IX71 inverted fluorescence microscope from Olympus, Japan."
"The DNASIS software was used to generate the hydrophobicity profile with the guidance of the Kyte and Doolittle method [44]. Following this, for the evolution analysis, the information-theoretic method developed by Plotkin and Dushoff [41] was applied. In this method, a plot was created demonstrating the diversity of amino acids and codons present in each residue. To calculate the diversity, a modified Simpson's index, D = 1-pi2, was used, where pi represents the relative frequency of an amino acid or codon in the residue's multiple sequence alignment.","Using DNASIS software, the Kyte and Doolittle method [44] was followed to generate the hydrophobicity profile. To carry out the evolution analysis, the information-theoretic method elaborated by Plotkin and Dushoff [41] was implemented, wherein a graph was produced portraying the diversity of codons and amino acids found at each residue. A variant Simpson's index, D = 1-pi2, was employed to evaluate the diversity of codons and amino acids, with pi indicating the relative frequency of the i-th codon or amino acid in the multiple sequence alignment at the residue.","The hydrophobicity profile was generated by the Kyte and Doolittle method [44], using the DNASIS software. The evolution analysis, on the other hand, was performed utilizing Plotkin and Dushoff's [41] information-theoretic method. The diversity of codons and amino acids found at each residue was evaluated by plotting a graph with the D value, representing a variant Simpson's index, which was calculated using the relative frequency pi of the i-th codon or amino acid in the residue's multiple sequence alignment."
"Breast cancer is a complex disease with a multifactorial etiology. While genetic factors play a role, non-genetic factors are equally important. The recent advancements in genome-wide association studies have identified several common genetic susceptibility variants that have a potential role in breast cancer development. These variants are mostly single nucleotide polymorphisms (SNPs) that are located in specific genes or chromosomes. Among the SNPs that have been identified, CASP8 had the strongest association with breast cancer risk. However, there is still some controversy surrounding the impact of SNPs in other genes and chromosomes, such as TGFB1 and ESR1, on breast cancer susceptibility.","The development of breast cancer is a complex interplay between genetic and non-genetic factors. Recent genome-wide association studies have identified several common genetic susceptibility variants that are associated with breast cancer. These variants primarily consist of single nucleotide polymorphisms (SNPs) located at specific genes, including FGFR2, LSP1, MAP3K1, TOX3, MRPS30, COX 11, SLC4A7, and at chromosomes 8p24 and 2q35 [1-5]. Among these, the SNP at CASP8 has been the most strongly associated with breast cancer risk. While evidence for the impact of SNPs in other genes such as TGFB1 and ESR1 is more equivocal, these genes may still play a role in breast cancer susceptibility. Ultimately, further research is needed to fully elucidate the complex genetics underlying breast cancer development.","Breast cancer is a malignancy that results from a combination of genetic and environmental factors. Genetic susceptibility is thought to be responsible for some cases of breast cancer. The identification of common genetic susceptibility variants, such as single nucleotide polymorphisms (SNPs) located in specific genes and chromosomes, has been the focus of recent genome-wide association studies. Notably, the SNP at CASP8 has been linked with increased breast cancer risk. However, the association of SNPs in other genes and chromosomes, including TGFB1 and ESR1, is still uncertain. As such, research into the genetic basis of breast cancer continues to be an area of intense study."
"It is crucial to evaluate the interaction between common SNPs and other known risk factors in determining breast cancer risk. Some of these risk factors include age at menarche, parity, age at first birth, and body mass index (BMI) [8,9]. This knowledge can be leveraged to improve risk prediction models [10,11]. Understanding the modifications of SNP associations by other risk factors can give insight into the biological mechanisms by which genetic variations are implicated in breast cancer etiology. In addition, it has been observed that many of these SNPs and risk factors have varying associations with estrogen receptor (ER)-positive and ER-negative disease [1,4,5,7,12,13], and these interactions may also display differences depending on the disease subtype.","To improve risk prediction models, it is crucial to examine how common SNPs interact with other established risk factors such as age at menarche, parity, age at first birth, and body mass index (BMI) [8,9] to determine breast cancer risk. Furthermore, investigating the modifications of SNP associations by other risk factors can bring to light the biological mechanisms involved in genetic variations and their relation to breast cancer etiology. These associations and risk factors have been demonstrated to have varying effects on estrogen receptor (ER)-positive and ER-negative disease [1,4,5,7,12,13], and the interplay between these factors may differ by subtype.","Evaluating how common SNPs combine with other established risk factors such as age at menarche, parity, age at first birth, and body mass index (BMI) [8,9] can help predict breast cancer risk and improve risk prediction models [10,11]. By studying the modifications of SNP associations by other risk factors, researchers can get deeper insights into the biological mechanisms that govern genetic variations and their implications in breast cancer etiology. Since estrogen receptor (ER)-positive and ER-negative diseases have varying associations with these risk factors [1,4,5,7,12,13], it is important to consider the disease subtype while assessing the interaction between these factors."
"Our investigation was primarily focused on determining the role of 12 SNPs in modifying the risks of breast cancer. While 10 of these SNPs were well-known for their association with breast cancer, the remaining two had less clear evidence. We examined the influence of several potential effect modifiers such as age of menarche, live births, and BMI on breast cancer susceptibility. Additionally, we evaluated how these factors interacted with the risk of developing different subtypes of breast cancer, based on their ER and PR statuses. Our study collated data from 21 case-control studies, which involved white women of European ancestry participating in the Breast Cancer Association Consortium (BCAC).","The goal of our study was to investigate the impact of 12 different SNPs on breast cancer risk. Ten of these SNPs had been previously associated with breast cancer, while the remaining two did not have well-established evidence. We analyzed the effect of various potential factors that could modify breast cancer risk, such as age of menarche, number of live births, and BMI. In addition, we examined the interactions of these factors with the risk of developing different subtypes of breast cancer based on their ER and PR statuses. To accomplish this, we compiled data from 21 case-control studies involving white women of European ancestry who participated in the Breast Cancer Association Consortium (BCAC).","The primary objective of our study was to explore the relationship between 12 SNPs and the risk of developing breast cancer. Of these SNPs, 10 were already known to be strongly associated with breast cancer, while the remaining two had less established evidence. We also investigated several potential effect modifiers, including age of menarche, number of live births, and BMI, to understand how these factors correlated with breast cancer risk. Additionally, we evaluated the impact of these factors on the susceptibility to ER and PR subtypes of breast cancer. Our findings were based on the combined data obtained from 21 case-control studies involving white women with European ancestry who participated in the Breast Cancer Association Consortium (BCAC)."
"Table 1 outlines the essential details of the 21 case-control studies that participated in the BCAC analysis together, while Additional Data Table S1 in Additional file 1 provides more detailed information. Out of these studies, 11 were population-based and the rest had at least 1,000 cases and 1,000 controls. The studies collected self-reported information for cases and controls and covered factors such as age at diagnosis, racial or ethnic background, and age at menarche, among others. The time-point of the data collection for each study is provided in Additional Data Table S1. The risk and other lifestyle factors were not available during the analysis except for information on the CNIO-BCS and LMBC studies, which sourced their data from medical records. Medical records were also the primary source of information for tumor status for a subset of cases in 19 studies.","In Table 1, you can find a summary of the 21 case-control studies that collaborated on the BCAC analysis. Additional Data Table S1 in Additional file 1 provides a more comprehensive overview. Out of these studies, 11 were population-based, while the rest involved at least 1,000 cases and 1,000 controls. All studies obtained self-reported data from cases and controls, including details such as age at diagnosis or interview and racial or ethnic background. Additional information collected included age at menarche, ever giving birth, number of live births, and BMI or height and weight. Additional Data Table S1 indicates when each study obtained this information. Except for the CNIO-BCS and LMBC studies, the studies relied entirely on structured questionnaires. Nineteen studies provided data on the tumor's hormone status for a subset of cases, which they obtained from medical records. No additional lifestyle or risk factor data were accessible at the time of analysis.","Table 1 provides a brief summary of the 21 case-control studies participating in the BCAC analysis, while Additional Data Table S1 in Additional file 1 provides more in-depth information. Of the studies included, 11 were population-based, and the others had at least 1,000 cases and 1,000 controls. Self-reported data gathered by collecting cases and controls included age at diagnosis/interview, race/ethnicity, and factors such as age at first period, live birth history, and BMI, or height and weight. Additional Data Table S1 provides information on when the data was gathered for each study. During the analysis, the researchers did not have access to any additional data on lifestyle and risk factors, except for the CNIO-BCS and LMBC studies, for which they used medical records as a data source. Nineteen studies included data on the ER and PR status of the tumors for some of the cases. Mostly, the data was obtained from medical records."
"Different techniques have been used for genotyping, as demonstrated in previous studies. Five research efforts implemented the MassARRAY system and iPLEX technology from Sequenom to study various SNPs, whereas other types of genotyping relied on Taqman® Assays-byDesignSM. It was discovered that SNP CASP8-rs17468277 and CASP8-rs1045485 were in complete linkage disequilibrium and the latter had previously been linked to breast cancer. Quality control measures were undertaken, including inclusion of a blank well per assay plate, duplicates of at least 2% of the samples, and a common set of 93 Centre d’Etude Polymorphisme Humain (CEPH) samples that were utilized by the HapMap Consortium. The call rates and duplicate concordance rates were examined and any samples that repeatedly failed were excluded, but both rates were over 95%. The concordance with CEPH genotypes was found to be greater than 98%.","Several methods have been described in previous studies for genotyping purposes. Most SNPs in five research efforts (ABCFS, GENICA, kConFab/AOCS, MARIE, and SASBAC) used Sequenom's MassARRAY system and iPLEX technology from Sequenom, while Taqman® Assays-byDesignSM was employed for other genotyping. Results showed that SNP CASP8-rs17468277 and CASP8-rs1045485 were in complete linkage disequilibrium and the latter was linked to breast cancer. To ensure reliability, measures such as including a blank well per assay plate, duplicates of at least 2% of all samples, and a common set of 93 CEPH samples from the HapMap Consortium were taken. Samples that repeatedly failed were removed, and the call rates and duplicate concordance rates calculated were over 95%. Concordance with CEPH genotypes was greater than 98%.","Genotyping methods have been described in previous studies, with five research projects employing Sequenom's MassARRAY system and iPLEX technology for most SNPs and Taqman® Assays-byDesignSM for other types of genotyping. The study found that CASP8-rs17468277 SNP was in complete linkage disequilibrium with CASP8-rs1045485 that had previously been linked to breast cancer. Quality control was maintained by using a blank well per assay plate, duplicates of at least 2% of the total samples, and 93 common CEPH samples from the HapMap Consortium. The call rates and duplicate concordance rates were greater than 95%, whereas the concordance with CEPH genotypes was over 98%."
"The study conducted a genetic association analysis on 12 SNPs using logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CI) for the risk allele, which was assumed to have multiplicative per-allele effects, in line with what was previously reported. Logistic regression was also employed to determine the main effects of various risk factors on the 11 population-based studies while taking into account age (categorical and continuous) and study (categorical). Risk factors like age at menarche (categorical and continuous), live birth history (yes or no), number of live births (categorical and continuous), age at first birth (categorical and continuous), and BMI (categorical and continuous) were evaluated.","To evaluate genetic associations, the study employed logistic regression analysis on each of the 12 SNPs, estimating the odds ratio (ORs) and 95% confidence intervals (CIs) of the risk allele, assuming multiplicative per-allele effects (as reported in the literature). For the main effects, logistic regression was used only on the 11 population-based studies, considering factors like age (categorical and continuous) and study (categorical). Age at menarche (categorical and continuous), live birth history (yes or no), the number of live births (categorical and continuous), age at first birth (categorical and continuous), and BMI (categorical and continuous) were the risk factors assessed.","The study analyzed the genetic associations of 12 SNPs using logistic regression to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) of the risk allele while assuming multiplicative per-allele effects based on previous literature (refer to Table 2). For the main effects, logistic regression was performed on the 11 population-based studies, with adjustments made for age (categorical and continuous) and study (categorical). Risk factors evaluated include age at menarche (categorical and continuous), live birth history (yes or no), number of live births (categorical and continuous), age at first birth (categorical and continuous), and BMI (categorical and continuous)."
"The study has considered the link between BMI and breast cancer risk separately for premenopausal (below 55 years) and postmenopausal women (55 years and above) since there is different evidence supporting positive and negative associations for these two populations. Using appropriate categorical variables, logistic regression models were generated to examine the effects of risk factors and SNPs on breast cancer incidence. Alternative age limits for the premenopausal category, such as 50 years, were tested, but no substantial differences were found in the resulting estimates.","To account for the differing associations between BMI and breast cancer risk in premenopausal and postmenopausal women, the study analyzed the impact of BMI on breast cancer separately for women aged below 55 (premenopausal) and women aged 55 and above (postmenopausal). Using relevant dummy variables and controlling for other risk factors, the study was able to estimate the per-allele odds ratios (ORs) for SNPs in each of these two age categories. Although the option of using 50 years as the cut-off for premenopausal status was explored, it did not change the results in any meaningful way.","BMI has been implicated in both the elevated and reduced risk of breast cancer in postmenopausal and premenopausal women, respectively. To explore these mixed associations and classify participants according to their menopausal status, the study used age categories of below and above 55 years for premenopausal and postmenopausal women, respectively. Subsequently, a logistic regression model was used to derive per-allele odds ratios (ORs) stratified by BMI, together with other risk factors as covariates in the models. Additional analyses using different age limits for premenopausal status, such as 50 years, yielded comparable findings with the primary analysis."
"Researchers analyzed the association between genetic risk factors and other potential risk factors for a specific disease. They used logistic regression models to assess the interaction or adjustment of genetic associations by these risk factors. The models included a dummy variable for the study, one parameter for the main per-risk-allele effect, and another for the main risk factor effect. Additionally, a single interaction term was included in each model to account for the number of risk alleles and the value of the risk factor. Through a likelihood ratio test, the researchers compared the model with and without the interaction term. The effect modification by BMI was also evaluated separately for two different age groups of women.","To examine the interplay of a genetic risk factor and other risk factors, researchers implemented logistic regression models. These models involved dummy variables for the study, alongside three parameters. One parameter accounted for the per-risk-allele effect, the second for the primary risk factor effect, and the third for the interaction of the number of risk alleles and the value of the risk factor. The models were tested statistically by comparing the version containing the interaction term to the version without it using a likelihood ratio test. To assess whether BMI resulted in effect modification, researchers analyzed separately women who were above 55 years and those who were not.","Scientists aimed to evaluate the possible modification of genetic associations caused by other risk factors. After analyzing each SNP/risk factor combination using logistic regression models, they included dummy variables for the study, one parameter for the main per-risk-allele effect, and one parameter for the main risk factor effect, with a single interaction term. The interaction term was used to observe the effect of the number of risk alleles multiplied by the risk factor value. Then, they compared this model to that without the interaction term by running a likelihood ratio test. Effect modification of BMI was determined by analyzing separately women who were younger than 55 and those who were older."
"A statistical test known as parametric bootstrap was adopted to estimate interaction P-values adjusted for multiple testing. For every one of the 72 interactions tested, individuals鈥 likelihood of having the condition were measured based on a logistic regression model incorporating only primary effects. Elements such as study (categorized), SNP (per-allele), and risk factor (continuous, except ever having had a live birth) were all considered. Each time the parametric bootstrap was replicated, a fake case-control status was generated for everyone by sampling from a binomial distribution founded on the estimated likelihood of having the condition. A minimum P-value was noted for every one of the 10,000 replicates, and adjusted P-values were determined by fraction of replications with P-value less than or equal to the corresponding unadjusted P-value. [15]","Adjusted interaction P-values were estimated using a parametric bootstrap test to account for multiple testing [15]. The probability of having the condition for each individual was assessed for each of the 72 interactions by applying a logistic regression model that only included main effects such as study (categorical), SNP (per-allele), and risk factor (continuous, except ever having had a live birth). For each iteration of the bootstrap, a simulated case-control status was generated for each individual based on their probability of having the condition, and the interaction model was fit to the actual data and the dummy case-control status. The likelihood ratio test P-value was then calculated for each iteration and the adjusted P-values were calculated as the proportion of iteration P-values that were smaller than the corresponding unadjusted P-value. The minimum P-value was recorded for each of the 10,000 bootstrap replications.","To account for multiple testing, a parametric bootstrap test was employed to estimate interaction P-values [15]. The likelihood of having the condition for each subject under the null hypothesis of no interaction was calculated for each of the 72 interactions tested, using a logistic regression model that included only the main factors: study (categorical), SNP (per-allele), and risk factor (continuous, except ever having had a live birth). Each bootstrap included 10,000 iterations, with a simulated case-control status generated for each subject based on their likelihood of having the condition. The interaction model was then fitted to the actual data and the dummy case-control status, and the likelihood ratio test P-value was computed for each iteration. The minimum P-value was recorded for each bootstrap, and the adjusted P-values were determined as the proportion of bootstrap P-values that were smaller than the corresponding unadjusted P-value."
"Statistically significant results were obtained by performing all the analyses with Stata: Release 10 (Statacorp, College Station, TX, USA) [16], excluding power calculations, which were executed using Quanto (University of Southern California, Los Angeles, CA, USA) [17,18].","The utilization of Stata: Release 10 (Statacorp, College Station, TX, USA) [16] was done for all statistical analyses, except for the power calculations, which were performed with Quanto (University of Southern California, Los Angeles, CA, USA) [17,18]. The outcomes were found to be statistically significant.","Using Stata: Release 10 (Statacorp, College Station, TX, USA) [16], all statistical analyses were conducted, with the exception of power calculations, which were accomplished using Quanto (University of Southern California, Los Angeles, CA, USA) [17,18]. The results were deemed to be statistically important."
"The study gathered data from 21 different studies involving 26,349 cases and 32,208 controls. All of the participants belonged to white European ethnicity and reported their race. The available data of at least one of the 12 SNPs and other risk factors were used in the study. Out of the total population, 17,603 cases were interviewed within two years of their breast cancer diagnosis along with 29,187 controls. Among them, approximately 46% of cases and 38% of controls were below the age of 55 years. The study also recorded the ER and PR statuses for 19,561 and 16,962 cases, respectively. The study details are given in Table 1. Moreover, 11 population-based studies contributed 12,822 cases and 19,703 minimal data controls, while seven studies with 1,000 or more cases and controls contributed 16,107 cases and 23,140 minimal data controls.","The study utilized data from 21 different studies with a total of 26,349 cases and 32,208 controls. All the participants belonged to self-reported white European race/ethnicity and had at least one of the 12 SNPs data and one of the other risk factors data available. Out of this population, 17,603 cases were interviewed within two years of their breast cancer diagnosis, whereas the 29,187 controls came from the same 18 studies. Among these, 46% of cases and 38% of controls were under the age of 55 years when interviewed. The study also recorded the ER and PR statuses for 19,561 and 16,962 cases, respectively. The Table 1 provides the detailed information about the study. The study included 12,822 cases and 19,703 controls with minimal data from eleven population-based studies and 16,107 cases and 23,140 controls with minimal data from seven studies with a minimum of 1,000 cases and 1,000 controls.","The present study utilized data from 21 different studies and involved 26,349 cases and 32,208 controls belonging to self-reported white European race/ethnicity. The study included at least one of the 12 SNPs data and one of the other risk factors data for all participants. The data was collected from participants in different studies. The study conducted interviews with 17,603 cases within two years of their breast cancer diagnosis and 29,187 controls from the same 18 studies. 46% of cases and 38% of controls were under the age of 55 years at the time of diagnosis and interview. The study also recorded information on the ER and PR statuses of 19,561 and 16,962 cases, respectively. The Table 1 provides detailed information about the study. The study included 12,822 cases and 19,703 controls with minimal data from eleven population-based studies and 16,107 cases and 23,140 controls with minimal data from seven studies with at least 1,000 cases and 1,000 controls."
"Upon limiting the analyses to population-based studies, the risk factors revealed anticipated associations with breast cancer, with an exception. After considering age and study, there was a 4% (95% CI = 2 to 5%) decrease in breast cancer risk with every one-year increase in the age at menarche. Parous women, on the other hand, had a 16% (95% CI = 10 to 22%) decreased risk. An 11% (95% CI = 8 to 13%) lowered risk was associated with each additional live birth among parous women, but a 7% (95% CI = 4 to 10%) increased risk was observed with every five-year growth in the age at first birth. It was found that among women under 55 years old, obesity (BMI鈮30.0 kg/m2) corresponds to a 20% (95% CI = 10 to 29%) decrease in breast cancer risk. Surprisingly, there was no association between obesity and breast cancer risk among women aged 55 years and older (OR = 0.96, 95% CI 0.88 to 1.04).","Upon analysis of population-based studies, the anticipated relationship between breast cancer and the risk factors was established, with an exception present. Generally, every one-year increase in age at menarche led to a 4% (95% CI = 2 to 5%) reduction in breast cancer risk upon controlling for age and study. Parity was linked to a 16% (95% CI = 10 to 22%) lowered risk for breast cancer. However, each additional live birth brought about an 11% (95% CI = 8 to 13%) decreased risk among parous women, while every five-year delay in age at first birth demonstrated a 7% (95% CI = 4 to 10%) increased risk. Women under the age of 55 categorised as obese and with a BMI of 鈮30.0 kg/m^2 were 20% less likely (95% CI = 10 to 29%) to have breast cancer. Unexpectedly, no association was observed between obesity and breast cancer risk in women aged 55 and above (OR = 0.96, 95% CI 0.88 to 1.04).","The analysis of population-based studies established an expected link between the risk factors and breast cancer. One exception was identified. After the adjustment for age and study, a decrease of 4% (95% CI = 2 to 5%) in breast cancer risk was associated with every one-year rise in the age at menarche. Furthermore, the study found that parous women had a 16% (95% CI = 10 to 22%) lower risk. Among parous women, there was an 11% (95% CI = 8 to 13%) lower risk associated with each live birth, but a five-year increase in age at first birth led to a 7% (95% CI = 4 to 10%) higher risk. Surprisingly, the study discovered that obese women with a BMI of 鈮30.0 kg/m^2 below the age of fifty-five were 20% less likely (95% CI = 10 to 29%) to develop breast cancer. However, obesity wasn't related to breast cancer risk in women aged 55 and above (OR = 0.96, 95% CI 0.88 to 1.04)."
"The ORs and their corresponding 95% CIs for the 12 SNPs investigated in this study are presented in Table 2. The data consists of the ORs and CIs for all participants with genotype information and for subgroups of women based on the four risk factors in consideration. The ORs for all groups were adjusted for study, while those for the subsets were adjusted for age and the relevant risk factor. Both the overall ORs and those for the subsets were alike. This indicates that there is no evidence of confounding or bias in the OR estimates due to the risk factors being analyzed or data availability.","In Table 2, the estimated per-allele ORs along with their 95% CIs for 12 SNPs evaluated in this study have been presented. These estimates were reported for all subjects with genotype data available as well as for further subsets of women with data on the four risk factors under consideration. All ORs were made study-adjusted and subsets were further adjusted for age and relevant risk factors. Both overall and subset OR estimates showed no sign of confounding by risk factors or bias in OR estimates on account of data availability.","Table 2 summarizes the estimated per-allele ORs and corresponding 95% CIs for the 12 SNPs assessed in this study. The data includes both all subjects with genotype information and subsets of women grouped based on the four risk factors of interest. To adjust for study differences, all ORs were calculated using study-adjusted methods. Additionally, subsets were further adjusted for age and the relevant risk factor. Similar OR estimates were found in both the overall and subset analyses, suggesting no confounding present nor any bias in OR estimates due to the availability of data."
"The majority of SNP/risk factor combinations did not show any significant differences in per-allele OR based on the category of the risk factor. This holds for analyses conducted across various studies, including population-based ones and those with substantial case and control numbers. The analysis conducted on studies with cases interviewed within two years after breast cancer diagnosis yielded results similar to the initial analysis, with no substantial difference observed. Similar null results were found in analyses of ER-positive and ER-negative, as well as PR-positive and PR-negative breast cancer patients. Additional Data Tables S2 to S8 in Additional file 1 provide the detailed findings.","The per-allele OR for the majority of SNP/risk factor combinations did not exhibit any discernible variation with regard to the category of the risk factor involved. This was discovered through a multitude of analyses, such as those based on data from all studies, population-based studies only, and studies that included at least 1,000 cases and 1,000 controls. Analyses focusing on studies with cases interviewed within two years of breast cancer diagnosis also yielded consistent results. Furthermore, null results were observed for analyses conducted on ER-positive and ER-negative, as well as PR-positive and PR-negative breast cancer patients. Additional Data Tables S2 to S8 in Additional file 1 provide more comprehensive information.","Across the majority of SNP/risk factor combinations, there was no significant variation in the per-allele OR based on the risk factor category. These findings remained consistent in analyses conducted on multiple studies, including population-based ones and studies with high case and control numbers. Results obtained from analyses of studies with cases interviewed within two years of breast cancer diagnosis were similar to the initial analysis, with no major differences observed. The null effect was also observed for ER-positive and ER-negative, as well as PR-positive and PR-negative breast cancer patients. Additional Data Tables S2 to S8 in Additional file 1 provide detailed information on the findings."
"A study found that the association between 11p15-rs3817198 (LSP1) and breast cancer risk may be influenced by the number of live births a woman has had. Those who have had at least four live births had a stronger effect than those who had only one. However, there is some uncertainty about these results since multiple tests were done, and the adjusted P-value for the modification of the association was 0.12. The study did not find a significant interaction in ER-negative and PR-negative breast cancer cases, but the trend was noticeable in ER-positive and PR-positive diseases. Although the results need to be interpreted with caution, they point towards a potential relationship between the number of live births and LSP1's effect on breast cancer.","A research study uncovered potential changes in the link between 11p15-rs3817198 (LSP1) and the risk of breast cancer based on a woman's history of live births. Those who had four or more live births showed a higher effect than those with only one, as demonstrated by an increase in the OR estimates from 1.04 to 1.24, respectively. However, while this interaction was noticed in ER-positive and PR-positive breast cancer cases, the results were less significant in ER-negative and PR-negative diseases. Although the study's adjusted P-value for the interaction was 0.12, caution should be taken in interpreting these outcomes as the possibility of chance cannot be ruled out. Nonetheless, these results highlight the need for further research into the association between LSP1 and breast cancer risk in populations of women with diverse numbers of live births.","The number of live births a woman has had may alter the relationship between 11p15-rs3817198 (LSP1) and breast cancer risk, according to a recent study. Women who had four or more live births had a stronger effect than those who only had one, with an increase in OR estimates from 1.04 to 1.24, respectively. However, there is some uncertainty about these findings due to the multiple tests done in the study, and the adjusted P-value for this interaction was 0.12. Although the interaction was significant in ER-positive and PR-positive breast cancer, it was not statistically significant in ER-negative and PR-negative cases. These results should be interpreted with caution, and future research should confirm this potential connection and its implications in women with diverse reproductive histories."
"Through post-hoc power calculations, we were able to determine that our study had a 90% power to detect interaction ORs of at least 1.06 for the loci tested, excluding the CASP8-rs17468277 locus, which had a minimum detectable interaction OR of 1.08. For BMI, a five-unit increase resulted in the study having 90% power to detect interaction ORs of at least 1.08 for the more common variants and 1.10 for the CASP8-rs17468277 locus. Furthermore, for parity, the study had the same power to detect interaction ORs of at least 1.20 for the CASP8-rs17468277 locus and 1.16 for the other loci when examining live birth history.","The post-hoc power calculations revealed that our study was sufficiently powered to detect interaction ORs of at least 1.06 for all loci tested except for the CASP8-rs17468277 locus, where the minimum detectable interaction OR was 1.08. The study had 90% power to detect interaction ORs of at least 1.08 and 1.10 for BMI and the more common variants, respectively. Finally, when examining live birth history, the study had equivalent power to detect interaction ORs of at least 1.20 for the CASP8-rs17468277 locus and 1.16 for the other loci.","Our post-hoc power calculations demonstrated that our study had the power to detect interaction ORs of at least 1.06 for all loci except for the CASP8-rs17468277 locus, for which the minimum OR was 1.08. The minimum detectable interaction ORs for BMI, with a five-unit increase, were 1.08 for the more common variants and 1.10 for the CASP8-rs17468277 locus. Furthermore, our study was able to detect interaction ORs of at least 1.20 and 1.16 for the CASP8-rs17468277 locus and other loci, respectively, when considering live birth history."
"The examination of over 50,000 cases and controls has failed to find conclusive evidence that variables including age at menarche, BMI, age at first birth, or parity alter the established link between genetic variants and breast cancer risk. These variants encompass 5p12-rs10941679, 10q26rs298158 (FGFR2), 8q24-rs13281615, 11p15-rs3817198 (LSP1), 5q11-rs889312 (MAP3K1), 16q12-rs2803662 (TOX3), 2q35-rs13387042, 17q23rs6504950, 3p24-rs4973768, and CASP8-rs17468277. Moreover, there is no evidence that these variables substantially impact potential associations with ESR1rs3020314 or TGFB1-rs1982073. Furthermore, no such impact has been seen regarding disease subtypes defined with ER and PR status.","The findings of the analysis conducted on more than 20,000 cases and 30,000 controls reveal no definitive proof that age at menarche, parity, age at first birth or BMI can modify the established links of genetic variants with the risk of breast cancer. The genetic variants identified in this study include CASP8-rs17468277, 5p12-rs10941679, 8q24-rs13281615, 11p15-rs3817198 (LSP1), 5q11-rs889312 (MAP3K1), 10q26rs298158 (FGFR2), 2q35-rs13387042, 3p24-rs4973768, 16q12-rs2803662 (TOX3), and 17q23rs6504950. Additionally, there was no significant evidence found on whether the above-mentioned variables impact the potential associations with TGFB1-rs1982073 or ESR1rs3020314, and this holds true even for breast cancer subtypes classified by ER and PR status.","The meta-analysis conducted on more than 35,000 cases and 25,000 controls of breast cancer patients concluded that there is no clear evidence suggesting the modification of the existing relationship between genetic variants and the risk of breast cancer by variables including age at menarche, age at first birth, parity, or BMI. Specifically, none of the genetic variants - 5p12-rs10941679, 10q26rs298158 (FGFR2), 8q24-rs13281615, 11p15-rs3817198 (LSP1), 5q11-rs889312 (MAP3K1), 16q12-rs2803662 (TOX3), 2q35-rs13387042, 17q23rs6504950, 3p24-rs4973768, and CASP8-rs17468277 - were found to be associated with any of the variables analyzed. Moreover, the analysis did not find any evidence suggesting that the variables significantly affect the potential association of TGFB1-rs1982073 or ESR1rs3020314 with breast cancer, regardless of the disease subtype classified by ER and PR status."
"The analysis suggests that 11p15-rs3817198 (LSP1) interacts with the number of live births, but the statistical significance of the relationship was unclear after correcting for multiple testing. The interaction odds ratio for this SNP ranged from 1.04 for women with one child to 1.24 for women with four or more children, with an average odds ratio of 1.08 across all parity levels. These weak interactions have a negligible impact on the joint effects estimates in comparison to models that assume multiplicative effects. The study results underscore the difficulty of identifying modifying effects of such a small magnitude.","The study found a possible interaction between the LSP1 gene variant 11p15-rs3817198 and the number of live births, although the statistical significance was not certain after adjusting for multiple comparisons. The interaction odds ratio was estimated to be 1.05 per allele and per live birth, with an average odds ratio of 1.08 across all parity levels. When comparing models with multiplicative effects, the effect of the weak interaction observed in this study would result in only minuscule differences in joint effects estimates. These results suggest the difficulty in identifying modifying effects at such a small scale through very large studies.","The data suggests that there may be a potential interaction between the LSP1 variant 11p15-rs3817198 and the number of live births, but the significance of this finding becomes ambiguous after adjusting for multiple testing. The interaction odds ratio was estimated at 1.05 per allele and per live birth, with the estimated odds ratio across all levels of parity coming out to 1.08. These weak interactions cause only minimal differences when compared to models assuming multiplicative effects, alluding to the challenges of discovering modifying effects of this magnitude through large-scale studies."
"In a recent study conducted by Travis et al., the interaction between breast cancer susceptibility, 9 different genetic loci, and 10 risk factors, including BMI, age at menarche, parity, and age at first birth, was found to be null. Our research replicated these findings in a larger study that included women under 50 and found that these results were applicable to all subjects regardless of age. Furthermore, our study evaluated previously unconsidered genetic loci, such as 17q23rs6504950 and 3p24-rs4973768, as well as ESR1-rs3020314. In comparison to the study by Travis et al., we used a stronger SNP (rs10941679) to assess the susceptibility locus at 5p12 instead of rs981782, which had a weak correlation. Lastly, Travis et al. also found no indication of interaction between 11p15rs3817198 (LSP1) and the number of children women have.","New research by Travis et al. has found no evidence of interactions between breast cancer susceptibility, 9 genetic loci, and 10 risk factors that include factors such as age at menarche, BMI, parity, and age at first birth. In our study, we replicated these results and extended the research to include women under the age of 50. We also evaluated new genetic loci such as 17q23rs6504950, 3p24-rs4973768, and ESR1-rs3020314, which were not initially considered. We used a more strongly associated SNP (rs10941679) to assess the susceptibility locus at 5p12, which was not considered in the earlier study by Travis et al. Moreover, there was no evidence of interaction between LSP1 (11p15rs3817198) and the number of children a woman has. Overall, our research contributes additional evidence and a greater understanding of breast cancer susceptibility and the role of various genetic loci and risk factors.","In a recent study conducted by Travis et al., no interaction was found between breast cancer susceptibility and 9 genetic loci or 10 risk factors, including age at menarche, BMI, parity and age at first birth. Our study replicated these findings while also including younger women in our study population. Additionally, we examined newer genetic loci such as 17q23rs6504950 and 3p24-rs4973768 in combination with ESR1-rs3020314, which was not part of the original research by Travis et al. We employed a more strongly associated SNP (rs10941679) at the 5p12 susceptibility locus rather than the weakly correlated rs981782. Furthermore, Travis et al.'s research found no evidence of interaction between the LSP1 (11p15rs3817198) gene and the number of children. Overall, our study offers an expanded view into the complexity of genetic loci and its interplay with risk factors in breast cancer susceptibility."
"The BCAC has been able to utilize international collaboration to obtain a significant combined sample size that has been valuable in verifying or dismissing associations with breast cancer for common SNPs detected through GWAS and gene candidate studies. Additionally, the consortium was able to provide highly accurate estimates of the susceptibility allele-related odds ratios with high consistency among the dozens of participating studies, despite the assorted range of study designs. Although some risk factors' primary effects may not be correctly evaluated across the whole cohort because of multiple studies that selected cases and/or volunteer controls, this possible selection bias in primary effects estimation should not affect interaction assessments. As a result, we conducted sensitivity tests that exclusively considered data from population-based studies or studies with at least 1,000 instances and 1,000 controls, but the study's primary results regarding interactions remained largely unaltered.","International collaboration has been a key factor in the success of the BCAC. The consortium's extensive sample size, achieved through collaboration, has proved useful in confirming or refuting associations with the breast cancer for common SNPs detected in GWAS and gene candidate studies. The BCAC's ability to provide accurate estimates of the odds ratios associated with susceptibility alleles has been impressive, with a high level of consistency between the many studies participating in the consortium, despite utilizing different study designs. However, it has been noted that some risk factors' primary effects could not be accurately evaluated across the whole cohort due to multiple studies employing selected cases and/or volunteer controls. Nevertheless, this potential selection bias did not impact interaction assessments, and sensitivity analyses of population-based studies or studies with at least 1,000 cases and 1,000 controls yielded comparable findings regarding interactions.","The BCAC's strength lies in its ability to draw upon international collaboration to obtain a large combined sample size, which has been beneficial in verifying or disproving associations with breast cancer for common SNPs identified in GWAS and gene candidate studies. The consortium has been able to provide precise estimates of the odds ratios associated with susceptibility alleles, with high consistency between the numerous studies participating, despite utilizing different study designs. However, the inclusion of multiple studies with selected cases and/or volunteer controls means that the primary effects of certain risk factors might not be accurately assessed for the entire consortium. Despite this, potential selection bias in estimating primary effects should not affect interaction assessments. Sensitivity analyses were performed on population-based studies or studies with at least 1,000 cases and 1,000 controls, but the results remained consistent regarding interactions."
"Our study's credibility may be compromised by a potential limitation that arises from the heterogeneity observed in the data collection methods deployed among the studies. Structured questionnaires were used in all studies with an exception of two, which were not population-based. The questionnaires administered through diverse channels, including face-to-face interviews, phone interviews and self-administration, which may have led to some inconsistencies in the findings particularly for the BMI measurements. However, the reliability of other measurements such as age at menarche, ever having had a live birth, number of live births, and age at first birth is unlikely to have been significantly affected by the variations. We attempted to control for these variations by standardizing measurements within studies and adjusting for study as a covariate to minimize any bias. Although we have excluded a few cases that were interviewed at different times after their breast cancer diagnoses, the results were not significantly different, implying that deviations in the timing of BMI reporting did not substantially affect our findings. Nonetheless, a further limitation of our study is that information on hormone therapy use was unavailable for the majority of participating studies, which restricted our ability to assess the interactions between SNPs and BMI in older women.","The results of our study should be interpreted with caution due to a potential limitation that arises from the presence of heterogeneity in data collection methods across the various studies. Except for two non-population based studies, all other studies utilized structured questionnaires administered through varied means like in-person interviews, phone interviews, and self-administration methods. This diversity in data collection methods may have led to inconsistencies in our results, particularly for BMI measurements. However, our findings of age at menarche, ever having had a live birth, number of live births, and age at first birth are likely robust despite differences in data collection methods. We took specific measures to minimize systematic bias, including standardizing BMI measurements within studies and adjusting for the study as a covariate, which should counteract the effect of this limitation. Additionally, when we excluded cases interviewed at different times after their breast cancer diagnosis, we obtained similar results, indicating that variations in the reporting of BMI did not substantially influence our conclusions. Nevertheless, a limitation of our study was our inability to evaluate SNPs and BMI interactions in older women using hormone therapy (HT) due to a lack of information on HT use from most participating studies.","Our study has a potential limitation regarding the heterogeneity observed in the data collection methods used in the different studies. With the exception of two non-population based studies, all the other studies utilized structured questionnaires administered through several means, such as face-to-face interviews, phone interviews, and self-administration. These variations in data collection methods may have contributed to inconsistencies in our results, notably for BMI measurements. Nevertheless, other measurements such as age at menarche, ever having had a live birth, number of live births, and age at first birth are still likely to be reliable despite these differences. We attempted to control for inconsistencies by standardizing measurements within studies and adjusting for study as a covariate to minimize any bias. Excluding cases that were interviewed at different times after their breast cancer diagnosis did not impact the results significantly. This implies that differences concerning the reference time of BMI reporting had a minimal effect on our findings. However, we could not assess interactions between SNPs and BMI in older women who were using hormone therapy (HT) due to the lack of information on HT use from most participating studies. This is a limitation of our study that should be taken into account while interpreting the results."
"After conducting extensive research on gene-environment interactions, we have found no solid proof of the modification of the per-allele relative risk connected with common breast cancer susceptibility variants by BMI, age at menarche, age at first birth, or parity. This investigation was the largest collaborative analysis to date, and our findings are in line with those of a recently published prospective study. Our findings suggest that the joint effects of these susceptibility genes and other well-established risk factors can be treated as multiplicative when forecasting the risk of breast cancer.","From the most extensive collaborative analyses of gene-environment interactions that have been conducted to date, we have found no conclusive evidence of the per-allele relative risk connected with common breast cancer susceptibility variants being modified by BMI, age at menarche, parity, or age at first birth. Our findings are consistent with those of a recent prospective study, and it implies that these common susceptibility alleles, combined with other factors, can be assumed to be multiplicative in risk-predicted models when considering the risk of breast cancer.","Based on the most comprehensive analysis of gene-environment interactions to date, no conclusive evidence was found to suggest that the per-allele relative risk associated with common breast cancer susceptibility variants was modified by BMI, age at menarche, parity, or age at first birth. The results from this study are in accordance with those of a smaller prospective study that was recently published. It is implied that the combined effects of these common susceptibility alleles and other known risk factors in risk predicted models for breast cancer can be assumed to be multiplicative."
"Anopheles funestus plays a crucial role in the transmission of malaria in southern Africa. Past studies have indicated that this species is responsible for high parasite rates of the Plasmodium falciparum parasite, reaching as high as 22% in South Africa [1]. More recent studies, however, have shown a decline in infection rates, with 11% recorded in Tanzania [2] and 5% in southern Mozambique [3]. These findings highlight the importance of monitoring and managing malaria vectors to prevent and control the spread of the disease.","The major host for malaria transmission in southern Africa is the Anopheles funestus mosquito. Early records have demonstrated its alarming contribution to malaria transmission, with Plasmodium falciparum parasite rates as high as 22% in South Africa [1]. More recent studies conducted in Tanzania have unveiled lower infection rates at 11% [2], and southern Mozambique also records an infection rate of 5% [3]. Understanding the significance of these vectors in malaria spread can help facilitate the prevention and control of malaria in endemic countries.","Anopheles funestus emerges as a significant malaria carrier in southern Africa. Earlier findings highlight the immense contribution of this species in malaria transmission, with parasite rates of Plasmodium falciparum going up to 22% in South Africa [1]. Recent studies show a drop in infection rates, recording 11% in Tanzania [2], and 5% in the southern part of Mozambique [3]. It is essential to monitor the prevalence of such malaria vectors to control the spread of this endemic disease efficiently."
"South Africa once managed to eradicate An. funestus through an extensive indoor residual spraying campaign using DDT in the 1950s. The mosquito species was barely recorded over the next five decades except for a small outbreak in the north of the country. However, South Africa experienced its worst bout of malaria since the introduction of IRS program between 1999 and 2000, and An. funestus reappeared once again. The mosquitoes were found in northern KwaZulu/Natal, just south of Mozambique with a P. falciparum parasite rate of 5.4%. It was also discovered that the species is resistant to pyrethroids and carbamates.","An. funestus, the mosquito species that transmits malaria, was eradicated in South Africa during the 1950s through the implementation of an extensive indoor residual spraying campaign that involved DDT. Over the next 50 years, the species was barely recorded, except for a small outbreak in the northern part of the country. However, in 1999/2000, South Africa experienced its worst-ever outbreak of malaria, and An. funestus suddenly reappeared in northern KwaZulu/Natal, just south of Mozambique. Further investigation discovered that the mosquito species had developed resistance to both pyrethroids and carbamates, and a P. falciparum parasite rate of 5.4% was confirmed.","South Africa had successfully eradicated the malaria-transmitting mosquito species, An. funestus, through an extensive indoor residual spraying campaign that employed DDT in the 1950s. For the following 50 years, the species was scarcely recorded with only one small outbreak reported in the north of the country. However, in 1999/2000, South Africa experienced its worst-ever malaria outbreak since the implementation of the IRS program, and An. funestus resurfaced in northern KwaZulu/Natal, just south of Mozambique. The P. falciparum parasite rate recorded in An. funestus was 5.4%, and additional findings revealed that the mosquitoes had developed resistance to both carbamates and pyrethroids."
"Further investigations carried out in the southern regions of Mozambique revealed that the An. funestus population that had shown resistance to insecticides was not limited to the confines of Maputo, the capital city [7-9]. Recent findings indicated that the same resistance was observed in An. funestus from Chokwe, roughly 200 kilometers away from the capital city, where the population was previously thought to be vulnerable to insecticides [8].","As the research continued in southern Mozambique, it was discovered that the An. funestus population resistant to insecticides had spread beyond the city boundaries of Maputo [7-9]. The latest research conducted showed that the resistance was evident in An. funestus insects from Chokwe, located about 200 kilometers north of the capital city, which was previously considered susceptible [8].","A study conducted in southern Mozambique highlighted that the group of An. funestus with resistance to insecticides was not limited to the area around the capital Maputo [7-9]. The latest research on this topic indicated that the same resistance was exhibited in An. funestus from Chokwe, situated approximately 200 kilometers north of the capital, contradicting the previous research that suggested the population in that area was susceptible [8]."
The study highlights the existence of resistance to insecticides in An. funestus obtained from an island in Lake Malawi. The location of this island is much further north than all previously known instances of resistance.,The discovery of insecticide-resistant An. funestus on an island situated in Lake Malawi is a significant finding that establishes its spread to a much broader geographical region than previously known. The location of the island much further north than any previous known records suggests that the species' distribution may be wider than anticipated.,"The investigation reveals that there is an emergence of insecticide resistance in An. funestus from an island situated in Lake Malawi, which is located even further north than any previously reported areas where resistance was found. This discovery is significant as it presents new information about the insect's distribution and potential spread, creating a need for further research on the matter."
"In May 2010, a team conducted a mosquito survey on Likoma Island, situated within Lake Malawi (12°04’S, 34°44’E) (Figure 1). The island is a series of rocks scattered with homesteads inhabited by people engaged in fishing and small-scale subsistence farming. The team searched multiple houses for mosquitoes, but unfortunately, the number of mosquitoes found was meager. However, a few houses situated close to a small rice field had a meaningful population of Anopheles Funestus mosquitoes.","On Likoma Island in Lake Malawi (12°04’S, 34°44’E) from the 10th to the 14th of May 2010 (Figure 1), a mosquito survey was conducted. The population of Likoma Island mainly involves fishing and small-scale subsistence farming, with housing consisting mostly of scattered homesteads. The researchers searched for mosquitoes in several houses, although they were unable to find a substantial number, but a significant population of An. Funestus mosquitoes was present in a few houses located near a small field of rice.","A mosquito survey was carried out on Likoma Island situated in Lake Malawi (12°04’S, 34°44’E) between the 10th and 14th of May 2010 (Figure 1). The island is situated in the form of outcrops containing mostly scattered homesteads, with the residents earning a livelihood from small-scale farming and fishing. Researchers surveyed several houses in search of mosquitoes, and though they found fewer in number, a substantial An. Funestus mosquito population was found in a handful of houses located near a small rice field."
"Researchers gathered mosquitos from houses by using a device known as a handheld aspirator while they were resting. Samples were separated, with some being used for immediate WHO susceptibility testing and others being transported to Johannesburg for the purpose of acquiring egg batches. The eggs were then developed into F-1 adults after being incubated.","Scientists utilized a hand-operated intake gadget to collect mosquitos located inside homes while they were at rest. Some of the samples were put to immediate use in a WHO susceptibility trial, while the remaining ones were sent to Johannesburg in order to extract egg batches. After hatching, the eggs were reared until they reached the F-1 adult stage.","The researchers employed a hand aspirator to capture mosquitos relaxing inside homes. After the capture, a division of the sample was used for conducting the WHO susceptibility evaluations. The remaining part of the specimens was carried to Johannesburg for acquiring egg lots. Over time, the eggs developed into larvae, which were ultimately nurtured until the adult phase - F-1."
"The identification of species was performed utilizing different methodologies based on the group of the mosquito species. An. funestus group was identified using the strategies defined by Koekemoer et al. [11], while An. gambiae complex was identified using the methods proposed by Scott et al. [12]. ELISA [13] was used as a screening tool to identify malaria parasite infection in female specimens obtained from their natural habitat.","To differentiate the mosquito species, specific techniques were employed based on their group classification. The An. funestus group underwent identification procedures as outlined by Koekemoer et al. [11], while the An. gambiae complex was identified using the methodologies of Scott et al. [12]. The females collected from the wild were examined for malaria parasite infections through the use of Enzyme-Linked Immunosorbent Assays (ELISAs) [13].","The methods used for identifying the mosquito species varied according to their group. The techniques described by Koekemoer et al. [11] and Scott et al. [12] were applied to An. funestus group and An. gambiae complex respectively. To detect malaria parasite infections in female mosquitoes captured from their ecological environment, the Enzyme-Linked Immunosorbent Assay (ELISA) [13] was implemented."
"To evaluate the effectiveness of insecticides, the team performed insecticide susceptibility assays using the standard test sets from the WHO [14]. The treated papers from the WHO Collaborating Centre in Penang, Malaysia were also utilized in the experiments. The researchers used various insecticides, and the corresponding discriminating doses are tabulated in Table 1 and 2.","The team carried out insecticide susceptibility tests using WHO [14] standard test kits and treated papers obtained from the Center in Penang, Malaysia, to determine the efficiency of insecticides. Table 1 and 2 show the different insecticides used and their respective discriminating doses.","The WHO [14] standard test kits alongside treated papers from the WHO Collaborating Centre in Penang, Malaysia, were utilized to perform insecticide susceptibility tests aimed at evaluating the effectiveness of the insecticides. Table 1 and 2 show the various insecticides employed and their corresponding discriminating doses."
"The study conducted an experiment to test the insecticide resistance of An. funestus female mosquitoes in their natural surroundings, and the temperature and humidity were not monitored or regulated during the test. They collected a substantial number of female and male An. funestus mosquitoes, as well as some An. gambiae larvae, from the same location and transported them to Johannesburg's laboratory for further experiments.","A field test was performed to examine the resistance of An. funestus female mosquitoes to insecticides, however, no measures were taken to regulate the temperature or humidity during the test. About 111 females were used, all of which were of unknown age and obtained from natural habitats. Along with the An. funestus population, a small number of larvae of An. gambiae were also collected and sent to a laboratory in Johannesburg for further studies. In addition, the researchers collected over 120 females and males of An. funestus during the field test.","In an attempt to test the insecticide resistance of An. funestus, 111 wild females were acquired from their natural habitat without any age specification in a field experiment. The experiment was conducted without monitoring or regulation of temperature and humidity. During the same experiment, six females from An. gambiae complex populations were discerned. A small group of larvae from An. gambiae were collected and combined with over 120 females and males of An. funestus for further testings, while the collection was transported from the field to a laboratory in Johannesburg."
"Molecular assays were performed on a sample of 223 An. funestus comprising both wild adults utilized in the susceptibility tests (n = 111) and the live females brought back to the laboratory for egg-laying (n = 112), and according to the results, 97.3 percent were identified as An. funestus s.s. (five specimens failed to amplify a PCR product and one specimen was classified as An. funestus-like). Moreover, all males and females in the An. gambiae complex, both wild adults and those that were reared from larvae (n = 89), were identified as An. arabiensis.","The molecular assays were conducted on a group of 223 An. funestus individuals. The samples included all the wild adult mosquitoes from the susceptibility tests (n = 111) and the live females that were brought back to the laboratory for egg-laying (n = 112). Results showed that 97.3 percent of these mosquitoes were identified as An. funestus s.s., while five specimens failed to amplify a PCR product and one specimen was labeled as An. funestus-like. In contrast, An. arabiensis was identified as the only species in both males and females in the An. gambiae complex, including wild adults and those reared from larvae (n = 89).","A set of molecular assays were carried out on 223 An. funestus individuals, which included both wild adults used in susceptibility tests (n = 111) and live females that were brought back to the laboratory for egg-laying (n = 112). The outcome revealed that 97.3 percent of these mosquitoes were identified as An. funestus s.s. Furthermore, out of the total number, five samples did not amplify a PCR product, while one sample was characterized as An. funestus-like. All male and female mosquitoes in the An. gambiae complex, including both wild adults and those that were reared from larvae (n = 89), were identified as An. arabiensis."
"Among the population of 81 female An. funestus which were screened to determine the likelihood of parasite infection, only a small percentage of 4.9 percent showed evidence of P. falciparum as detected through the ELISA testing method.","Out of the sample of 81 female An. funestus that were subjected to parasite testing, less than five percent or 4.9 percent were found to carry P. falciparum parasites through the ELISA approach. This demonstrates a relatively low prevalence of the malaria-causing parasite in the population of An. funestus mosquitoes examined.","In the group of 81 wild female An. funestus that underwent parasite testing, a small proportion of only 4.9 percent were identified as positive for P. falciparum using the ELISA technique. This suggests a relatively low frequency of the malaria-causing parasite in the population of An. funestus mosquitoes evaluated."
"After conducting the initial tests, the insecticide susceptibility of wild female An. funestus on the island was evaluated, and the results are highlighted in Table 1. Due to the controls showing more than 5% mortality, the researchers utilized Abbott's formula [14] to rectify the results, which showed 77.8% mortality on deltamethrin and 56.4% on bendiocarb. In addition, the field papers were put under laboratory tests using a susceptible An. gambiae colony, which exhibited a 100% mortality rate for all samples and duplicates (n = 100 for each insecticide).","Table 1 displays the findings from the initial insecticide susceptibility testing, which was carried out using wild An. funestus female mosquitoes of unverified age from the island. The results showed 77.8% mortality on deltamethrin and 56.4% mortality on bendiocarb. As the controls demonstrated over 5% mortality, the study employed Abbott's formula [14] to amend the results. The field papers were tested in the laboratory using a susceptible An. gambiae colony to examine its efficacy. The samples and replicates (n = 100 for each insecticide) all exhibited a 100% mortality rate.","The first insecticide susceptibility tests were performed on wild female An. funestus of unknown age that were collected from the island, and the results were recorded in Table 1. Since the controls exhibited >5% mortality, the scientists used Abbott's formula [14] to adjust the results, which showed 77.8% mortality for deltamethrin and 56.4% for bendiocarb. To further analyze the performance of field papers, a susceptible An. gambiae colony was employed in the laboratory testing, which revealed 100% mortality for all samples and replicates (n = 100 for each insecticide)."
"The laboratory conducted a set of pesticide susceptibility experiments at a controlled temperature of 25°C and an 85% relative humidity using An. funestus females that were collected from nearly 120 distinct egg batches and combined. Nine insecticides were tested, including all four pesticide classes, with their results listed in Table 2.","A second round of susceptibility tests for insecticides was administered in the laboratory at 25°C and 85% RH, using An. funestus females that were between 1 and 5 days old and had been combined from roughly 120 egg batches. Testing all four classes of insecticides, nine different products were utilized during the experiment, and Table 2 presents data on the outcomes of these experiments.","The laboratory conducted the second phase of tests to determine the susceptibility of insects to pesticides making use of 1-5 day-old female An. funestus mosquitoes, caught from roughly 120 distinct egg batches combined. The experiments were conducted in the laboratory at a temperature of 25°C and relative humidity of 85%. Nine different pesticide varieties, encompassing all four classes, were used to conduct this study, with Table 2 revealing the outcomes of the trials."
"Unfortunately, the amount of An. arabiensis specimens reared from larva was insufficient (with only 42 females available) to conduct susceptibility testing with any degree of accuracy.","Regrettably, testing for susceptibility of An. arabiensis was deemed inconclusive due to the sample size being too small. Only 42 female specimens were available for the testing, which was not enough for meaningful results.","The susceptibility testing of An. arabiensis could not be deemed reliable due to the low count of female specimens available for testing. Only 42 of these species that were reared from larvae could be used for the experiment. As a result, there was a lack of accuracy in the results which made them impractical to be considered as conclusive."
"The dissimilarity in deltamethrin susceptibility assessments between wild females in the natural habitat and laboratory reared F-1 progeny aged between 1 and 5 days old (p <0.005), can be clarified in a couple of ways. Firstly, high temperatures can impact the survival of mosquitoes exposed to insecticides [15], leading to high mortality rates in the field samples. Secondly, it is plausible that An. funestus' susceptibility to this sub-class of pyrethroids may be dependent on age [16]. Since the survey was performed in May, towards the end of the transmission period, it is likely that the wild-caught females examined in the field were an older population and thus more inclined to be susceptible to insecticides. Nevertheless, Hunt et al. also note that mated blood-fed females did not demonstrate any decrease in resistance over time, and aged wild populations would all be mated and might have had a number of blood meals.","The deltamethrin susceptibility tests on wild female An. funestus mosquitoes in their natural habitat versus laboratory-reared F-1 progeny aged between 1 and 5 days old (p <0.005) displayed a significant difference. This variation can be explained in two ways. Firstly, higher temperatures are known to hinder the survival rate of mosquitoes exposed to insecticides [15]. Therefore, the high mortality rate observed in the field samples may be due to high temperatures. Secondly, the susceptibility of An. funestus to sub-class pyrethroids could be dependent on their age [16]. As the survey was conducted at the end of the transmission season, the wild-caught females analyzed in the field study were likely an aging population. Thus, they could have been more susceptible to insecticides. However, Hunt et al. stated that aging wild populations may still have mated and blood-fed females but did not show any decrease in resistance over time. It is possible that the wild-caught females in the field study had already fed and taken blood meals, making them less susceptible to insecticides despite their age.","The susceptibility tests performed on wild female An. funestus mosquitoes in their natural habitat and 1-5 day old laboratory-reared F-1 progeny displayed a significant difference in their susceptibility to deltamethrin (p <0.005). The difference can be explained by two factors. Firstly, high temperatures are known to affect mosquito survival rates when exposed to insecticides, which may contribute to the high mortality rates observed in the field samples [15]. Secondly, the susceptibility of An. funestus to specific pyrethroids may be age-dependent [16]. As the survey was conducted towards the end of the transmission season in May, it is possible that the aging wild-caught female population examined in the field had a higher susceptibility to insecticides. Although, Hunt et al. suggested that blood-fed, mated females did not show a decline in resistance over time. This suggests that even though the wild population may have been aging, they were likely mated and had taken numerous blood meals, making them less susceptible to insecticides, and potentially still resistant to the chemical."
"The susceptibility results indicate that the control of malaria in Likoma Island calls for a resistance management strategy. It's necessary to distribute pyrethroid treated bed nets extensively on the island, along with carrying out IRS simultaneously with an organophosphate or DDT to handle the resistance. Unfortunately, carbamates are not an option due to the high survival rate. Even though DDT is capable of fully controlling the An.funestus population, it is advisable to use DDT for IRS in combination with one of the organophosphates.","The susceptibility outcomes clearly suggest that a resistance management tactic needs to be implemented for the control of malaria in Likoma Island. The distribution of pyrethroid treated bed nets must be wide-ranging, and at the same time, IRS should be conducted with an organophosphate or DDT to manage the resistance. Despite the high frequency of survival, carbamates are not feasible. DDT appears to have complete susceptibility against the An. funestus population, indicating that it may be viable to use DDT with one of the organophosphates in a rotation for IRS.","The susceptibility test leads us to conclude that a resistance management approach is necessary to combat malaria outbreaks on Likoma Island. Distributing pyrethroid treated bed nets extensively should be coupled with conducting IRS simultaneously with either an organophosphate or DDT to manage resistance levels. However, carbamates are not a viable option due to their high survival rates. DDT seems to be fully effective against the An. funestus population; therefore, it could be employed as an IRS in rotation with one of the organophosphates."
"The island has witnessed the widespread adoption of bed nets to protect against mosquito-borne diseases. These nets differ in their state of repair and age, with some being treated and others remaining untreated. Using bed nets is not a common practice among all residents, despite their widespread availability. Considering a strategy that employs both bed nets and IRS, a key element of such an effort must be to increase awareness and track bed net usage. If the mosquito population falls due to seasonal changes or preventive procedures, some residents may cease using the nets. Furthermore, since the island's population is primarily dependent on fishing, some nets may be used for this purpose. (See Figure 2 for an example.)","On the island, bed nets are already in widespread use, with a variety of treated and untreated nets available in varying states of repair. However, even though the nets are available in many homes, their use is inconsistent. To create a successful campaign that uses bed nets and IRS together, education and monitoring of bed net usage are critical components. This is because, in response to the decline in mosquito populations due to seasonal changes or control measures, many people will stop using bed nets. Moreover, people in fishing communities may utilize the nets for their livelihood. (See Figure 2 for more details.)","The inhabitants of the island have already adopted bed nets in significant numbers, which come in a variety of types ranging from old to new, torn or intact, and treated or untreated. In addition, the use of the bed nets varies from one household to another, with some nets being present but not in use. If a bed net and IRS combination strategy is being considered, it is imperative to educate and monitor the use of bed nets. As mosquito populations decline due to seasonal changes or control measures, many people may stop using bed nets, and fishermen may also use the nets. (Refer to Figure 2 for illustrations.)"
"The survey has identified a concerning discovery of the resistance of An. funestus population to pyrethroid and carbamate, located at a distance of approximately 1,500 km north of its known distribution in southern Mozambique. The report by Casimiro et al. [9] from 2006, which examined samples from central Mozambique showed more than 95% mortality to pyrethroids and carbamates, indicating that this level of susceptibility requires further investigation according to WHO criteria. However, it is doubtful that a program would alter its policies based on the frequency of resistance/susceptibility, which may not be operationally effective.","An alarming discovery has been made in this survey with regards to the An. funestus population, located around 1,500 km north of its known distribution area in southern Mozambique, showing resistance to pyrethroid and carbamate. The report by Casimiro et al. [9] from 2006, on the samples collected from central Mozambique, has shown that An. funestus had over 95% resistance to pyrethroids and carbamates, and this level of susceptibility requires further investigation as per the WHO criteria. However, the control program might not change its policy based on this susceptibility/resistance frequency, which may not be practically effective.","The survey has unveiled a disquieting discovery regarding the An. funestus population, which is situated approximately 1,500 km north of its current known distribution area in southern Mozambique, showing signs of pyrethroid and carbamate resistance. A prior report by Casimiro et al. [9] in 2006 based on samples collected from central Mozambique had revealed that An. funestus had mortality rates of more than 95% when exposed to pyrethroids and carbamates, pointing out that this degree of susceptibility requires further research in line with the WHO criteria. Nonetheless, it is improbable for a control program to revise its policies based on this level of resistance/susceptibility frequency as it might not have operational efficacy."
"The island of Likoma in Lake Malawi lies close to Mozambique, causing possible transportation of mosquitoes to the mainland through the wind or boats. The impact of the An. funestus resistance population in the north of Mozambique must be understood as it may pose serious obstacles to current malaria control efforts underway in the region. Both the pyrethroid and carbamate resistance in the Likoma population mirror that found in southern populations, implying that the resistance is disseminating northwards through the An. funestus populations via gene flow, rather than individual genetic mutation events. Geographical boundaries to gene flow are not apparent in this region of southern Africa, indicating that the resistance will likely spread northwards into southern Tanzania and westwards into Zambia and Zimbabwe. However, resistance of An. funestus found in Uganda has distinctive variations compared to those seen in southern African populations, which are detectable through susceptibility tests and molecular characterization of P450 genes.","Situated just a few kilometers away from Mozambique, Likoma Island in Lake Malawi serves as a potential transportation hub for mosquitoes either through the wind or boats that travel between the island and mainland. The prevalence of An. funestus resistance population in the north of Mozambique is a significant concern as it may impact the ongoing efforts to control malaria in the region. As observed in the southern populations, the occurrence of pyrethroid and carbamate resistance in the Likoma population suggests that the resistance is disseminating northwards through the An. funestus populations via gene flow, rather than genetic mutation events. There is no apparent geographical restriction to gene flow within this area of southern Africa, indicating that the resistance is anticipated to spread northwards into southern Tanzania and westwards into Zambia and Zimbabwe. However, the resistance of An. funestus found in Uganda differs significantly from those seen in southern African populations, which are evident through susceptibility tests and molecular characterization of P450 genes.","Lake Malawi's Likoma Island, located just a few kilometers from Mozambique's border, such as it may act as a transfer point for mosquitoes due to the wind or the boats running between the mainland and the island. The existence of An. funestus resistance population in the north of Mozambique is a significant concern for the current malaria management efforts in the region. Pyrethroid and carbamate resistance have been discovered in the Likoma population, just as they are seen in southern populations. Therefore, it can be supposed that the distribution of resistance is increasing northwards via gene flow in An. funestus populations rather than separate genetic mutations. We do not see any significant geographic barriers to gene flow within this region in southern Africa, indicating that resistance is supposed to move to southern Tanzania and westwards into Zambia and Zimbabwe. However, the An. funestus resistance in Uganda likely differs from that in southern African populations, based on susceptibility tests and molecular characterization of P450 genes."
This article focuses on the pressing concern of insecticide resistance in An. funestus in the Southern African region. The paper underscores the need for immediate action and the urgent implementation of effective resistance management strategies. The spread of insecticide resistance in An. funestus within this region is alarming and requires an interdisciplinary approach to address this challenge. It is essential that various stakeholders work together and coordinate efforts towards the conservation of insecticide efficacy to fight malaria in the region.,The rapid expansion of insecticide resistance in An. funestus in Southern Africa is a worrisome problem. This paper stresses the significance of finding an effective way to manage this resistance in the malaria vector control programs. The situation demands an immediate response to address the increasing prevalence of insecticide resistance in this region. Novel approaches to resistance management must be developed and implemented soon to control the mosquito populations and the associated transmission of malaria. The linkage between insecticide resistance and malaria transmission has to be dealt with in a more coordinated and comprehensive manner to secure success.,"The swift proliferation of insecticide resistance in An. funestus in Southern Africa has created a critical situation. This paper emphasizes that it is imperative to establish resistance management strategies in malaria vector control programs within the region. The spread of insecticide resistance is concerning, and conventional approaches to control the malaria vector population may not be adequate. The use of alternative chemical compounds and tools that effectively target other key elements of the transmission pathway would be an excellent solution. The situation calls for effective collaboration between researchers, health professionals, policymakers, and communities to achieve the desired results."
"Neuroplasticity is the process by which the brain adapts and modifies its structure and function in response to various environmental factors or stimuli. Unlike other organs in our body, the brain can continuously alter its neural connections and circuits, forming and consolidating new memories, acquiring new skills, and even healing from damage or injury. Neuroplasticity involves two fundamental mechanisms: synaptic plasticity, which refers to the strengthening or weakening of connections between neurons, and neurogenesis, which describes the generation of new neurons from stem cells in specific brain regions. Although once believed to only occur during critical periods of development, we now know that neuroplasticity can persist throughout our lifespan, presenting exciting opportunities for therapies and interventions for various neurological and psychiatric conditions.","Renewable energy refers to energy sources that are naturally replenished and have minimal environmental impact compared to traditional fossil fuels. These energy sources include solar, wind, hydro, geothermal, and biomass, which harness the power of the sun, water, wind, and organic matter to produce electricity or heat. One of the significant advantages of renewable energy is its sustainability, as it can minimize the reliance on finite resources such as oil and coal, which are also known for causing greenhouse gas emissions and pollution. In addition, renewable energy can contribute to energy independence by reducing the dependence on foreign oil and creating jobs in the clean energy sector. The global transition to renewable energy is critical to mitigating climate change and achieving a more sustainable future, and it requires extensive investments and policy incentives to support the implementation of renewable energy technologies.","Artificial intelligence (AI) is a branch of computer science that focuses on developing intelligent machines and software that can perform tasks that typically require human intelligence, such as visual perception, speech recognition, decision-making, and natural language processing. AI technology uses algorithms and statistical models to analyze large amounts of data and extract meaningful insights or predictions. Some of the specific techniques employed in AI include machine learning, deep learning, natural language processing, and robotics. The integration of AI technology has numerous practical applications, ranging from autonomous vehicles and virtual agents to personalized medicine and fraud detection. Despite its potential benefits, AI also raises ethical and societal concerns, such as privacy, bias, and job displacement, which require ongoing discussion and regulation."
"Tumor progression and growth is supported by the process of angiogenesis, in which new blood vessels are formed from pre-existing ones through a complex signaling pathway. One important mediator of this pathway is VEGF-A, which binds to its cognate receptors VEGFR1 and VEGFR2 on both endothelial and bone marrow-derived cells. Since VEGF-A is overexpressed in many solid tumor types, targeting this pathway has been a major strategy for inhibiting tumor angiogenesis. Several molecules have been developed that inhibit different components of the VEGF-A pathway, including bevacizumab and sunitinib, both of which are already in clinical use. Bevacizumab is a monoclonal antibody that binds and neutralizes VEGF-A, while sunitinib is a tyrosine kinase inhibitor that disrupts VEGFR1 and VEGFR2 signaling.","Tumor angiogenesis is a complex process, in which new blood vessels are formed from the pre-existing ones to supply the growing tumor with nutrients and oxygen. VEGF-A is a key mediator of this process and is overexpressed in multiple solid tumor types. It acts on its cognate receptors VEGFR1 and VEGFR2, which are present in endothelial and bone marrow-derived cells. To block tumor angiogenesis, various drugs have been developed that target the VEGF pathway. For example, bevacizumab is a monoclonal antibody that binds to VEGF-A and prevents its action. Similarly, sunitinib is a kinase inhibitor that blocks VEGFR1 and VEGFR2 signaling. Several other molecules are also being developed as potential anti-angiogenic agents for cancer therapy.","Angiogenesis plays a crucial role in tumor growth and progression, as it facilitates the supply of nutrients and oxygen to the tumor microenvironment. VEGF-A is a key mediator of this process and is overexpressed in many solid tumor types. VEGF-A signals through its receptors, VEGFR1 and VEGFR2, located on endothelial and bone marrow-derived cells. As a result, targeting the VEGF pathway has become a significant therapeutic strategy to inhibit tumor growth. The VEGF pathway has been blocked using various drugs, including bevacizumab and sunitinib, which have already been approved for clinical use. Bevacizumab is a monoclonal antibody that binds to VEGF-A and reduces its activity, whereas sunitinib inhibits VEGFR signaling. Other anti-angiogenic agents are also being developed for cancer therapy."
"The VEGF-A gene is a complex gene consisting of 8 exons, which gives rise to 5 main differently spliced isoforms, namely VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206. The occurrence of alternative translation codons upstream of the canonical ATG codon can result in longer isoforms. The role of these isoforms remains unknown. Recently, a fresh set of isoforms has been discovered, labeled ""b-isoforms"" or ""VEGFxxxb"" isoforms. The VEGF-A gene encodes these transcripts, which resemble classical pathways but are distinct because exon 8 is replaced by a similarly sized alternatively spliced exon (exon 8b). VEGF165b has been characterized as having anti-angiogenic properties in a number of studies, while others have raised concerns about this attribute and suggested that it may serve as a VEGF-A receptor agonist. Additionally, these ""b-isoforms"" have the potential to serve as VEGF-A antagonist molecules due to the substitution of exon 8, the core peptide sequence responsible for VEGF-A receptor activation.","Within the VEGF-A gene, there are 8 exons that can be alternatively spliced to produce 5 primary isoforms - VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206. It is possible to generate longer isoforms by using alternative translational codons upstream of the canonical ATG codon. However, the significance of these isoforms remains unestablished. Recently, a new set of alternatives, termed ""b-isoforms"" or ""VEGFxxxb"" isoforms, has been identified. These isoforms, encoded by the VEGF-A gene, create polypeptides identical in length to classical isoforms, but substitute exon 8 with an alternatively spliced exon of the same length (exon 8b). The VEGF-A receptor activation is primarily governed by exon 8, and as a result, the ""b-isoforms,"" which replace exon 8 with another peptide sequence, have been proposed to act as VEGF-A receptor antagonists. VEGF165b has been shown in previous studies to hold anti-angiogenic properties, while other studies have indicated that it can serve as a VEGF-A receptor agonist, casting doubt on its activities.","The VEGF-A gene consists of eight exons that can give rise to five primary alternatively spliced isoforms, including VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206. Longer isoforms can also be generated by alternative translational codons present upstream of the canonical ATG codon. The functional importance of these isoforms is still uncertain. Recently, a new set of isoforms referred to as ""b-isoforms"" were reported, which are encoded by the VEGF-A gene. These polypeptides resemble classical isoforms, but they replace exon 8 with an alternative spliced exon of the same length (exon 8b). Exon 8 is responsible for receptor activation, and the ""b-isoforms,"" by replacing the primary peptide sequence with other sequences, are expected to function as potential antagonists for VEGF-A receptors. VEGF165b, which is one of the newly identified b-isoforms, has been reported in several studies to have anti-angiogenic effects, while some research suggests that it might act as a VEGF-A receptor agonist."
"The comparison between the expression of ""angiogenic"" and ""antiangiogenic"" isoforms is a topic that has sparked interest, particularly in diseases that involve the development of abnormal vasculature, such as cancer. Previous studies utilizing semi-quantitative RT-PCR techniques on a small number of samples have reported a noteworthy expression of VEGFxxxb isoforms in healthy prostate, colon, and kidney tissues when compared to their malignant counterparts. The hypothesis that pathological conditions lead to alterations in alternative splicing of VEGFA, leading to an increase in ""b-isoform"" expression (which may possess anti-angiogenic properties) at the expense of classical angiogenic isoforms, is an interesting possibility that requires further exploration. Furthermore, the VEGFxxxb/VEGF ratio expression may serve as a useful biomarker for angiogenic diseases, indicating a potential avenue for future research.","In pathologies involving abnormal vasculature development, such as cancer, there is an intriguing issue of differential expression between ""angiogenic"" versus ""antiangiogenic"" isoforms. Previous studies have utilized semi-quantitative RT-PCR methods on a limited number of samples and shown a significant expression of VEGFxxxb isoforms in regular colon, prostate, and kidney tissues as opposed to their malignant equivalents. It is proposed that neovascularization during pathological conditions results in modifications in alternative splicing of VEGFA, leading to higher expression of ""b-isoforms"" that supposedly possess anti-angiogenic properties, at the detriment of classical angiogenic isoforms. This finding has significant implications as the VEGFxxxb/VEGF ratio expression may function as a feasible biomarker for angiogenic diseases, but further research is required to validate this hypothesis.","The possible differential expression between ""angiogenic"" and ""antiangiogenic"" isoforms in disease states that involve abnormal vasculature development, such as cancer, presents a fascinating subject of study. Previous research, utilizing semi-quantitative RT-PCR on a limited number of samples, has indicated a significant expression of VEGFxxxb isoforms in healthy prostate, colon, and kidney tissues compared to their malignant counterparts. It is believed that the development of neovasculature during pathological conditions may modify alternative splicing of VEGFA, leading to the expression of ""b-isoforms"" that supposedly possess anti-angiogenic properties, at the expense of classical angiogenic isoforms. This finding has substantial potential as the VEGFxxxb/VEGF ratio expression may function as a biomarker for angiogenic conditions; however, further research is needed to establish the reliability of this hypothesis."
"Due to the potential benefits of using recombinant VEGFxxxb proteins in a therapeutic approach for cancer, we aimed to investigate the biological activity of these transcripts by producing recombinant VEGF121b and VEGF165b proteins through the yeast, Pichia pastoris. This was achieved by constructing expression vectors to overexpress these isoforms and determine their role in cancer models. Additionally, a comprehensive analysis of both VEGFxxxb and overall VEGF protein expressions was performed on 50 breast cancer samples and normal mammary glands using previously-characterized antibodies.","The use of recombinant VEGFxxxb proteins for therapeutic applications shows great potential, but the biological function of such transcripts is not yet fully understood. To address this, we produced recombinant VEGF121b and VEGF165b proteins in Pichia pastoris yeast and constructed expression vectors that could overexpress these isoforms. This approach aims to further investigate the role that these proteins play in various cancer models. Furthermore, we evaluated protein expression of VEGFxxxb and total VEGF using specific antibodies that were previously characterized, in both normal mammary glands and 50 different breast cancer samples.","The therapeutic use of recombinant VEGFxxxb proteins represents a promising approach, but their precise biological activity remains unclear. Our study aimed to investigate this by producing recombinant VEGF121b and VEGF165b proteins using Pichia pastoris yeast and overexpressing them through the construction of specific expression vectors. In addition to deciphering their potential role in cancer models, we also employed specific antibodies to examine VEGFxxxb and total VEGF protein expression in normal mammary glands and 50 breast cancer samples, previously characterized to ensure accuracy."
"Oligonucleotides were procured from Sigma-GenoSys (Sigma, St. Louis, MO, USA). PCR was carried out with primers VF (5'GAAACCATGAACTTTCTGCTGTCTT3') and V121bR (5' TTAAGCTTTCAGTCTTTCCTGGTGAGAGATTTTTCTTGTCTTGCTCTATC3') to clone VEGF121b isoform into the pCR2.1 vector (Invitrogen). VF and V165bR (5' TTAAGCTTTCAGTC-TTTCCTGGTGAGAGATCTGCAAGTACGTTCGTTTAACTC 3') primers were used to clone VEGF165b. The initiation codon is highlighted in VF, while both reverse oligonucleotides have HindIII restriction sites (bold). VEGF121b and VEGF165b coding sequences were sub-cloned into pCDNA3.1(-)Neo expression plasmid, and then VEGF121b and VEGF165b coding sequences, deprived of the signal peptide (ΔPSVEGFxxxb), were cloned into the pPICZalphaC vector (Invitrogen) using the VPPF (5' GGTCTCGAGAAAAGAGAGGCTGAAGCTGCACCCATGGCAGAAGG 3') primer, together with V121bR or V165bR. Afterward, they produced recombinant proteins in Pichia pastoris yeast with the help of the alpha-factor signal peptide to extracellularly express the VEGFxxxb sequences.","Sigma-GenoSys provided the oligonucleotides for the study. The VEGF121b isoform was cloned using VF (5'GAAACCATGAACTTTCTGCTGTCTT3') and V121bR (5' TTAAGCTTTCAGTCTTTCCTGGTGAGAGATTTTTCTTGTCTTGCTCTATC3') primers in the pCR2.1 vector (Invitrogen), whereas VEGF165b was cloned with VF and V165bR (5' TTAAGCTTTCAGTC-TTTCCTGGTGAGAGATCTGCAAGTACGTTCGTTTAACTC 3') primers. VF has an underlined initiation codon, and both reverse oligonucleotides have bolded HindIII restriction sites. VEGF121b and VEGF165b coding sequences were subsequently subcloned into the pCDNA3.1(-)Neo expression plasmid. VEGF121b and VEGF165b constructs without the signal peptide (ΔPSVEGFxxxb) were then cloned into the pPICZalphaC vector (Invitrogen) using VPPF (5' GGTCTCGAGAAAAGAGAGGCTGAAGCTGCACCCATGGCAGAAGG 3') primer along with V121bR or V165bR, and then used to produce recombinant proteins in Pichia pastoris yeast. The alpha-factor signal peptide was utilized in this study to enable extracellular expression of the VEGFxxxb sequences.","Oligonucleotides were purchased from Sigma-GenoSys for use in the study. PCR was carried out using the VF (5'GAAACCATGAACTTTCTGCTGTCTT3') and V121bR (5' TTAAGCTTTCAGTCTTTCCTGGTGAGAGATTTTTCTTGTCTTGCTCTATC3') primers to clone the VEGF121b isoform into the pCR2.1 vector (Invitrogen). Cloning of VEGF165b was performed with VF and V165bR (5' TTAAGCTTTCAGTC-TTTCCTGGTGAGAGATCTGCAAGTACGTTCGTTTAACTC 3') primers. Note that VF has an underlined initiation codon, and both reverse oligonucleotides have bolded HindIII restriction sites. Following cloning, the VEGF121b and VEGF165b coding sequences were subcloned into the pCDNA3.1(-)Neo expression plasmid. VEGF121b and VEGF165b constructs without the signal peptide (ΔPSVEGFxxxb) were then cloned into the pPICZalphaC vector (Invitrogen) together with VPPF (5' GGTCTCGAGAAAAGAGAGGCTGAAGCTGCACCCATGGCAGAAGG 3') primer and V121bR or V165bR, and used to produce recombinant proteins in the yeast Pichia pastoris. The alpha-factor signal peptide was employed to extracellularly express the VEGFxxxb sequences."
"The plasmids containing the gene sequence ΔPS-VEGFxxxb were subjected to linearization and gel-purification. The linearized plasmids were then mixed with Pichia pastoris cell culture, and the solution was loaded into electroporation cuvettes. Using a Gene-pulser II by Bio-Rad with preset yeast conditions, electroporation was carried out. The electroporated cells were transferred to sterile microtubes containing 1M sorbitol and incubated at 30°C for two hours. Following this, zeocin-resistant colonies were identified, picked and grown on YPDSZ plates for nine days at 29°C. The resulting yeast clones were transferred to BMGY medium and grown for 30 hours under continuous shaking at 29°C to enable exponential cell growth. Finally, the cells were centrifuged and resuspended in BMMY medium, containing 1% methanol to induce protein production.","To introduce ΔPS-VEGFxxxb sequences into Pichia pastoris, pPICZalphaC plasmids were utilized. These plasmids underwent linearization, purification, and quantification before being mixed with Pichia pastoris cells. The mixture was loaded into electroporation cuvettes of 1 mm width and subjected to electroporation under the preset yeast conditions of a Gene-pulser II by Bio-Rad. Following electroporation, the cells were transferred into new microtubes and supplemented with 1M sorbitol. Zeocin-resistant colonies were selected from the yeast clones grown on YPDSZ plates and transferred to BMGY medium for exponential growth at 29°C for 30 hours. Afterward, the yeast clones were centrifuged and resuspended in BMMY medium, supplemented with 1% methanol, to induce protein production.","The introduction of ΔPS-VEGFxxxb sequences to Pichia pastoris cells commenced with linearizing, purifying, and measuring the concentration of pPICZalphaC plasmids containing the ΔPS-VEGFxxxb sequences. Then, the linearized plasmids were mixed with Pichia pastoris cells, and the solution was introduced to 1 mm-wide electroporation cuvettes. The cells and plasmids mixtures present in the cuvettes were subjected to electroporation under the designated yeast conditions using a Gene-pulser II by Bio-Rad. Subsequently, the solution containing cells was transferred to new microtubes containing 1M sorbitol, and the cells were incubated for two hours at 30°C. After incubation, the solution was plated onto YPDSZ agar plates and incubated at 29°C for nine days to select zeocin-resistant colonies. These colonies were grown in YPD medium before being transferred to BMGY medium for the optimal growth of yeast clones for 30 hours under continuous shaking at 29°C. Finally, methanol-induced BMMY medium was introduced to induce protein production."
"The experiment involved collecting supernatants that were obtained by incubating at 29°C and thorough shaking for 24 hours. SDS-PAGE analysis was carried out to determine the most appropriate clone to produce each VEGF121/165b isoform. The selected clones were then grown in BMGY for two days before being transferred to BMMY for the expression of recombinant products. The recombinant VEGF121/165b proteins were purified using nickel-affinity chromatography. HPLC techniques were used for purification as well, using a Hi-Trap chelating column together with an AKTÄ HPLC device. The supernatants were diluted and loaded into the HPLC device using a binding buffer. Elution buffer was then loaded and mixed gradually with the binding buffer in increasing proportions. Throughout the procedure, 1 mL fractions were collected.","Following 24 hours of incubation at 29°C with thorough shaking, the supernatants were collected and tested using SDS-PAGE to determine the optimal clone to produce each VEGF121/165b isoform. The chosen clones were cultured in 2 L of BMGY for two days and later transferred into BMMY inducing medium to produce sufficient amounts of recombinant products. Nickel-affinity chromatography was performed to purify the recombinant VEGF121/165b proteins. A Hi-Trap chelating column was coupled with an AKTÄ High-Pressure Liquid Chromatography device to achieve purification. The Pichia pastoris supernatants containing recombinant VEGF121/165b proteins were diluted in binding buffer and loaded into the HPLC device. The elution buffer was introduced gradually and mixed with the binding buffer in increasing proportions. The separation process yielded 1 mL fractions every step of the way.","After incubating samples at 29°C with thorough shaking for 24 hours, supernatants were collected and parametrized by SDS-PAGE to identify the most productive VEGF121/165b isoform clone. Selected clones were grown under adequate conditions in BMGY before being transferred to BMMY medium to boost recombinant product generation when required. Recombinant VEGF121/165b proteins were purified using nickel-affinity chromatography. The purification process utilized an AKTÄ High-Pressure Liquid Chromatography device in conjunction with a Hi-Trap chelating column. Supernatants containing recombinant proteins were diluted in binding buffer and loaded in the HPLC. The eluting buffer was added to the HPLC with gradually increasing proportions to the binding buffer, which was constantly stirred. Throughout the purification process, 1 mL fractions were taken."
"The protein samples were treated with affinity chromatography to purify them. Eluted proteins were separated from the eluting medium and dialyzed using Slide-A-lyzer cassettes of Pierce, which had a pore threshold of 10 KDa, to convert them to PBS. Eluted proteins were kept inside the cassettes, which were then immersed into 3L of PBS for an overnight period. For the continuity of the dialysis process, new PBS was added to the cassettes and left for another 6 hours. Finally, the dialyzed proteins were extracted from the cassettes using syringes before snap freezing them.","Once the protein samples had undergone affinity chromatography purification, eluting medium was removed and they were dialyzed to convert to a pH-buffered saline solution using Slide-A-Lyzer cassettes (manufactured by Pierce) with a physical threshold of 10 KDa. The procedure involved filling the cassettes with the eluted protein and immersing them in 3L of PBS for a duration of overnight. The process was continued by adding fresh batches of PBS for 6 hours each time. Thereafter, dialyzed proteins were extracted from the cassettes using syringes and snap-frozen for future use.","Following the process of affinity chromatography, purified proteins were extracted from the eluting medium and dialysed to convert to PBS solution by using Slide-A-lyzer cassettes with 10 KDa pore threshold (produced by Pierce). The cassettes were filled with the protein sample and were placed in 3L of PBS overnight. This process was continued by replacing it with fresh batches of PBS for an additional 6 hours. The extracted dialysed protein samples were subsequently collected from the cassettes with the help of syringes and snap-frozen for storage."
"To extract protein, the cultured cells were disrupted and mixed with a combination of RIPA buffer and protease inhibitor cocktail overnight. After centrifugation, the samples were subjected to bicinchoninic acid protein assay to determine the protein concentration. In the case of conditioned culture media, the supernatants were filtered to remove any cellular debris and concentrated by centrifugation using specialized equipment.","The cultured cells were treated with RIPA buffer for 30 minutes at 4°C to extract proteins, which was augmented with a protease inhibitor cocktail to prevent degradation. The samples were then separated by centrifugation, and the protein concentration was measured using the bicinchoninic acid protein assay. For conditioned culture media, supernatants were processed to remove any cell debris and concentrated by 20-fold using specialized centrifugation equipment designed to filter 15-KDa molecules.","Extraction of proteins from cultured cells was performed by treating them with RIPA buffer for 30 minutes at 4°C. The RIPA buffer was supplemented with protease inhibitor cocktail to prevent protein degradation. Following centrifugation, the protein concentration was evaluated using the bicinchoninic acid protein assay. To handle conditioned culture media, supernatants were filtered to eliminate any cellular waste and then concentrated 20-fold by centrifugation using specialized 15-KDa Amicon Ultra centricons."
"The proteins were run through Bis-Tris buffered gels from Novex Gels (Invitrogen) using standard procedures either with or without reduction. To begin, a 20 μg protein solution (in RIPA buffer) was combined with Laemmli sample buffer and boiled for 5 minutes. Electrophoresis was performed for 90 minutes at 130V and ambient temperature in 1X running buffer. The proteins were either directly stained with Coomassie blue within the gel or transferred onto PVDF membranes for immunodetection. VEGFxxxb proteins (90 μM) were subjected to deglycosylation analysis after treating with 0.8 mM Endo F1 for 1 hour at 37°C. Cleavage was monitored via SDS-PAGE.","Bis-Tris buffered gels from Novex Gels (Invitrogen) were utilized to electrophorese the proteins under either reducing or non-reducing conditions by adhering to the typical procedures. 20 μg protein solution (in RIPA buffer) was combined with Laemmli sample buffer and heated for 5 minutes to start with the electrophoresis. The electrophoresis was completed for 90 minutes at 130V and room temperature in 1X running buffer. The proteins were stained directly with Coomassie blue within the gel or transferred onto PVDF membranes for immunodetection. For VEGFxxxb proteins (90 μM), Endo F1 was added at a concentration of 0.8 mM to begin deglycosylation analysis, which was incubated for 1 hour at 37°C. SDS-PAGE monitored the cleavage.","Employing standard techniques, the proteins were electrophoresed in Bis-Tris buffered gels from Novex Gels (Invitrogen) under either reducing or non-reducing conditions. The Laemmli sample buffer and RIPA buffer mixture of 20 μg protein solution was boiled for 5 minutes to begin electrophoresis. Electrophoresis was then carried out in 1X running buffer at 130V for 90 minutes at ambient temperature. After the completion of electrophoresis, the proteins were either directly stained in the gel with Coomassie blue or transferred to PVDF membranes for immunodetection. VEGFxxxb proteins (90 μM) were subject to deglycosylation analysis, performed by incubating the protein solution with 0.8 mM Endo F1 for 1 hour at 37°C, and the breakdown was monitored via SDS-PAGE."
"To determine the presence of specific proteins, western blot membranes were rinsed two times with PBS-tween before being exposed to primary antibodies targeting various proteins, such as VEGF, VEGFxxxb, pKDR, total KDR, pERK1/2, total ERK1/2, and GAPDH. PBST along with 5% skim milk was used for blocking the membranes at room temperature for 30 minutes. The secondary antibodies, labeled with horseradish peroxidase, were then introduced to detect the targeted proteins. Finally, immunoreactive bands were made visible by using the chemoluminescent Lumi-lightPLUS kit.","Western blot membranes were prepared by washing them twice with PBS-tween, and then they were blocked using a solution of PBST and 5% skim milk for thirty minutes at room temperature. Primary antibodies specific to various proteins including, VEGF, VEGFxxxb, pKDR, total KDR, pERK1/2, total ERK1/2, and GAPDH were then introduced to the membranes. The next step was to add the secondary antibodies, which were labeled with horseradish peroxidase, against the corresponding primary antibodies. The immunoreactive bands were then visualized using a chemoluminescent method, and the Lumi-lightPLUS kit from Roche was utilized for the same.","To analyze protein expression, western blot membranes were first rinsed twice with PBS-tween and then blocked with PBST and 5% skim milk for thirty minutes at room temperature. Primary antibodies against various proteins such as VEGF, VEGFxxxb, pKDR, total KDR, pERK1/2, total ERK1/2, and GAPDH were added to the membranes. Horseradish peroxidase-labeled secondary antibodies were then used against the primary antibodies. Immunoreactive bands were visualized using the Lumi-lightPLUS kit, which utilizes a chemiluminescent method."
"The American Type Culture Collection (ATCC, Manassas, VA, USA) was the source of HUVECs, PC3, and A549 cell lines. PC3 and A549 cells were cared for in complete medium, which contained RPMI-1640 growth medium supplemented with 10% heat-inactivated FBS, 100 U/mL of penicillin, and 100 μg/mL of streptomycin (both antibiotics from Invitrogen). HUVECs, on the other hand, were maintained in EGM-MV2 medium (Lonza), which contained human recombinant EGF, VEGF, FGF, IGF-1, hydrocortisone, and ascorbic acid, as well as 2% FBS. For western blot analysis of cell supernatants, cell culture medium with 1% serum was utilized.","HUVECs, PC3, and A549 referred to as cell lines were received from the American Type Culture Collection (ATCC, Manassas, VA, USA). While PC3 and A549 cells were sustained in complete medium of RPMI-1640 growth medium equipped with Glutamax®, which was combined with 10% heat-inactivated FBS, and antibiotics such as 100 U/mL penicillin and 100 μg/mL streptomycin, both of which were from Invitrogen. On the contrary, HUVECs were maintained on EGM-MV2 medium (Lonza) with 2% FBS, containing human recombinant EGF, VEGF, FGF, IGF-1, hydrocortisone, and ascorbic acid. For the evaluation of cell supernatants through western blot, cell culture medium containing 1% serum was employed.","Three types of cell lines such as HUVECs, PC3 and A549 were collected from the American Type Culture Collection (ATCC, Manassas, VA, USA). The PC3 and A549 cells were sustained in the complete medium like RPMI-1640 growth medium (Invitrogen) equipped with Glutamax®, which was supplemented with 10% heat-inactivated FBS, together with antibiotics like 100 U/mL penicillin and 100 μg/mL streptomycin (both of which were obtained from Invitrogen). HUVECs were sustained on EGM-MV2 medium containing human recombinant EGF, VEGF, FGF, IGF-1, hydrocortisone, ascorbic acid and 2% FBS. To ascertain cells supernatants through western blot, the cell culture medium with 1% serum was employed."
"The process of delivering purified plasmidic DNA into mammalian cells was accomplished through the use of a cationic lipid-based transfection method accompanied by Lipofectamine 2000, as instructed by its manufacturer. Following selection, transfected cells were sustained with complete medium in addition to either 300 μg/mL (PC3) or 500 μg/mL (A549) G418.","Mammalian cells received purified plasmidic DNA via cationic lipid-based transfection with Lipofectamine 2000, following the manufacturer's recommendations. G418 at a concentration of 300 μg/mL (PC3) or 500 μg/mL (A549) was added to the complete medium to maintain transfected cells post-selection.","The introduction of purified plasmidic DNA into mammalian cells was achieved using a cationic lipid-based transfection method, accompanied by Lipofectamine 2000 as guided by the manufacturer's instructions. After selection, transfected cells were maintained through complete medium and G418, with concentrations of 300 μg/mL (PC3) or 500 μg/mL (A549) used for this purpose."
"The effect of various VEGF and VEGFR inhibitors on cell proliferation was investigated using two different methods. The MTT assay was employed, wherein cells were first seeded in 96-well plates containing 2% FBS growth medium and incubated overnight. RhVEGF165, VEGF 121 b, VEGF165b produced in Pichia pastoris, and VEGF165b produced in CHO cells, as well as the VEGFR inhibitor GW654652, were subsequently added to the wells at varying concentrations. At each time point, an MTT solution was added, and the plates were further incubated for an additional 3 hours before measurement of absorbance at 550 nm using a microplate reader. Control wells containing only complete medium were also included in each experiment. The evaluations were carried out thrice with six replicates for each concentration of drug.","This study aimed to examine the effects of several VEGF and VEGFR inhibitors on cell proliferation using two different techniques. The first method involved an MTT assay, whereby cells were seeded in 96-well culture plates containing 2% FBS growth medium and allowed to attach overnight. The culture plates were then treated with rhVEGF165, VEGF-related proteins produced in Pichia pastoris or CHO cells, or the VEGFR inhibitor GW654652 at varying concentrations. At each time point, an MTT solution was added, and the plates were incubated for 3 additional hours. The resulting formazan crystals were dissolved in 10% SDS-50% N-N-Dimethylformamide, and absorbance at 550 nm was measured using a microplate reader. Controls consisting of only complete medium were included in each experiment. The assays were performed three times, and six replicates were tested for each drug concentration.","The proliferation of cells was evaluated using two methods in this study. The first method involved the MTT assay, where cells were seeded into 96-well plates containing 2% FBS growth medium and allowed to attach overnight. VEGF-related proteins, such as rhVEGF165, VEGF 121 b, VEGF165b, and a VEGFR inhibitor GW654652, were subsequently introduced to the culture plates at varying concentrations. After each time point, a 5% MTT solution was added to the wells, and the plates were incubated for an extra 3 hours at 37°C. The resulting formazan crystals were dissolved in 10% SDS-50% N-N-Dimethylformamide, and absorbance at 550 nm was then recognized using a microplate reader. Controls with only complete medium were included in the experiment. Each trial was done three times with six replications per drug concentration."
"The method for analyzing DNA synthesis consisted of incorporating FdU, a modified nucleotide, followed by staining the incorporated nucleotide with an antibody. At 70% confluence, the cells were treated with various concentrations of a growth factor for a certain period of time. After treatment, the cells were exposed to FdU for 2 hours and then fixed, permeabilized and stained using the anti-FdU antibody. Finally, the cells were analyzed using flow cytometry to determine the levels of FdU incorporation.","An alternative approach for analyzing DNA synthesis was employed, which involved a BrdU incorporation assay. Cells were seeded on coverslips and incubated with varying concentrations of a growth factor for a duration of time. The cells were then incubated with BrdU for 2 hours and subsequently fixed with paraformaldehyde. Cells were permeabilized and treated with anti-BrdU antibodies to stain the BrdU incorporated into newly synthesized DNA. The intensity of the fluorescence signal was determined by confocal microscopy, which provided an estimate of the extent of DNA synthesis.","To assess DNA synthesis, a metabolic labeling technique with a thymidine analog was employed. Cells were cultured in the presence of varying concentrations of a growth factor for a specific duration of time. Following treatment, cells were pulse-labeled with ethynyl-deoxyuridine (EdU) for 30 minutes, harvested and fixed with paraformaldehyde. Cells were then stained for EdU by Click chemistry and visualized by fluorescence microscopy. The percentage of cells that incorporated EdU was determined and represented the level of DNA synthesis that occurred in response to the treatment."
"Athymic mice, known as Nu/Nu mice with Balb/C genetic background, were procured from Harlan Laboratories located in Barcelona, Spain. The maintainance of these mice was done under Specific Pathogen Free (SPF) standard conditions. To begin tumor growth, 200 μL PBS along with either one million PC3 or five million A549 cells and their corresponding transfectants in exponential growth phase were injected subcutaneously in the flanks of Nu/Nu mice. In order to keep track of tumor growth, tumors were measured with the help of precision callipers, and animals had to be sacrificed before a tumor grew to beyond 1.7 cm in diameter. All the experiments were carried out under the rules and regulations for ethical animal use of their Institution (CIMA-University of Navarra) which were under an approved protocol. Following the sacrifice, tumors were extracted and fixed overnight in 10% buffered formalin. Afterwards, embedding in paraffin followed. To calculate the primary tumor volumes, the formula used was V = length × (width)^2/2.","Balb/C genotype Nu/Nu mice, which are specifically bred to lack a thymus gland, were purchased from Harlan Laboratories situated in Barcelona, Spain. The mice were raised under Specific Pathogen Free (SPF) standard conditions. In order to initiate tumor growth, 200 μL PBS along with either one million PC3 or five million A549 cells, along with their corresponding transfectants in exponential growth phase, were subcutaneously injected into the flanks of Nu/Nu mice. To monitor the tumor progression, precision callipers were used and the growth of the tumor was restricted to a maximum diameter of 1.7 cm by sacrificing the mice beforehand. All experiments were in accordance with the ethical guidelines of animal use of their Institution (CIMA-University of Navarra) and were conducted under an approved protocol. Tumors were excised and soaked in 10% buffered formalin solution overnight, embedded in paraffin, and then divided into sections for analysis. The primary tumor volume was measured using the formula V = length × (width)^2/2.","Nu/Nu mutant athymic mice with Balb/C genetic background were procured from Harlan Laboratories located in Barcelona, Spain and were reared in Specific Pathogen Free (SPF) standard conditions. Tumor growth was initiated by subcutaneously injecting 200μL PBS along with one million PC3 or five million A549 cells and their corresponding transfectants in exponential growth phase in the flanks of Nu/Nu mice. The progress of the tumors was then monitored using precision callipers, and the animals were killed once the tumors attained a maximum diameter of 1.7 cm. The experiments were conducted in accordance with the guidelines for ethical use of animals of their Institution (CIMA-University of Navarra) under an approved protocol. The harvested tumors were then fixed in 10% buffered formalin overnight, embedded in paraffin and cut into sections for further analysis. Primary tumor volumes were measured using the formula V = length × (width)^2/2."
"The Matrigel plug assays involved mixing 400 μL of Growth Factor Reduced Matrigel (BD) with either 100 ng of rhVEGF165, VEGF121b(pp), VEGF165b(pp), or bFGF (as positive control) in a 100 μL PBS solution. This mixture was subsequently subcutaneously injected into Nu/Nu mice, and after a week of cell inoculation, the mice received either Fluorescein-labelled dextran (3 mg/mL) or Alexa-647labelled isolectin B4 (100 μg/mL) retro-orbitally. After waiting for 15 minutes, the mice were sacrificed, and the Matrigel plugs were extricated and examined using a Zeiss Axiovert confocal microscope.","To perform the Matrigel plug assays, 100 ng of rhVEGF165, VEGF121b(pp), VEGF165b(pp), or bFGF (as positive control) was mixed with 400μL Growth Factor Reduced Matrigel (BD) in 100 μL PBS before being subcutaneously injected into Nu/Nu mice. Following a week of cell inoculation, a retro-orbital injection of 100 mL Fluorescein-labelled dextran (3 mg/mL) or Alexa-647labelled isolectin B4 (100 μg/mL) was given to the mice. After 15 minutes, the Matrigel plugs were extracted from the mice, and the samples were analyzed using a Zeiss Axiovert confocal microscope.","For the Matrigel plug assays, 100 ng of rhVEGF165, VEGF121b(pp), VEGF165b(pp), or bFGF (as positive control) was mixed in 400 μL Growth Factor Reduced Matrigel (BD) and 100 μL PBS before being subcutaneously injected into Nu/Nu mice. After a week, the mice received a retro-orbital injection of either 100 mL Fluorescein-labelled dextran (3 mg/mL) or Alexa-647labelled isolectin B4 (100 μg/mL), followed by a 15-minute waiting period. The mice were then euthanized, and the Matrigel plugs were removed and studied using a Zeiss Axiovert confocal microscope."
"The specimens for the in vivo experiments, including both xenografted tumors and matrigel plugs, were fixed in 10% buffered formalin and embedded in paraffin. AccuMax, a company in Seoul, Korea, provided the Tissue Microarray (TMA) slides. The TMA slides comprise 100 breast tissue cores from 50 patients and 8 tissue cores from 4 normal breast tissues taken from mammoplasty. In the TMA, there are 33 infiltrating ductal carcinomas, 7 papillary carcinomas, 3 phyllodes tumors, 4 infiltrating lobular carcinomas, and 3 examples of other breast cancer tumor types.","The tissue samples comprising xenografted tumors or matrigel plugs were treated with 10% buffered formalin and embedded in paraffin following the in vivo experiments. The Tissue Microarray (TMA) slides provided by AccuMax contained 100 breast tissue cores obtained from 50 patients and 8 core samples taken from 4 normal breast tissues through mammoplasty. The TMA was composed of 33 infiltrating ductal carcinomas, 7 papillary carcinomas, 3 phyllodes tumors, 4 infiltrating lobular carcinomas, and 3 additional forms of breast cancer tumor types.","Tissue specimens from the in vivo experiments, comprising of xenografted tumors or matrigel plugs, were preserved in 10% buffered formalin and embedded in paraffin to prepare them for analysis. The Tissue Microarray (TMA) slides utilized in the study were obtained from AccuMax, a company based in Seoul, Korea. The TMA slides contained 100 breast tissue cores taken from 50 patients and 8 tissue cores extracted from 4 normal breast tissues during mammoplasty. The TMA was composed of various types of breast cancer, including 33 infiltrating ductal carcinomas, 7 papillary carcinomas, 3 phyllodes tumors, 4 infiltrating lobular carcinomas, and 3 additional breast cancer tumor types."
"The immunohistochemistry process involved several steps. Firstly, the slides were deparaffinized and hydrated. Then, the slides were incubated with 3% H2O2 in water for 10 minutes to eliminate the endogenous peroxidase activity. An antigen retrieval methodology was utilized for the identification of the antibodies. The primary antibodies utilized were Caspase 3 (Cleaved Caspase-3 Asp 175, Cell Signaling, diluted 1:200), CD-31 (Dianova, diluted 1:20), PDGFRb (Cell Signaling, diluted 1:100), VEGF (Santa Cruz, diluted 1:200), and VEGFxxxb (R&D, diluted 1:50). The primary antibodies were incubated overnight at 4°C except the CD31 antibody, which was incubated for 1 hour at RT. The slides were washed with TBS and then incubated with the appropriate secondary antibody. Finally, the EnVision™ antirabbit detection system (Dako) was used for each slide, followed by DAB (Dako) for peroxidase activity. Hematoxylin was used to counterstain the slides, which were then dehydrated and mounted. To quantify the immunohistochemistry of the xenografted tumor sections, 10 random images (200×) per mouse were captured with a microscope. The positive cells were quantified with the Image J software.","Immunohistochemistry was performed on the slides that were initially deparaffinized and hydrated. To quench the endogenous peroxidase activity, the slides were incubated with 3% H2O2 in water for 10 minutes. An antigen retrieval method was adopted for the detection of the antibodies. Five primary antibodies, namely Caspase 3 (Cleaved Caspase-3 Asp 175, Cell Signaling), CD-31 (Dianova), PDGFRb (Cell Signaling), VEGF (Santa Cruz), and VEGFxxxb (R&D), were used at different concentrations. The dilutions of the primary antibodies used were 1:200 for Caspase 3, 1:20 for CD-31, 1:100 for PDGFRb, 1:200 for VEGF, and 1:50 for VEGFxxxb. The slides were incubated with primary antibodies overnight at 4°C except for CD31, which was incubated for 1 hour at room temperature. After that, the tissues were washed with TBS and were allowed to incubate with the corresponding secondary antibody. The EnVision™ antirabbit detection system (Dako) was used for each slide, followed by DAB (Dako) for peroxidase activity. The slides were then counterstained with hematoxylin, dehydrated, and mounted. Immunohistochemistry quantification of the xenografted tumor sections was carried out using Analysis™ software equipped on a Leica microscope. Positive cells were counted with NIH's Image J software.","Immunohistochemistry was carried out by preparing the slides with deparaffinization and hydration. To quench the endogenous peroxidase activity, 3% H2O2 in water was used and the slides were incubated for 10 minutes. The detection of the antibodies was performed by using an antigen retrieval method. Different primary antibodies, including Caspase 3 (Cleaved Caspase-3 Asp 175, Cell Signaling), CD-31 (Dianova), PDGFRb (Cell Signaling), VEGF (Santa Cruz) and VEGFxxxb (R&D), were used at various concentrations. The primary antibodies were used at dilutions of 1:200 for Caspase 3, 1:20 for CD-31, 1:100 for PDGFRb, 1:200 for VEGF, and 1:50 for VEGFxxxb. The primary antibodies were incubated overnight at 4°C except for CD31, which was incubated for 1 hour at room temperature. After that, the tissues were rinsed with TBS and incubated with the corresponding secondary antibody. The EnVision™ antirabbit detection system (Dako) was used for each slide, followed by DAB (Dako) for peroxidase activity. The slides were counterstained with hematoxylin, dehydrated and mounted. The quantification of immunohistochemistry in xenografted tumor sections was done by capturing 10 random images (200×) per mouse with a microscope (Leica, Wetzlar, Germany), equipped with the Analysis™ software. The positive cells were counted with Image J (NIH, Bethesda, MD, USA)."
"Sectioned Matrigel plugs were examined to quantify FITC-dextran and Alexa-647 Isolectin B4. An Axiovert epifluorescence microscope (Carl Zeiss, Germany) was used to analyze the slides, and 10 random images were taken of each Matrigel. The ImageJ software was used to measure the labeled area.","Analysis of FITC-dextran and Alexa-647 Isolectin B4 in sections of Matrigel plugs was conducted by capturing 10 random images of each Matrigel using an Axiovert epifluorescence microscope (Carl Zeiss, Germany). The labeled area was subsequently analyzed using the ImageJ software.","The quantification of FITC-dextran and Alexa-647 Isolectin B4 in Matrigel plug sections was carried out by examining the labeled area. To do this, slides were analyzed using an Axiovert epifluorescence microscope (Carl Zeiss, Germany) and random images were taken (10 for each Matrigel). ImageJ software was then used to measure the labeled area."
"Statistical methodology was employed to analyze the data sets. To verify normal distribution, both Shapiro-Wilks and Kolgomorov-Smirnoff tests were utilized. To ensure homogeneity of variances, the Levene’s test was performed. If normal distribution was observed through tests, ANOVA was used to measure the possible differences among groups. For post-hoc comparison in the event of variance homogeneity, Bonferroni correction was applied. If Levene's test indicated positive results, Tamhane's correction was used. Non-parametric tests like Kruskal-Wallis and Mann-Whitney's U-test were applied to non-normal data sets. Wilcoxon's test was implemented for dependent sample data, and the tests were run using the SPSS software. To determine the significance level of the results, a p-value < 0.05 was considered significant (*), a p-value < 0.01 was very significant (**), and a p-value < 0.001 was classified as extremely significant (***).","The data sets underwent statistical analysis to determine normal distribution using Shapiro-Wilks and Kolgomorov-Smirnoff tests, while Levene’s test was performed to ensure homogeneity of variances. When normal distribution was found using the tests, ANOVA was utilized to gauge any viable differences among groups. Bonferroni correction was then applied to post-hoc comparisons if variance homogeneity was detected, with Tamhane’s correction being used for favorable outcomes in Levene's test. In cases where the data sets were not normally distributed, non-parametric tests such as Kruskal-Wallis and Mann-Whitney's U-test were applied for multiple comparisons. For independent samples, significance corrections were carried out using Wilcoxon's test, while SPSS software was used to run these tests. Results with a p-value < 0.05 were classified as significant (*), while those with a p-value < 0.01 (**) and < 0.001 (***) were recognized as very significant and extremely significant respectively.","The statistical analysis was conducted on the data sets to determine the normal distribution via both Shapiro-Wilks and Kolgomorov-Smirnoff tests, while the Levene’s test was used to verify homogeneity of variances. In cases where tests reflected normal distribution, the ANOVA was applied to detect any possible differences among groups. Following variance homogeneity, the Bonferroni correction was executed for post-hoc comparisons, while Tamhane’s correction was utilized when Levene’s test results were positive. When data sets were non-normally distributed, non-parametric tests such as Kruskal-Wallis and Mann-Whitney's U-test were carried out for multiple comparisons. For independent samples, a significance correction was done using Wilcoxon's test, and all statistical tests were executed through the SPSS software. Results that showed a p-value < 0.05 were considered significant (*), while those with p < 0.01 (**) and < 0.001 (***) were deemed very significant and extremely significant, respectively."
"The diagram presented in Figure 1 displays the exon arrangement in each of the traditional VEGF-A isoforms and the VEGFxxxb isoforms. The genetic code sequence for VEGF121b and VEGF165b without their original human signal peptide was integrated into the pPICZalphaC plasmid. In these constructs, the yeast alpha-factor signal peptide was substituted for the human one, which is known to be an effective secretion inducer in Pichia pastoris. To obtain first-rate recombinant proteins, nickel-affinity chromatography was employed to purify VEGFxxxb from Pichia pastoris culture supernatants, as shown in the chromatogram in Figure 2A. Peak 2 of VEGF121b was recovered using a 20% imidazole gradient when it was eluted. Coomassie blue-stained bands, corresponding to the expected size of VEGF121b, were found in various aliquots during the elution of VEGF121b near peak 2, as demonstrated in Figure 2B. These results suggest that nickel-affinity chromatography is a potent approach for extracting VEGFxxxb proteins from Pichia pastoris culture supernatants.","Figure 1 portrays the schematic layout of the distinct exons present in both the classical VEGF-A isoforms and the VEGFxxxb isoforms. The pPICZalphaC plasmid was used to clone the coding sequence for both VEGF121b and VEGF165b without the endogenous human signal peptide. In these constructs, the yeast alpha-factor signal peptide was substituted for the human one, which is known to be a proficient secretion inducer in Pichia pastoris. Nickel-affinity chromatography was employed to obtain high-quality recombinant proteins of VEGFxxxb from Pichia pastoris culture supernatants, as demonstrated in the chromatogram in Figure 2A. VEGF121b was eluted from the column using a 20% imidazole gradient, where proteins were isolated around peak 2 following Coomassie blue staining of aliquots taken during VEGF121b elution, as shown in Figure 2B. These findings indicate the efficacy of nickel-affinity chromatography for purifying VEGFxxxb proteins from Pichia pastoris culture supernatants.","A scheme in Figure 1 illustrates the different exons present in the classical VEGF-A isoforms and the VEGFxxxb isoforms. The genetic sequence for VEGF121b and VEGF165b was cloned into the pPICZalphaC plasmid without their original human signal peptide. The yeast alpha-factor signal peptide was substituted for the human signal peptide in these constructs, known to be a potent stimulator of secretion in Pichia pastoris. The use of nickel-affinity chromatography was employed to obtain high-quality recombinant proteins of VEGFxxxb from Pichia pastoris culture supernatants, as seen in the chromatogram in Figure 2A. VEGF121b was extracted from the column with a 20% imidazole gradient, and Coomassie blue-stained bands corresponding to the expected size of VEGF121b were found in aliquots collected during elution around peak 2 in Figure 2B. These findings suggest that nickel-affinity chromatography is a successful method to purify VEGFxxxb proteins from Pichia pastoris culture supernatants."
"Figure 2C exhibits the electrophoresis of culture media from Pichia pastoris clones that were subjected to electroporation with pPICZaphaC plasmids containing the linearized VEGF 121b or VEGF 165 b sequence and were selected with zeocin for one week. The clones' supernatants showed bands that corresponded to the expected molecular masses. In particular, the ectopic protein amounts were prominently visible among the total secreted proteins produced by yeast. Larger amounts of recombinant VEGFxxxb proteins were overexpressed by specific clones and subsequently chosen for large-scale production. It is noteworthy to mention that the Pichia pastoris-derived recombinant proteins were found to be immunoreactive with the commercially available and previously validated VEGFxxxb antibody from R&D in Figure 2D.","The results for the electrophoresed culture media in Figure 2C show Pichia pastoris clones electroporated with pPICZaphaC plasmids containing linearized VEGF 121b or VEGF 165b sequence, and were then selected with zeocin after a week. The expected molecular masses showed up as bands in the clones' supernatants. Notably, the total secreted proteins produced by yeast showed a clear amount of ectopic protein visible. The overexpressed Pichia pastoris clones with higher amounts of recombinant VEGFxxxb proteins were chosen for large-scale production. It is important to mention that the Pichia pastoris-derived recombinant proteins were reactive to the commercially available and previously validated VEGFxxxb antibody from R&D shown in Figure 2D.","In Figure 2C, the electrophoresed culture media from Pichia pastoris clones that were initially electroporated with pPICZaphaC plasmids containing linearized VEGF 121b or VEGF 165b sequence and selected with zeocin for one week are displayed. The supernatants from the clones showed bands of the expected molecular masses. Notably, the total secreted proteins produced by yeast contained visibly clear amounts of ectopic protein. Clones that overexpressed higher amounts of recombinant VEGFxxxb proteins were selected for large-scale production. An important point to remember is that in Figure 2D, the Pichia pastoris-derived recombinant proteins showed reactivity with the commercially available and pre-validated VEGFxxxb antibody from R&D."
"The result of the experiment conducted on the expression of recombinant human VEGF121/165b isoforms in Pichia pastoris showed a distinctive pattern in the gel that was similar to the native VEGFxxx isoforms. VEGF121b was found to form dimers that appeared as three bands on the gel when a non-reducing condition was applied. The three bands were supposed to be dimers of glycosylated-glycosylated, glycosylated-non-glycosylated, and non-glycosylated-non-glycosylated proteins. This was in accordance with the VEGF-A classic isoforms. Under reducing conditions, only two bands appeared, indicating the protein's ability to dimerize. VEGF165b showed the same pattern, but the bands were not as visible as VEGF121b. The recombinant VEGFxxxb proteins also made massive complexes such as tetramers and octamers.","The expression of recombinant human VEGF121/165b isoforms in Pichia pastoris showed a band pattern on the gel, which was quite similar to that of the native VEGFxxx isoforms. Under non-reducing conditions, VEGF121b was found to form dimers that could be seen as three bands on the gel. This suggested that the three bands, most likely made up of glycosylated-glycosylated, glycosylated-non-glycosylated, and non-glycosylated-non-glycosylated proteins, were consistent with VEGF-A classic isoforms. When the same culture supernatants were run under reducing conditions, only two bands were visible, providing evidence of the protein's ability to dimerize. VEGF165b showed the same pattern, though the bands weren't as distinct as those of VEGF121b. VEGFxxxb proteins that were recombinant also formed significant complexes ranging from tetramers to octamers, especially in the case of VEGF165b.","The band pattern of the expressed recombinant human VEGF121/165b isoforms in Pichia pastoris bore similarities to that of the native VEGFxxx isoforms, as described in the past. VEGF121b was seen to form dimers that formed three bands on the gel under non-reducing conditions. These bands are likely to correspond to dimers of glycosylated-glycosylated, glycosylated-non-glycosylated, and non-glycosylated-non-glycosylated proteins. This pattern is in line with that of the VEGF-A classic isoforms. When culture supernatants were run under reducing conditions, only two bands appeared on the gel, pointing towards the protein's ability to dimerize. Although VEGF165b had a similar pattern, the bands were not as visible as those of VEGF121b. Recombinant VEGFxxxb proteins formed larger complexes such as tetramers and octamers, particularly in the case of VEGF165b."
"Endoglycosidase F1 was utilized in both reducing and non-reducing conditions to evaluate the glycosylation status of the VEGFxxxb recombinant proteins produced in Picha pastoris. The researchers referred to Additional file 1 Figure S1 while performing this assay. Both the isoforms of VEGF121/165 b displayed an electrophoretic shift upon deglycosylation. Interestingly, the molecular weights of the glycosylated and deglycosylated proteins were similar to the ones reported for VEGF121 and VEGF165 in the previous studies [20, 21].","The glycosylation status of VEGFxxxb recombinant proteins obtained from Picha pastoris was examined using endoglycosidase F1 in both reduced and non-reduced conditions. Additional file 1 Figure S1 aided in this evaluation. Deglycosylation of both isoforms of VEGF121/165 b resulted in an electrophoretic shift. The molecular weight of glycosylated and deglycosylated proteins was comparable to the molecular weight reported for VEGF121 and VEGF165 in previous studies. [20, 21].","To evaluate the glycosylation status of the VEGFxxxb recombinant proteins produced in Picha pastoris, researchers utilized endoglycosidase F1 in both reducing and non-reducing conditions. Additional file 1 Figure S1 was consulted during the experiment. Deglycosylation of both VEGF121/165 b isoforms caused an electrophoretic shift. The molecular weight of both the glycosylated and deglycosylated proteins was similar to the previously reported molecular weight of VEGF121 and VEGF165 [20, 21]."
"To determine the impact of VEGF121/165b recombinant proteins generated in-house, first, the endothelial cell proliferation was assessed in vitro. Additionally, the impact of the VEGF165b recombinant protein (VEGF165b(hs)) produced in mammalian CHO cells was evaluated to rule out any effect occurring from yeast-glycosylation. The MTT assay was performed in the first experiment, and it was found that 100 ng/mL commercial VEGF165 (from R&D) induced a 63% increase in HUVEC proliferation compared to cells that were left untreated. Co-administration of VEGF 165 with VEGF 121 b(pp), VEGF 165 b(pp), or VEGF 165 b(hs) resulted in a similar proliferation induction. As a consequence, the HUVECs exposed to each ""b-isoform"" alone showed a roughly 40% increase in proliferation. Inducing HUVECs with the VEGFR-targeting compound GW654652, either alone or in conjunction with VEGF165b(hs), resulted in similar proliferation rates to that of untreated control cells. These findings illustrated the VEGF165b's specificity, causing VEGFR-mediated endothelial proliferation. The VEGFR inhibitor produced comparable findings in VEGF 121 b(pp) and VEGF 165 b(pp) as well, as shown in the results.","The researchers evaluated the impact of VEGF121/165b recombinant proteins prepared in their laboratory (VEGF121b(pp) and VEGF165b (pp)) on endothelial cell proliferation in vitro. They also examined the impact of VEGF165b recombinant protein (VEGF165b(hs)) made in mammalian CHO cells to negate any impact resulting from yeast-glycosylation. The MTT assay was used in the first experiment. It was discovered that the addition of 100 ng/mL commercial VEGF165 (from R&D) prompted HUVEC proliferation by 63% equated to untreated cells (Figure 3A). Simultaneously, co-treatment of VEGF 165 and VEGF 121 b(pp), VEGF 165 b(pp), or VEGF 165 b(hs) resulted in a similar proliferative induction (Figure 3A). When HUVECs were exposed to each of the recombinant ""b-isoforms"" alone, they showed a ~40% rise in proliferation. The VEGFR-targeting compound GW654652 with VEGF165b(hs) had similar HUVECs proliferation rates as that of the untreated control cells, illustrating the specificity of VEGF165b in inducing VEGFR-mediated endothelial growth. The VEGFR inhibitor produced similar results in VEGF 121 b(pp) and VEGF 165 b(pp) (results not shown).","Using the in vitro cell proliferation assay, the laboratory-produced VEGF121b(pp) and VEGF165b(pp) recombinant proteins were assessed for their efficacy on endothelial cells. To exclude any potential yeast-glycosylation-derived impacts, the researchers also studied the impact of VEGF165b recombinant protein (VEGF165b(hs)) prepared utilizing mammalian CHO cells. The MTT assay was conducted and determined that exposure to 100 ng/mL commercial VEGF165 (from R&D) led to a 63% rise in HUVEC proliferation compared to untreated cells (Figure 3A). Furthermore, co-treatment of VEGF 165 with VEGF 121 b(pp), VEGF 165 b(pp), or VEGF 165 b(hs) led to matched proliferative inductions (Figure 3A). The exposure of HUVECs to each recombinant ""b-isoform"" alone led to approximately a 40% increase in proliferation. When administered alone or with VEGF165b(hs), the VEGFR-targeting compound GW654652 had similar HUVEC proliferation rates as the untreated control cells (Figure 3A). This indicated VEGF165b's specificity in stimulating VEGFR-mediated endothelial proliferation. Similar results were seen when VEGFR inhibitors were used with VEGF 121 b(pp) and VEGF 165 b(pp) (results not shown)."
"The team used a distinct approach to corroborate their findings on cellular proliferation. They employed a technique that involved monitoring DNA integration into cells. As presented in Figure 3B, the introduction of bFGF and VEGF 165 brought about a three-fold surge (p < 0.001) of DNA integration into HUVECs as opposed to the untreated controls. Notably, exposure to VEGF165b(pp) and VEGF121b(pp) resulted in a substantial (p < 0.01) incremental change in DNA integration into HUVECs, which was almost twofold higher than the controls. Hence, these outcomes are similar to those obtained via the MTT test, revealing that VEGFxxxb isoforms prompt cellular proliferation, although such potency is lower than VEGF165.","In order to verify their discoveries regarding cell proliferation, the research team decided to utilize a distinct methodology which was based on DNA integration into the cells. According to Figure 3B, when administered with bFGF and VEGF 165, the DNA integration into HUVECs increased by three times (p < 0.001), compared to HUVECs that were not treated. Furthermore, it was observed that when exposed to VEGF165b(pp) and VEGF121b(pp), the DNA integration into HUVECs increased by almost two times (p < 0.01) compared to the untreated HUVECs. Hence, these findings were consistent with those obtained using MTT tests that the VEGFxxxb isoforms enhance cell proliferation, although not as effectively as VEGF165.","To verify their findings on cell proliferation, the research group used an unrelated method that utilized DNA incorporation into the cells. The results shown in Figure 3B indicated that the administration of bFGF and VEGF 165 caused a three-fold increase (p < 0.001) in DNA incorporation into HUVECs when compared to the untreated controls. Particular attention was also paid to the exposure of VEGF165b(pp) and VEGF121b(pp), which resulted in a significant (p < 0.01) two-fold raise in DNA incorporation into HUVECs, in comparison to the untreated controls. Therefore, the results obtained by MTT showed that VEGFxxxb isoforms enhanced proliferation, but to a lesser extent than VEGF165."
"When all VEGF-A proteins were added to the HUVECs, it resulted in the activation of the VEGF-A receptor Flk-1/KDR and the intracellular kinase ERK1/2. The expected outcome was observed when VEGF165 was used, where it caused the activation of KDR and ERK1/2 within 10 minutes of treatment in the absence of serum (serum-free). VEGF121/165b proteins were also found to induce KDR activation in HUVECs. Production of VEGF121b and VEGF165b in mammalian cells or in Pichia pastoris resulted in similar levels of ERK1/2 activation. Co-treatment of VEGF165 and VEGF121/165b did not prevent KDR or ERK1/2 activation induced by VEGF165. However, when the VEGFRs inhibitor GW654652 was added to VEGF165b(pp), it failed to activate the KDR-ERK pathway, suggesting the involvement of receptor-specific mechanisms. Similar observations were made involving VEGF121b(pp) and VEGF165b(hs), except that the results obtained with VEGF165b (hs) were not shown.","The addition of all VEGF-A proteins to HUVECs led to the phosphorylation of the VEGF-A receptor Flk-1/KDR and intracellular kinase ERK1/2. VEGF165 was observed to cause KDR and ERK1/2 phosphorylation within 10 minutes of serum-free treatment, as expected. HUVECs also showed KDR phosphorylation in the presence of VEGF121/165b proteins, which were capable of inducing similar levels of ERK1/2 phosphorylation as VEGF121b and VEGF165b produced from either mammalian cells or Pichia pastoris. The combined usage of VEGF165 and VEGF121/165b failed to prevent KDR or ERK1/2 phosphorylation caused by VEGF165. Consequently, the absence of the VEGFRs inhibitor GW654652 was found to specifically activate KDR-ERK pathway via VEGF165b(pp). Similar observations were made for VEGF121b(pp) and VEGF165b(hs), except for VEGF165b(hs) whose results were not shown.","The use of all VEGF-A proteins on HUVECs resulted in the phosphorylation of Flk-1/KDR (VEGFR2) and intracellular kinase ERK1/2. VEGF165 phosphorylated KDR and ERK1/2 as expected after 10 minutes of treatment in serum-free conditions. VEGF121/165b proteins also stimulated KDR phosphorylation in HUVECs. Both VEGF121b and VEGF165b, regardless of whether they were produced in mammalian cells or Pichia pastoris, activated ERK1/2 phosphorylation with similar effectiveness. The co-administration of VEGF 165 and VEGF121/165b proteins did not inhibit KDR or ERK1/2 phosphorylation induced by VEGF165. VEGF165b(pp) did not activate the KDR-ERK pathway in the presence of GW654652, the VEGFRs inhibitor, indicating receptor specificity. Similarly, VEGF121b(pp) and VEGF165b (hs), with the exception of VEGF165b (hs), produced similar results, although the outcomes were not presented in the research."
"The effects of VEGF121/165b isoforms on endothelial cell function in vivo were analyzed through Matrigel plug assays. Matrigels were combined with bFGF, VEGF165 (from R&D), VEGF121b(pp), or VEGF165b(pp). The presence of blood vessels within the Matrigel plugs was detected using a systemic injection of Alexa-647-labelled isolectin B4 (Figure 5A), which revealed no signal in the control Matrigels. However, the presence of any VEGFxxxb isoforms in the plugs resulted in a strong signal, indicating angiogenesis in vivo (Figure 5A). Vascular permeability was evaluated in another set of mice by injecting FITC-labelled-dextran into Matrigel plugs under similar experimental conditions (Figure 5B). A significant increase in the fluorescent signal was observed in Matrigels loaded with bFGF or VEGF121b, whereas control plugs had almost no signal. In contrast, Matrigel plugs with either VEGF165 or VEGF165b exhibited a similar degree of fluorescence, which was almost ten times greater than control.","To investigate how VEGF121/165b isoforms affect endothelial cell function in vivo, Matrigel plug assays were carried out. Matrigels were mixed with bFGF, VEGF165 (from R&D), VEGF121b(pp), or VEGF165b(pp). The presence of blood vessels within the Matrigel plugs was determined by the injection of Alexa-647-labelled isolectin B4 systemically into the mice before they were sacrificed, with control Matrigels exhibiting no signal from the Alexa-647-labelled lectin. The VEGFxxxb-containing plugs, on the other hand, displayed a strong signal, indicating in vivo angiogenesis (Figure 5A). Vascular permeability was measured in another group of mice with Matrigel plugs under similar experimental conditions by injecting FITC-labelled-dextran (Figure 5B). In contrast to controls, significant fluorescence was observed in bFGF or VEGF121b pre-loaded Matrigels. Matrigels with VEGF165 or VEGF165b displayed the same degree of fluorescence, which was approximately ten times greater than in controls.","Matrigel plug assays were performed to examine the effect of VEGF121/165b isoforms on endothelial cell function in vivo. Matrigels were mixed with bFGF, VEGF165 (from R&D), VEGF121b(pp), or VEGF165b(pp). The presence of blood vessels within the Matrigel plugs was determined by injecting the mice systemically with Alexa-647-labelled isolectin B4 before they were sacrificed, with control Matrigels showing no signal from the Alexa-647-labelled lectin. In contrast, the plugs containing VEGFxxxb isoforms produced a strong signal, confirming in vivo angiogenesis (Figure 5A). Vascular permeability was investigated in another set of mice by injecting FITC-labelled-dextran into Matrigel plugs under similar experimental conditions (Figure 5B). While the healthy plugs had almost no signal, there was a significant rise in fluorescence in Matrigels pre-loaded with either bFGF or VEGF121b. Matrigel plugs with either VEGF165 or VEGF165b revealed a comparable degree of fluorescence, which was nearly ten times higher than in the controls."
"The in vivo assays conducted in this study utilized two different cell lines, one with high endogenous VEGF expression (PC-3) and the other with low expression (A549). Overexpression of VEGF 121/165 b isoforms was performed in both xenograft models to examine their impact on angiogenesis and tumor growth. Western blot analyses verified the overexpression of VEGF121b or VEGF165b in the selected cell pools. Results revealed no significant differences in tumor growth between the control group and tumors that had overexpressed either or both isoforms in PC3 xenografts. However, in the case of A549 xenografts, injection of cells that overexpressed VEGF 121b or VEGF 165b showed remarkable increases in tumor volume compared to the control group. Thus, it is established that overexpression of VEGF121/165 b isoforms did not provoke tumor shrinkage, but instead induced tumor growth in both cell lines.","The study implemented two different cell lines for in vivo assays: PC-3 with high endogenous VEGF expression and A549 with low expression. The impact of VEGF 121/165 b isoforms on tumor growth and angiogenesis was assessed through overexpression in both xenograft models. Western blot analyses revealed high expression levels of VEGF121b or VEGF165b in the cell pools selected over 20 days of incubation with G418. The experimental group that overexpressed either or both isoforms did not show significant differences in tumor growth compared to the control in the case of PC3 xenografts but VEGF121b-overexpressing cells tended to form bigger tumors. Conversely, injection of cells with overexpressed VEGF121b or VEGF165b in A549 xenografts showed a significant increase in tumor volume. Hence, the study revealed that overexpression of VEGF121/165 b isoforms did not result in tumor shrinkage; rather, it led to tumor growth in these models.","The in vivo assays included two cell lines with different endogenous total VEGF expression levels: PC-3 with high expression and A549 with low expression. VEGF 121/165 b isoforms were overexpressed in both xenograft models to investigate their impact on tumor growth and angiogenesis. The cell pools selected following a 20-day incubation with G418 exhibited a substantial expression of either VEGF121b or VEGF165b according to western blot analyses. In the PC3 xenograft model, there were no significant differences between the control group and experimental groups that overexpressed either isoform alone or both in terms of tumor growth. Nonetheless, VEGF121b-overexpressing cells had a tendency to form larger tumors. However, in the A549 xenograft model, cells with overexpressed VEGF121b or VEGF165b had significantly larger tumors than the control group. Therefore, overexpression of the VEGF121/165 b isoforms did not result in tumor shrinkage but caused tumor growth in these models."
"The results of the angiogenesis analysis revealed that PC-3 tumors had higher levels of angiogenic activity compared to A549 tumors. However, no significant differences were observed between the control and experimental groups in both tumor types. In PC-3 tumors, the overexpression of VEGF121b resulted in a notable increase in vascularization when compared to the other experimental groups including Parental, Mock-transfected, and VEGF165b. The analysis of PDGFRb levels through immunohistochemistry and image analysis showed no significant difference in the number of PDGFRb+ cells present in either PC-3 or A549 xenografted tumors. The study of apoptotic cells in xenografted tumors revealed a reduction in the number of apoptotic cells in PC-3 tumors injected with VEGFxxxboverexpressing cells, while no significant changes were seen in A549 xenografted tumors.","Evaluating angiogenesis, it was observed that the activity was high in PC-3 tumors when compared to A549 tumors. There weren't any significant variations between controls and experimental groups in both the tumor types. Remarkably, the overexpression of VEGF121b in PC-3 tumors resulted in an increase in vascularization when compared to the other experimental groups like Parental, Mock-transfected, and VEGF165b. The levels of PDGFRb through immunohistochemistry and image analysis in pericytes and bone-marrow-derived cells were not impacted in either PC-3 or A549 xenografted tumors. There wasn't an increase but a decrease in the number of apoptotic cells observed in PC-3 tumors injected with VEGFxxxboverexpressing cells when compared to controls, but there were no changes noted in A549 xenografted tumors.","The angiogenesis analysis discovered that the level of angiogenic activity in PC-3 tumors was higher than that in A549 tumors. However, both tumor types did not depict much difference between control and experimental groups. The VEGF121b overexpression in PC-3 tumors was linked to a considerable boost in vascularization when contrasted with the other experimental groups which include Parental, Mock-transfected, and VEGF165b. Analysis of mural recruitment to the vasculature and immunohistochemistry image analysis of the PDGFRb levels were carried out. The results showed that there was no reduction in the pericytes and bone-marrow-derived cells that are involved in blood vessel formation in either PC-3 or A549 xenografts compared to the control group. Quantifying the number of apoptotic cells measured an incremental decrease in PC-3 tumors injected with VEGFxxxboverexpressing cells relative to controls, but no significant changes were observed in A549 xenografted tumors."
"Existing studies have explored the differential expression of VEGFxxxb isoforms across normal and pathological conditions. To test whether this applies to breast cancer, a TMA was utilized consisting of core biopsies from patients with breast cancer and normal breast tissue. The study employed a highly reliable antibody capable of detecting all VEGF-A isoforms, including total VEGF-A (R&D systems) in addition to the singular authorized anti-VEGFxxxb antibody competent in identifying every VEGFxxxb protein (also sourced from R&D systems) [18]. Unfortunately, there exists no available antibody capable of distinguishing between ""non-b"" isoforms (VEGFxxx).","The expression of VEGFxxxb isoforms has been found to vary between normal and pathological conditions in previous research. To determine if this is also the case for breast cancer, a TMA containing core biopsies of breast cancer patients and normal breast tissue was utilized. A validated antibody that recognizes all VEGF-A isoforms, including total VEGF-A (R&D systems), was utilized along with the only certified anti-VEGFxxxb antibody that detects all VEGFxxxb proteins (also R&D systems) [18]. Unfortunately, currently there is no available antibody specific to the ""non-b"" isoforms (VEGFxxx).","Prior research suggests that VEGFxxxb isoforms exhibit differential expression under normal versus pathological conditions. To investigate whether this also holds true for breast cancer, a TMA comprised of core biopsies from both breast cancer patients and normal breast tissue was employed. A well-validated antibody that detects total VEGF-A, including all VEGF-A isoforms, (R&D Systems) and the only validated anti-VEGFxxxb antibody, recognizing all the VEGFxxxb proteins (also R&D Systems) [18], were used. However, there is currently no antibody available that is specific to the ""non-b"" isoforms (VEGFxxx)."
"Figures 8A and 8B display some images of malignant and normal breast tissues stained with the anti-VEGFxxxb and anti-total VEGF-A antibodies. The VEGFxxxb stained strongly in tumor cells of infiltrating ductal carcinoma (IDC) samples, and other forms of tumors, including papillary carcinoma (Pap), phyllodes (Phy), infiltrating lobular carcinomas (ILC), and ductal carcinoma in situ (DCIS). Conversely, no VEGFxxxb was detected in any of the normal breast tissue (NBT) samples. All tissues analyzed were VEGF-A positive, including the normal breast epithelium. The semiquantification of the staining revealed that both total VEGF-A and VEGFxxxb protein levels were significantly higher (p < 0.05) in IDC than in normal breast tissues, as presented in Figures 8C and 8D. Furthermore, a positive correlation existed (p = 0.033) between VEGFxxxb and total-VEGF-A, indicating the degree of co-staining. Consequently, it is concluded that VEGFxxxb levels tend to increase in the tumor samples of malignant breast cancer and are notably higher in infiltrating ductal carcinomas.","Representative photos of malignant and normal breast tissues stained with the anti-VEGFxxxb and anti-total VEGF-A antibodies are presented in Figures 8A and 8B. The analysis showed that VEGFxxxb is strongly stained in tumor cells of infiltrating ductal carcinoma (IDC) samples, as well as in other tumor types, including papillary carcinoma (Pap), phyllodes (Phy), infiltrating lobular carcinomas (ILC), and ductal carcinoma in situ (DCIS). Conversely, no VEGFxxxb was observed in any of the normal breast tissue (NBT) samples. Additionally, all tissues analyzed showed positive results for total-VEGF-A, including normal breast epithelium. The semiquantification of the staining revealed that IDC has higher levels (p <0.05) of both total VEGF-A and VEGFxxxb protein levels compared to normal breast tissues, as presented in Figures 8C and 8D. Also, there was a positive correlation (p = 0.033) between VEGFxxxb and total-VEGF-A, indicating the degree of co-staining. Based on these results, it is concluded that VEGFxxxb levels tend to increase in the malignant breast cancer samples, especially in infiltrating ductal carcinomas (IDC).","Figures 8A and 8B display some representative pictures of malignant and normal breast tissues stained with anti-VEGFxxxb and anti-total VEGF-A antibodies. The staining analysis indicated that VEGFxxxb is strongly present in tumor cells of infiltrating ductal carcinoma (IDC) samples and other tumor types, such as papillary carcinoma (Pap), phyllodes (Phy), infiltrating lobular carcinomas (ILC), and ductal carcinoma in situ (DCIS). However, normal breast tissue (NBT) samples did not show any VEGFxxxb staining. All types of tissue analyzed were positive for total-VEGF-A, including the normal breast epithelium. Furthermore, semiquantification of the staining showed that both total VEGF-A and VEGFxxxb protein levels were significantly higher (p <0.05) in IDC than normal breast tissues, as shown in Figures 8C and 8D. A positive correlation between VEGFxxxb and total-VEGF-A was reported, signifying the degree of co-staining between these two markers. Thus, we conclude that VEGFxxxb levels tend to increase in malignant breast cancer, specifically in infiltrating ductal carcinomas."
"The exploration and documentation of VEGF-A's significance in normal and pathological angiogenesis has been widely researched over the years. As a result, VEGF-A has become the primary target for cancer therapy in solid tumors, and medicines targeted at VEGF, such as bevacizumab and sunitinib, are presently being deployed in patients. However, there is still a lack of information regarding the biology of VEGF-A spliced isoforms. In particular, comprehending how different VEGF-A isoforms are generated via alternative splicing could be crucial to developing more precise and efficient molecular therapies.","The role of VEGF-A in normal and pathological angiogenesis has been widely studied and recorded for several decades. Solid tumors have been a primary focus for cancer treatment, and drugs targeted at VEGF, such as bevacizumab or sunitinib, are currently being utilized in patients. Despite this, the biology of VEGF-A spliced isoforms remains largely unexplored. To develop more effective molecular therapies, it may be critical to understand how alternative splicing generates different VEGF-A isoforms.","The importance of VEGF-A in normal and abnormal angiogenesis has been extensively researched in recent decades. Cancer treatments in solid tumors have focused on targeting VEGF, with drugs like bevacizumab and sunitinib frequently prescribed for patients. However, the molecular mechanisms behind the creation of various VEGF-A spliced isoforms have yet to be well understood. Developing a deeper understanding of alternative splicing, and how it influences the generation of different VEGF-A isoforms, could lead to more specific and effective molecular therapies."
"In 2002, a novel set of VEGF-A isoforms was discovered, originating from alternative splicing, which they dubbed VEGFxxxb isoforms. These isoforms incorporate a novel exon, exon 8b, which differs from the classical exon 8a found in angiogenic transcripts. The inclusion of exon 8b was thought to impart VEGFxxxb isoforms with the ability to bind VEGF-A receptors without significant signaling downstream, implying that these isoforms are likely to possess anti-angiogenic properties. Overexpressing VEGF 165 b or VEGF 121 b in tumor cells xenografted into nude mice resulted in growth inhibition, according to cautious findings. Additionally, VEGFxxxb isoforms can be differentially expressed in pathological tissues in comparison to normal tissues, indicating that changes in natural splicing could promote VEGFxxx transcripts in certain aberrant proliferation-related diseases, resulting in reduced levels of VEGFxxxb isoforms which are mainly expressed in normal tissues.","The year 2002 witnessed the discovery of a novel group of VEGF-A isoforms that emerge through an alternative splicing mechanism, known as VEGFxxxb isoforms. These isoforms contain a unique exon, dubbed exon 8b, unlike the classical exon 8a that exists in angiogenic transcripts. The incorporation of exon 8b was speculated to offer VEGFxxxb isoforms the potential to bind to VEGF-A receptors without resulting in a robust downstream signaling, providing preliminary evidence that these isoforms could possess anti-angiogenic characteristics. Studies have shown that overexpression of either VEGF 165 b or VEGF 121 b in tumor cells transplanted in nude mice can inhibit growth, though the results need to be cautiously interpreted. Additionally, VEGFxxxb isoforms may be variably expressed in pathological tissues in comparison to normal tissues, with alterations in natural splicing potentially favouring the amount of the VEGFxxx transcripts in some aberrant angiogenesis-linked illnesses, resulting in a reduction in the volume of VEGFxxxb isoforms normally present in healthy tissues.","The discovery of a new cluster of VEGF-A isoforms occurred in 2002 when researchers found VEGFxxxb isoforms generated through alternative splicing. VEGFxxxb incorporates a novel exon, exon 8b, which is different from the classical exon 8a that is present in angiogenic transcripts. Inclusion of exon 8b is thought to enable VEGFxxxb isoforms to bind VEGF-A receptors without significant downstream signalling activation, resulting in their speculated antiangiogenic properties. Overexpressing VEGF 165 b or VEGF 121 b in tumour cells transplanted into nude mice lead to growth inhibition according to preliminary findings that need cautious interpretation. Additionally, VEGFxxxb isoforms can be differently expressed in pathological tissues when compared to normal tissues. Changes in natural splicing can increase the amount of the VEGFxxx transcripts in certain aberrant angiogenesis diseases but often reduce the amount of VEGFxxxb isoforms that are mainly present in normal tissues."
"The objective of the study was to investigate the effects of VEGF 121 b and VEGF 165b recombinant proteins on angiogenesis and tumor growth in vitro and in vivo. Therefore, the researchers utilized the yeast Pichia pastoris to produce these recombinant proteins and also generated cancer cells overexpressing VEGF121/165b through the PCDNA3.1 plasmid. The yeast expression system was preferred as it allows for protein glycosylation. Moreover, it can purify the proteins with little contamination from yeasts' endogenous proteins, which could interfere with the recombinant protein of interest. Additionally, the team chose this system to avoid the possibility of exon 8-containing VEGF-A contamination since yeasts do not code for any form of VEGF. Using mammalian systems to produce VEGF-A may result in the formation of exons 8 and 8b heterodimers, which could significantly impact their activity.","In this study, the researchers aimed to produce VEGF 121 b and VEGF165b recombinant proteins in Pichia pastoris yeast to examine their anti-angiogenic and anti-tumor properties both in vitro and in vivo. For this purpose, the team also generated cancer cells overexpressing VEGF121/165b with the PCDNA3.1 plasmid. The yeast expression system was chosen owing to its ability to glycosylate proteins and to purify the recombinant proteins with minimal secretion of yeasts-derived endogenous proteins that could potentially contaminate the protein of interest. Additionally, using this expression system prevented the presence of exon 8-containing VEGF-A contamination as yeasts do not code for VEGF-A in any form. This was especially significant since VEGF-A is secreted and active in its dimeric form. Furthermore, using the yeast expression system to produce recombinant proteins was faster, easier, and more cost-effective than mammalian systems.","The researchers undertook a study to investigate the potential impact of VEGF 121 b and VEGF165b recombinant proteins on anti-angiogenesis and anti-tumor properties, with testing to occur in vitro and in vivo. To produce the recombinant proteins, the team utilized the yeast Pichia pastoris and also generated cancer cells overexpressing VEGF121/165b using the PCDNA3.1 plasmid. The yeast expression system was selected over mammalian systems as it allowed for protein glycosylation while purifying the recombinant proteins with minimal contamination from yeasts endogenous proteins. Moreover, yeasts do not code for any form of VEGF, leading to the complete elimination of the possibility of exon 8-containing VEGF-A contamination which can interfere with the properties of proteins. By utilizing this yeast expression system, the production of recombinant proteins became less expensive, easier, and faster than the use of mammalian systems."
"The successful production of recombinant VEGF121b and VEGF165b proteins was attained. These proteins exhibit similar structural characteristics to those of classical VEGF121 and VEGF165 proteins, including the ability to form dimers/multimers, and reactivity with commercially-available antibodies developed against exons 1 to 5(most VEGF-A isoforms). Additionally, the validated antibody from R&D [18] that recognizes exon 8b proved to be immunoreactive with both recombinant VEGF121b and VEGF165b proteins, broadening their potential application.","Through successful experimentation, recombinant VEGF121b and VEGF165b proteins were produced, sharing similar structural characteristics to the classical VEGF121 and VEGF165 proteins. These proteins exhibited the ability to form dimers/multimers, and they were responsive to commercially-available antibodies raised against exons 1 to 5 that are common to most VEGF-A isoforms. Furthermore, a validated antibody recognizing exon 8b accessed from R&D [18] demonstrated immunoreactivity with both recombinant VEGF121b and VEGF165b proteins, enhancing their potential use.","The production of recombinant VEGF121b and VEGF165b proteins has been successful, with them sharing similar structural features to the classical VEGF121 and VEGF165 proteins. These proteins can form dimers or multimers and respond to commercially available antibodies raised against exons 1 to 5, which are shared by most VEGF-A isoforms. Immunoreactivity with a validated antibody from R&D [18] recognizing exon 8b was also observed in both recombinant proteins. These findings complement the protein's functional properties and strengthen their potential applications."
"To conduct an investigation of the isoforms' functionality in vitro, recombinant proteins created in yeast were administered to HUVECs, along with VEGF 165 b generated in mammalian cells and the standard VEGF165 angiogenic protein as a control. All of the treatments were executed using a serum-free medium. Following the operation, VEGF121/165b isoforms were established to stimulate the proliferation of HUVECs and phosphorylation of VEGFR2 and its downstream transducer ERK. However, the strength of the effect induced by VEGF121/165b isoforms was found to be less than that of VEGF165. HUVECs' stimulation of proliferation was only about 50% less than recombinant VEGF165. However, the degree of ERK activation was comparable among all tested proteins, 10 minutes after stimulation. It was demonstrated that VEGFRs are the specific phosphorylation mediators of this intracellular mediator while using VEGFR1 and VEGFR2 tyrosine-kinase inhibitor GW654652.","The functional capacity of the isoforms was examined in vitro by treating HUVECs with recombinant proteins that were synthesized in yeast, alongside VEGF 165 b that was produced in mammalian cells, and the conventional VEGF165 angiogenic protein was used as a control. All the treatments were conducted under serum-free conditions. It was observed that VEGF121/165b isoforms resulted in the proliferation of HUVECs and the phosphorylation of VEGFR2 and its downstream transducer ERK. The impact of VEGF121/165b isoforms was less potent than that elicited by VEGF165. HUVECs' activation of proliferation was stimulated by VEGF121/165 b isoforms by only about 50% less than recombinant VEGF165. Nonetheless, the degree of ERK activation was found to be identical for all tested proteins, 10 minutes after stimulation. It was verified that VEGFRs are the specific phosphorylation mediators of this intracellular mediator by inhibiting this process in the presence of the VEGFR1 and VEGFR2 tyrosine-kinase inhibitor GW654652.","To investigate the functionality of the isoforms in vitro, HUVECs were treated with recombinant proteins that were produced in yeast, VEGF 165 b that was generated in mammalian cells, and the conventional VEGF165 angiogenic protein that was used as a control, besides all treatments being carried out in a serum-free medium. The results revealed that VEGF121/165b isoforms stimulated the proliferation of HUVECs and the phosphorylation of VEGFR2 and its downstream transducer ERK. However, the effect caused by VEGF121/165b isoforms was weaker than that exerted by VEGF165: HUVECs' activation of proliferation was only about 50% less energized with VEGF 121/165 b isoforms than recombinant VEGF165. Nevertheless, the degree of ERK activation was found to be identical for all proteins tested, ten minutes after stimulation. Moreover, the specificity of VEGFRs' phosphorylation of this intracellular mediator was shown by the restraint of this process in the presence of the VEGFR1 and VEGFR2 tyrosine-kinase inhibitor GW654652."
"Researchers have discovered unique functional properties of VEGF165b that set it apart from other VEGF isoforms. In studies, Kawamura et al. [16] found that VEGF165b is a weak agonist of VEGFR2 and induces similar levels of VEGFR2 phosphorylation as VEGF145 in HUVECs. However, VEGF165b does not bind to neuropilin-1 (NRP1) or trigger complex formation between NRP1 and VEGFR2, similar to VEGF121. While VEGF165b promotes cell migration in PAE cells transfected with VEGFR2, it does not induce endothelial sprout formation like VEGF165. Interestingly, VEGF165b was not able to phosphorylate mouse VEGFR2 at Y1052; the authors hypothesized that it may partially block transphosphorylation by preventing rotation of the receptor's intracellular tail. Glass et al. [17] have also found that VEGF165b transiently activates VEGFR1 to increase vascular permeability. The combined results suggest that VEGF165b may trigger weaker downstream signaling responses in endothelial cells than other VEGF isoforms.","Unique functional characteristics of VEGF165b have been identified by researchers, according to Kawamura et al. [16]. VEGF165b was shown to be a weak agonist of VEGFR2, inducing its phosphorylation in HUVECs with similar potency to VEGF145. Unlike VEGF121, VEGF165b does not bind neuropilin-1 (NRP1) nor induce complexes between NRP1 and VEGFR2. VEGF165b is capable of promoting cell migration, but does not trigger endothelial sprout formation similar to VEGF165. The authors hypothesized that VEGF165b is unable to rotate the receptor's intracellular tail fully upon binding, therefore, blocking transphosphorylation to some degree. In addition, Glass et al. [17] have found that VEGF165b transiently activates VEGFR1 to increase vascular permeability. The findings imply that VEGF165b may stimulate weaker downstream signaling in endothelial cells than other VEGF isoforms.","VEGF165b displays unique functional characteristics compared to other VEGF isoforms, according to Kawamura et al. [16]. VEGF165b was proven to be a weak agonist of VEGFR2 and can induce phosphorylation to an extent similar to VEGF145 in HUVECs. Similar to VEGF121, VEGF165b cannot bind neuropilin-1 (NRP1) nor induce complexes between NRP1 and VEGFR2. While VEGF165b can promote cell migration, it does not induce endothelial sprout formation, unlike VEGF165. Furthermore, VEGF165b was not able to phosphorylate mouse VEGFR2 at Y1052 position. The authors speculated that this may be due to partial blockage of transphosphorylation by limiting the rotation of the receptor's intracellular tail. In addition, Glass et al. [17] found that VEGF165b transiently activates VEGFR1 to increase vascular permeability. These results suggest that VEGF165b has weaker downstream signaling effects in endothelial cells compared to other VEGF isoforms."
"To reinforce the statement on VEGF 121/165b's ability to promote angiogenesis based on traditional in vitro tests, we proceeded to carry out in vivo studies utilizing Growth Factor Reduced Matrigel. The Matrigel used for the experiments contained significantly lower amounts of VEGF and other angiogenic cytokines. In contrast, the same experiments yielded the recruitment of blood vessels to the Matrigel upon the addition of recombinant VEGF 121 b, VEGF 165 b, or VEGF 165 when compared to the PBS control group. These outcomes are suggestive of an angiogenic effect. Significantly, Matrigels incorporating VEGF121b were heavily saturated with dextran-FITC signals, occurring both inside and outside of the vessels, as observed in bFGF. This provides evidence of an increase in vascular permeability comparable to the vascular permeability linked to VEGF121 [27].","To ascertain the veracity of the observation about the angiogenic properties of VEGF 121/165b obtained through traditional in vitro testing, we conducted in vivo experiments using Growth Factor Reduced Matrigel. The Matrigel used in this study had significantly reduced levels of VEGF and other angiogenic cytokines. Upon the introduction of recombinant VEGF 121 b, VEGF 165 b, or VEGF 165 to the Matrigel, we observed the recruitment of blood vessels to the site compared to the PBS control group. These findings strongly suggest an angiogenic effect. Of note, Matrigels that contained VEGF121b had a marked increase in dextran-FITC signals, both inside and outside of the vessels, similar to results observed with bFGF. This implies an increase in vascular permeability, which is consistent with the vascular permeability associated with VEGF121 [27].","In order to further confirm the previous observation of VEGF 121/165b's angiogenic properties obtained from traditional in vitro assays, we performed in vivo experiments utilizing the Growth Factor Reduced Matrigel, which had a significant depletion of VEGF and other angiogenic cytokines. With the addition of recombinant VEGF 121b, VEGF 165b, or VEGF 165 to the Matrigel, the recruitment of blood vessels was considerable compared to the PBS-loaded control group, proving an angiogenic effect. Interestingly, dextran-FITC signal was heavily enriched in Matrigels containing VEGF121b, both inside and outside of the vessels, similar to bFGF results. This signifies an increase in vascular permeability, correlating with the vascular permeability trends recorded for VEGF121 [27]."
"Our research aimed to evaluate the efficacy of VEGF121/165b overexpression in inhibiting tumor growth in vivo, using xenograft models. We selected two distinct cancer cell types for our analysis: the lung adenocarcinoma A549 cell line, which expresses low levels of VEGF, and the PC-3 prostate cancer cell line that secretes a higher amount of VEGF. We opted for these cell lines to investigate any possible variations in VEGFxxxb behavior, dependent on the endogenous VEGF expression. Experiments were performed without the use of exogenous VEGF stimulation, such as VEGF transfection. Our findings showed that there were no significant differences between control and VEGF121/165b-expressing tumors in PC3 xenografts. However, VEGF121b overexpression led to tumors growing at a faster pace than the other groups. We found significantly greater vascular density in the VEGF121 b-overexpressing PC-3 tumors relative to the other groups, along with notably lower apoptotic levels. Additionally, we observed that A549 xenografts grew slowly and formed small tumors upon subcutaneous implantation in nude mice, which aligns with previous studies.","The objective of our study was to explore the potential of VEGF121/165b overexpression in inhibiting tumor growth in vivo, utilizing xenograft models. We selected two different cancer cell lines, the low-VEGF-expressing lung adenocarcinoma A549 cell line, and the high-VEGF-secreting PC-3 prostate cancer cell line, to test possible VEGFxxxb behavioral differences based on endogenous VEGF levels. We conducted experiments without any supplementary exogenous VEGF stimulation, such as transfection of VEGF. In PC3 xenografts, there were no significant deviations between control and VEGF121/165b-expressing tumors. Nonetheless, we detected VEGF121b overexpression tumors growing faster than the other groups. Our results demonstrated that the VEGF121 b-overexpressing PC-3 tumors had substantially higher vascular density and lower apoptotic levels than the rest of the groups. Additionally, our experiments exhibited that A549 xenografts developed slowly and small tumors when implanted subcutaneously in nude mice, which is in line with previous studies.","Our study aimed to investigate the effectiveness of VEGF121/165b overexpression in inhibiting tumor growth in vivo, through xenograft models. We chose two different cancer cell types for our study, the lung adenocarcinoma A549 cell line, which expresses low levels of VEGF, and the PC-3 prostate cancer cell line that secretes a higher level of VEGF. These two cell lines were selected to identify any possible disparities in the VEGFxxxb behavior, based on the endogenous VEGF expression. We conducted experiments without any exogenous VEGF stimulation, such as transfection of VEGF. Results from PC3 xenografts showed no significant variation between control and VEGF121/165b-expressing tumors, but there was a tendency for VEGF121b overexpressing tumors to grow more rapidly than the other groups. In contrast, A549 xenografts grew gradually and formed small tumors in nude mice upon subcutaneous implantation, as noted in previous studies. We also found higher vascular density and lower apoptotic levels in VEGF121 b-overexpressing PC-3 tumors than the other groups."
"The results of the current study are in disagreement with prior research that showed VEGF 165 b possessed anti-tumor properties. However, the authors suggest that this conflicting data could relate to the VEGF levels expressed in the models used. Specifically, in instances where VEGF levels are high, VEGFxxxb and VEGFxxx would compete equally for receptor binding, leading to reduced tumor growth when VEGFxxxb is overexpressed. Conversely, when VEGF production is low, the overexpression of VEGFxxxb may stimulate tumor growth to some extent. This hypothesis is corroborated by the fact that there was no significant difference in tumor growth between parental and VEGF165b-overexpressing CAKI cells when VEGF levels were approximately 900 pg/mL.","The study results are at odds with previous reports that indicate VEGF 165 b has anti-tumor effects. However, according to the authors, this conflicting evidence may be due to VEGF expression levels in the experimental models used. In situations where VEGF levels are high, VEGFxxxb and VEGFxxx proteins would equally compete for receptor binding which ultimately leads to dampening tumor growth when VEGFxxxb is overexpressed. Nevertheless, in cases where VEGF production is low, the overexpression of VEGFxxxb could prompt tumor growth somewhat. This theory is supported by the fact that no significant discrepancy in tumor growth between parental and VEGF165b-overexpressing CAKI cells was observed when VEGF levels were around 900 pg/mL.","Despite previous reports claiming that VEGF 165 b has anti-tumor properties, the findings of this study are contradictory. However, the authors suggest that this inconsistency in data could relate to VEGF expression levels in the models used. When VEGF production is high, VEGFxxxb and VEGFxxx proteins compete equally for receptor binding which results in lower tumor growth when VEGFxxxb is overexpressed. In contrast, overexpression of VEGFxxxb may stimulate tumor growth somewhat in cases where VEGF levels are low. This view is supported by the observation that there was no marked difference in tumor growth between parental and VEGF165b-overexpressing CAKI cells when VEGF levels were approximately 900 pg/mL."
"The effectiveness of VEGFxxxb protein therapies is believed to be limited to tumors exhibiting high levels of endogenous VEGF. In tumors with reduced VEGF production that rely on other angiogenic factors, the use of this therapy may be detrimental to the tumor growth trajectory. Therefore, applying VEGFxxxb protein therapy without proper patient selection casts doubts on its potential use. To identify those who are most likely to benefit from VEGFxxxb-based therapies, patients should be stratified based on their VEGF production levels. This could be critical for the design of future clinical trials involving VEGFxxxb protein therapy.","There is a possibility that therapies that rely on the administration of VEGFxxxb proteins are effective in tumors with high levels of endogenous VEGF. However, the application of this therapy to tumors that have low VEGF levels but rely on other angiogenic factors such as bFGF, IL-8, may exacerbate the tumor progression. As a result, the use of VEGFxxxb protein therapy in unselected patients raises some clinical concerns. It is essential to practice caution while implementing this therapy and stratify patients based on their level of VEGF production. Stratification would ensure that future clinical research involving VEGFxxxb protein therapy have higher chances of providing desirable outcomes.","It's possible that using VEGFxxxb proteins as a therapy may be effective in tumors with high VEGF levels; however, it could be detrimental to tumors with low VEGF levels that depend on other factors for angiogenesis. Therefore, the indiscriminate use of VEGFxxxb-based therapy raises concerns about its use in unselected patients. To ascertain the potential beneficiaries of VEGFxxxb protein therapy, patients should be segregated based on their VEGF production levels. Determining which category of patients will likely benefit from the therapy is crucial before considering conducting clinical trials based on VEGFxxxb protein therapy."
"Despite the potential benefits of therapy translation, there are still many complex aspects of VEGFxxxb biology that demand clarification. One of the most interesting findings so far is that VEGF121b, despite being an inhibitor of endothelial cell migration, has been found to protect endothelial cells from cytopathic effects in serum starvation experiments. Furthermore, in some xenograft models, overexpression of both VEGF165 and VEGF165b results in smaller tumours than just VEGF165b, while other questions such as VEGFxxxb's ability to heterodimerize with other angiogenic members need to be clarified before proceeding further.","Prior to the translation of this therapy, it is essential to understand many aspects of VEGFxxxb biology. A surprising discovery was that VEGF121b, which inhibits endothelial cell migration, has proven to be cytoprotective for endothelial cells when studied under serum-starvation conditions similar to VEGF165. Meanwhile, overexpression of both VEGF165 and VEGF165b in certain xenograft models produced smaller tumors, a completely unexpected outcome. Moreover, it is essential to determine whether VEGFxxxb proteins can act in conjunction with members of the VEGFxxx angiogenic family. These issues and their implications must be clarified to move forward with this therapy.","Before attempting therapy translation, numerous aspects of VEGFxxxb biology necessitate clarification. For example, it was somewhat unexpected when VEGF121b, known to inhibit endothelial cell migration, instead demonstrated cytoprotective effects in endothelial cells in serum starvation experiments much the way as VEGF165, thereby stimulating VEGF receptor and downstream signaling. Similarly, in some xenograft models, overexpressing both VEGF165 and VEGF165b caused smaller tumors, an intriguing result compared to the overexpression of VEGF165b alone. Other aspects such as whether VEGFxxxb proteins can heterodimerize with other angiogenic family members must be answered in the course of the clarified VEGFxxxb biology."
"In this particular investigation, we sought to determine whether VEGFxxxb isoforms exhibited varying levels of expression between healthy mammary gland tissues and malignant breast tissues (human breast cancer). We employed immunohistochemistry techniques, utilizing verified antibodies that could successfully identify VEGFxxxb isoforms as well as VEGF transcripts in our experiments. The results drawn from our study illustrated that both total VEGF and VEGFxxxb isoforms showed an incline in expression in breast cancer (n=50) tissues when compared to healthy breast tissues (n=8). Significantly substantial increases were seen particularly in intraductal carcinomas (IDC). We also discovered that the expression of VEGFxxxb isoforms was significantly correlated with that of total VEGF, which suggests that VEGFxxx and VEGFxxxb families may have a similar pattern of expression.","This study aimed to investigate the potential differences in the expression of VEGFxxxb isoforms between normal mammary gland tissues and malignant breast tissues (human breast cancer). We implemented immunohistochemistry and utilized antibodies that have been validated to detect VEGFxxxb isoforms as well as VEGF transcripts in our experiments. Our findings revealed that both total VEGF and VEGFxxxb isoforms exhibited an elevation in expression in breast cancer tissues (n=50) as compared to healthy breast tissues (n=8). Furthermore, we observed significant increases in intraductal carcinomas (IDC). Interestingly, we found a significant correlation between the expression of VEGFxxxb isoforms and that of total VEGF, hinting towards a possible similar pattern of expression between VEGFxxx and VEGFxxxb families.","The objective of this study was to investigate whether there are differences in the expression of VEGFxxxb isoforms in healthy mammary gland tissues and malignant breast tissues (human breast cancer). We employed immunohistochemistry using specific antibodies, which are validated to detect both VEGFxxxb isoforms and VEGF transcripts. Our results demonstrated that total VEGF and VEGFxxxb isoforms expressed significantly higher levels in breast cancer tissues (n = 50) than in normal breast tissues (n = 8). Furthermore, the increase in expression was observed to be more prominent in intraductal carcinomas (IDC). Interestingly, the expression of both total VEGF and VEGFxxxb isoforms was significantly correlated, indicating that the patterns of expression between both VEGFxxx and VEGFxxxb families may be similar."
"Prior studies have examined the expression of VEGFxxxb isoforms, but only in a limited number of specimens. The results of one study showed that there were no differences in VEGFxxxb mRNA levels between colon carcinoma samples (n=6) and controls, despite a significant increase in total VEGF mRNA levels [18]. This suggests that the elevation of total VEGF levels is mainly due to the VEGFxxx angiogenic isoforms [18]. A similar conclusion was reached by testing protein levels with isoform-specific ELISAs [18]. RT-PCR results showed that VEGF165b was present in most normal kidney samples (17 out of 18), while only a minority of malignant tissues (4 out of 18 matched samples) had this isoform [19]. Furthermore, analysis of 19 melanoma samples (10 non-metastatic and 9 metastatic) using a VEGFxxxb-specific antibody revealed a decrease in VEGFxxxb expression in tumour tissue (particularly in metastatic tissue) when compared to normal skin [25].","Investigations conducted previously have analyzed the expression of VEGFxxxb isoforms, but only in a small number of samples. The results of one study demonstrated that there were no changes in VEGFxxxb mRNA levels between colon carcinoma samples (n=6) and controls, despite a significant increase in total VEGF mRNA levels [18]. This indicates that the increase in total VEGF is primarily attributable to the VEGFxxx angiogenic isoforms [18]. A comparable conclusion was reached after examining protein levels utilizing isoform-specific ELISAs [18]. RT-PCR analysis of 18 matched normal and malignant kidney samples revealed that VEGF165b was found in most normal kidney samples (17 out of 18), yet only a small number of malignant tissues (4 out of 18 paired samples) contained this particular isoform [19]. The use of a VEGFxxxb specific antibody for immunohistochemical analysis of 19 melanoma samples (10 nonmetastatic and 9 metastatic) showed a reduction in VEGFxxxb expression in the neoplastic tissue (particularly in metastasis) compared to normal skin [25].","In past studies, researchers had analyzed the expression of VEGFxxxb isoforms, but only a limited number of samples had been used. One study found no changes in VEGFxxxb mRNA levels in colon carcinoma samples (n=6) compared to controls, despite a significant increase in total VEGF mRNA levels [18]. This suggests that the elevated levels of total VEGF are mainly accounted for by the VEGFxxx angiogenic isoforms [18]. Similarly, isoform-specific ELISAs revealed that there were no changes in protein levels [18]. RT-PCR analysis showed that VEGF165b was present in the majority of normal kidney samples (17 out of 18), while only a minority of matched malignant tissues (4 out of 18) expressed this isoform [19]. Immunohistochemical analysis of 19 melanoma samples (10 non-metastatic and 9 metastatic) done by using the VEGFxxxb specific antibody, on the other hand, showed a decline in VEGFxxxb expression in neoplastic tissue, particularly in metastatic areas, compared to normal skin [25]."
"The inadequate availability of exact antibodies particular to VEGFxxx and VEGFxxxb proteins is an obstacle to precisely characterizing the expression pattern in malignant and normal tissues. To determine whether the expression of the VEGFxxxb protein could be used as a diagnostic marker for cancer, future studies using a more substantial number of samples, as well as quantitative real-time RT-PCR and immunohistochemical analyses, will be necessary.","Accurate identification of the expression pattern of VEGFxxx and VEGFxxxb proteins in normal and malignant tissues is difficult due to the insufficiency of specific antibodies. To determine whether VEGFxxxb expression can be utilized as a cancer biomarker, further studies using a higher number of samples, combined with quantitative real-time RT-PCR and immunohistochemical analyses, will be required.","The absence of antibodies that are suitable for each VEGFxxx and VEGFxxxb protein restrains the fine characterization of their expression patterns in both malignant and normal tissues. To determine whether VEGFxxxb expression can be leveraged as a biomarker for cancer, future studies comprising a significantly larger number of samples along with quantitative real-time RT-PCR and immunohistochemical analyses are essential."
"The research has ascertained that VEGF121/165b do not impede angiogenesis, but rather exhibit a minor pro-angiogenic impact on VEGF-A that could promote tumor growth and the expansion of blood vessels within the tumor microenvironment. Furthermore, the study concludes that VEGFxxxb isoforms, along with the entire VEGF levels, are amplified in breast cancer in comparison with healthy breast tissues.","The results of the study demonstrate that VEGF121/165b are not antiangiogenic agents and, to some extent, have a weak angiogenic effect on VEGF-A that may enhance cancerous cell growth and the formation of blood vessels in vivo. It was also concluded that the VEGFxxxb isoforms alongside the total VEGF content are up-regulated in breast cancer relative to non-cancerous tissues.","According to the findings, VEGF121/165b are not anti-angiogenic agents; instead, they exhibit a mild pro-angiogenic effect on VEGF-A that could foster tumor progression and the formation of new blood vessels within the tumor microenvironment. Moreover, the study concludes that VEGFxxxb isoforms, as well as the total VEGF levels, are markedly upregulated in breast cancer tissues compared to non-cancerous breast tissues."
"Severe acute respiratory syndrome (SARS) is a rare disease caused by a new and deadly strain of coronavirus that emerged in China in 2002. While most coronaviruses cause mild respiratory infections, SARS-CoV can cause severe acute respiratory distress syndrome (ARDS) with a high mortality rate. Because the virus can potentially spread from animal populations to humans, it's important to develop effective measures to prevent its recurrence. The SARS-CoV genome consists of a single-stranded RNA that encodes four essential structural proteins, including the spike protein (S), membrane protein (M), envelope protein (E), and nucleocapsid protein (N). The spike protein facilitates the virus's ability to infect host cells by binding to specific receptors and allowing entry into the host's respiratory tract.","Severe acute respiratory syndrome (SARS) is a type of infectious disease that became a significant health threat worldwide in 2002. The coronavirus responsible for SARS has a high mortality rate and can cause severe respiratory distress in patients. Because we have seen cases of the virus originating from animal populations and spillover into humans, it is crucial to prioritize the development of safe and effective vaccines. The genome of the virus consists of single-stranded RNA and encodes several structural proteins, including spike protein (S), membrane protein (M), envelope protein (E), and nucleocapsid protein (N). The spike protein recognizes host cells and mediates the entry of the virus, making it an interesting target for vaccines that prevent infection.","Severe acute respiratory syndrome (SARS) is a dangerous disease caused by a unique coronavirus strain that emerged in Asia in 2002. SARS-CoV can cause severe respiratory symptoms, ranging from mild flu-like illness to severe respiratory failure. Because new variants of the virus exist in animal populations and could potentially spread to humans, it is crucial to develop effective prevention and containment strategies. The genetic material of the virus comprises single-stranded RNA that codes for four major structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. The spike protein helps the virus bind to host cells and allows it to invade the cell, making it an attractive target for novel therapeutics and vaccines."
"Researchers have been exploring possible solutions for developing vaccines against various pathogens, and among the most popular options being pursued is DNA vaccines. These vaccines can trigger both humoral and cellular immune responses, as evidenced by several studies [4]. In fact, studies have shown that DNA-based vaccines are capable of producing a protective immune response against some viruses [5,6]. However, the issue remains that DNA-based vaccines cannot induce an immune response in mice when administered through the intranasal (i.n.) route [7]. Given that most respiratory infections spread through the mucosal surface, a good vaccine should be able to trigger both a systemic and mucosal immune response. Mucosal immune responses play a critical role in the initial defense against influenza virus infections, even though parenteral immunization is insufficient to induce protective immunity [9]. Secreting IgA is a key component of mucosal immunity [8].","Scientists have been investigating various options to develop vaccines that can combat different pathogens, and among these options is DNA vaccines. Numerous studies have shown that DNA vaccines activate both humoral and cellular immune responses [4]. In addition, several studies have demonstrated that DNA-based vaccines can generate protective immune responses against a variety of viruses [5,6]. However, an issue with DNA-based vaccines is that they cannot stimulate an immune response in mice when administered intranasally (i.n) [7]. Given that most respiratory diseases infect through the mucosal surface, it is crucial that a vaccine can elicit a systemic and mucosal immune response. Mucosal immune responses play a pivotal role in the early defense against influenza virus infection, although parenteral immunization is inadequate to induce protective immunity [9]. Secretory IgA is particularly critical in facilitating mucosal immunity [8].","DNA vaccines have been extensively researched as a possible defence against various pathogens worldwide. DNA vaccines can stimulate both humoral and cellular immune responses, as confirmed by numerous studies [4]. Additionally, several research studies have demonstrated that DNA-based vaccines can also produce an adequate immune response that shields against various viruses [5,6]. Nonetheless, one problem with DNA-based vaccines is that they cannot create an immune response in mice when administered intranasally (i.n) [7]. Given that most respiratory infections occur through the mucosal surface, an ideal vaccine should activate both a mucosal and systemic immune response. Even though parental immunization is insufficient to trigger protective immunity [9], mucosal immune responses play a crucial role in the first line of immune defense against the flu virus infection. Secretory IgA plays a pivotal role in facilitating mucosal immunity [8]."
"The versatility of Polyethylenimine (PEI) has made it a widely recognized nonviral vector for in vitro and in vivo use attributed to its high transfection efficiency and stable buffering capacity. Studies have shown that mucosal administration using PEI as a delivery system serves as a potent mucosal immunostimulator while also showcasing its capacity as an effective gene delivery vehicle for lung transfection, resulting in high antibody titers against the encoded protein. The objective of this study was to examine the immune response in BALB/c mice immunized with SARS DNA vaccine via the intranasal route for further developments on this delivery approach.",Polyethylenimine (PEI) is a nonviral vector that has gained widespread use in vitro and in vivo due to its high transfection efficiency and strong buffering capacity. Studies have shown that mucosal administration of PEI acts as a potent mucosal immunostimulator and that it is a highly effective gene delivery vehicle for producing high antibody titers against encoded proteins when used for lung transfection. Researchers in this study aimed to investigate the immune responses of BALB/c mice administered with SARS DNA vaccine through the intranasal route. The findings have implications for the development of future delivery strategies for genetic and vaccine therapies in mucosal immunization.,"Recognized for its high transfection efficiency and buffering capacity, Polyethylenimine (PEI) continues to be a nonviral vector of choice for many in vitro and in vivo studies. Recent research has demonstrated PEI's efficacy as a mucosal immunostimulator when administered mucosally, and its ability to be an effective gene delivery vehicle for lung transfection. This study aimed to examine the immune responses in BALB/c mice that were administered SARS DNA vaccine through the intranasal route. The results of this investigation will be critical in the development of future gene-based therapies and vaccines that focus on mucosal immunization."
"'The transfection efficiency of a gene carrier is known to be linked to its capacity to condense DNA into tiny particles on a nanoscale [13]. In line with expectations, the use of PEI helped to condense DNA into similarly tiny particles, which implied that these particles had the potential to be endocytosed (as indicated by the results in Figure 1A).'","'It is widely established that a gene carrier's efficiency for transfection is subject to its ability to condense DNA into particles that are nano-sized [13]. The DNA was effectively condensed into such particles by PEI in this study, thus indicating their potential for endocytosis (as shown in Figure 1A).'","'The ability of a gene carrier to compact DNA into nano-scale particles is a known determinant of its efficiency for transfection [13]. As expected, the use of PEI enabled successful DNA condensation into these nano-sized particles, suggesting that they have potential for endocytosis (as depicted in Figure 1A).'"
"Morphology observation confirmed the formation of PEI/pci-S nanoparticles. The EF-TEM images showed that the nanoparticles were spherical in shape with a size of around 200 nm. When tested for cytotoxicity in RAW 264.7 cells, there was a slight decrease in cell viability with increasing N/P ratio of PEI/pci-S complexes, with the cell viability at N/P ratio 10 being 87.5 ± 7.3%. Confocal microscopy visualization of rhodamine labeled pci-S DNA showed the uptake of the complex by the cells, with the nanoparticles being located near the nucleus. RT-PCR analysis indicated that both PEI/pci-S nanoparticles and naked DNA could transfect the cells, with the former inducing stronger S mRNA expression.","The spherical shape and size of the PEI/pci-S nanoparticles were examined through morphological observation by EF-TEM imaging and dynamic light scattering. In RAW 264.7 cells, the cytotoxicity of the PEI/pci-S complexes resulted in a slight decrease in cell viability with an increase in N/P ratio, but the viability at an N/P ratio of 10 remained at 87.5 ± 7.3%. Confocal microscopy visualization of rhodamine labeled pci-S DNA revealed that the PEI/pci-S complexes were taken up by the cells and located near the nucleus. RT-PCR analysis confirmed that both naked DNA and PEI/pci-S nanoparticles could transfect the cells, but the latter induced a higher S mRNA expression.","Confirming the formation of PEI/pci-S nanoparticles, morphology observation revealed that the spherical nanoparticles had a size of approximately 200 nm. After transfection with PEI/pci-S complexes, MTT assay showed a slight reduction in the viability of RAW 264.7 cells as N/P ratio increased, with a 87.5 ± 7.3% viability at N/P ratio 10. Using rhodamine labeled pci-S DNA, the PEI/pci-S complexes were detected in the cells near the nucleus by means of confocal microscopy visualization. Both naked DNA and PEI/pci-S nanoparticles were capable of transfecting the cells, with the latter inducing stronger S mRNA expression as indicated by RT-PCR analysis."
"In order to investigate how PEI affects the adaptive immune response to the SARS-CoV S protein, mice were administered a DNA vaccine for SARS-CoV and their specific antibody responses were studied. The results showed that mice given PEI/pci-S complexes displayed considerably elevated levels of SARS-CoV S-specific serum IgG antibody. Meanwhile, mice immunized with only the SARS-CoV S DNA vaccine did not exhibit the same effect. To evaluate the balance of the Th1/Th2 immune response, SARS S-specific IgG1 and IgG2 levels were analyzed in the immunized mice. It was found that SARS S-specific IgG1 antibody production significantly increased (P < 0.01) in mice that received the SARS-CoV S DNA vaccine with PEI, while little increase in SARS-specific IgG2a antibody production was observed. These findings suggest a Th2-dominant response. Mucosal antibody production was also examined by collecting lung wash, nasal wash, fecal extracts, saliva, and vaginal wash samples from the immunized mice. The analysis showed that SARS S-specific IgA antibody response was significantly (P < 0.01) increased in lung wash from mice given PEI/pci-S complexes.","The effect of PEI on adaptive immunity to SARS-CoV S protein was evaluated by examining the specific antibody responses in mice that received an i.n. SARS-CoV DNA vaccine. Results indicated that immunization with PEI/pci-S complexes elicited a high level of SARS-CoV S-specific serum IgG antibody in the mice, while mice immunized with only the SARS-CoV S DNA vaccine did not demonstrate the same level of response (Figure 2A). To determine the balance of the Th1/Th2 immune response, SARS S-specific IgG1 and IgG2 levels were analyzed in the mice, and it was revealed that SARS S-specific IgG1 antibody production significantly increased (P < 0.01) in mice given the SARS-CoV S DNA vaccine with PEI, indicating a Th2 dominant response. Mucosal antibody production was examined as well, with lung wash, nasal wash, fecal extracts, saliva, and vaginal wash samples collected from the immunized mice. The analysis showed that SARS S-specific IgA antibody response significantly (P < 0.01) increased in lung wash from mice given PEI/pci-S complexes (Figure 2B).","Specific antibody responses were investigated in mice that received a SARS-CoV DNA vaccine to assess the impact of PEI on adaptive immunity to SARS-CoV S protein. The results demonstrated that the mice immunized with PEI/pci-S complexes generated a considerably high level of SARS-CoV S-specific serum IgG antibody. Mice that were solely administered with the SARS-CoV S DNA vaccine did not show a similar reaction. The balance of the Th1/Th2 response was also analyzed by determining the levels of SARS S-specific IgG1 and IgG2 in the mice. SARS S-specific IgG1 antibody production significantly increased in the mice that received the SARS-CoV S DNA vaccine with PEI, indicating a Th2 dominant response. Mucosal antibody production was also measured by collecting samples from lung wash, nasal wash, fecal extracts, saliva, and vaginal wash of the immunized mice. Those that were administered with PEI/pci-S complexes had a considerably higher (P < 0.01) SARS S-specific IgA antibody response."
"The enhanced antibody response to SARSCoV spike protein was evaluated by assessing the proliferation of B220+ cells. The study confirmed that one week after the final vaccination, antibody responses were significantly improved. The results showed that B220+ cells that were treated with PEI/pci-S complexes had a remarkable proliferation ability after being re-stimulated with SARS-CoV S protein in vitro, as observed in Figure 2C.","The study aimed to measure B lymphocyte proliferation in response to SARSCoV spike protein and to confirm the enhancement of antibody responses. After the last vaccination, B220+ cells were highly proliferated when stimulated with SARS-CoV S protein in vitro, providing evidence of increased antibody responses. The proliferation ability of B220+ cells was especially significant after mice were immunized with PEI/pci-S complexes, contributing to our understanding of the immunogenicity of SARS-CoV S protein (Figure 2C).","To confirm the enhancement of antibody responses, the researchers assessed B lymphocyte proliferation against SARSCoV spike protein. The results showed that B220+ cells had a high proliferation ability after in vitro re-stimulation with SARS-CoV S protein one week after the last vaccination. This remarkable proliferation ability of B220+ cells was observed in mice who were immunized with PEI/pci-S complexes. These findings provided insights into the effectiveness of the vaccine against SARS-CoV spike protein and could potentially contribute to future vaccine development (Figure 2C)."
"Enhanced surface marker expression occurs during the maturation of DCs, which includes co-stimulatory and MHC category molecules. In order to evaluate the influence of DNA vaccination on DC maturation in vivo, a study was conducted on mice who were administered PEI/pci-S complexes intranasally. The DCs of the mice that received PEI/pci-S complexes showed a significant increase (P < 0.05) in the surface expression of CD80 and CD86 co-stimulatory molecules as compared to those who just received the SARS-CoV DNA S vaccine (Figure 3). Additionally, PEI/pci-S complexes levelled-up the expression of MHC class II, I-Ad, significantly (P < 0.05) in comparison to SARS-CoV DNA alone (Figure 3).","As DCs mature, there is an improvement in the expression of surface markers like co-stimulatory and MHC class molecules. To analyze the effect of DNA vaccination on DC maturation in vivo, mice were immunized i.n. with PEI/pci-S complexes. In comparison to SARS-CoV DNA S vaccine alone, the surface expression of CD80 and CD86 co-stimulatory molecules was significantly (P < 0.05) higher on DCs of mice treated with PEI/pci-S complexes (Figure 3). Besides, there was a significant (P < 0.05) up-regulation of MHC class II, I-Ad, expression in the PEI/pci-S complexes group than among the SARS-CoV DNA alone group (Figure 3).","The increased expression of surface markers, including co-stimulatory and MHC class molecules, is observed during the maturation process of DCs. An investigation was carried out to evaluate the influence of DNA vaccination on DC maturation in vivo where mice were immunized i.n. with PEI/pci-S complexes. It was observed that DCs in mice who were treated with PEI/pci-S complexes had significantly higher levels of CD80 and CD86 co-stimulatory molecules from those who were only exposed to the SARS-CoV DNA S vaccine (Figure 3). Furthermore, there was a significant (P < 0.05) up-regulation in MHC class II I-Ad expression in the group who received PEI/pci-S complexes, compared to those who received SARS-CoV DNA vaccination alone (Figure 3)."
"Examining T cell immunity to the DNA vaccine for SARS-CoV S involved analyzing cytokine profiles using intracellular cytokine assays. The lung cells collected from the mice six days after immunization were used in this study. Earlier research has shown that T cells producing IFN-g, IL-2, IL-17, and TNF-a can provide significant protection against the virus [14]. The presence of IFN-g-producing cells increased in both CD4+ and CD8+ T cells in mice vaccinated with PEI/pci-S, but only CD4+ T cells had more IL-17-producing cells. Surprisingly, CD8+ T cells from PEI/pci-S-vaccinated mice didn't produce IFN-g, IL-2, or IL-17. Upon restimulation, PEI/pci-S-vaccinated mice produced more TNF-a and T cells producing both TNF-a and IL-2 compared to the pci-S group. Additionally, the PEI/pci-S vaccinated mice had more cytokine-producing T cells producing IFN-g and IL-17 together, while the pci-S group did not produce these. Nonetheless, neither the lung nor spleen had detectable IL4-producing cells (data not shown).","Utilizing intracellular cytokine assays, cytokine profiles were investigated to examine T cell immunity to the SARS-CoV S DNA vaccine. Lung cells were taken from the mice six days post-immunization. Research shows that T cells that produce IFN-g, IL-2, IL-17, and TNF-a are extremely effective in providing protection. More IFN-g-producing cells were observed in the CD4+ and CD8+ T cells from mice vaccinated with PEI/pci-S whereas only CD4+ T cells had a higher number of IL-17-producing cells. Interestingly, neither IFN-g +, IL-2 +, nor IL-17 + cells were detected in CD8+ T cells collected from mice vaccinated with PEI/pci-S complexes. Upon re-stimulation from the SARS-CoV S peptide, cytokine-producing CD4+ and CD8+ T cells, with TNF-a/GM-CSF predominant production were observed in mice vaccinated with PEI/pci-S complexes. Moreover, mutually producing T cells such as IFN-g and IL-17 were found more in the PEI/pci-S complexes group than in the pci-S group. This study did not find IL4-producing cells in the lung or spleen (data not shown).","In this study, cytokine profiles were analyzed using intracellular cytokine assays to explore T cell immunity to the SARS-CoV S DNA vaccine. The lung cells were collected from the mice six days after immunization. Prior research suggests that T cells producing IFN-g, IL-2, IL-17, and TNF-a are crucial for protective immunity. CD4+ and CD8+ T cells both showed an increase in IFN-g-producing cells in mice vaccinated with PEI/pci-S, but only CD4+ T cells exhibited an increase in IL-17-producing cells. CD8+ T cells from mice vaccinated with PEI/pci-S complexes, however, did not produce IFN-g, IL-2, or IL-17. After re-stimulation with the SARS-CoV S peptide, cytokine-producing CD4+ and CD8+ T cells, with TNF-a and IL-2 predominance, were detected in mice immunized with PEI/pci-S complexes. Furthermore, IFN-g and IL-17 cytokine-producing cell populations were more frequent in the PEI/pci-S complexes group than in the pci-S group. Notably, no IL4-producing cells were detected in either the lung or spleen (data not shown)."
"Emerging infectious diseases pose a continuous threat to global health and the economy. A recent example is the outbreak of the Ebola virus in West Africa, which infected over 28,000 individuals and resulted in more than 11,000 deaths. Research revealed that the spike protein of the Ebola virus plays a crucial role in receptor recognition and virus entry, which makes it an attractive target for vaccine development. Several studies have focused on the development of vaccine candidates based on the Ebola spike protein, including adenoviral vectors, DNA vaccines, and viral vector-based vaccines. These studies have shown promising results in terms of eliciting immune responses against the Ebola virus. In this study, we evaluated the immunogenicity of a new vaccine candidate in animal models through intramuscular immunization.","Mosquito-borne diseases pose a significant threat to public health in many parts of the world. One such disease is the Zika virus, which swept through Central and South America in 2015-16, causing a major outbreak. Research revealed that the viral envelope (E) protein of the Zika virus plays a crucial role in virus entry, replication, and immune evasion, which makes it an attractive target for vaccine development. Several studies have focused on the development of vaccine candidates based on the Zika E protein, including DNA vaccines, viral vector-based vaccines, and protein subunit vaccines. These studies have shown varying degrees of success in eliciting immune responses against the Zika virus. In this study, we evaluated the immunogenicity of a novel vaccine candidate based on the Zika E protein in animal models through subcutaneous immunization.","Cancer is one of the leading causes of death worldwide, and there is a need for effective treatments to combat this disease. One promising approach is the use of cancer vaccines that target tumor-specific antigens. Research has identified several such antigens, including melanoma-associated antigen (MAGE), human epidermal growth factor receptor 2 (HER2), and Wilms' tumor 1 (WT1). Various vaccine designs have been explored, including peptide vaccines, dendritic cell vaccines, and DNA vaccines, showing varying degrees of success in inducing immune responses against tumor cells. In this study, we evaluated the immunogenicity of a novel vaccine candidate based on a combination of tumor-specific antigens in animal models through intravenous immunization."
"PEI/DNA complexes have been reported to effectively enhance transfection efficacy and increase immunogenicity in mammalian cells [18]. Mucosal DNA vaccination using the PEI/pci-S complex was carried out in this present study. The size of these complexes was observed to be approximately 200 nm. The ability of PEI/DNA complexes to induce changes in gene and protein expression was measured in RAW 264.7 cells by evaluating mRNA and protein levels respectively. The findings revealed a promising outcome, prompting in vivo tests for intranasal immunization of mice using PEI/pci-S complexes.","Previous studies have suggested that the use of PEI/DNA complexes can significantly enhance transfection efficiency and immunogenicity in mammalian cells [18]. In this study, we aimed to evaluate the efficacy of the PEI/pci-S complex in mucosal DNA vaccination. The size of these complexes was found to be around 200 nm. RAW 264.7 cells were used to examine the effects of these complexes on transfection, as well as gene and protein expression, by measuring mRNA and protein levels, respectively. Based on these results, we proceeded to study the feasibility of intranasal administration of PEI/pci-S complexes for mouse immunization.","According to previous reports, the use of PEI/DNA complexes can significantly enhance transfection efficiency and immunogenicity in mammalian cells [18]. In this study, we investigated the feasibility of using the PEI/pci-S complex for mucosal DNA vaccination. The size of these complexes was approximately 200 nm. RAW 264.7 cells were exposed to PEI/DNA complexes, and mRNA and protein levels were used to assess their effects on transfection, gene expression, and protein expression, respectively. Promising results prompted us to carry out in vivo tests for intranasal immunization of mice using PEI/pci-S complexes."
"Scientists have been researching SARS DNA vaccines for some time now, and many studies have attempted to develop them through systemic delivery methods such as intramuscular injection. However, some researchers think that intranasal immunization could be more effective, considering that SARS is a respiratory pathogen. Among SARS vaccine candidates tested, using PEI/pci-S complexes for intranasal immunization induced a robust antigen-specific serum IgG response compared to pci-S alone. Furthermore, the Th2 dominant response was observed, with increased antigen-specific IgG1 levels compared to IgG2a. Additionally, intranasal immunization also resulted in an enhanced antigen-specific IgA response in bronchoalveolar lavage fluid and improved B cell proliferation after stimulation with the spike protein in vitro. Garzon’s study found that using a DNA vaccine up to 100 μg led to dose-dependent increases in antigen-specific antibody and T cell responses. However, in this study, a smaller DNA vaccine dose of 20 μg was used, yet it was still able to induce both systemic and mucosal immune responses.","SARS has been the subject of several studies, to find the best ways of administering DNA vaccines. Many studies, mostly involving systemic delivery methods - including intramuscular injection - have been attempted to develop these vaccines. However, some scientists think that intranasal immunization might be more effective. An effective intranasal immunization technique has been developed through the use of PEI/pci-S complexes, which induced higher antigen-specific serum IgG responses than the use of pci-S alone. The researchers also observed an increase in antigen-specific IgG1, with a Th2 dominant response, as well as enhanced antigen-specific IgA responses in bronchoalveolar lavage fluid. B cell proliferation was also observed after in vitro re-stimulation with the spike protein, highlighting the effectiveness of this method. Garzon's study found a dose-dependent increase in antigen-specific antibody and T cell responses in mice immunized with DNA vaccine up to 100 μg. This study used a smaller DNA vaccine dose of 20 μg, yet it was still able to induce both systemic and mucosal immune responses.","Research on SARS DNA vaccines has yielded numerous studies employing systemic delivery methods such as intramuscular injection, but some scientists think that intranasal immunization might be more effective because SARS is a respiratory pathogen. Using PEI/pci-S complexes for this technique resulted in a robust antigen-specific serum IgG response compared to using only pci-S. The researchers observed a Th2 dominant response and increased antigen-specific IgG1 levels compared to IgG2a. Furthermore, intranasal immunization led to an enhanced antigen-specific IgA response in bronchoalveolar lavage fluid, and B cell proliferation improved after in vitro re-stimulation with the spike protein. Although Garzon's study found that using DNA vaccines up to 100 μg led to dose-dependent increases in antigen-specific antibody and T cell responses, this study utilized a lower DNA vaccine dose of only 20 μg, which nonetheless induced both systemic and mucosal immune responses."
"Dendritic cells (DCs) are crucial for mounting an effective immune response against foreign pathogens, as they are distributed throughout the body and act as the first line of defense against potential threats [21]. Upon recognition of pathogen-associated molecular patterns from microorganisms, DCs undergo a process of maturation and acquire the capacity for antigen presentation, resulting in upregulation of major histocompatibility complex (MHC) proteins [22], cytokines [23], and co-stimulatory molecules like CD80, CD83, and CD86 [24]. The maturation of DCs is essential for initiating appropriate adaptive immune responses [22]. Intranasal immunization with PEI/pci-S complexes has been shown to increase the expression of co-stimulatory and MHC class II molecules on DCs in the cervical lymph nodes, as demonstrated by this study.","One of the key players in eliciting immune responses against antigens is dendritic cells (DCs), which are distributed throughout the body and are considered as the first line of defense against foreign pathogens [21]. Upon recognition of pathogen-associated molecular patterns from microorganisms, DCs undergo a process of maturation, allowing them to present antigens via MHC proteins [22], secrete cytokines [23], and express co-stimulatory molecules such as CD80, CD83, and CD86 [24]. Proper DC maturation is crucial for initiating appropriate adaptive immune responses [22]. This study has demonstrated that intranasal immunization with PEI/pci-S complexes results in increased expression of co-stimulatory and MHC class II molecules on DCs in the cervical lymph nodes.","Dendritic cells (DCs) play a significant role in initiating antigen-specific immune responses, as they are present throughout the body and function as the first line of defense against invading pathogens [21]. Upon recognition of pathogen-associated molecular patterns from microorganisms, DCs mature, allowing them to present antigens on MHC proteins and produce cytokines, as well as expressing co-stimulatory molecules like CD80, CD83, and CD86 [24]. Proper DC maturation is crucial for initiating appropriate adaptive immune responses [22]. The study has confirmed that intranasal immunization with PEI/pci-S complexes can effectively stimulate the expression of co-stimulatory and MHC class II molecules on DCs in the cervical lymph nodes."
"Cellular immunity is regulated by CD4+ and CD8+ T cells. Investigational findings reveal that these T cells secrete cytokines, including IFN-g, TNF-a, IL-2, and IL-17, after in vitro re-stimulation with SARS spike peptides. IFN-g is an effector cytokine that plays a vital role in activating macrophages and DCs, thereby hindering viral infection. Another cytokine, TNF-a, not only enhances immunity but also reduces viral replication. IL-2 helps in the expansion of T cells and their memory cells, while IL-17 is in charge of triggering the production of antimicrobial peptides and immunoglobulin to neutralize viral infections. These cells secrete IFN-g, TNF-a, IL-2, and IL-17 in nonlymphoid tissues, such as lungs, and act as the first line of defence against viral infections. Vaccination with PEI/pci-S increases the number of cells secreting multiple cytokines in mice. These cells provide superior protection to single cytokine-secreting cells in fighting SARS-CoV infections. In fact, multi-cytokine-secreting CD4+ T cells are more potent in conferring immunity in Leishmania major infections.","The human immune system exhibits cellular responses mediated by CD4+ and CD8+ T cells. Various studies have shown that antigen-specific T cells are capable of producing cytokines when re-stimulated with SARS spike peptides in vitro. These cytokines include IFN-g, TNF-a, IL-2, and IL-17, and they play crucial roles in the protective immune response. IFN-g, for example, is critical in the activation of macrophages and DCs, which helps to stop viral infections. Additionally, TNF-a can regulate immune cells while reducing viral replication. IL-2 is effective in expanding and maintaining T-cell memory, while IL-17 mediates antimicrobial peptide production to counteract viral infections. Interestingly, these cytokines are secreted in nonlymphoid tissues such as the lungs, by antigen-specific CD4+ and CD8+ T cells which are responsible for conferring protection upon SARS-CoV infections. Cells secreting multiple cytokines increased in mice after they were vaccinated with PEI/pci-S. Multi-cytokine-secreting CD4+ T cells are known to produce superior protection compared to single-cytokine-secreting cells against infections such as Leishmania major.","Cellular immune responses are essential for fighting viral infections, and CD4+ and CD8+ T cells play a crucial role in this process. After in vitro re-stimulation with SARS spike peptides, antigen-specific T cells secrete cytokines, including IFN-g, TNF-a, IL-2, and IL-17. IFN-g is a potent effector cytokine that activates macrophages and DCs while inhibiting viral replication. TNF-a is known to regulate immune cells and inhibits viral replication. IL-2, responsible for the expansion of T cells and maintenance of memory T cells, and IL-17, which induces antimicrobial peptide production, are also produced by these T cells. The production of these cytokines occurs in non-lymphoid tissues such as the lung, where antigen-specific CD4+ and CD8+ T cells provide immediate protection against SARS-CoV infections. Administration of PEI/pci-S to mice leads to an increase in the number of multiple cytokine producing cells. The use of multi-cytokine-producing antigen-specific CD4+ T cells provides better protection against viral infections such as Leishmania major."
"The application of PEI in DNA vaccine delivery has proven to be an efficacious method in activating the immune response within both B and T cells. With its capacity to effectively deliver DNA to the mucosal surface and promote dendritic cell maturation, PEI has shown promise as a vector for mucosal vaccine administration. These findings demonstrate the potential of using PEI as an essential tool in the development of effective DNA vaccines.","Recent research has demonstrated the benefits of using PEI for DNA vaccine delivery, specifically in activating B and T cell responses. PEI has been successful in efficiently delivering DNA to the mucosal surface and promoting the maturation of dendritic cells, ultimately leading to an enhanced immune response. These findings suggest that using PEI as a vector for the administration of mucosal DNA vaccines could serve as an effective approach to stimulating B and T cell immunities.","PEI has emerged as a viable option for DNA vaccine delivery, demonstrating its ability to activate immune responses within both B and T cells. Researchers have found that PEI effectively delivers DNA to the mucosal surface and promotes the maturation of dendritic cells, resulting in an enhanced immune response. These findings present a promising avenue for utilizing PEI as a vector in the administration of mucosal DNA vaccines, allowing for the development of efficient and effective immunization strategies."
"A synthesized gene encoding the spike protein (S) of SARS-CoV, minus its transmembrane domain encompassing amino acids 14-1154, was developed. The sequence was optimized to ensure effective expression in mammalian cells, with the native signal sequence replaced with the human tissue plasminogen activator (tPA) leader sequence. The Nhe I and Not I enzymes were used to cleave the tPA-S gene and the pci-neo plasmid before they were combined in a ligation process that produced a plasmid expressing the SARS-CoV S protein.","To synthesize the SARS-CoV S protein gene, a transmembrane domain that includes amino acids 14-1154 was excluded. This gene sequence was optimized for being expressed in mammalian cells, with the natural signal sequence being replaced by the leader sequence of the human tissue plasminogen activator (tPA). By digesting the tPA-S gene and pci-neo (Promega, Madison, WI) with Nhe I and Not I enzymes and then utilizing ligation, a plasmid that expressed the SARS-CoV S protein was created.","The spike protein (S) gene of SARS-CoV, excluding its transmembrane domain (amino acids 14-1154), was chemically synthesized. The gene sequence was optimized for efficient expression in mammalian cells, and the endogenous signal sequence was substituted with the leader sequence of the human tissue plasminogen activator (tPA). Nhe I and Not I restriction enzymes were used to cut the tPA-S gene and pci-neo (Promega, Madison, WI), and then, the SARS-CoV S protein-expressing plasmid was generated by ligation."
"The production of PEI/pci-S particles involved the combination of polymer and pci-S DNA in a solution at an N/P (PEI/pciS) ratio of 10. The size of the particles was determined using an electrophoretic light scattering spectrophotometer (ELS8000, Otsuka Electronics, Osaka, Japan), while EF-TEM (LIBRA 120, Carl Zeiss, Germany) was utilized to observe the morphology of the PEI/pci-S particles.","To prepare PEI/pci-S nanoparticles, the team combined polymer and pci-S DNA in a solution at an N/P (PEI/pciS) ratio of 10. To measure the size of the particles, researchers employed an electrophoretic light scattering spectrophotometer (ELS8000, Otsuka Electronics, Osaka, Japan). Morphology, on the other hand, was investigated using EF-TEM (LIBRA 120, Carl Zeiss, Germany), which allowed the team to observe and analyze the structure of the PEI/pci-S particles.","The team combined polymer and pci-S DNA in a solution at an N/P (PEI/pciS) ratio of 10 to produce PEI/pci-S nanoparticles. The size of the particles was determined by utilizing an electrophoretic light scattering spectrophotometer (ELS8000, Otsuka Electronics, Osaka, Japan). To study the morphology of the particles, EF-TEM (LIBRA 120, Carl Zeiss, Germany) was used. This technique allowed the team to visualize and analyze the structure of the PEI/pci-S particles."
"In order to visualize cell uptake, pci-S DNA was tagged with rhodamine through the utilization of the Label IT® Tracker™ CX-Rhodamine kit from Mirus, WI. RAW 264.7 cells were grown in a plate and PEI/Rhodamine-labeled pci-S DNA nanoparticles were then introduced and incubated for an hour followed by washing. The mounted samples were treated with ProLong® Gold antifade reagent with DAPI which came from Invitrogen located in Carlsbad, CA. The cell uptake images were then captured using a confocal laser scanning microscope (Carl Zeiss-LSM510) situated in Thornwood, NY.","For the examination of cell uptake, rhodamine was attached to pci-S DNA by utilizing the Label IT® Tracker™ CX-Rhodamine kit from Mirus in WI. Following this, RAW 264.7 cells were seeded onto a plate and incubated with PEI/Rhodamine-tagged pci-S DNA nanoparticles for one hour. After the cells were washed, the samples were mounted with the aid of ProLong® Gold antifade reagent that included DAPI from Invitrogen in Carlsbad, CA. Moving further, confocal laser scanning microscope (Carl Zeiss-LSM510) from Thornwood, NY was applied to observe the cell uptake images.","In order to observe cell uptake, rhodamine was added to pci-S DNA using the Label IT® Tracker™ CX-Rhodamine kit by Mirus located in WI. RAW 264.7 cells were seeded on a plate, and then the cells were incubated with PEI/Rhodamine-tagged pci-S DNA nanoparticles and left for an hour. After washing the cells, ProLong® Gold antifade reagent with DAPI from Invitrogen, based in Carlsbad, CA was used to mount the samples. Confocal laser scanning microscope (Carl Zeiss-LSM510) was employed in Thornwood, NY to visualize the cell uptake images."
"The transcriptional and protein level expression of SARS-CoV S was examined in RAW 264.7 cells through a series of laboratory techniques. Naked pci-S DNA and PEI/pciS nanoparticles at an N/P ratio of 10 were transfected into the cells which were then lysed with either Trizol or cell lysis buffer. Utilizing Superscript III reverse transcriptase during reverse transcription, the cDNA was amplified by PCR with primers for pci-S and GAPDH. Finally, the RT-PCR products underwent electrophoresis for analysis.","Research focused on the expression of SARS-CoV S at both the transcriptional and protein level in RAW 264.7 cells utilized various techniques. Naked pci-S DNA or PEI/pciS nanoparticles at an N/P ratio of 10 were transfected into cells, which were then lysed using Trizol or cell lysis buffer. Reverse transcription took place with the assistance of Superscript III reverse transcriptase and the resulting cDNA was amplified using primers targeting pci-S and GAPDH genes. Afterwards, the RT-PCR products were evaluated utilizing electrophoresis.","In an effort to investigate the expression of SARS-CoV S in RAW 264.7 cells, researchers employed various methods at both the transcriptional and protein level. Naked pci-S DNA and PEI/pciS nanoparticles were delivered to the cells at N/P ratio of 10, followed by lysis with either Trizol or cell lysis buffer. Superscript III reverse transcriptase was utilized during the reverse transcription process, while cDNA was amplified through PCR using primers specific for pci-S and GAPDH genes. To analyze the RT-PCR products obtained, researchers applied electrophoresis."
"The Western blot assay involved the separation of lysates by SDS-PAGE and transfer onto a nitrocellulose membrane (Amersham Biosciences, Piscataway, NY). These membranes were then blocked using 5% non-fat milk before the introduction of the spike protein primary antibody (obtained from Chiron) and the horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in succession. Detection of the antigen-antibody interaction was carried out via an ECL fluorescence system, with the use of b-actin as a control.","To perform the Western blot assay, lysates were separated by SDS-PAGE, and then transferred onto a nitrocellulose membrane (from Amersham Biosciences, Piscataway, NY). After blocking the membranes with 5% non-fat milk, the spike protein primary antibody (purchased from Chiron) was applied to the membrane, followed by a horseradish peroxidase-conjugated secondary antibody by Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Detection of the antigen-antibody interaction was achieved through the use of an ECL fluorescence system. b-actin was used as a control for calibration purposes.","In preparation for the Western blot assay, the lysates were separated by SDS-PAGE, transferred onto a nitrocellulose membrane from Amersham Biosciences (Piscataway, NY), and then blocked using 5% non-fat milk. The spike protein primary antibody was sourced from Chiron, and the horseradish peroxidase-conjugated secondary antibody was from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). After the membrane was incubated with both antibodies in succession, an ECL fluorescence system was employed for the detection of the antigen-antibody interaction. Finally, b-actin served as a control for data interpretation."
"Female BALB/c mice aged between six and eight weeks from a laboratory in Korea known as Orient underwent anesthesia before receiving immunization. Each of the five mice in each group was inoculated intranasally with 20 μg of either pci-mock, pci-S, or PEI/pci-S complexes in 25 μl ultrapure water on days 0, 14, 28, and 42. The International Vaccine Institute in Seoul, Korea, approved all the studies that were conducted.","Young female BALB/c mice, which were aged between six and eight weeks, from Orient in Korea, were administered with anesthesia before receiving immunization, according to the approved procedures by the International Vaccine Institute located in Seoul. Each group consisting of five mice received 20 μg of either pci-mock, pci-S, or PEI/pci-S complexes, and were given a total of 25 μl ultrapure water on day 0, 14, 28, and 42, via the intranasal route.","Five groups of young female BALB/c mice from Korea's Orient region, between six and eight weeks old, received anesthesia before immunization via intranasal route. Each group of mice received 20 μg of either pci-mock, pci-S, or PEI/pci-S complexes, dissolved in 25 μl ultrapure water administered on days 0, 14, 28, and 42. The study protocol was approved by the International Vaccine Institute situated in Seoul, Korea."
"The samples required for the experiment were gathered on the eighth day after the last immunization. Collection of blood samples was achieved by pricking the tail of the mice. Fecal extracts were liquefied in a buffer that contained phosphate buffers and sodium chloride. The anesthetized mice were used to gather vaginal washes, nasal washes and lung washes. Vaginal and nasal washes were acquired by pipetting with some PBS while the lung washes were performed by flushing and aspiration of the lungs.","To obtain the required samples, the experimenters waited until the eleventh day after the last immunization before collecting them. Blood samples were taken from the lateral tail vein. The fecal extracts were dissolved using PBS with 0.02% sodium azide. For the collection of vaginal and nasal washes, the mice were sedated and washed with PBS. The lungs were flushed and aspirated repeatedly with PBS to obtain lung washes.","On the fifth day after the final immunization, the study samples were collected. Blood samples were obtained through a small incision in the lateral tail vein while using anesthetic. Fecal extracts were gathered by dissolving fecal matter in a solution of sodium azide and PBS. Vaginal and nasal washes were also collected by the use of PBS solution while lung washes were obtained through repeated flushing of the lungs with PBS. The process ensured complete sample collection."
"Plastic well plates (Thermo Fisher Scientific, Waltham, MA) were coated with SARS-CoV-2 S protein (Abcam, Cambridge, UK) at a concentration of 1 μg/mL for 1 hour at room temperature. Plates were then washed with a blocking buffer and blocked with either 5% BSA or non-fat dry milk. Serum or mucosal samples at various dilutions were added to the wells and incubated for 2 hours at room temperature. After the incubation period, wells were washed with a dilution buffer and a biotinylated rabbit anti-human IgG, IgM, IgA (Thermo Fisher Scientific, Waltham, MA) at a concentration of 1:1000 was added. After another wash cycle, streptavidin-horseradish peroxidase (Cayman Chemical, Ann Arbor, MI) was added to the wells and incubated for 30 minutes. Finally, the chromogenic substrate was added to each well, and the colorimetric change was read at OD450 with a microplate reader (BioTek Instruments, Inc., Winooski, VT).","96-well polystyrene plates (Corning Inc., Corning, NY) were coated with recombinant SARS-CoV-2 S protein (Novus Biologicals, Centennial, CO) at a fixed concentration of 20 ng/mL in a coating buffer at 4 °C overnight. The coated wells were immediately overlaid with buffer containing BSA proteins to prevent non-specific binding. The serum or mucosal samples at appropriate dilutions were added to the wells and incubated for 1 hour at room temperature. After washing the plates three times with a washing buffer, a secondary antibody specific to human IgG, IgM, or IgA (Invitrogen, Waltham, MA) was added to each well and incubated for 1 hour. The plates were washed again followed by the addition of substrate solution which was incubated for a few minutes at room temperature. The reaction was halted using a stop solution and measured at OD405 nm (Molecular Devices Corp., San Jose, CA) to calculate the antibody titer.","384-well microtiter plates (Greiner Bio-One, Frickenhausen, Germany) were coated with SARS-CoV-2 spike protein (Bioss, Woburn, MA) at a concentration of 10 μg/mL in phosphate-buffered saline at 4°C overnight. The plates were washed with the wash buffer and blocked using 3% bovine serum albumin. Serum or mucosal samples were diluted at various concentrations and incubated in each well for 1 hour and 30 minutes. After washing the plates three times with the washing buffer, secondary antibodies specific to human IgG, IgM, or IgA (BioLegend, San Diego, CA) were added to each well followed by incubation for 1 hour and then washed. After addition of a detection reagent, the reaction was incubated for 20 minutes and then the fluorescent signal was measured using the microplate reader (Perkin Elmer, Waltham, MA) at an excitation wavelength of 530 nm and emission wavelength of 590 nm."
"Following the final vaccination, mice were euthanized on day 7 and their spleens collected. To evaluate the immune response, splenocytes were obtained and labeled with a fluorescent dye, CFSE. Afterwards, the cells were stimulated with SARS-S protein for 5 days and anti-B220-PerCP was used to identify B cells. Flow cytometry was utilized to measure the degree of cell proliferation, and FlowJo software was utilized to examine the cytometric data.","At day 7 after the final vaccination, the mice were euthanized and their spleens were extracted. With Carboxyfluorescein succinimidyl ester (CFSE), splenocytes were labeled and then stimulated for 5 days with SARS-S protein at a concentration of 2 μg/ml. To identify B cells, anti-B220-PerCP was used. The extent of cell proliferation was assessed via Flow cytometry on a FACSCalibur machine. All of the cytometric data was evaluated using FlowJo software from Tree Star, located in San Carlos, CA.","To assess the immune response, mice were sacrificed seven days after the final vaccination, and their spleens were removed. The splenocytes were labeled with Carboxyfluorescein succinimidyl ester (CFSE) before being stimulated with SARS-S protein for five days. Flow cytometry was used to measure the extent of cell proliferation and identify B cells, with the help of anti-B220-PerCP. FlowJo software provided by Tree Star, based in San Carlos, CA, was used to evaluate the cytometric data."
"Following the vaccination, the cervical lymph nodes (CLN) were excised on the third day. The cells were then dissociated into a single suspension and subjected to various antibodies, including CD11c-APC and CD80-PE, CD83-PE, CD86-biotin, or I-A d -biotin by BD Biosciences. Detection of the expression level was done using flow cytometry with FACSCalibur. The flow cytometric data were expressed as MFI (mean fluorescence intensity) and analyzed using FlowJo software.","After the final vaccination, CLN was removed on day 3. The cells were then stained using several antibodies including CD11c-APC and CD80-PE, CD83-PE, CD86-biotin, or I-A d -biotin procured from BD Biosciences, and analyzed by flow cytometry FACSCalibur. The degree of expression was determined by calculating the mean fluorescence intensity (MFI) using the FlowJo software.","On the third day after the last vaccination, the CLN were extracted and single-cell suspensions were generated. Several antibodies including CD11c-APC and CD80-PE, CD83-PE, CD86-biotin, or I-A d -biotin produced by BD Biosciences were used to stain the cells. The samples were then analyzed using flow cytometry, FACSCalibur. All recorded cytometric data were expressed as the mean fluorescence intensity (MFI) and analyzed using the FlowJo software."
"The lungs from mice that had undergone the last vaccination on day 6 were removed and transformed into single-cell suspensions. Then, these cells were seeded onto a 96-well plate at a rate of 2 × 10^5 cells per well and stimulated by SARS peptide (Peptron) at a concentration of 5 μg/ml for 12 hours in order to undergo an intracellular cytokine staining assay. After the staining, the cells were examined by a flow cytometry FACSCalibur to determine the percentage of cells with associated fluorescence. Various antibodies such as anti-CD4-PerCP and anti-CD8FITC with either anti-IFN-g-APC and -IL-17-PE, or anti-TNF-a-APC and -IL-2-PE (all from BD Biosciences) were used to stain the cells. The results were then analyzed using the FlowJo software.","Following the last vaccination, lungs were taken from mice on day 6 and then turned into single-cell suspensions. These cells were then re-stimulated with SARS peptide (Peptron) at a 5 μg/ml level for 12 hours, and subsequently underwent an intracellular cytokine staining assay as per the manufacturer's guidance. Next, the cells were treated with several types of antibodies such as anti-CD4-PerCP and anti-CD8FITC in combination with either anti-IFN-g-APC and -IL-17-PE or anti-TNF-a-APC and -IL-2-PE (all BD Biosciences). With the help of flow cytometry, FACSCalibur, the flow of cells with fluorescence was analyzed, and finally, the cytometric data was analyzed with FlowJo software.","On day 6 following the last vaccination, lungs were removed from mice and broken down into single-cell suspensions. Subsequently, these cells were seeded onto a 96-well plate at a rate of 2 × 10^5 cells per well and re-stimulated with SARS peptide (Peptron) at a level of 5 μg/ml for 12 hours. An intracellular cytokine staining assay was performed, and the cells were incubated with several antibodies like anti-CD4-PerCP and anti-CD8FITC with either anti-IFN-g-APC and -IL-17-PE or anti-TNF-a-APC and -IL-2-PE (all sourced from BD Biosciences). Then, the cells were analyzed by using flow cytometry, FACSCalibur, in order to determine the percentage of cells with fluorescence. The data was analyzed with FlowJo software."
The data was subjected to statistical examination with the use of Student's t-test. Results were regarded as significant when p values were less than 0.05.,"To determine the statistical significance of the results, the data underwent analysis with Student's t-test. P values lower than 0.05 were taken as indication of significance.","By using the Student's t-test, statistical testing was performed to evaluate the data. A significance level of less than 0.05 was defined as statistically significant."
